{"meta":{"dataset":"ephemerisx-atlas-crl","version":"2026-10-09.1","built":"2026-10-09","outcomes_as_of":"2026-10-09","letters":456,"applications":336,"pairs":118,"sponsors":283,"categories":{"FAC":"Facility inspection","CMC":"Product quality (CMC)","EFF":"Efficacy evidence","SAF":"Safety","CLP":"Clinical pharmacology","DEV":"Device / human factors","NCL":"Nonclinical","AAP":"Accelerated approval","REG":"Regulatory / administrative"},"rule_agreement":{"FAC":{"n":93,"recall":0.96,"precision":1.0},"CMC":{"n":68,"recall":0.93,"precision":0.8},"EFF":{"n":35,"recall":0.69,"precision":0.92},"SAF":{"n":14,"recall":0.57,"precision":0.73},"CLP":{"n":20,"recall":0.75,"precision":0.88},"DEV":{"n":8,"recall":1.0,"precision":0.67},"NCL":{"n":23,"recall":0.57,"precision":0.68},"AAP":{"n":8,"recall":1.0,"precision":0.67}},"corpus":{"id":"sec","available":true,"programs":283,"concepts":923},"definitions":{"letter":"A complete response letter (CRL) in the SEC Ephemeris corpus: every letter openFDA publishes, matched to its sponsor.","application":"An NDA or BLA number. Letters naming the same number belong to one application; cycle is a letter's order within it.","letter_type":"Original application or supplement: the two coders' call for 2024+ letters, else the openFDA file's supplement number, else 'supplement' when Drugs@FDA shows the application approved before the letter.","era":"issued: the application's first letter is dated 2024 or later, when the FDA began publishing letters as issued. after_approval: earlier, when a letter was published only once the product was approved.","categories":"Taxonomy v1 (FAC, CMC, EFF, SAF, CLP, DEV, NCL, AAP, REG). Two-coder coding for 2024+ letters; section-aware rules over the knowledge graph for the rest (agreement in rule_agreement).","outcome":"approved: Drugs@FDA lists an original approval of the same application after its first letter. resubmitted / discontinued: a public source says so (2024+ only). not_covered: a CBER biologic (BLA 125xxx) with no Drugs@FDA record. no_public_outcome: none of these, which is not a rejection. supplement: the application's letters are all on supplements.","time_to_approval":"Days from the first original-application letter to approval; applications not approved are censored at outcomes_as_of. Kaplan-Meier with log(-log) Greenwood 95% intervals.","pair":"Two consecutive letters of the same application on different dates."},"coverage":[{"to":"2023-12-31","kind":"after_approval","note":"Before 2024 the FDA published a complete response letter only once the product was later approved, so these years hold almost only eventually approved applications."},{"from":"2024-01-01","kind":"issued","note":"From 2024 the FDA publishes letters as they are issued, approved or not."}],"sources":{"letters":"https://open.fda.gov/data/crl/","approvals":"https://api.fda.gov/drug/drugsfda.json","filings":"https://www.sec.gov/edgar/search/"}},"letters":[{"id":"CRL_NDA208288_20160506","program":"3m_health_care_infection_prevention_division","apps":["NDA208288"],"app":"NDA208288","date":"2016-05-06","file":"208288_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208288_2018_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC","EFF","NCL"],"cat_source":"rule","rule_cats":["CLP","CMC","EFF","NCL"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA208288_20160506:p1:s22","page":1,"text":"1. You have failed to demonstrate replicative efficacy in two pivotal clinical simulation studies, based on the previously agreed upon primary endpoints and statistical analyses."},{"sid":"CRL_NDA208288_20160506:p1:s23","page":1,"text":"Study EM05-012760 passed on all primary efficacy analyses; however, Study EM-05-013260 did not pass the > 70% responder rate primary endpoint for the inguinal site."},{"sid":"CRL_NDA208288_20160506:p1:s27","page":1,"text":"Conduct a repeat study of the inguinal region with adequate controls that meets the prespecified primary endpoint."}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"SoluPrep™","product_type":"not_classified","sponsor":"3M Health Care (Infection Prevention Division)"},{"id":"CRL_NDA208288_20170901","program":"3m_health_care_infection_prevention_division","apps":["NDA208288"],"app":"NDA208288","date":"2017-09-01","file":"208288_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208288_2018_Orig1s000OtherActionLtrs.pdf","cats":["CMC","NCL"],"cat_source":"rule","rule_cats":["CMC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"SoluPrep™","product_type":"not_classified","sponsor":"3M Health Care (Infection Prevention Division)"},{"id":"CRL_NDA216962_20230317","program":"abbvie","apps":["NDA216962"],"app":"NDA216962","date":"2023-03-17","file":"216962_2025_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/216962_2025_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["DEV","NCL"],"new_trial":"no","passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Vyalev (foscarbidopa/foslevodopa) subcutaneous infusion","product_type":"505b2_new_formulation","sponsor":"AbbVie Inc."},{"id":"CRL_NDA216962_20240618","program":"abbvie","apps":["NDA216962"],"app":"NDA216962","date":"2024-06-18","file":"216962_2025_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/216962_2025_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"Vyalev (foscarbidopa/foslevodopa) subcutaneous infusion","product_type":"505b2_new_formulation","sponsor":"AbbVie Inc."},{"id":"CRL_BLA761459_20260422","program":"abbvie","apps":["BLA761459"],"app":"BLA761459","date":"2026-04-22","file":"CRL_BLA761459_20260422.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761459_20260422.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761459_20260422:p1:s22","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on FDA Form 483 prior to your complete response to your application."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"trenibotulinumtoxinE (TrenibotE; AGN-151586), botulinum toxin serotype E","product_type":"novel","sponsor":"AbbVie Inc."},{"id":"CRL_UNKNOWN_20240416","program":"abeona_therapeutics","apps":["BLA125807"],"app":"BLA125807","date":"2024-04-16","file":"CRL_BLA125807_20240416.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125807_20240416.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Zevaskyn (prademagene zamikeracel), autologous gene-modified cell sheets for RDEB","product_type":"novel","sponsor":"Abeona Therapeutics, Inc."},{"id":"CRL_NDA209510_20181005","program":"acacia_pharma","apps":["NDA209510"],"app":"NDA209510","date":"2018-10-05","file":"209510_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209510_2020_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Barhemsys","product_type":"not_classified","sponsor":"Acacia Pharma Ltd"},{"id":"CRL_NDA209510_20190502","program":"acacia_pharma","apps":["NDA209510"],"app":"NDA209510","date":"2019-05-02","file":"209510_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209510_2020_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"Barhemsys","product_type":"not_classified","sponsor":"Acacia Pharma Ltd"},{"id":"CRL_BLA761147_20240405","program":"accord_biopharma","apps":["BLA761147"],"app":"BLA761147","date":"2024-04-05","file":"CRL_BLA761147_20240405.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761147_20240405.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761147_20240405:p1:s21","page":1,"text":"Your complete response should include the date of the facility's response to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":3,"product":"Ennumo (pegfilgrastim-pccg), pegfilgrastim biosimilar","product_type":"biosimilar","sponsor":"Accord BioPharma Inc."},{"id":"CRL_BLA761147_20241029","program":"accord_biopharma","apps":["BLA761147"],"app":"BLA761147","date":"2024-10-29","file":"CRL_BLA761147_20241029.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761147_20241029.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":3,"product":"Ennumo (pegfilgrastim-pccg), pegfilgrastim biosimilar","product_type":"biosimilar","sponsor":"Accord BioPharma Inc."},{"id":"CRL_BLA761424_20250313","program":"accord_biopharma","apps":["BLA761424"],"app":"BLA761424","date":"2025-03-13","file":"CRL_BLA761424_20250313.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761424_20250313.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761424_20250313:p1:s16","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA Form 483 prior to your complete response to your application."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Jubereq / Osvyrti (denosumab-desu), denosumab biosimilars","product_type":"biosimilar","sponsor":"Accord BioPharma Inc."},{"id":"CRL_BLA761027_20250626","program":"accord_biopharma","apps":["BLA761027"],"app":"BLA761027","date":"2025-06-26","file":"CRL_BLA761027_20250626.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761027_20250626.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761027_20250626:p1:s24","page":1,"text":"Your complete response should include the date(s) of the facility's response to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include reinspection of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"FILKRI (filgrastim-laha), filgrastim biosimilar","product_type":"biosimilar","sponsor":"Accord BioPharma Inc."},{"id":"CRL_BLA761147_20250805","program":"accord_biopharma","apps":["BLA761147"],"app":"BLA761147","date":"2025-08-05","file":"CRL_BLA761147_20250805.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761147_20250805.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":3,"n_app":3,"product":"Ennumo (pegfilgrastim-pccg), pegfilgrastim biosimilar","product_type":"biosimilar","sponsor":"Accord BioPharma Inc."},{"id":"CRL_NDA215000_20210430","program":"accord_healthcare","apps":["NDA215000"],"app":"NDA215000","date":"2021-04-30","file":"215000_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215000_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"bendamustine hydrochloride","product_type":"not_classified","sponsor":"Accord Healthcare Inc."},{"id":"CRL_NDA218470_20240130","program":"accord_healthcare","apps":["NDA218470"],"app":"NDA218470","date":"2024-01-30","file":"CRL_NDA218470_20240130.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218470_20240130.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"epinephrine injection (Accord)","product_type":"unknown","sponsor":"Accord Healthcare Inc."},{"id":"CRL_NDA215749_20240307","program":"accord_healthcare","apps":["NDA215749"],"app":"NDA215749","date":"2024-03-07","file":"CRL_NDA215749_20240307.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA215749_20240307.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Bendamustine hydrochloride injection (Accord)","product_type":"505b2_copy","sponsor":"Accord Healthcare Inc."},{"id":"CRL_NDA218762_20240417","program":"accord_healthcare","apps":["NDA218762"],"app":"NDA218762","date":"2024-04-17","file":"CRL_NDA218762_20240417.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218762_20240417.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"Paclitaxel protein-bound particles for injectable suspension (albumin-bound), Accord","product_type":"505b2_copy","sponsor":"Accord Healthcare Inc."},{"id":"CRL_NDA216987_20240510","program":"accord_healthcare","apps":["NDA216987"],"app":"NDA216987","date":"2024-05-10","file":"CRL_NDA216987_20240510.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA216987_20240510.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"bendamustine hydrochloride injection (Accord)","product_type":"unknown","sponsor":"Accord Healthcare Inc."},{"id":"CRL_NDA218762_20241205","program":"accord_healthcare","apps":["NDA218762"],"app":"NDA218762","date":"2024-12-05","file":"CRL_NDA218762_20241205.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218762_20241205.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"Paclitaxel protein-bound particles for injectable suspension (albumin-bound), Accord","product_type":"505b2_copy","sponsor":"Accord Healthcare Inc."},{"id":"CRL_NDA216987_20251106","program":"accord_healthcare","apps":["NDA216987"],"app":"NDA216987","date":"2025-11-06","file":"CRL_NDA216987_20251106.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA216987_20251106.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"bendamustine hydrochloride injection (Accord)","product_type":"unknown","sponsor":"Accord Healthcare Inc."},{"id":"CRL_NDA209128_20171011","program":"acelrx_pharmaceuticals","apps":["NDA209128"],"app":"NDA209128","date":"2017-10-11","file":"209128Orig1s000OtherActionLtr.pdf","url":"https://download.open.fda.gov/crl/209128Orig1s000OtherActionLtr.pdf","cats":["DEV","SAF"],"cat_source":"rule","rule_cats":["DEV","SAF"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA209128_20171011:p1:s25","page":1,"text":"We have determined that the human factors (HF) validation study data did not demonstrate that the user interface supports safe and effective use of the product by intended users for intended uses and environments."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"DSUVIA","product_type":"not_classified","sponsor":"AcelRx Pharmaceuticals, Inc."},{"id":"CRL_NDA214860_20220615","program":"acer_therapeutics","apps":["NDA214860"],"app":"NDA214860","date":"2022-06-15","file":"214860_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214860_2023_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sodium phenylbutyrate","product_type":"not_classified","sponsor":"Acer Therapeutics Inc."},{"id":"CRL_NDA218995_20260620","program":"achieve_life_sciences","apps":["NDA218995"],"app":"NDA218995","date":"2026-06-20","file":"CRL_NDA218995_20260620_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218995_20260620_Redacted.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["AAP","FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_NDA218995_20260620:p1:s19","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on FDA Form 483 prior to your Complete Response submission."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"cytisinicline tablets","product_type":"novel","sponsor":"Achieve Life Sciences, Inc."},{"id":"CRL_NDA208419_20170926","program":"actavis","apps":["NDA208419"],"app":"NDA208419","date":"2017-09-26","file":"208419_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208419_2021_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Pemetrexed","product_type":"not_classified","sponsor":"Actavis, L.L.C."},{"id":"CRL_NDA208419_20180626","program":"actavis_an_indirect_wholly_owned_subsidiary_teva_pharmaceuti","apps":["NDA208419"],"app":"NDA208419","date":"2018-06-26","file":"208419_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208419_2021_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"Pemetrexed","product_type":"not_classified","sponsor":"Actavis, L.L.C."},{"id":"CRL_NDA212854_20191122","program":"adamis_pharmaceuticals","apps":["NDA212854"],"app":"NDA212854","date":"2019-11-22","file":"212854_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212854_2022_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC","DEV","NCL"],"cat_source":"rule","rule_cats":["CLP","CMC","DEV","NCL"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA212854_20191122:p2:s32","page":2,"text":"We are withholding any comments on the relative bioavailability study until after you submit a response to this Complete Response letter."}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Naloxone HCI","product_type":"not_classified","sponsor":"Adamis Pharmaceuticals Corporation"},{"id":"CRL_NDA212854_20201113","program":"adamis_pharmaceuticals","apps":["NDA212854"],"app":"NDA212854","date":"2020-11-13","file":"212854_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212854_2022_Orig1s000OtherActionLtrs.pdf","cats":["DEV"],"cat_source":"rule","rule_cats":["DEV"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA212854_20201113:p1:s37","page":1,"text":"Based on this risk analysis, you will need to submit the results of a human factors (HF) validation study conducted under simulated use conditions with representative users performing necessary tasks to demonstrate safe and effective use of the product."},{"sid":"CRL_NDA212854_20201113:p1:s33","page":1,"text":"Submit your updated comprehensive use-related risk analysis (URRA) taking into consideration the changes to the user interface."},{"sid":"CRL_NDA212854_20201113:p1:s34","page":1,"text":"The comprehensive use-related risk analysis should include a comprehensive and systematic evaluation of all the steps involved in using your product (e.g., based on a task analysis) the errors that users might commit or the tasks they might fail to perform and the potential negative clinical consequences of use errors and task failures."}]},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"Naloxone HCI","product_type":"not_classified","sponsor":"Adamis Pharmaceuticals Corporation"},{"id":"CRL_BLA761082_20180510","program":"adello_biologics","apps":["BLA761082"],"app":"BLA761082","date":"2018-05-10","file":"761082_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761082_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":4,"product":"TPI-120","product_type":"not_classified","sponsor":"Adello Biologics, LLC"},{"id":"CRL_NDA209471_20171222","program":"aft_pharmaceuticals","apps":["NDA209471"],"app":"NDA209471","date":"2017-12-22","file":"209471_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209471_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC","NCL"],"cat_source":"rule","rule_cats":["CMC","FAC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"sirolimus","product_type":"not_classified","sponsor":"AFT Pharmaceuticals Ltd."},{"id":"CRL_NDA209471_20201106","program":"aft_pharmaceuticals","apps":["NDA209471"],"app":"NDA209471","date":"2020-11-06","file":"209471_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209471_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{"FAC":[{"sid":"CRL_NDA209471_20201106:p1:s19","page":1,"text":"Currently, the need for a facility inspection, and an assessment of the findings, is the only deficiency with your application."}]},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"sirolimus","product_type":"not_classified","sponsor":"AFT Pharmaceuticals Ltd."},{"id":"CRL_NDA215320_20220630","program":"aft_pharmaceuticals","apps":["NDA215320"],"app":"NDA215320","date":"2022-06-30","file":"215320_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215320_2024_Orig1s000OtherActionLtrs.pdf","cats":["NCL"],"cat_source":"rule","rule_cats":["NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sirolimus","product_type":"not_classified","sponsor":"AFT Pharmaceuticals Ltd."},{"id":"CRL_NDA218528_20240125","program":"aft_pharmaceuticals","apps":["NDA218528"],"app":"NDA218528","date":"2024-01-25","file":"CRL_NDA218528_20240125.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218528_20240125.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"unclear","passages":{"CMC":[{"sid":"CRL_NDA218528_20240125:p3:s2","page":3,"text":"The following CMC comments/recommendations that are not approvability issues should be addressed in your resubmission:"}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"sirolimus cream (Pascomer), topical sirolimus for facial angiofibroma","product_type":"505b2_new_formulation","sponsor":"AFT Pharmaceuticals Ltd."},{"id":"CRL_NDA204017_20130213","program":"agile_therapeutics","apps":["NDA204017"],"app":"NDA204017","date":"2013-02-13","file":"204017_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/204017_2020_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA204017_20130213:p1:s34","page":1,"text":"The study should use your proposed to-be-marketed product after you have adequately addressed the product quality deficiencies (see below) that may have impacted the efficacy findings in your completed studies."},{"sid":"CRL_NDA204017_20130213:p4:s20","page":4,"text":"1. Address whether the product quality deficiencies described above may have impacted the findings in your clinical pharmacology studies."},{"sid":"CRL_NDA204017_20130213:p4:s25","page":4,"text":"If the product quality deficiencies can be adequately addressed, provide a revised analysis that corrects for/compensates for this potential carry-over effect."}],"FAC":[{"sid":"CRL_NDA204017_20130213:p3:s0","page":3,"text":"8. During the facility inspection, it was noted that different equipment was used for the manufacture of clinical trial supplies as compared to that proposed for the commercial product."}]},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"levonorgestrel/ethinyl estradiol","product_type":"not_classified","sponsor":"Agile Therapeutics, Inc."},{"id":"CRL_NDA204017_20130717","program":"agile_therapeutics","apps":["NDA204017"],"app":"NDA204017","date":"2013-07-17","file":"204017_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/204017_2020_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"levonorgestrel/ethinyl estradiol","product_type":"not_classified","sponsor":"Agile Therapeutics, Inc."},{"id":"CRL_NDA204017_20171221","program":"agile_therapeutics","apps":["NDA204017"],"app":"NDA204017","date":"2017-12-21","file":"204017_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/204017_2020_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC","NCL"],"cat_source":"rule","rule_cats":["CMC","FAC","NCL"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA204017_20171221:p1:s37","page":1,"text":"Therefore, we have identified the following drug product quality deficiencies:"}]},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"levonorgestrel/ethinyl estradiol","product_type":"not_classified","sponsor":"Agile Therapeutics, Inc."},{"id":"CRL_NDA215192_20220329","program":"akebia_therapeutics","apps":["NDA215192"],"app":"NDA215192","date":"2022-03-29","file":"215192_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215192_2024_Orig1s000OtherActionLtrs.pdf","cats":["SAF"],"cat_source":"rule","rule_cats":["SAF"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"vadadustat","product_type":"not_classified","sponsor":"Akebia Therapeutics, Inc."},{"id":"CRL_BLA761258_20240119","program":"akeso_biopharma","apps":["BLA761258"],"app":"BLA761258","date":"2024-01-19","file":"761258_2025_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761258_2025_Orig1s000OtherActionLtrs.pdf","cats":["AAP","CMC","FAC"],"cat_source":"coded","rule_cats":["AAP","CMC","FAC"],"new_trial":"yes","passages":{"FAC":[{"sid":"CRL_BLA761258_20240119:p2:s39","page":2,"text":"Satisfactory responses to these deficiencies should be provided by the facility to the email address provided on the Form FDA 483 Inspectional Observations, prior to submitting your complete response."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Penpulimab-kcqx (AK105), anti-PD-1 antibody","product_type":"novel","sponsor":"Akeso Biopharma Co., Ltd."},{"id":"CRL_NDA216442_20250402","program":"aldeyra_therapeutics","apps":["NDA216442"],"app":"NDA216442","date":"2025-04-02","file":"CRL_NDA216442_20250402.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA216442_20250402.pdf","cats":["EFF"],"cat_source":"coded","rule_cats":["EFF"],"new_trial":"yes","passages":{"EFF":[{"sid":"CRL_NDA216442_20250402:p1:s15","page":1,"text":"There is a lack of substantial evidence consisting of adequate and well-controlled investigations, as defined in § 314.126, that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling."}]},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"reproxalap ophthalmic solution, RASP inhibitor for dry eye disease","product_type":"novel","sponsor":"Aldeyra Therapeutics, Inc."},{"id":"CRL_NDA216442_20260316","program":"aldeyra_therapeutics","apps":["NDA216442"],"app":"NDA216442","date":"2026-03-16","file":"CRL_NDA216442_20260316.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA216442_20260316.pdf","cats":["EFF"],"cat_source":"coded","rule_cats":[],"new_trial":"unclear","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"reproxalap ophthalmic solution, RASP inhibitor for dry eye disease","product_type":"novel","sponsor":"Aldeyra Therapeutics, Inc."},{"id":"CRL_NDA213378_20201113","program":"alkermes","apps":["NDA213378"],"app":"NDA213378","date":"2020-11-13","file":"213378Orig1Orig2s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213378Orig1Orig2s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Lybalvi","product_type":"not_classified","sponsor":"Alkermes, Inc."},{"id":"CRL_NDA215721_20230113","program":"almatica_pharma","apps":["NDA215721"],"app":"NDA215721","date":"2023-01-13","file":"215721_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215721_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"zolpidem tartrate","product_type":"not_classified","sponsor":"Almatica Pharma, LLC"},{"id":"CRL_NDA213072_20200526","program":"althera_life_sciences","apps":["NDA213072"],"app":"NDA213072","date":"2020-05-26","file":"213072_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213072_2021_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"rosuvastatin","product_type":"not_classified","sponsor":"Althera Life Sciences, LLC"},{"id":"CRL_BLA761299_20221220","program":"alvotech_usa","apps":["BLA761299"],"app":"BLA761299","date":"2022-12-20","file":"761299_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761299_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"AVTO5","product_type":"not_classified","sponsor":"Alvotech USA Inc."},{"id":"CRL_BLA761299_20230628","program":"alvotech_usa","apps":["BLA761299"],"app":"BLA761299","date":"2023-06-28","file":"761299_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761299_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"AVTO5","product_type":"not_classified","sponsor":"Alvotech USA Inc."},{"id":"CRL_BLA761343_20231011","program":"alvotech_usa","apps":["BLA761343"],"app":"BLA761343","date":"2023-10-11","file":"761343_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761343_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"AVTO5","product_type":"not_classified","sponsor":"Alvotech USA Inc."},{"id":"CRL_BLA761462_20251031","program":"alvotech_usa","apps":["BLA761462"],"app":"BLA761462","date":"2025-10-31","file":"CRL_BLA761462_20251031.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761462_20251031.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"AVT05, golimumab biosimilar (Gobivaz ex-US)","product_type":"biosimilar","sponsor":"Alvotech USA Inc."},{"id":"CRL_BLA761435_20251124","program":"alvotech_usa","apps":["BLA761435"],"app":"BLA761435","date":"2025-11-24","file":"CRL_BLA761435_20251124.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761435_20251124.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"AVT06, aflibercept (Eylea) biosimilar","product_type":"biosimilar","sponsor":"Alvotech USA Inc."},{"id":"CRL_BLA761461_20251126","program":"alvotech_usa","apps":["BLA761461"],"app":"BLA761461","date":"2025-11-26","file":"CRL_BLA761461_20251126.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761461_20251126.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761461_20251126:p1:s19","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA Form 483 prior to your complete response to your application."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"AVT05, golimumab biosimilar (Simponi/Simponi Aria)","product_type":"biosimilar","sponsor":"Alvotech USA Inc."},{"id":"CRL_BLA125522_20150827","program":"amgen","apps":["BLA125522"],"app":"BLA125522","date":"2015-08-27","file":"125522Orig2s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/125522Orig2s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Kanjinti","product_type":"not_classified","sponsor":"Amgen Inc."},{"id":"CRL_BLA761062_20170713","program":"amgen","apps":["BLA761062"],"app":"BLA761062","date":"2017-07-13","file":"761062_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761062_2019_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Kanjinti","product_type":"not_classified","sponsor":"Amgen Inc."},{"id":"CRL_BLA761073_20180525","program":"amgen","apps":["BLA761073"],"app":"BLA761073","date":"2018-05-25","file":"761073_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761073_2019_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Kanjinti","product_type":"not_classified","sponsor":"Amgen Inc."},{"id":"CRL_NDA218345_20240701","program":"amneal_eu","apps":["NDA218345"],"app":"NDA218345","date":"2024-07-01","file":"CRL_NDA218345_20240701.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218345_20240701.pdf","cats":["CMC","NCL"],"cat_source":"coded","rule_cats":["CMC","NCL"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"phenylephrine hydrochloride in sodium chloride injection (premixed)","product_type":"unknown","sponsor":"Amneal EU, Limited"},{"id":"CRL_NDA218345_20250402","program":"amneal_eu","apps":["NDA218345"],"app":"NDA218345","date":"2025-04-02","file":"CRL_NDA218345_20250402.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218345_20250402.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"phenylephrine hydrochloride in sodium chloride injection (premixed)","product_type":"unknown","sponsor":"Amneal EU, Limited"},{"id":"CRL_NDA208969_20170217","program":"amphastar_pharmaceuticals","apps":["NDA208969"],"app":"NDA208969","date":"2017-02-17","file":"208969_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208969_2023_Orig1s000OtherActionLtrs.pdf","cats":["DEV","FAC"],"cat_source":"rule","rule_cats":["DEV","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":null,"product_type":"not_classified","sponsor":"Amphastar Pharmaceuticals, Inc."},{"id":"CRL_BLA761403_20260226","program":"amphastar_pharmaceuticals","apps":["BLA761403"],"app":"BLA761403","date":"2026-02-26","file":"CRL_BLA761403_20260226.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761403_20260226.pdf","cats":["CLP","FAC"],"cat_source":"coded","rule_cats":["CLP","CMC","FAC"],"new_trial":"yes","passages":{"FAC":[{"sid":"CRL_BLA761403_20260226:p1:s19","page":1,"text":"Due to the deficiencies identified in bioanalytical method validation and bioanalysis for insulin aspart quantitation as indicated on the FDA Form 483 issued on ae."},{"sid":"CRL_BLA761403_20260226:p1:s30","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA Form 483 prior to your complete response to your application."},{"sid":"CRL_BLA761403_20260226:p1:s31","page":1,"text":"Your complete response should include the date(s) of the facility's response to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Insulin aspart biosimilar to NovoLog (Amphastar)","product_type":"biosimilar","sponsor":"Amphastar Pharmaceuticals, Inc."},{"id":"CRL_NDA215064_20220226","program":"amryt_pharmaceuticals_dac","apps":["NDA215064"],"app":"NDA215064","date":"2022-02-26","file":"215064_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215064_2024_Orig1s000OtherActionLtrs.pdf","cats":["EFF","NCL"],"cat_source":"rule","rule_cats":["EFF","NCL"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA215064_20220226:p1:s17","page":1,"text":"(1) The submitted data do not provide substantial evidence of effectiveness for the use of Filsuvez (birch triterpenes) gel for the proposed indication of treatment of wounds associated with inherited epidermolysis bullosa (EB)."},{"sid":"CRL_NDA215064_20220226:p1:s18","page":1,"text":"Although the primary endpoint for Study BEB-13 was met (Filsuvez treatment resulted in an increased proportion of subjects with first complete closure of the EB target wound within 45 days relative to control gel), the pre-specified and exploratory secondary endpoints provide limited support for a substantial benefit with active treatment."},{"sid":"CRL_NDA215064_20220226:p1:s21","page":1,"text":"Due to their design and significant amounts of data unavailable for blinded assessment, these studies are not suitable for providing confirmatory evidence."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Filsuvez","product_type":"not_classified","sponsor":"Amryt Pharmaceuticals DAC"},{"id":"CRL_NDA209863_20171020","program":"antares_pharma","apps":["NDA209863"],"app":"NDA209863","date":"2017-10-20","file":"209863_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209863_2019_Orig1s000OtherActionLtrs.pdf","cats":["EFF"],"cat_source":"rule","rule_cats":["EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA209863_20171020:p1:s19","page":1,"text":"1. Based on the findings in Studies QST13-003 and QST15-005, we are concerned that your testosterone enanthate product could cause a clinically meaningful increase in blood pressure."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"hydrocortisone sodium phosphate","product_type":"not_classified","sponsor":"Antares Pharma, Inc."},{"id":"CRL_NDA218026_20240816","program":"antares_pharma","apps":["NDA218026"],"app":"NDA218026","date":"2024-08-16","file":"CRL_NDA218026_20240816.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218026_20240816.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":[],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Hydrocortisone sodium phosphate injection (Antares; likely ATRS-1902 autoinjector)","product_type":"505b2_new_formulation","sponsor":"Antares Pharma, Inc."},{"id":"CRL_NDA217202_20230531","program":"aop_orphan_pharmaceuticals","apps":["NDA217202"],"app":"NDA217202","date":"2023-05-31","file":"217202_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/217202_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"landiolol","product_type":"not_classified","sponsor":"AOP Orphan Pharmaceuticals GmbH"},{"id":"CRL_NDA219107_20260721","program":"apiject_systems","apps":["NDA219107"],"app":"NDA219107","date":"2026-07-21","file":"CRL_NDA219107_20260721.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA219107_20260721.pdf","cats":["CMC","DEV"],"cat_source":"coded","rule_cats":["CMC","DEV"],"new_trial":"no","passages":{"DEV":[{"sid":"CRL_NDA219107_20260721:p1:s36","page":1,"text":"These foreseeable issues were identified in the results of your Human Factors (HF) validation study."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"glycopyrrolate solution in ApiJect prefilled blow-fill-seal syringe","product_type":"505b2_copy","sponsor":"Apiject Systems Corp."},{"id":"CRL_NDA219195_20241127","program":"applied_therapeutics","apps":["NDA219195"],"app":"NDA219195","date":"2024-11-27","file":"CRL_NDA219195_20241127.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA219195_20241127.pdf","cats":["AAP","EFF"],"cat_source":"coded","rule_cats":["AAP"],"new_trial":"yes","passages":{"AAP":[{"sid":"CRL_NDA219195_20241127:p2:s24","page":2,"text":"For accelerated approval, you will need to provide substantial evidence of effectiveness of govorestat on the RLSE based on adequate and well controlled clinical investigation(s) and confirmatory evidence, if one single adequate and well controlled trial is being considered as primary evidence."},{"sid":"CRL_NDA219195_20241127:p2:s3","page":2,"text":"The discussion under the Confirmatory Evidence section above describing the limitations of the evidence to support the role of galactitol in the pathogenesis of the CG applies to the consideration of galactitol as a reasonably likely surrogate endpoint (RLSE) for the purpose of accelerated approval."},{"sid":"CRL_NDA219195_20241127:p2:s12","page":2,"text":"In summary, the Agency concludes the currently available evidence does not support plasma galactitol as a reasonably likely surrogate endpoint for CG."}],"EFF":[{"sid":"CRL_NDA219195_20241127:p1:s19","page":1,"text":"Based on our review of the data, we are unable to conclude there is substantial evidence of effectiveness."},{"sid":"CRL_NDA219195_20241127:p2:s14","page":2,"text":"Provide substantial evidence of effectiveness for govorestat for the treatment of CG."},{"sid":"CRL_NDA219195_20241127:p2:s24","page":2,"text":"For accelerated approval, you will need to provide substantial evidence of effectiveness of govorestat on the RLSE based on adequate and well controlled clinical investigation(s) and confirmatory evidence, if one single adequate and well controlled trial is being considered as primary evidence."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"govorestat (AT-007) for classic galactosemia","product_type":"novel","sponsor":"Applied Therapeutics, Inc."},{"id":"CRL_NDA219870_20260130","program":"aquestive_therapeutics","apps":["NDA219870"],"app":"NDA219870","date":"2026-01-30","file":"CRL_NDA219870_20260130.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA219870_20260130.pdf","cats":["CLP","DEV","SAF"],"cat_source":"coded","rule_cats":["CLP","DEV"],"new_trial":"yes","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"dibutepinephrine sublingual film (Anaphylm), epinephrine prodrug","product_type":"other","sponsor":"Aquestive Therapeutics Inc."},{"id":"CRL_NDA213931_20210728","program":"ardelyx","apps":["NDA213931"],"app":"NDA213931","date":"2021-07-28","file":"213931_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213931_2024_Orig1s000OtherActionLtrs.pdf","cats":["AAP","EFF"],"cat_source":"rule","rule_cats":["AAP","EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA213931_20210728:p2:s18","page":2,"text":"Although we agree that the submitted data provide substantial evidence that tenapanor is effective in reducing serum phosphorus in CKD patients on dialysis, the magnitude of the treatment effect is small and of unclear clinical significance."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"tenapanor hydrochloride","product_type":"not_classified","sponsor":"Ardelyx, Inc."},{"id":"CRL_NDA205920_20140522","program":"armstrong_pharmaceuticals","apps":["NDA205920"],"app":"NDA205920","date":"2014-05-22","file":"205920_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/205920_2018_Orig1s000OtherActionLtrs.pdf","cats":["CMC","DEV","NCL"],"cat_source":"rule","rule_cats":["CMC","DEV","NCL"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA205920_20140522:p2:s10","page":2,"text":"2. Conduct a behavioral (human factors) study with the revised label using the actual product (not a dummy product) to assess consumers' ability to use epinephrine HFA inhalation aerosol."}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Primatene Mist","product_type":"not_classified","sponsor":"Armstrong Pharmaceuticals"},{"id":"CRL_NDA205920_20161223","program":"armstrong_pharmaceuticals","apps":["NDA205920"],"app":"NDA205920","date":"2016-12-23","file":"205920_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/205920_2018_Orig1s000OtherActionLtrs.pdf","cats":["DEV"],"cat_source":"rule","rule_cats":["DEV"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA205920_20161223:p1:s20","page":1,"text":"Specifically, the human factors (HF) study (G3) failed to demonstrate that the user interface supports safe and effective use of the product by intended users for the proposed uses in the OTC setting."},{"sid":"CRL_NDA205920_20161223:p2:s21","page":2,"text":"Applying Human Factors and Usability Engineering to Medical Devices, available online at:"}]},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"Primatene Mist","product_type":"not_classified","sponsor":"Armstrong Pharmaceuticals"},{"id":"CRL_NDA214697_20230919","program":"ars_pharmaceuticals","apps":["NDA214697"],"app":"NDA214697","date":"2023-09-19","file":"214697_2025_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214697_2025_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC","DEV","EFF"],"cat_source":"rule","rule_cats":["CLP","CMC","DEV","EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA214697_20230919:p1:s22","page":1,"text":"The submitted data do not provide substantial evidence of effectiveness for the use of ARS-1 (epinephrine nasal spray) for its proposed indication, the treatment of allergic reactions (Type 1), including anaphylaxis, in adult and pediatric patients who weigh 2 30 kg, under conditions likely to be encountered by the target population."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Neffy","product_type":"not_classified","sponsor":"ARS Pharmaceuticals, Inc."},{"id":"CRL_NDA220544_20260702","program":"ascelia_pharma","apps":["NDA220544"],"app":"NDA220544","date":"2026-07-02","file":"CRL_NDA220544_20260702_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA220544_20260702_Redacted.pdf","cats":["CMC","EFF"],"cat_source":"coded","rule_cats":["CMC","EFF"],"new_trial":"yes","passages":{"EFF":[{"sid":"CRL_NDA220544_20260702:p1:s24","page":1,"text":"In the absence of a successful adequate and wellcontrolled study, substantial evidence of effectiveness has not been demonstrated."},{"sid":"CRL_NDA220544_20260702:p1:s19","page":1,"text":"©) images to pre-contrast images alone for both lesion contrast and lesion border delineation co-primary endpoints."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Orviglance (manganese chloride tetrahydrate powder for oral solution), oral liver MRI contrast agent","product_type":"other","sponsor":"Ascelia Pharma AB"},{"id":"CRL_NDA216490_20230428","program":"ascendis_pharma_bone_diseases_a_s","apps":["NDA216490"],"app":"NDA216490","date":"2023-04-28","file":"216490_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/216490_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","DEV"],"cat_source":"rule","rule_cats":["CMC","DEV"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA216490_20230428:p3:s7","page":3,"text":"Alternatively, you could address the above-listed CMC deficiencies and provide data verifying that your existing device is capable of consistently meeting your proposed ug dose delivered specification at release and stability per your revised quality control strategy."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"palopegteriparatide","product_type":"not_classified","sponsor":"Ascendis Pharma Bone Diseases A/S"},{"id":"CRL_NDA209529_20170828","program":"astellas_pharma_us","apps":["NDA209529"],"app":"NDA209529","date":"2017-08-28","file":"209529_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209529_2020_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"IZERVAY","product_type":"not_classified","sponsor":"Astellas Pharma US, Inc."},{"id":"CRL_BLA761365_20240104","program":"astellas_pharma_us","apps":["BLA761365"],"app":"BLA761365","date":"2024-01-04","file":"761365_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761365_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761365_20240104:p1:s16","page":1,"text":"Following the pre-license inspection of a listed in this application, FDA conveyed deficiencies to the facility's representative."},{"sid":"CRL_BLA761365_20240104:p1:s19","page":1,"text":"Your complete response should include the date of the facility's response to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"VYLOY (zolbetuximab-clzb; IMAB362)","product_type":"novel","sponsor":"Astellas Pharma US, Inc."},{"id":"CRL_NDA217225_20241115","program":"astellas_pharma_us","apps":["NDA217225"],"app":"NDA217225","date":"2024-11-15","file":"217225-s001_OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/217225-s001_OtherActionLtrs.pdf","cats":["EFF"],"cat_source":"coded","rule_cats":[],"new_trial":"yes","passages":{},"type":"supplement","era":"issued","cycle":1,"n_app":1,"product":"IZERVAY","product_type":"not_classified","sponsor":"Astellas Pharma US, Inc."},{"id":"CRL_NDA212122_20190930","program":"astrazeneca","apps":["NDA212122"],"app":"NDA212122","date":"2019-09-30","file":"212122_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212122_2021_Orig1s000OtherActionLtrs.pdf","cats":["EFF"],"cat_source":"rule","rule_cats":["EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA212122_20190930:p1:s17","page":1,"text":"The submitted data do not provide substantial evidence of the efficacy and safety for the use of Breztri Aerosphere (budesonide, glycopyrrolate and formoterol fumarate)"},{"sid":"CRL_NDA212122_20190930:p1:s26","page":1,"text":"In order to address the above deficiency, conduct an additional trial or trials to provide data to demonstrate the efficacy of the Breztri Aerosphere combination product and the contribution of budesonide to the combination product."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Breztri Aerosphere","product_type":"not_classified","sponsor":"AstraZeneca AB"},{"id":"CRL_BLA761451_20251010","program":"astrazeneca_pharmaceuticals","apps":["BLA761451"],"app":"BLA761451","date":"2025-10-10","file":"CRL_BLA761451_20251010.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761451_20251010.pdf","cats":["EFF"],"cat_source":"coded","rule_cats":["EFF"],"new_trial":"no","passages":{"EFF":[{"sid":"CRL_BLA761451_20251010:p1:s15","page":1,"text":"This amendment identifies critical data quality issues that affect key analyses, including the primary endpoint, indicating specific deficiencies related to errors in the data submitted at the beginning of the review cycle."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"anifrolumab-fnia (Saphnelo) subcutaneous","product_type":"other","sponsor":"AstraZeneca Pharmaceuticals LP"},{"id":"CRL_UNKNOWN_20250115","program":"atara_biotherapeutics","apps":["BLA125745"],"app":"BLA125745","date":"2025-01-15","file":"CRL_BLA125745_20250115.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125745_20250115.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"tabelecleucel (Ebvallo), allogeneic EBV-specific T-cell therapy","product_type":"novel","sponsor":"Atara Biotherapeutics, Inc."},{"id":"CRL_NDA210735_20180426","program":"auromedics_pharma","apps":["NDA210735"],"app":"NDA210735","date":"2018-04-26","file":"210735_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210735_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC","NCL"],"cat_source":"rule","rule_cats":["CMC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"Cyclophosphamide","product_type":"not_classified","sponsor":"AuroMedics Pharma LLC"},{"id":"CRL_NDA210735_20190115","program":"auromedics_pharma","apps":["NDA210735"],"app":"NDA210735","date":"2019-01-15","file":"210735_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210735_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"Cyclophosphamide","product_type":"not_classified","sponsor":"AuroMedics Pharma LLC"},{"id":"CRL_NDA210735_20191001","program":"auromedics_pharma","apps":["NDA210735"],"app":"NDA210735","date":"2019-10-01","file":"210735_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210735_2022_Orig1s000OtherActionLtrs.pdf","cats":["FAC","NCL"],"cat_source":"rule","rule_cats":["FAC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"Cyclophosphamide","product_type":"not_classified","sponsor":"AuroMedics Pharma LLC"},{"id":"CRL_NDA204408_20130606","program":"aveo_pharmaceuticals","apps":["NDA204408"],"app":"NDA204408","date":"2013-06-06","file":null,"url":null,"cats":["CMC","EFF","SAF"],"cat_source":"rule","rule_cats":["CMC","EFF","SAF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA204408_20130606:p1:s29","page":1,"text":"While the results of the primary endpoint of progression-free survival (PFS) statistically favored tivozanib [hazard ratio of 0.80; p value of 0.04], a potential 25% decrease in overall survival (OS) was also demonstrated [hazard ratio: 1.25; p value: 0.1]."},{"sid":"CRL_NDA204408_20130606:p1:s34","page":1,"text":"We recommend that you perform an adequate and well-controlled randomized trial(s) of tivozanib using PFS as the primary endpoint and OS as a secondary endpoint."}],"SAF":[{"sid":"CRL_NDA204408_20130606:p1:s31","page":1,"text":"The inconsistent PFS and OS results and imbalance in post study treatments make the trial's results uninterpretable and inconclusive when making a risk-benefit assessment necessary for drug approval."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"tivozanib hydrochloride","product_type":"not_classified","sponsor":"AVEO Pharmaceuticals, Inc."},{"id":"CRL_NDA213593_20210128","program":"azurity_pharmaceuticals","apps":["NDA213593"],"app":"NDA213593","date":"2021-01-28","file":"213593_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213593_2023_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC"],"cat_source":"rule","rule_cats":["CLP","CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sitagliptin","product_type":"not_classified","sponsor":"Azurity Pharmaceuticals, Inc."},{"id":"CRL_NDA214273_20210528","program":"azurity_pharmaceuticals","apps":["NDA214273"],"app":"NDA214273","date":"2021-05-28","file":"214273_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214273_2023_Orig1s000OtherActionLtrs.pdf","cats":["FAC","NCL"],"cat_source":"rule","rule_cats":["FAC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sitagliptin","product_type":"not_classified","sponsor":"Azurity Pharmaceuticals, Inc."},{"id":"CRL_NDA219122_20241104","program":"azurity_pharmaceuticals","apps":["NDA219122"],"app":"NDA219122","date":"2024-11-04","file":"219122Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/219122Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Brynovin (sitagliptin oral solution)","product_type":"505b2_new_formulation","sponsor":"Azurity Pharmaceuticals, Inc."},{"id":"CRL_NDA204957_20170928","program":"b_braun_medical","apps":["NDA204957"],"app":"NDA204957","date":"2017-09-28","file":"204957_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/204957_2021_Orig1s000OtherActionLtrs.pdf","cats":["FAC","NCL"],"cat_source":"rule","rule_cats":["FAC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"Acetaminophen","product_type":"not_classified","sponsor":"B. Braun Medical, Inc."},{"id":"CRL_NDA204957_20190327","program":"b_braun_medical","apps":["NDA204957"],"app":"NDA204957","date":"2019-03-27","file":"204957_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/204957_2021_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"Acetaminophen","product_type":"not_classified","sponsor":"B. Braun Medical, Inc."},{"id":"CRL_NDA204957_20200424","program":"b_braun_medical","apps":["NDA204957"],"app":"NDA204957","date":"2020-04-24","file":"204957_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/204957_2021_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"Acetaminophen","product_type":"not_classified","sponsor":"B. Braun Medical, Inc."},{"id":"CRL_NDA211039_20190719","program":"bausch_health_ireland","apps":["NDA211039"],"app":"NDA211039","date":"2019-07-19","file":"211039_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211039_2020_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"fluorescein sodium","product_type":"not_classified","sponsor":"Bausch Health Ireland Limited"},{"id":"CRL_NDA213645_20210429","program":"baxter_healthcare","apps":["NDA213645"],"app":"NDA213645","date":"2021-04-29","file":"213645_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213645_2022_Orig1s000OtherActionLtrs.pdf","cats":["NCL"],"cat_source":"rule","rule_cats":["NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"DAPZURA RT","product_type":"not_classified","sponsor":"Baxter Healthcare Corporation"},{"id":"CRL_NDA218408_20240327","program":"baxter_healthcare","apps":["NDA218408"],"app":"NDA218408","date":"2024-03-27","file":"CRL_NDA218408_20240327.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218408_20240327.pdf","cats":["CMC"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Baxter product (name redacted in CRL; ends '...chloride'); API field says Dapzura RT, unverified","product_type":"unknown","sponsor":"Baxter Healthcare Corporation"},{"id":"CRL_NDA218224_20240329","program":"baxter_healthcare","apps":["NDA218224"],"app":"NDA218224","date":"2024-03-29","file":null,"url":null,"cats":["CMC"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Dapzura RT (daptomycin for injection, room-temperature lyophilized vial, Baxter)","product_type":"unknown","sponsor":"Baxter Healthcare Corporation"},{"id":"CRL_NDA218506_20240613","program":"bayer_healthcare","apps":["NDA218506"],"app":"NDA218506","date":"2024-06-13","file":"CRL_NDA218506_20240613.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218506_20240613.pdf","cats":["CMC","FAC","NCL"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Naproxen sodium capsule (Bayer)","product_type":"505b2_new_formulation","sponsor":"Bayer HealthCare LLC"},{"id":"CRL_NDA207987_20151209","program":"belcher_pharmaceuticals","apps":["NDA207987"],"app":"NDA207987","date":"2015-12-09","file":"207987_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/207987_2018_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA207987_20151209:p1:s25","page":1,"text":"2. From the chemistry, manufacturing and controls (CMC) perspective, NDA 207987 cannot be recommended for approval because of unresolved CMC deficiencies, resulting in the 'withhold' recommendation issued by the Office of Process and Facility for the drug substance manufacturing facility."},{"sid":"CRL_NDA207987_20151209:p1:s27","page":1,"text":"A. Drug Product Specification: You need to provide CMC information concerning the validated analytical methods to be included in the revised drug product specification."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Ablysinol","product_type":"not_classified","sponsor":"Belcher Pharmaceuticals, LLC."},{"id":"CRL_NDA215291_20240117","program":"bendarx_usa","apps":["NDA215291"],"app":"NDA215291","date":"2024-01-17","file":"CRL_NDA215291_20240117.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA215291_20240117.pdf","cats":["CLP","NCL"],"cat_source":"coded","rule_cats":["CLP","NCL"],"new_trial":"yes","passages":{"CLP":[{"sid":"CRL_NDA215291_20240117:p1:s21","page":1,"text":"To resolve these deficiencies, you will need to conduct a comparative bioavailability/bioequivalence (BA/BE) study in humans to demonstrate that the formulation differences between the proposed drug product and the LDs do not impact overall PK/disposition and safety of the proposed drug product."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Bendamustine injection (BendaRx), 505(b)(2)","product_type":"unknown","sponsor":"BendaRx USA Corporation"},{"id":"CRL_BLA761198_20211119","program":"bio_thera_solutions","apps":["BLA761198"],"app":"BLA761198","date":"2021-11-19","file":"761198_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761198_2024_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC","EFF","FAC"],"cat_source":"rule","rule_cats":["CLP","CMC","EFF","FAC"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_BLA761198_20211119:p1:s23","page":1,"text":"BAT1706 has no clinically meaningful differences from US-Avastin in terms of safety, purity, and potency."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"BAT1706","product_type":"not_classified","sponsor":"Bio-Thera Solutions Ltd."},{"id":"CRL_NDA209531_20250922","program":"biogen","apps":["NDA209531"],"app":"NDA209531","date":"2025-09-22","file":"CRL_NDA209531_20250922.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA209531_20250922.pdf","cats":["CMC","NCL"],"cat_source":"coded","rule_cats":["CMC","NCL"],"new_trial":"unclear","passages":{},"type":"supplement","era":"issued","cycle":1,"n_app":1,"product":null,"product_type":"not_classified","sponsor":"Biogen, Inc."},{"id":"CRL_NDA210862_20251104","program":"biohaven_therapeutics","apps":["NDA210862"],"app":"NDA210862","date":"2025-11-04","file":"CRL_NDA210862_20251104.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA210862_20251104.pdf","cats":["EFF","NCL"],"cat_source":"coded","rule_cats":["EFF","NCL"],"new_trial":"yes","passages":{"EFF":[{"sid":"CRL_NDA210862_20251104:p1:s21","page":1,"text":"We noted that such a study would likely be inadequate to provide substantial evidence of effectiveness, particularly with consideration that Study 206, the randomized, double-blind, placebo-controlled study, failed on all primary and secondary endpoints in the pre-specified analysis population."},{"sid":"CRL_NDA210862_20251104:p1:s29","page":1,"text":", during which we stated that Study 206-RWE was not considered to be an adequate and well-controlled investigation, and therefore, it would not be capable of providing the primary support for demonstration of substantial evidence of effectiveness."},{"sid":"CRL_NDA210862_20251104:p1:s31","page":1,"text":"After a comprehensive and detailed review of the submission, we have determined that substantial evidence of effectiveness has not been established for troriluzole for the treatment of spinocerebellar ataxia."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Vyglxia (troriluzole), glutamate modulator for spinocerebellar ataxia","product_type":"novel","sponsor":"Biohaven Therapeutics, Ltd."},{"id":"CRL_NDA211150_20190814","program":"bioprojet_pharma","apps":["NDA211150"],"app":"NDA211150","date":"2019-08-14","file":"211150Orig2s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211150Orig2s000OtherActionLtrs.pdf","cats":["EFF"],"cat_source":"rule","rule_cats":["EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA211150_20190814:p1:s22","page":1,"text":"FDA has concluded that your NDA submission does not provide substantial evidence of effectiveness to support the approval of pitolisant for treatment of cataplexy in adult patients with narcolepsy."},{"sid":"CRL_NDA211150_20190814:p1:s23","page":1,"text":"Substantial evidence typically consists of at least two adequate and well-controlled trials, each convincing on its own."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Wakix","product_type":"not_classified","sponsor":"Bioprojet Pharma"},{"id":"CRL_BLA761164_20201113","program":"bioverativ_usa","apps":["BLA761164"],"app":"BLA761164","date":"2020-11-13","file":"761164_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761164_2022_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sutimlimab","product_type":"not_classified","sponsor":"Bioverativ USA, Inc."},{"id":"CRL_NDA217347_20230922","program":"botanix_sb","apps":["NDA217347"],"app":"NDA217347","date":"2023-09-22","file":"217347_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/217347_2024_Orig1s000OtherActionLtrs.pdf","cats":["DEV"],"cat_source":"rule","rule_cats":["DEV"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA217347_20230922:p1:s19","page":1,"text":"Based on the evaluation of the human factors (HF) study results, the user interface does not support the safe and effective use of the proposed product."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sofpironium bromide","product_type":"not_classified","sponsor":"Botanix SB Inc."},{"id":"CRL_NDA210136_20201201","program":"braeburn","apps":["NDA210136"],"app":"NDA210136","date":"2020-12-01","file":"210136_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210136_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":4,"product":"BRIXADI","product_type":"not_classified","sponsor":"Braeburn Pharmaceuticals Inc."},{"id":"CRL_NDA210136_20211215","program":"braeburn","apps":["NDA210136"],"app":"NDA210136","date":"2021-12-15","file":"210136_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210136_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":4,"n_app":4,"product":"BRIXADI","product_type":"not_classified","sponsor":"Braeburn Pharmaceuticals Inc."},{"id":"CRL_NDA210136_20180119","program":"braeburn_pharmaceuticals","apps":["NDA210136"],"app":"NDA210136","date":"2018-01-19","file":"210136_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210136_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","NCL"],"cat_source":"rule","rule_cats":["CMC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":4,"product":"BRIXADI","product_type":"not_classified","sponsor":"Braeburn Pharmaceuticals Inc."},{"id":"CRL_NDA210136_20181221","program":"braeburn_pharmaceuticals","apps":["NDA210136"],"app":"NDA210136","date":"2018-12-21","file":"210136_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210136_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA210136_20181221:p1:s32","page":1,"text":"In addition to a safety update, the amendment should also identify changes, if any, in the conditions under which your product was tentatively approved, i.e., updated labeling; chemistry, manufacturing, and controls data; and risk evaluation and mitigation strategy (REMS)."}]},"type":"original","era":"after_approval","cycle":2,"n_app":4,"product":"BRIXADI","product_type":"not_classified","sponsor":"Braeburn Pharmaceuticals Inc."},{"id":"CRL_NDA213135_20200313","program":"braintree_laboratories","apps":["NDA213135"],"app":"NDA213135","date":"2020-03-13","file":"213135_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213135_2020_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Suflave","product_type":"not_classified","sponsor":"Braintree Laboratories, Inc."},{"id":"CRL_NDA215344_20220606","program":"braintree_laboratories","apps":["NDA215344"],"app":"NDA215344","date":"2022-06-06","file":"215344_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215344_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Suflave","product_type":"not_classified","sponsor":"Braintree Laboratories, Inc."},{"id":"CRL_NDA218600_20241021","program":"bridge_regulatory_affairs","apps":["NDA218600"],"app":"NDA218600","date":"2024-10-21","file":"CRL_NDA218600_20241021.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218600_20241021.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_NDA218600_20241021:p1:s24","page":1,"text":"Following resolution of the CGMP inspection, FDA may need to conduct a pre-approval inspection (PAI) of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"CAM2029 / Oclaiz (octreotide subcutaneous depot), Camurus","product_type":"505b2_new_formulation","sponsor":"Bridge Regulatory Affairs, LLC"},{"id":"CRL_NDA218600_20260610","program":"bridge_regulatory_affairs","apps":["NDA218600"],"app":"NDA218600","date":"2026-06-10","file":"CRL_NDA218600_20260610_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218600_20260610_Redacted.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC","NCL"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_NDA218600_20260610:p1:s19","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA Form 483 prior to your complete response."}]},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"CAM2029 / Oclaiz (octreotide subcutaneous depot), Camurus","product_type":"505b2_new_formulation","sponsor":"Bridge Regulatory Affairs, LLC"},{"id":"CRL_NDA202293_20120117","program":"bristol_myers_squibb","apps":["NDA202293"],"app":"NDA202293","date":"2012-01-17","file":"CRL_NDA202293_20120117.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA202293_20120117.pdf","cats":["EFF","SAF"],"cat_source":"rule","rule_cats":["EFF","SAF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA202293_20120117:p3:s10","page":3,"text":"To address the above deficiencies, you will need to submit additional clinical trial data to increase the patient-years of exposure to dapagliflozin and comparators."}],"SAF":[{"sid":"CRL_NDA202293_20120117:p3:s1","page":3,"text":"More importantly, we cannot include any suggested CV benefit observed in the original meta-analysis in a risk-benefit consideration in regard to the cancer and liver safety signals."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"dapagliflozin","product_type":"not_classified","sponsor":"Bristol-Myers Squibb"},{"id":"CRL_NDA022450_20100210","program":"cadence_pharmaceuticals","apps":["NDA022450"],"app":"NDA022450","date":"2010-02-10","file":"022450Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/022450Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Ofirmev","product_type":"not_classified","sponsor":"Cadence Pharmaceuticals"},{"id":"CRL_NDA208232_20160415","program":"camargo_pharmaceutical_services","apps":["NDA208232"],"app":"NDA208232","date":"2016-04-15","file":"208232_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208232_2020_Orig1s000OtherActionLtrs.pdf","cats":["CLP"],"cat_source":"rule","rule_cats":["CLP"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA208232_20160415:p1:s35","page":1,"text":"Although meeting strict criteria for bioequivalence is not required for products reviewed under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, absence of bioequivalence between Mycapssa and the listed drug necessitated that you demonstrate the safety and effectiveness of Mycapssa with data generated in study CH-ACM-01."},{"sid":"CRL_NDA208232_20160415:p1:s29","page":1,"text":"89.78% failed to meet the bioequivalence criteria."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Mycapssa","product_type":"not_classified","sponsor":"Camargo Pharmaceutical Services"},{"id":"CRL_UNKNOWN_20250709","program":"capricor","apps":["BLA125842"],"app":"BLA125842","date":"2025-07-09","file":"CRL_BLA125842_20250709.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125842_20250709.pdf","cats":["CMC","EFF"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"yes","passages":{"EFF":[{"sid":"CRL_UNKNOWN_20250709:p1:s21","page":1,"text":"However, as outlined below, these post hoc analyses are not sufficient to provide substantial evidence of effectiveness to support approval of deramiocel."},{"sid":"CRL_UNKNOWN_20250709:p1:s37","page":1,"text":"Service Act (PHS Act) require substantial evidence of effectiveness from adequate and well-controlled studies to support a marketing application of a drug or biological product."},{"sid":"CRL_UNKNOWN_20250709:p1:s31","page":1,"text":"These 50 secondary and exploratory endpoints were not prespecified for hypothesis testing, and no prespecified multiplicity adjustment strategy was employed for control of the overall Type 1 error rate."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"deramiocel (CAP-1002), allogeneic cardiosphere-derived cell therapy for DMD cardiomyopathy","product_type":"novel","sponsor":"Capricor, Inc."},{"id":"CRL_BLA761219_20211124","program":"celitrion","apps":["BLA761219"],"app":"BLA761219","date":"2021-11-24","file":"761219_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761219_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","DEV","FAC"],"cat_source":"rule","rule_cats":["CMC","DEV","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"CT-P17","product_type":"not_classified","sponsor":"Celitrion, Inc."},{"id":"CRL_BLA761219_20221123","program":"celitrion","apps":["BLA761219"],"app":"BLA761219","date":"2022-11-23","file":"761219_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761219_2023_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"CT-P17","product_type":"not_classified","sponsor":"Celitrion, Inc."},{"id":"CRL_UNKNOWN_20210818","program":"celltrans","apps":["BLA125734"],"app":"BLA125734","date":"2021-08-18","file":"CRL_BLA125734_20210818.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125734_20210818.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"FAC":[{"sid":"CRL_UNKNOWN_20210818:p1:s17","page":1,"text":"CellTrans Inc. manufacturing facility between June 7, 2021 to June 11, 2021, as detailed in Form FDA 483 issued to you on June 11, 2021, have yet to be resolved."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":null,"product_type":"not_classified","sponsor":"CellTrans Inc."},{"id":"CRL_BLA761088_20180228","program":"celltrion","apps":["BLA761088"],"app":"BLA761088","date":"2018-02-28","file":"761088_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761088_2018_Orig1s000OtherActionLtrs.pdf","cats":["CMC","EFF","FAC"],"cat_source":"rule","rule_cats":["CMC","EFF","FAC"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_BLA761088_20180228:p1:s24","page":1,"text":"You have not provided adequate information and scientific justification that Study CT-P10 3.3, in patients with advanced follicular lymphoma, is adequate to detect differences between the products, should they exist, to support a demonstration of no clinically meaningful differences between CT-P10 and US-licensed Rituxan in terms of the safety, purity, and potency of the product."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Steqeyma","product_type":"not_classified","sponsor":"CELLTRION, Inc."},{"id":"CRL_BLA761091_20180330","program":"celltrion","apps":["BLA761091"],"app":"BLA761091","date":"2018-03-30","file":"761091_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761091_2018_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC","FAC"],"cat_source":"rule","rule_cats":["CLP","CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Steqeyma","product_type":"not_classified","sponsor":"CELLTRION, Inc."},{"id":"CRL_BLA761377_20240627","program":"celltrion","apps":["BLA761377"],"app":"BLA761377","date":"2024-06-27","file":"CRL_BLA761377_20240627.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761377_20240627.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761377_20240627:p1:s38","page":1,"text":"Your complete response should include the date(s) of the facility's response to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"Eydenzelt (aflibercept-boav, CT-P42), aflibercept biosimilar","product_type":"biosimilar","sponsor":"CELLTRION, Inc."},{"id":"CRL_BLA761338_20240930","program":"celltrion","apps":["BLA761338"],"app":"BLA761338","date":"2024-09-30","file":"761338Orig1Orig2s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761338Orig1Orig2s000OtherActionLtrs.pdf","cats":["REG"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"STEQEYMA (ustekinumab-stba; CT-P43), ustekinumab biosimilar","product_type":"biosimilar","sponsor":"CELLTRION, Inc."},{"id":"CRL_BLA761338_20241217","program":"celltrion","apps":["BLA761338"],"app":"BLA761338","date":"2024-12-17","file":"761338Orig1Orig2s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761338Orig1Orig2s000OtherActionLtrs.pdf","cats":["REG"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"STEQEYMA (ustekinumab-stba; CT-P43), ustekinumab biosimilar","product_type":"biosimilar","sponsor":"CELLTRION, Inc."},{"id":"CRL_BLA761377_20250326","program":"celltrion","apps":["BLA761377"],"app":"BLA761377","date":"2025-03-26","file":"CRL_BLA761377_20250326.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761377_20250326.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"Eydenzelt (aflibercept-boav, CT-P42), aflibercept biosimilar","product_type":"biosimilar","sponsor":"CELLTRION, Inc."},{"id":"CRL_BLA761297_20231215","program":"checkpoint_therapeutics","apps":["BLA761297"],"app":"BLA761297","date":"2023-12-15","file":"761297_2025_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761297_2025_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{"FAC":[{"sid":"CRL_BLA761297_20231215:p1:s17","page":1,"text":"Satisfactory responses to these deficiencies should be provided by the facility to the email address provided on he Form FDA 483 Inspectional Observations, prior to submitting your complete response."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"cosibelimab","product_type":"not_classified","sponsor":"Checkpoint Therapeutics, Incorporated"},{"id":"CRL_NDA203202_20120328","program":"chelsea_therapeutics","apps":["NDA203202"],"app":"NDA203202","date":"2012-03-28","file":"CRL_NDA203202_20120328.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA203202_20120328.pdf","cats":["CLP","CMC","EFF"],"cat_source":"rule","rule_cats":["CLP","CMC","EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA203202_20120328:p1:s27","page":1,"text":"Accordingly, the primary endpoint of study 301 was changed to the composite OHQ score."},{"sid":"CRL_NDA203202_20120328:p1:s46","page":1,"text":"The finding on the primary endpoint is statistically persuasive."},{"sid":"CRL_NDA203202_20120328:p2:s3","page":2,"text":"Despite the enrichment strategy used in studies 302 and 303 to select subjects who both respond to and tolerate the drug, neither study succeeded on its primary endpoint."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"NORTHERA","product_type":"not_classified","sponsor":"Chelsea Therapeutics, Inc."},{"id":"CRL_NDA219029_20250529","program":"chemo_research_sl","apps":["NDA219029"],"app":"NDA219029","date":"2025-05-29","file":"CRL_NDA219029_20250529.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA219029_20250529.pdf","cats":["SAF"],"cat_source":"coded","rule_cats":["SAF"],"new_trial":"no","passages":{"SAF":[{"sid":"CRL_NDA219029_20250529:p1:s15","page":1,"text":"1. Review of the safety database from Study LPRI-424/303 clearly demonstrates a markedly increased risk of venous thromboembolism (VTE) rate."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"LPRI-424, dienogest/ethinyl estradiol 2 mg/0.02 mg extended-release COC tablets","product_type":"505b2_new_formulation","sponsor":"Chemo Research, S.L."},{"id":"CRL_NDA202049_20190619","program":"chiesi_usa","apps":["NDA202049"],"app":"NDA202049","date":"2019-06-19","file":"202049_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/202049_2021_Orig1s000OtherActionLtrs.pdf","cats":["DEV"],"cat_source":"rule","rule_cats":["DEV"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA202049_20190619:p1:s17","page":1,"text":"The submitted data from the human factors (HF) validation studies do not provide sufficient evidence to demonstrate that healthcare providers can reliably and accurately perform the Mannitol Tolerance Test (MTT) to correctly identify the intended target patient population."}]},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"PRX-102","product_type":"not_classified","sponsor":"Pharmaxis Ltd."},{"id":"CRL_BLA761161_20210427","program":"chiesi_usa","apps":["BLA761161"],"app":"BLA761161","date":"2021-04-27","file":"761161_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761161_2023_Orig1s000OtherActionLtrs.pdf","cats":["AAP","EFF","SAF"],"cat_source":"rule","rule_cats":["AAP","EFF","SAF"],"new_trial":null,"passages":{"AAP":[{"sid":"CRL_BLA761161_20210427:p1:s34","page":1,"text":"Prior to your resubmission, we recommend an End-of-Review meeting to discuss whether accelerated approval remains an appropriate pathway for your product."},{"sid":"CRL_BLA761161_20210427:p1:s25","page":1,"text":"You requested accelerated approval of PRX-102 based on a reduction in renal peritubular capillary globotriaosylceramide (Gb3) inclusions."},{"sid":"CRL_BLA761161_20210427:p1:s32","page":1,"text":"Your product will no longer qualify for accelerated approval if it does not provide a therapeutic advantage over available therapy."}],"EFF":[{"sid":"CRL_BLA761161_20210427:p1:s36","page":1,"text":"An alternative approach to seeking accelerated approval may be to establish that the reduction in renal Gb3 inclusions with PRX-102 predicts clinical benefit, allowing for full approval of your product."}],"SAF":[{"sid":"CRL_BLA761161_20210427:p3:s21","page":3,"text":"You also have not provided sufficient reasoning for excluding adverse events that you considered related to the infusion procedure rather than PRX-102. You have also not provided a clear narrative regarding premedication that was given in your safety database."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"PRX-102","product_type":"not_classified","sponsor":"Chiesi USA, Inc."},{"id":"CRL_NDA220283_20260529","program":"cingulate_therapeutics","apps":["NDA220283"],"app":"NDA220283","date":"2026-05-29","file":"CRL_NDA220283_20260529_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA220283_20260529_Redacted.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"CTx-1301, dexmethylphenidate HCl extended-release tablets","product_type":"505b2_new_formulation","sponsor":"Cingulate Therapeutics, LLC"},{"id":"CRL_NDA210168_20240322","program":"cipla_usa","apps":["NDA210168"],"app":"NDA210168","date":"2024-03-22","file":"CRL_NDA210168_20240322.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA210168_20240322.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"unknown (Cipla USA NDA, product redacted)","product_type":"unknown","sponsor":"Cipla USA, Inc."},{"id":"CRL_NDA210168_20250620","program":"cipla_usa","apps":["NDA210168"],"app":"NDA210168","date":"2025-06-20","file":"CRL_NDA210168_20250620.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA210168_20250620.pdf","cats":["CMC"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"unclear","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"unknown (Cipla USA NDA, product redacted)","product_type":"unknown","sponsor":"Cipla USA, Inc."},{"id":"CRL_BLA761312_20230728","program":"citius_pharmaceuticals","apps":["BLA761312"],"app":"BLA761312","date":"2023-07-28","file":"761312Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761312Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Lymphir","product_type":"not_classified","sponsor":"Citius Pharmaceuticals, Inc."},{"id":"CRL_NDA206089_20141103","program":"clarus_therapeutics","apps":["NDA206089"],"app":"NDA206089","date":"2014-11-03","file":"206089_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206089_2019_Orig1s000OtherActionLtrs.pdf","cats":["CLP"],"cat_source":"rule","rule_cats":["CLP"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA206089_20141103:p4:s36","page":4,"text":"Based on physicochemical properties, it is possible that alcohol will solubilize your product, leading to increased absorption via the portal vein, a high first pass effect, and reduced TU bioavailability."},{"sid":"CRL_NDA206089_20141103:p4:s37","page":4,"text":"However, it is also possible that alcohol could instead enhance absorption via the lymphatics, leading to increased bioavailability of TU."}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"testosterone undecanoate","product_type":"not_classified","sponsor":"Clarus Therapeutics, Inc."},{"id":"CRL_NDA206089_20180322","program":"clarus_therapeutics","apps":["NDA206089"],"app":"NDA206089","date":"2018-03-22","file":"206089_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206089_2019_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"testosterone undecanoate","product_type":"not_classified","sponsor":"Clarus Therapeutics, Inc."},{"id":"CRL_NDA208574_20191104","program":"class_2_resubmission","apps":["NDA208574"],"app":"NDA208574","date":"2019-11-04","file":"208574Orig1s000,Orig2s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208574Orig1s000%2COrig2s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"Romidepsin","product_type":"not_classified","sponsor":"Teva Pharmaceuticals USA"},{"id":"CRL_NDA211950_20191018","program":"clearside_biomedical","apps":["NDA211950"],"app":"NDA211950","date":"2019-10-18","file":"211950_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211950_2022_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"XIPERE","product_type":"not_classified","sponsor":"Clearside Biomedical, Inc."},{"id":"CRL_NDA213260_20201016","program":"cmp_development","apps":["NDA213260"],"app":"NDA213260","date":"2020-10-16","file":"213260_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213260_2023_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC","FAC"],"cat_source":"rule","rule_cats":["CLP","CMC","FAC"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA213260_20201016:p2:s12","page":2,"text":"4. Reformulate the proposed product and conduct additional relative bioavailability studies to demonstrate the bioequivalence to the listed drug or conduct a Clinical study to support the effective and safe use of the proposed atorvastatin oral suspension product."},{"sid":"CRL_NDA213260_20201016:p1:s27","page":1,"text":"4. Since the application does not contain clinical efficacy and safety data for the proposed atorvastatin calcium oral suspension (proposed product), relative bioavailability results are the fundamental bridge to the efficacy and safety data of the listed drug product."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sildenafil","product_type":"not_classified","sponsor":"CMP Development LLC"},{"id":"CRL_NDA214522_20210223","program":"cmp_development","apps":["NDA214522"],"app":"NDA214522","date":"2021-02-23","file":"214522_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214522_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sildenafil","product_type":"not_classified","sponsor":"CMP Development LLC"},{"id":"CRL_NDA214439_20210422","program":"cmp_development","apps":["NDA214439"],"app":"NDA214439","date":"2021-04-22","file":"214439_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214439_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sildenafil","product_type":"not_classified","sponsor":"CMP Development LLC"},{"id":"CRL_NDA214952_20220428","program":"cmp_development","apps":["NDA214952"],"app":"NDA214952","date":"2022-04-28","file":"214952_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214952_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sildenafil","product_type":"not_classified","sponsor":"CMP Development LLC"},{"id":"CRL_BLA761039_20170609","program":"coherus_biosciences","apps":["BLA761039"],"app":"BLA761039","date":"2017-06-09","file":"761039_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761039_2018_Orig1s000OtherActionLtrs.pdf","cats":["CMC","EFF"],"cat_source":"rule","rule_cats":["CMC","EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_BLA761039_20170609:p1:s25","page":1,"text":"Your observed difference in ADA between groups may not be sufficient to support a demonstration that there are no clinically meaningful differences between CHS-1701 and US-licensed Neulasta."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"toripalimab-tpzi","product_type":"not_classified","sponsor":"Coherus BioSciences, Inc."},{"id":"CRL_BLA761240_20220429","program":"coherus_biosciences","apps":["BLA761240"],"app":"BLA761240","date":"2022-04-29","file":"761240_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761240_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"toripalimab-tpzi","product_type":"not_classified","sponsor":"Coherus BioSciences, Inc."},{"id":"CRL_NDA218923_20241010","program":"conjupro_biotherapeutics","apps":["NDA218923"],"app":"NDA218923","date":"2024-10-10","file":"CRL_NDA218923_20241010.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218923_20241010.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_NDA218923_20241010:p1:s21","page":1,"text":"FDA Form 483. If the FDA determines the deficiencies resolved following a full review of the inspection and 483 responses after this Complete Response Letter, the facility will be informed."}]},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"irinotecan liposome injection (CSPC/Conjupro), Onivyde-referencing","product_type":"505b2_copy","sponsor":"Conjupro Biotherapeutics Inc."},{"id":"CRL_NDA218923_20250730","program":"conjupro_biotherapeutics","apps":["NDA218923"],"app":"NDA218923","date":"2025-07-30","file":"CRL_NDA218923_20250730.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218923_20250730.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_NDA218923_20250730:p1:s22","page":1,"text":"Your complete response should include the date(s) of the facility's response to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"irinotecan liposome injection (CSPC/Conjupro), Onivyde-referencing","product_type":"505b2_copy","sponsor":"Conjupro Biotherapeutics Inc."},{"id":"CRL_NDA018680_20231218","program":"coopersurgical","apps":["NDA018680"],"app":"NDA018680","date":"2023-12-18","file":"018680-s074_OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/018680-s074_OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"supplement","era":"after_approval","cycle":1,"n_app":1,"product":"Paragard","product_type":"not_classified","sponsor":"CooperSurgical, Inc."},{"id":"CRL_NDA219398_20260128","program":"corcept_therapeutics","apps":["NDA219398"],"app":"NDA219398","date":"2026-01-28","file":"CRL_NDA219398_20260128.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA219398_20260128.pdf","cats":["EFF","SAF"],"cat_source":"coded","rule_cats":["EFF","SAF"],"new_trial":"yes","passages":{"EFF":[{"sid":"CRL_NDA219398_20260128:p2:s21","page":2,"text":"As substantial evidence of effectiveness was not demonstrated we are unable to conduct a final benefit risk assessment for relacorilant for the proposed indication."}],"SAF":[{"sid":"CRL_NDA219398_20260128:p2:s21","page":2,"text":"As substantial evidence of effectiveness was not demonstrated we are unable to conduct a final benefit risk assessment for relacorilant for the proposed indication."},{"sid":"CRL_NDA219398_20260128:p3:s9","page":3,"text":"Based on the currently available information, we cannot conclude that relacorilant has a favorable benefit risk assessment for the proposed indication."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"relacorilant, selective glucocorticoid receptor modulator for hypercortisolism","product_type":"novel","sponsor":"Corcept Therapeutics"},{"id":"CRL_NDA212304_20200723","program":"corium","apps":["NDA212304"],"app":"NDA212304","date":"2020-07-23","file":"212304_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212304_2022_Orig1s000OtherActionLtrs.pdf","cats":["CLP","EFF"],"cat_source":"rule","rule_cats":["CLP","EFF"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA212304_20200723:p2:s4","page":2,"text":"To demonstrate the product at the beginning of shelf life is equivalent to product at the end of shelf life, you should conduct a bioequivalence study on product near the beginning of shelf life comparing it to product near the end of the proposed shelf-life."},{"sid":"CRL_NDA212304_20200723:p2:s5","page":2,"text":"Alternatively, you should develop a formulation which exhibits greater stability with respect to excipient degradation, migration, ® etc. We also refer you to Complete Response deficiency #3, which recommends a new bioequivalence study with oral Aricept, and Complete Response deficiency #1, which may result in a reformulation."},{"sid":"CRL_NDA212304_20200723:p2:s12","page":2,"text":"Bioequivalence (BE) and Registration Product Comparison, compared batches with different manufacturing processes, active product ingredient particle sizes, storage times, and storage temperatures in addition to scale changes."}],"EFF":[{"sid":"CRL_NDA212304_20200723:p3:s44","page":3,"text":"The clinical relevance of these lower concentrations is not known, and to ensure clinical benefit, oral supplementation with 5 mg/day ARICEPT may be required during the first 2 weeks of oral-totransdermal system switch."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"ADLARITY","product_type":"not_classified","sponsor":"Corium, Inc."},{"id":"CRL_NDA214520_20210226","program":"cormedix","apps":["NDA214520"],"app":"NDA214520","date":"2021-02-26","file":"214520_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214520_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"taurolidine","product_type":"not_classified","sponsor":"CorMedix Inc."},{"id":"CRL_NDA214520_20220804","program":"cormedix","apps":["NDA214520"],"app":"NDA214520","date":"2022-08-04","file":"214520_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214520_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"taurolidine","product_type":"not_classified","sponsor":"CorMedix Inc."},{"id":"CRL_BLA761367_20241007","program":"csl_behring","apps":["BLA761367"],"app":"BLA761367","date":"2024-10-07","file":"761367Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761367Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761367_20241007:p1:s17","page":1,"text":"1. Following pre-license inspection of CSL Behring GmbH, Emil-von-BehringStrasse 76, Marburg, Hesse, Germany (FEI 3003098680), listed in this application, the FDA conveyed the deficiencies to the representative of the facility."},{"sid":"CRL_BLA761367_20241007:p1:s19","page":1,"text":"Your complete response should include the date(s) of the facility's response to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"CSL312, garadacimab (Andembry)","product_type":"novel","sponsor":"CSL Behring LLC"},{"id":"CRL_NDA022335_20210625","program":"cyclomedica_australia","apps":["NDA022335"],"app":"NDA022335","date":"2021-06-25","file":"022335Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/022335Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA022335_20210625:p4:s1","page":4,"text":"Also note our recommendation to cover the to-be-marketed range of sodium pertechnetate Tc 99m loadings from minimum to maximum when conducting new CMC investigation under CMC Issue #1."},{"sid":"CRL_NDA022335_20210625:p4:s10","page":4,"text":"CMC investigation under Product Quality Issue #1."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":null,"product_type":"not_classified","sponsor":"Cyclomedica Australia Pty Ltd."},{"id":"CRL_NDA210895_20180824","program":"daiichi_sankyo","apps":["NDA210895"],"app":"NDA210895","date":"2018-08-24","file":"210895_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210895_2019_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA210895_20180824:p1:s16","page":1,"text":"We also acknowledge receipt of your amendment dated May 31, 2018, containing additional chemistry, manufacturing and controls information which was not reviewed for this action."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"this action below","product_type":"not_classified","sponsor":"Daiichi Sankyo, Inc."},{"id":"CRL_BLA761366_20240626","program":"daiichi_sankyo","apps":["BLA761366"],"app":"BLA761366","date":"2024-06-26","file":"CRL_BLA761366_20240626.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761366_20240626.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["AAP","FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761366_20240626:p1:s17","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA Form 483 prior to your resubmission of the application."},{"sid":"CRL_BLA761366_20240626:p1:s15","page":1,"text":"1. Following pre-license inspection of Ch)"},{"sid":"CRL_BLA761366_20240626:p1:s18","page":1,"text":"Your resubmission should include the date(s) of the facility's response to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies will be evaluated upon receipt of the resubmission and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"patritumab deruxtecan (HER3-DXd), HER3-directed ADC","product_type":"novel","sponsor":"Daiichi Sankyo, Inc."},{"id":"CRL_UNKNOWN_20200803","program":"dbv_technologies","apps":["BLA125713"],"app":"BLA125713","date":"2020-08-03","file":"CRL_BLA125713_20200803.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125713_20200803.pdf","cats":["CMC","DEV","EFF","SAF"],"cat_source":"rule","rule_cats":["CMC","DEV","EFF","SAF"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_UNKNOWN_20200803:p2:s14","page":2,"text":"Based on the submitted human factors (HF) study results, including the root cause analysis, study participants' subjective feedback, and your analysis of the results, we have determined that the product user interface does not support safe and effective use."},{"sid":"CRL_UNKNOWN_20200803:p2:s12","page":2,"text":"Human Factors Consult review deficiencies identified:"}],"SAF":[{"sid":"CRL_UNKNOWN_20200803:p2:s11","page":2,"text":"Ultimately, the impact of adhesion performance on effectiveness and safety will be considered as part of the benefit-risk framework in our review of a licensure application for a re-designed product."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":null,"product_type":"not_classified","sponsor":"DBV Technologies S.A."},{"id":"CRL_NDA214315_20240125","program":"defender_pharmaceuticals","apps":["NDA214315"],"app":"NDA214315","date":"2024-01-25","file":"CRL_NDA214315_20240125.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA214315_20240125.pdf","cats":["CMC","DEV"],"cat_source":"coded","rule_cats":["CMC","DEV"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"DPI-386, scopolamine intranasal gel","product_type":"505b2_new_formulation","sponsor":"Defender Pharmaceuticals, Inc"},{"id":"CRL_NDA201848_20130912","program":"delcath_systems","apps":["NDA201848"],"app":"NDA201848","date":"2013-09-12","file":"201848_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/201848_2024_Orig1s000OtherActionLtrs.pdf","cats":["CLP","DEV","FAC"],"cat_source":"rule","rule_cats":["CLP","DEV","FAC"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA201848_20130912:p6:s13","page":6,"text":"15. The NDA cannot be approved because the methods to be used in, and the facilities and controls used for, the manufacture, processing, packing, or holding of the drug substance or the drug product are inadequate to preserve its identity, strength, quality, purity, stability, and bioavailability [21 CFR 314.125(b)(1)]."}],"DEV":[{"sid":"CRL_NDA201848_20130912:p6:s21","page":6,"text":"16. | The Human Factors engineering summary report indicated that the product design and labeling were modified after completion of clinical studies in order to address six userelated hazards observed."},{"sid":"CRL_NDA201848_20130912:p7:s1","page":7,"text":"The purpose of a human factors validation study is to demonstrate that the device can be used by representative users under simulated use conditions without producing patterns of failures that could result in negative clinical impact to patients or injury to device users."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Melblez","product_type":"not_classified","sponsor":"Delcath Systems, Incorporated"},{"id":"CRL_NDA220707_20260213","program":"disc_medicine","apps":["NDA220707"],"app":"NDA220707","date":"2026-02-13","file":"CRL_NDA220707_20260213.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA220707_20260213.pdf","cats":["AAP"],"cat_source":"coded","rule_cats":["AAP","EFF"],"new_trial":"yes","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"bitopertin tablets for erythropoietic protoporphyria","product_type":"novel","sponsor":"Disc Medicine, Inc."},{"id":"CRL_NDA209354_20180615","program":"dow_pharmaceutical_sciences","apps":["NDA209354"],"app":"NDA209354","date":"2018-06-15","file":"209354_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209354_2019_Orig1s000OtherActionLtrs.pdf","cats":["CLP","NCL"],"cat_source":"rule","rule_cats":["CLP","NCL"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA209354_20180615:p1:s22","page":1,"text":"In particular, the relative bioavailability assessment showed that the bioavailability of the proposed combination product, halobetasol propionate and tazarotene lotion, 0.01%/0.045%, was higher than each of the listed drugs for the individual monads."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"halobetasol propionate","product_type":"not_classified","sponsor":"Dow Pharmaceutical Sciences, Inc."},{"id":"CRL_NDA206927_20141217","program":"dr_reddys_laboratories","apps":["NDA206927"],"app":"NDA206927","date":"2014-12-17","file":"206927_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206927_2019_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC"],"cat_source":"rule","rule_cats":["CLP","CMC"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA206927_20141217:p1:s39","page":1,"text":"2. The waiver request for the CFR requirement to provide data from an in vivo bioequivalence study for the intravenous route of administration cannot be granted at this time due to outstanding issues with the identity of the drug substance (refer to DMF) and the identity of the structures in the drug product and reconstituted solution."},{"sid":"CRL_NDA206927_20141217:p1:s40","page":1,"text":"You may resubmit the biowaiver request or alternatively you may conduct a bioequivalence study between the proposed drug product and the listed drug product for the intravenous route of administration."}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"AVT03","product_type":"not_classified","sponsor":"Dr. Reddy’s Laboratories, Inc."},{"id":"CRL_NDA206927_20160504","program":"dr_reddys_laboratories","apps":["NDA206927"],"app":"NDA206927","date":"2016-05-04","file":"206927_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206927_2019_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC","FAC"],"cat_source":"rule","rule_cats":["CLP","CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"AVT03","product_type":"not_classified","sponsor":"Dr. Reddy’s Laboratories, Inc."},{"id":"CRL_NDA206966_20160830","program":"dr_reddys_laboratories","apps":["NDA206966"],"app":"NDA206966","date":"2016-08-30","file":"206966_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206966_2020_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"AVT03","product_type":"not_classified","sponsor":"Dr. Reddy’s Laboratories, Inc."},{"id":"CRL_NDA210852_20180724","program":"dr_reddys_laboratories","apps":["NDA210852"],"app":"NDA210852","date":"2018-07-24","file":"210852_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210852_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":6,"product":"AVT03","product_type":"not_classified","sponsor":"Dr. Reddy’s Laboratories, Inc."},{"id":"CRL_NDA210852_20190503","program":"dr_reddys_laboratories","apps":["NDA210852"],"app":"NDA210852","date":"2019-05-03","file":"210852_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210852_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":6,"product":"AVT03","product_type":"not_classified","sponsor":"Dr. Reddy’s Laboratories, Inc."},{"id":"CRL_NDA210852_20191120","program":"dr_reddys_laboratories","apps":["NDA210852"],"app":"NDA210852","date":"2019-11-20","file":"210852_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210852_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":6,"product":"AVT03","product_type":"not_classified","sponsor":"Dr. Reddy’s Laboratories, Inc."},{"id":"CRL_NDA210852_20200521","program":"dr_reddys_laboratories","apps":["NDA210852"],"app":"NDA210852","date":"2020-05-21","file":"210852_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210852_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":4,"n_app":6,"product":"AVT03","product_type":"not_classified","sponsor":"Dr. Reddy’s Laboratories, Inc."},{"id":"CRL_NDA210852_20201106","program":"dr_reddys_laboratories","apps":["NDA210852"],"app":"NDA210852","date":"2020-11-06","file":"210852_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210852_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":5,"n_app":6,"product":"AVT03","product_type":"not_classified","sponsor":"Dr. Reddy’s Laboratories, Inc."},{"id":"CRL_NDA210852_20220418","program":"dr_reddys_laboratories","apps":["NDA210852"],"app":"NDA210852","date":"2022-04-18","file":"210852_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210852_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":6,"n_app":6,"product":"AVT03","product_type":"not_classified","sponsor":"Dr. Reddy’s Laboratories, Inc."},{"id":"CRL_BLA761376_20240419","program":"dr_reddys_laboratories","apps":["BLA761376"],"app":"BLA761376","date":"2024-04-19","file":"CRL_BLA761376_20240419.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761376_20240419.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"ZIMRIXBY (rituximab-cdxx; DRL_RI), rituximab biosimilar","product_type":"biosimilar","sponsor":"Dr. Reddy’s Laboratories, Inc."},{"id":"CRL_BLA761376_20251016","program":"dr_reddys_laboratories","apps":["BLA761376"],"app":"BLA761376","date":"2025-10-16","file":"CRL_BLA761376_20251016.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761376_20251016.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"ZIMRIXBY (rituximab-cdxx; DRL_RI), rituximab biosimilar","product_type":"biosimilar","sponsor":"Dr. Reddy’s Laboratories, Inc."},{"id":"CRL_BLA761471_20251230","program":"dr_reddys_laboratories","apps":["BLA761471"],"app":"BLA761471","date":"2025-12-30","file":"CRL_BLA761471_20251230.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761471_20251230.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"AVT03, denosumab biosimilar (Prolia/Xgeva), Alvotech/Dr. Reddy's","product_type":"biosimilar","sponsor":"Dr. Reddy’s Laboratories, Inc."},{"id":"CRL_NDA204803_20140212","program":"durect","apps":["NDA204803"],"app":"NDA204803","date":"2014-02-12","file":"204803_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/204803_2022_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"POSIMIR","product_type":"not_classified","sponsor":"DURECT Corporation"},{"id":"CRL_NDA220045_20260413","program":"eagle_pharmaceuticals","apps":["NDA220045"],"app":"NDA220045","date":"2026-04-13","file":"CRL_NDA220045_20260413_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA220045_20260413_Redacted.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_NDA220045_20260413:p1:s18","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to our office indicated on the FDA Form 483 prior to your complete response."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Fulvestrant injection (Eagle)","product_type":"unknown","sponsor":"Eagle Pharmaceuticals, Inc."},{"id":"CRL_NDA205054_20150529","program":"elc_group","apps":["NDA205054"],"app":"NDA205054","date":"2015-05-29","file":"205054Orig1s000OtherActionLtr.pdf","url":"https://download.open.fda.gov/crl/205054Orig1s000OtherActionLtr.pdf","cats":["AAP","CMC","EFF","FAC"],"cat_source":"rule","rule_cats":["AAP","CMC","EFF","FAC"],"new_trial":null,"passages":{"AAP":[{"sid":"CRL_NDA205054_20150529:p1:s18","page":1,"text":"1. In the approval of gonadotropin releasing hormone agonists for the palliative treatment of advanced prostate cancer, testosterone levels serve as a surrogate marker of efficacy."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Lutrate®","product_type":"not_classified","sponsor":"ELC Group"},{"id":"CRL_NDA216586_20240516","program":"elevar_therapeutics","apps":["NDA216586"],"app":"NDA216586","date":"2024-05-16","file":"CRL_NDA216586_20240516.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA216586_20240516.pdf","cats":["FAC","REG"],"cat_source":"coded","rule_cats":[],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":3,"product":"rivoceranib (apatinib) tablets, with camrelizumab for 1L uHCC","product_type":"novel","sponsor":"Elevar Therapeutics, Inc."},{"id":"CRL_NDA216586_20250320","program":"elevar_therapeutics","apps":["NDA216586"],"app":"NDA216586","date":"2025-03-20","file":"CRL_NDA216586_20250320.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA216586_20250320.pdf","cats":["REG"],"cat_source":"coded","rule_cats":[],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":3,"product":"rivoceranib (apatinib) tablets, with camrelizumab for 1L uHCC","product_type":"novel","sponsor":"Elevar Therapeutics, Inc."},{"id":"CRL_NDA216586_20260709","program":"elevar_therapeutics","apps":["NDA216586"],"app":"NDA216586","date":"2026-07-09","file":"CRL_NDA216586_20260709_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA216586_20260709_Redacted.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":3,"n_app":3,"product":"rivoceranib (apatinib) tablets, with camrelizumab for 1L uHCC","product_type":"novel","sponsor":"Elevar Therapeutics, Inc."},{"id":"CRL_BLA761215_20211217","program":"eli_lilly","apps":["BLA761215"],"app":"BLA761215","date":"2021-12-17","file":"761215Orig2s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761215Orig2s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"lebrikizumab","product_type":"not_classified","sponsor":"Eli Lilly and Company"},{"id":"CRL_BLA761215_20211217_2","program":"eli_lilly","apps":["BLA761215"],"app":"BLA761215","date":"2021-12-17","file":"Pages from 761215Orig2s000.pdf","url":"https://download.open.fda.gov/crl/Pages%20from%20761215Orig2s000.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"lebrikizumab","product_type":"not_classified","sponsor":"Eli Lilly and Company"},{"id":"CRL_BLA761248_20230118","program":"eli_lilly","apps":["BLA761248"],"app":"BLA761248","date":"2023-01-18","file":"761248_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761248_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","SAF"],"cat_source":"rule","rule_cats":["CMC","SAF"],"new_trial":null,"passages":{"SAF":[{"sid":"CRL_BLA761248_20230118:p1:s29","page":1,"text":"A future resubmission intended to adequately characterize the long-term safety of Kisunla would likely need to include the unblinded controlled safety data from Study AACI, once it is completed, as we are not aware of other extant or pending safety data that have the potential to adequately characterize the long-term safety of Kisunla."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"lebrikizumab","product_type":"not_classified","sponsor":"Eli Lilly and Company"},{"id":"CRL_BLA761279_20230330","program":"eli_lilly","apps":["BLA761279"],"app":"BLA761279","date":"2023-03-30","file":"761279_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761279_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"lebrikizumab","product_type":"not_classified","sponsor":"Eli Lilly and Company"},{"id":"CRL_BLA761306_20230928","program":"eli_lilly","apps":["BLA761306"],"app":"BLA761306","date":"2023-09-28","file":"761306_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761306_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"FAC":[{"sid":"CRL_BLA761306_20230928:p1:s21","page":1,"text":"RRA and conducted a pre-license inspection (PLI) to further evaluate the facility."},{"sid":"CRL_BLA761306_20230928:p1:s25","page":1,"text":"Your complete response should include the date of the facility's response to the FDA Form 483. The assessment of the application approvability and resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include a re-inspection of the facility."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"lebrikizumab","product_type":"not_classified","sponsor":"Eli Lilly and Company"},{"id":"CRL_NDA022561_20110228","program":"emd_serono","apps":["NDA022561"],"app":"NDA022561","date":"2011-02-28","file":"022561Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/022561Orig1s000OtherActionLtrs.pdf","cats":["CMC","EFF","SAF"],"cat_source":"rule","rule_cats":["CMC","EFF","SAF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA022561_20110228:p1:s30","page":1,"text":"We believe that the data, taken as a whole, meet the standard for substantial evidence of effectiveness, as provided by one adequate and well controlled clinical trial and confirmatory evidence."},{"sid":"CRL_NDA022561_20110228:p1:s26","page":1,"text":"Substantial evidence of cladribine's effectiveness was provided by the CLARITY study."}],"SAF":[{"sid":"CRL_NDA022561_20110228:p1:s38","page":1,"text":"When considering the entire safety database, in completed studies of cladribine and ongoing controlled studies of cladribine, there were 33 cases of malignancy in cladribine-treated subjects and two in placebo-treated subjects."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"cladribine","product_type":"not_classified","sponsor":"EMD Serono, Inc."},{"id":"CRL_NDA210526_20210121","program":"emory_partners","apps":["NDA210526"],"app":"NDA210526","date":"2021-01-21","file":"210526_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210526_2022_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"Dyanavel XR","product_type":"not_classified","sponsor":"Tris Pharma, Inc."},{"id":"CRL_NDA213426_20200615","program":"esteve_pharmaceuticals","apps":["NDA213426"],"app":"NDA213426","date":"2020-06-15","file":"213426_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213426_2022_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"celecoxib","product_type":"not_classified","sponsor":"Esteve Pharmaceuticals, S.A."},{"id":"CRL_NDA216900_20260626","program":"evergreen_theragnostics","apps":["NDA216900"],"app":"NDA216900","date":"2026-06-26","file":"CRL_NDA216900_20260626_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA216900_20260626_Redacted.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"unclear","passages":{"FAC":[{"sid":"CRL_NDA216900_20260626:p1:s44","page":1,"text":"FDA may need to conduct a pre-approval inspection (PAI) of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Kit for preparation of gallium Ga 68 edotreotide injection (LNTH-2501; Evergreen/Lantheus)","product_type":"505b2_new_formulation","sponsor":"Evergreen Theragnostics, Inc."},{"id":"CRL_NDA208352_20160428","program":"evofem","apps":["NDA208352"],"app":"NDA208352","date":"2016-04-28","file":"208352_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208352_2020_Orig1s000OtherActionLtrs.pdf","cats":["DEV","FAC"],"cat_source":"rule","rule_cats":["DEV","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Amphora","product_type":"not_classified","sponsor":"Evofem, Inc."},{"id":"CRL_NDA209388_20190401","program":"evoke_pharma","apps":["NDA209388"],"app":"NDA209388","date":"2019-04-01","file":"209388_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209388_2021_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC","DEV"],"cat_source":"rule","rule_cats":["CLP","CMC","DEV"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Gimoti","product_type":"not_classified","sponsor":"Evoke Pharma, Inc."},{"id":"CRL_BLA761085_20180515","program":"evolus","apps":["BLA761085"],"app":"BLA761085","date":"2018-05-15","file":"761085_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761085_2019_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"otulinum toxin Type A","product_type":"not_classified","sponsor":"Evolus, Inc."},{"id":"CRL_NDA215352_20211022","program":"eyenovia","apps":["NDA215352"],"app":"NDA215352","date":"2021-10-22","file":"215352_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215352_2023_Orig1s000OtherActionLtrs.pdf","cats":["CLP","DEV"],"cat_source":"rule","rule_cats":["CLP","DEV"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA215352_20211022:p3:s24","page":3,"text":"8. You have not submitted human factors validation study data to demonstrate that your user interface supports the safe and effective use of your product by the intended users, for intended uses, and in the intended use environment."},{"sid":"CRL_NDA215352_20211022:p3:s25","page":3,"text":"We recommend you include a comprehensive use-related risk analysis if you have not already completed one."},{"sid":"CRL_NDA215352_20211022:p3:s26","page":3,"text":"The comprehensive use-related risk analysis should include a comprehensive and systematic evaluation of all the steps involved in using your product (e.g., based on a task analysis) the errors that users might commit or the tasks they might fail to perform and the potential negative clinical consequences of use errors and task failures."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"MYDCOMBI","product_type":"not_classified","sponsor":"Eyenovia, Inc."},{"id":"CRL_NDA021164_20071102","program":"fabre_kramer_pharmaceuticals","apps":["NDA021164"],"app":"NDA021164","date":"2007-11-02","file":"021164Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/021164Orig1s000OtherActionLtrs.pdf","cats":["EFF"],"cat_source":"rule","rule_cats":["EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA021164_20071102:p1:s19","page":1,"text":"First you have failed to provide substantial evidence for the effectiveness of gepirone ER in the short-term or longer-term treatment of major depressive disorder (MDD)."},{"sid":"CRL_NDA021164_20071102:p2:s8","page":2,"text":"3.5%) and does not represent substantial evidence of effectiveness."},{"sid":"CRL_NDA021164_20071102:p1:s27","page":1,"text":"Although this was not the protocol specified primary endpoint for 3 of the 12 trials, we felt it was a reasonable common measure because it is so widely used as a primary endpoint in depression trials."}]},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"Gepirone Hydrochloride Extended Release","product_type":"not_classified","sponsor":"Organon, Inc."},{"id":"CRL_NDA200655_20160915","program":"feinstein_institute_for_medical_research","apps":["NDA200655"],"app":"NDA200655","date":"2016-09-15","file":"200655_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/200655_2019_Orig1s000OtherActionLtrs.pdf","cats":["EFF"],"cat_source":"rule","rule_cats":["EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA200655_20160915:p1:s25","page":1,"text":"This study does not provide sufficient confirmatory evidence of effectiveness and the Fluorodopa F 18 PET scan's performance is not adequately characterized."}]},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"Fluorodopa F","product_type":"not_classified","sponsor":"Thomas Chaly, Ph.D., FAIC"},{"id":"CRL_NDA212937_20200810","program":"fennec_pharmaceuticals","apps":["NDA212937"],"app":"NDA212937","date":"2020-08-10","file":"212937_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212937_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"PEDMARK","product_type":"not_classified","sponsor":"Fennec Pharmaceuticals, Inc."},{"id":"CRL_NDA212937_20211126","program":"fennec_pharmaceuticals","apps":["NDA212937"],"app":"NDA212937","date":"2021-11-26","file":"212937_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212937_2023_Orig1s000OtherActionLtrs.pdf","cats":["FAC","SAF"],"cat_source":"rule","rule_cats":["FAC","SAF"],"new_trial":null,"passages":{"SAF":[{"sid":"CRL_NDA212937_20211126:p1:s32","page":1,"text":"Provide an analysis of hypophosphatemia and hyponatremia in your safety database to support your conclusion that these treatment-emergent adverse events are not related to sodium thiosulfate injection to inform our decision-making regarding whether hypophosphatemia and hyponatremia should be described in Section 5 (Warnings and Precautions) of product labeling for sodium thiosulfate injection."}]},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"PEDMARK","product_type":"not_classified","sponsor":"Fennec Pharmaceuticals, Inc."},{"id":"CRL_NDA202408_20140331","program":"fera_pharmaceuticals","apps":["NDA202408"],"app":"NDA202408","date":"2014-03-31","file":"202408_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/202408_2019_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"Avaclyr","product_type":"not_classified","sponsor":"Fera Pharmaceuticals, LLC"},{"id":"CRL_NDA202408_20160624","program":"fera_pharmaceuticals","apps":["NDA202408"],"app":"NDA202408","date":"2016-06-24","file":"202408_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/202408_2019_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"Avaclyr","product_type":"not_classified","sponsor":"Fera Pharmaceuticals, LLC"},{"id":"CRL_NDA202408_20190328","program":"fera_pharmaceuticals","apps":["NDA202408"],"app":"NDA202408","date":"2019-03-28","file":"202408_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/202408_2019_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"Avaclyr","product_type":"not_classified","sponsor":"Fera Pharmaceuticals, LLC"},{"id":"CRL_NDA022517_20100422","program":"ferring_pharmaceuticals","apps":["NDA022517"],"app":"NDA022517","date":"2010-04-22","file":"022517Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/022517Orig1s000OtherActionLtrs.pdf","cats":["CLP","EFF","NCL"],"cat_source":"rule","rule_cats":["CLP","EFF","NCL"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA022517_20100422:p1:s28","page":1,"text":"2. The pharmacokinetic information of the to-be-marketed formulation including the bioequivalence study (CS019) was derived using an analytical method that was not properly validated."},{"sid":"CRL_NDA022517_20100422:p1:s35","page":1,"text":"This bridge was supposed to be provided by the clinical bioequivalence study which utilized an analytic method that was not properly validated."}],"EFF":[{"sid":"CRL_NDA022517_20100422:p2:s24","page":2,"text":"Your clinical development program did not provide any direct evidence that reduced frequency of nocturnal voids is associated with a clinical benefit."}]},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"progesterone","product_type":"not_classified","sponsor":"Ferring Pharmaceuticals Inc."},{"id":"CRL_NDA022517_20130130","program":"ferring_pharmaceuticals","apps":["NDA022517"],"app":"NDA022517","date":"2013-01-30","file":"022517Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/022517Orig1s000OtherActionLtrs.pdf","cats":["EFF"],"cat_source":"rule","rule_cats":["EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA022517_20130130:p1:s22","page":1,"text":"In Study CS40, Nocdurna 25 meg in women was nominally significant versus placebo (p<0.05) for the co-primary endpoints of change from baseline in the average number of nocturnal voids over 3 months and 33% responder status over 3 months."},{"sid":"CRL_NDA022517_20130130:p1:s24","page":1,"text":"In Study CS41, Nocdurna 50 mcg and 75 mcg in men were each statistically significant versus placebo for the same co-primary endpoints and supported by sensitivity analyses."},{"sid":"CRL_NDA022517_20130130:p2:s0","page":2,"text":"Given the modest treatment effect and a persistent risk for hyponatremia, we remind you that in our April 22, 2010, Complete Response letter, we referenced the importance of an acceptable health-related quality of life tool to provide supportive evidence for the clinical benefit of treating nocturia."}]},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"progesterone","product_type":"not_classified","sponsor":"Ferring Pharmaceuticals Inc."},{"id":"CRL_NDA022517_20150130","program":"ferring_pharmaceuticals","apps":["NDA022517"],"app":"NDA022517","date":"2015-01-30","file":"022517Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/022517Orig1s000OtherActionLtrs.pdf","cats":["EFF"],"cat_source":"rule","rule_cats":["EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA022517_20150130:p1:s30","page":1,"text":"To address this deficiency you will need to conduct a trial to demonstrate that Nocdurna provides a meaningful clinical benefit that is associated with the reduction in number of nocturnal voids in adults with nocturia due to nocturnal polyuria."}]},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"progesterone","product_type":"not_classified","sponsor":"Ferring Pharmaceuticals Inc."},{"id":"CRL_NDA201110_20161123","program":"ferring_pharmaceuticals","apps":["NDA201110"],"app":"NDA201110","date":"2016-11-23","file":"201110_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/201110_2020_Orig1s000OtherActionLtrs.pdf","cats":["DEV"],"cat_source":"rule","rule_cats":["DEV"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"progesterone","product_type":"not_classified","sponsor":"Teva Women’s Health, Inc."},{"id":"CRL_BLA761253_20260227","program":"ferring_pharmaceuticals","apps":["BLA761253"],"app":"BLA761253","date":"2026-02-27","file":"CRL_BLA761253_20260227.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761253_20260227.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761253_20260227:p1:s17","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA Form 483 prior to your complete response to your application."},{"sid":"CRL_BLA761253_20260227:p1:s16","page":1,"text":"Following a pre-license inspection of ecerceconicreaccirt listed in this application, conveyed deficiencies fo the representative of the facility."},{"sid":"CRL_BLA761253_20260227:p1:s18","page":1,"text":"Your complete response should include the date(s) of the facility's response to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"FE 999049, follitropin delta (Rekovelle in EU/Canada)","product_type":"novel","sponsor":"Ferring Pharmaceuticals Inc."},{"id":"CRL_NDA216190_20240329","program":"fidelity_biopharma","apps":["NDA216190"],"app":"NDA216190","date":"2024-03-29","file":"216190Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/216190Orig1s000OtherActionLtrs.pdf","cats":["CMC","NCL"],"cat_source":"coded","rule_cats":["CMC","NCL"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"tizanidine oral solution 2 mg/5 mL (Ontralfy)","product_type":"505b2_new_formulation","sponsor":"Fidelity BioPharma Co."},{"id":"CRL_BLA761275_20230531","program":"fresenius_kabi_usa","apps":["BLA761275"],"app":"BLA761275","date":"2023-05-31","file":"761275_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761275_2024_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"MSB11456","product_type":"not_classified","sponsor":"Fresenius Kabi USA, LLC"},{"id":"CRL_NDA214610_20241211","program":"fresenius_kabi_usa","apps":["NDA214610"],"app":"NDA214610","date":"2024-12-11","file":"CRL_NDA214610_20241211.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA214610_20241211.pdf","cats":["NCL"],"cat_source":"coded","rule_cats":[],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"Amino acids, electrolytes, dextrose and lipid injectable emulsion (Fresenius Kabi three-chamber parenteral nutrition)","product_type":"505b2_new_formulation","sponsor":"Fresenius Kabi USA, LLC"},{"id":"CRL_NDA215818_20250425","program":"fresenius_kabi_usa","apps":["NDA215818"],"app":"NDA215818","date":"2025-04-25","file":"CRL_NDA215818_20250425.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA215818_20250425.pdf","cats":["CMC","NCL"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"Fresenius Kabi amino acids, dextrose and lipid injectable emulsion (parenteral nutrition; listed drug Kabiven)","product_type":"505b2_new_formulation","sponsor":"Fresenius Kabi USA, LLC"},{"id":"CRL_NDA214610_20260227","program":"fresenius_kabi_usa","apps":["NDA214610"],"app":"NDA214610","date":"2026-02-27","file":"CRL_NDA214610_20260227.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA214610_20260227.pdf","cats":["CMC","NCL"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"Amino acids, electrolytes, dextrose and lipid injectable emulsion (Fresenius Kabi three-chamber parenteral nutrition)","product_type":"505b2_new_formulation","sponsor":"Fresenius Kabi USA, LLC"},{"id":"CRL_NDA215818_20260227","program":"fresenius_kabi_usa","apps":["NDA215818"],"app":"NDA215818","date":"2026-02-27","file":"CRL_NDA215818_20260227.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA215818_20260227.pdf","cats":["CMC","NCL"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"Fresenius Kabi amino acids, dextrose and lipid injectable emulsion (parenteral nutrition; listed drug Kabiven)","product_type":"505b2_new_formulation","sponsor":"Fresenius Kabi USA, LLC"},{"id":"CRL_BLA761311_20230929","program":"galderma_r_d","apps":["BLA761311"],"app":"BLA761311","date":"2023-09-29","file":"CRL_BLA761311_20230929_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761311_20230929_Redacted.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"relabotulinumtoxinA injection (Relfydess, Galderma; QM-1114)","product_type":"novel","sponsor":"Galderma R&D, LLC"},{"id":"CRL_NDA215040_20230505","program":"galephar_pharmaceutical_research","apps":["NDA215040"],"app":"NDA215040","date":"2023-05-05","file":"215040_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215040_2024_Orig1s000OtherActionLtrs.pdf","cats":["CLP","SAF"],"cat_source":"rule","rule_cats":["CLP","SAF"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA215040_20230505:p1:s18","page":1,"text":"The completed relative bioavailability study with Legubeti and the acetylcysteine oral solution (a reference standard as a substitute for the relied-upon listed drug) conducted with 1 gm of acetylcysteine is not adequate to address palatability because most patients will receive higher doses (up to 15 gm) based on the proposed weight-based dosage."}],"SAF":[{"sid":"CRL_NDA215040_20230505:p1:s27","page":1,"text":"You have not provided adequate information to support the safety of L-lysine administration to pediatric patients weighing down to 1 kg. This information is needed to inform the benefit-risk assessment of this product in the pediatric population."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Legubeti","product_type":"not_classified","sponsor":"Galephar Pharmaceutical Research Inc."},{"id":"CRL_BLA761357_20240326","program":"gan_lee_pharmaceuticals","apps":["BLA761357"],"app":"BLA761357","date":"2024-03-26","file":"CRL_BLA761357_20240326.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761357_20240326.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Gan & Lee insulin lispro, proposed Humalog biosimilar","product_type":"biosimilar","sponsor":"Gan & Lee Pharmaceuticals"},{"id":"CRL_BLA761356_20240412","program":"gan_lee_pharmaceuticals","apps":["BLA761356"],"app":"BLA761356","date":"2024-04-12","file":"CRL_BLA761356_20240412.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761356_20240412.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Gan & Lee insulin aspart, proposed insulin aspart biosimilar","product_type":"biosimilar","sponsor":"Gan & Lee Pharmaceuticals"},{"id":"CRL_NDA214410_20201123","program":"genentech","apps":["NDA214410"],"app":"NDA214410","date":"2020-11-23","file":"214410Orig2s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214410Orig2s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"XOFLUZA","product_type":"not_classified","sponsor":"Genentech, Incorporated"},{"id":"CRL_NDA202860_20120518","program":"geno","apps":["NDA202860"],"app":"NDA202860","date":"2012-05-18","file":"202860_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/202860_2019_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"GENOsyl® © Delivery","product_type":"not_classified","sponsor":"GeNO LLC"},{"id":"CRL_NDA202860_20130628","program":"geno","apps":["NDA202860"],"app":"NDA202860","date":"2013-06-28","file":"202860_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/202860_2019_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"GENOsyl® © Delivery","product_type":"not_classified","sponsor":"GeNO LLC"},{"id":"CRL_NDA219624_20251223","program":"genzyme","apps":["NDA219624"],"app":"NDA219624","date":"2025-12-23","file":"CRL_NDA219624_20251223.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA219624_20251223.pdf","cats":["EFF","REG","SAF"],"cat_source":"coded","rule_cats":["EFF","SAF"],"new_trial":"no","passages":{"EFF":[{"sid":"CRL_NDA219624_20251223:p5:s11","page":5,"text":"Overall, substantial evidence of effectiveness has not been established in a clinically identifiable population for whom the benefits potentially outweigh the risks."},{"sid":"CRL_NDA219624_20251223:p3:s14","page":3,"text":"For subjects with GdE lesions at baseline, the hazard ratio (HR) (95% confidence interval [Cl]) for the primary endpoint was 0.346 (0.183, 0.656), and without GdE lesions at baseline was 0.777 (0.601, 1.006)."},{"sid":"CRL_NDA219624_20251223:p4:s1","page":4,"text":"Phase 3 studies in the RMS population (Studies EFC16033 and EFC16034) that did not meet their primary endpoint."}],"SAF":[{"sid":"CRL_NDA219624_20251223:p1:s22","page":1,"text":"Given the gravity of this serious and potentially fatal risk, the review of your application focused on attempting to identify a population in whom the benefit-risk assessment is favorable to support approval, such as a population of patients with multiple sclerosis (MS) that has the greatest unmet need because there are no approved therapies."},{"sid":"CRL_NDA219624_20251223:p4:s25","page":4,"text":"The Division considered the issues cited above in the benefit-risk assessment for he proposed indication of nrSPMS."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"tolebrutinib tablets for nrSPMS","product_type":"novel","sponsor":"Genzyme Corporation"},{"id":"CRL_NDA215973_20220228","program":"gilead_sciences","apps":["NDA215973"],"app":"NDA215973","date":"2022-02-28","file":"215973,215974Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215973%2C215974Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"lenacapavir","product_type":"not_classified","sponsor":"Gilead Sciences, Inc."},{"id":"CRL_NDA215974_20220228","program":"gilead_sciences","apps":["NDA215974"],"app":"NDA215974","date":"2022-02-28","file":"215973,215974Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215973%2C215974Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA215974_20220228:p1:s17","page":1,"text":"We have identified deficiencies in the product quality information for the lenacapavir injection NDA 215973. As the approval of lenacapavir tablet is contingent on the approval of lenacapavir injection, the lenacapavir injection deficiencies must be adequately addressed before this application can be approved."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"lenacapavir","product_type":"not_classified","sponsor":"Gilead Sciences, Inc."},{"id":"CRL_BLA761440_20251023","program":"glaxosmithkline","apps":["BLA761440"],"app":"BLA761440","date":"2025-10-23","file":"CRL_BLA761440_20251023.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761440_20251023.pdf","cats":["CLP","EFF","SAF"],"cat_source":"coded","rule_cats":["SAF"],"new_trial":"yes","passages":{"EFF":[{"sid":"CRL_BLA761440_20251023:p1:s23","page":1,"text":"While the DREAMM-8 trial met its primary endpoint of progression free survival, benefit was not established for the key secondary endpoint of overall survival."}],"SAF":[{"sid":"CRL_BLA761440_20251023:p1:s22","page":1,"text":"The Agency has determined that the results of Study 207499 (DREAMM-8) do not support a favorable benefit-risk assessment, given the significant safety and tolerability concerns, the lack of demonstration of an overall survival benefit, and the limited applicability to the U.S. patient population."}]},"type":"supplement","era":"issued","cycle":1,"n_app":1,"product":"Exdensur lepemokimab-ulaa)","product_type":"not_classified","sponsor":"GlaxoSmithKline LLC"},{"id":"CRL_BLA761458_20251216","program":"glaxosmithkline","apps":["BLA761458"],"app":"BLA761458","date":"2025-12-16","file":"CRL_BLA761458_20251216.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761458_20251216.pdf","cats":["CLP","EFF"],"cat_source":"coded","rule_cats":["EFF","SAF"],"new_trial":"unclear","passages":{"EFF":[{"sid":"CRL_BLA761458_20251216:p1:s26","page":1,"text":"Participants were followed for 52 weeks to assess the co-primary endpoints of change from baseline on endoscopic nasal polyp score and self-reported symptoms on a nasal obstruction mean score."},{"sid":"CRL_BLA761458_20251216:p1:s28","page":1,"text":"The co-primary endpoints of nasal polyp score and nasal obstruction score were statistically significant in ANCHOR-1 & 2. However, the nasal obstruction scores were not robust to sensitivity analyses for missing data and handling of intercurrent events."},{"sid":"CRL_BLA761458_20251216:p1:s29","page":1,"text":"In addition to the statistical deficiencies, the effect sizes for both co-primary endpoints were numerically small and, specifically for the nasal obstruction score, of uncertain clinical meaningfulness."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Exdensur lepemokimab-ulaa)","product_type":"not_classified","sponsor":"GlaxoSmithKline LLC"},{"id":"CRL_NDA211746_20190620","program":"glenmark_pharmaceuticals","apps":["NDA211746"],"app":"NDA211746","date":"2019-06-20","file":"211746_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211746_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"GSP","product_type":"not_classified","sponsor":"Glenmark Pharmaceuticals, Inc."},{"id":"CRL_NDA220304_20260423","program":"grace_therapeutics_us","apps":["NDA220304"],"app":"NDA220304","date":"2026-04-23","file":"CRL_NDA220304_20260423_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA220304_20260423_Redacted.pdf","cats":["CMC","FAC","NCL"],"cat_source":"coded","rule_cats":["CMC","FAC","NCL"],"new_trial":"unclear","passages":{"FAC":[{"sid":"CRL_NDA220304_20260423:p1:s25","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA Form 483 prior to your complete response."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"GTx-104, nimodipine injection for IV infusion (aSAH)","product_type":"505b2_new_formulation","sponsor":"Grace Therapeutics U.S., Inc."},{"id":"CRL_UNKNOWN_20220225","program":"green_cross","apps":["BLA125743"],"app":"BLA125743","date":"2022-02-25","file":"CRL_BLA125743_20220225.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125743_20220225.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"immune globulin","product_type":"not_classified","sponsor":"Green Cross Corporation"},{"id":"CRL_NDA205508_20250728","program":"heritage_pharmaceuticals_d_b_a_avet_pharmaceuticals","apps":["NDA205508"],"app":"NDA205508","date":"2025-07-28","file":"CRL_NDA205508_20250728.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA205508_20250728.pdf","cats":["CLP","CMC","FAC"],"cat_source":"coded","rule_cats":["CLP","CMC","FAC"],"new_trial":"unclear","passages":{"CMC":[{"sid":"CRL_NDA205508_20250728:p1:s48","page":1,"text":"Prominently identify in your cover letter that the submission contains new CMC data."}],"FAC":[{"sid":"CRL_NDA205508_20250728:p1:s37","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA Form 483 prior to your complete response submission to this application."},{"sid":"CRL_NDA205508_20250728:p1:s41","page":1,"text":"Your complete response submission to this application should include the date(s) of the facility's response(s) to the FDA Form 483 observations."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"atazanavir sulfate and ritonavir tablets (fixed-dose combination)","product_type":"505b2_new_formulation","sponsor":"Heritage Pharmaceuticals Inc. d/b/a/ Avet Pharmaceuticals Inc."},{"id":"CRL_NDA211988_20190430","program":"heron_therapeutics","apps":["NDA211988"],"app":"NDA211988","date":"2019-04-30","file":"211988_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211988_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC","DEV","NCL"],"cat_source":"rule","rule_cats":["CMC","DEV","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Zynrelef","product_type":"not_classified","sponsor":"Heron Therapeutics, Inc."},{"id":"CRL_NDA211988_20200626","program":"heron_therapeutics","apps":["NDA211988"],"app":"NDA211988","date":"2020-06-26","file":"211988_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211988_2022_Orig1s000OtherActionLtrs.pdf","cats":["NCL"],"cat_source":"rule","rule_cats":["NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"Zynrelef","product_type":"not_classified","sponsor":"Heron Therapeutics, Inc."},{"id":"CRL_NDA212045_20200228","program":"hikma_pharmaceuticals_usa","apps":["NDA212045"],"app":"NDA212045","date":"2020-02-28","file":"212045_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212045_2021_Orig1s000OtherActionLtrs.pdf","cats":["CMC","DEV"],"cat_source":"rule","rule_cats":["CMC","DEV"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA212045_20200228:p4:s8","page":4,"text":"Update the extractable leachable assessment to address the Chemistry, Manufacturing, and Controls deficiencies in the resubmission."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"phenobarbital sodium","product_type":"not_classified","sponsor":"Hikma Pharmaceuticals USA Inc."},{"id":"CRL_NDA218258_20240123","program":"hikma_pharmaceuticals_usa","apps":["NDA218258"],"app":"NDA218258","date":"2024-01-23","file":"CRL_NDA218258_20240123.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218258_20240123.pdf","cats":["CMC","EFF","FAC","SAF"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Phenobarbital sodium injection (Hikma), for neonatal seizures","product_type":"other","sponsor":"Hikma Pharmaceuticals USA Inc."},{"id":"CRL_NDA219045_20241021","program":"hikma_pharmaceuticals_usa","apps":["NDA219045"],"app":"NDA219045","date":"2024-10-21","file":"CRL_NDA219045_20241021.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA219045_20241021.pdf","cats":["CLP","SAF"],"cat_source":"coded","rule_cats":["CLP","DEV"],"new_trial":"unclear","passages":{"CLP":[{"sid":"CRL_NDA219045_20241021:p1:s23","page":1,"text":"Regarding efficacy, your comparative bioavailability study demonstrated that the proposed product has comparable or higher systemic exposure and comparable or quicker onset of action than Narcan (naloxone HCI, 4 mg) nasal spray."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"naloxone HCl nasal spray 4 mg, nonprescription (Hikma)","product_type":"505b2_copy","sponsor":"Hikma Pharmaceuticals USA Inc."},{"id":"CRL_NDA219357_20241223","program":"hikma_pharmaceuticals_usa","apps":["NDA219357"],"app":"NDA219357","date":"2024-12-23","file":"CRL_NDA219357_20241223.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA219357_20241223.pdf","cats":["CMC"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"unknown (Hikma NDA; API field says phenobarbital sodium)","product_type":"unknown","sponsor":"Hikma Pharmaceuticals USA Inc."},{"id":"CRL_NDA209191_20170426","program":"hospira","apps":["NDA209191"],"app":"NDA209191","date":"2017-04-26","file":"209191_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209191_2018_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA209191_20170426:p2:s5","page":2,"text":"In addition to a safety update, the amendment should also identify changes, if any, in the conditions under which your product was tentatively approved, i.e., updated labeling; chemistry, manufacturing, and controls data; and risk evaluation and mitigation strategy (REMS)."}]},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"Daptomycin","product_type":"not_classified","sponsor":"Hospira, Inc."},{"id":"CRL_NDA209191_20171103","program":"hospira","apps":["NDA209191"],"app":"NDA209191","date":"2017-11-03","file":"209191_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209191_2018_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"Daptomycin","product_type":"not_classified","sponsor":"Hospira, Inc."},{"id":"CRL_NDA209191_20180222","program":"hospira","apps":["NDA209191"],"app":"NDA209191","date":"2018-02-22","file":"209191_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209191_2018_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"Daptomycin","product_type":"not_classified","sponsor":"Hospira, Inc."},{"id":"CRL_NDA210282_20180319","program":"hospira","apps":["NDA210282"],"app":"NDA210282","date":"2018-03-19","file":"210282_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210282_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Daptomycin","product_type":"not_classified","sponsor":"Hospira, Inc."},{"id":"CRL_NDA219112_20250117","program":"hospira","apps":["NDA219112"],"app":"NDA219112","date":"2025-01-17","file":"CRL_NDA219112_20250117.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA219112_20250117.pdf","cats":["CMC","NCL"],"cat_source":"coded","rule_cats":["NCL"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Diazepam injection (Hospira)","product_type":"unknown","sponsor":"Hospira, Inc."},{"id":"CRL_NDA211413_20181019","program":"hq_specialty_pharma","apps":["NDA211413"],"app":"NDA211413","date":"2018-10-19","file":"211413_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211413_2024_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"Meropenem","product_type":"not_classified","sponsor":"HQ Specialty Pharma Corporation"},{"id":"CRL_NDA211413_20191226","program":"hq_specialty_pharma","apps":["NDA211413"],"app":"NDA211413","date":"2019-12-26","file":"211413_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211413_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","NCL"],"cat_source":"rule","rule_cats":["CMC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"Meropenem","product_type":"not_classified","sponsor":"HQ Specialty Pharma Corporation"},{"id":"CRL_NDA211413_20210108","program":"hq_specialty_pharma","apps":["NDA211413"],"app":"NDA211413","date":"2021-01-08","file":"211413_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211413_2024_Orig1s000OtherActionLtrs.pdf","cats":["NCL"],"cat_source":"rule","rule_cats":["NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"Meropenem","product_type":"not_classified","sponsor":"HQ Specialty Pharma Corporation"},{"id":"CRL_NDA215212_20210914","program":"hq_specialty_pharma","apps":["NDA215212"],"app":"NDA215212","date":"2021-09-14","file":"215212_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215212_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","NCL"],"cat_source":"rule","rule_cats":["CMC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Meropenem","product_type":"not_classified","sponsor":"HQ Specialty Pharma Corporation"},{"id":"CRL_BLA761225_20220331","program":"hugel","apps":["BLA761225"],"app":"BLA761225","date":"2022-03-31","file":"761225_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761225_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"letibotulinumtoxinA","product_type":"not_classified","sponsor":"Hugel, Inc"},{"id":"CRL_BLA761225_20230412","program":"hugel","apps":["BLA761225"],"app":"BLA761225","date":"2023-04-12","file":"761225_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761225_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"letibotulinumtoxinA","product_type":"not_classified","sponsor":"Hugel, Inc"},{"id":"CRL_BLA761211_20250806","program":"immedica_pharma","apps":["BLA761211"],"app":"BLA761211","date":"2025-08-06","file":"CRL_BLA761211_20250806.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761211_20250806.pdf","cats":["CLP","EFF"],"cat_source":"coded","rule_cats":["AAP","EFF"],"new_trial":"unclear","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"LOARGYS (pegzilarginase-nbln)","product_type":"novel","sponsor":"Immedica Pharma AB"},{"id":"CRL_BLA761115_20190117","program":"immunomedics","apps":["BLA761115"],"app":"BLA761115","date":"2019-01-17","file":"761115_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761115_2020_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"FAC":[{"sid":"CRL_BLA761115_20190117:p1:s19","page":1,"text":"1. Reference is made to the pre-license inspection at Immunomedics Inc. (Morris Plains, NJ) and subsequent communications between Immunomedics and the Agency:"}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sacituzumab govitecan","product_type":"not_classified","sponsor":"Immunomedics, Inc"},{"id":"CRL_NDA217186_20230630","program":"impax_laboratories","apps":["NDA217186"],"app":"NDA217186","date":"2023-06-30","file":"217186Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/217186Orig1s000OtherActionLtrs.pdf","cats":["CLP","SAF"],"cat_source":"rule","rule_cats":["CLP","SAF"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA217186_20230630:p2:s2","page":2,"text":"Alternatively, you may consider reformulating your proposed product to reduce exposure of carbidopa to levels that are comparable to a listed drug and can be supported by a relative bioavailability study."}],"SAF":[{"sid":"CRL_NDA217186_20230630:p1:s23","page":1,"text":"Furthermore, the long-term safety database is insufficient to adequately characterize the long-term safety of Crexont for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Crexont Extended Release","product_type":"not_classified","sponsor":"Impax Laboratories, LLC"},{"id":"CRL_NDA212501_20200114","program":"ingenus_pharmaceuticals","apps":["NDA212501"],"app":"NDA212501","date":"2020-01-14","file":"212501_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212501_2021_Orig1s000OtherActionLtrs.pdf","cats":["FAC","NCL"],"cat_source":"rule","rule_cats":["FAC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"Cyclophosphamide","product_type":"not_classified","sponsor":"Ricon Pharma, LLC"},{"id":"CRL_NDA209511_20181130","program":"innocoll_pharmaceuticals","apps":["NDA209511"],"app":"NDA209511","date":"2018-11-30","file":"209511_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209511_2021_Orig1s000OtherActionLtrs.pdf","cats":["CMC","NCL"],"cat_source":"rule","rule_cats":["CMC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":null,"product_type":"not_classified","sponsor":"Innocoll Pharmaceuticals"},{"id":"CRL_NDA206968_20161115","program":"innopharma_licensing","apps":["NDA206968"],"app":"NDA206968","date":"2016-11-15","file":"206968_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206968_2023_Orig1s000OtherActionLtrs.pdf","cats":["FAC","NCL"],"cat_source":"rule","rule_cats":["FAC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":4,"product":"Acetaminophen","product_type":"not_classified","sponsor":"nnoPharma Licensing LLC"},{"id":"CRL_NDA206968_20181109","program":"innopharma_licensing","apps":["NDA206968"],"app":"NDA206968","date":"2018-11-09","file":"206968_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206968_2023_Orig1s000OtherActionLtrs.pdf","cats":["FAC","NCL"],"cat_source":"rule","rule_cats":["FAC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":4,"product":"Acetaminophen","product_type":"not_classified","sponsor":"nnoPharma Licensing LLC"},{"id":"CRL_NDA206968_20201222","program":"innopharma_licensing","apps":["NDA206968"],"app":"NDA206968","date":"2020-12-22","file":"206968_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206968_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","NCL"],"cat_source":"rule","rule_cats":["CMC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":4,"n_app":4,"product":"Acetaminophen","product_type":"not_classified","sponsor":"nnoPharma Licensing LLC"},{"id":"CRL_NDA206976_20170324","program":"institut_biochimique_ibsa","apps":["NDA206976"],"app":"NDA206976","date":"2017-03-24","file":"206976_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206976_2018_Orig1s000OtherActionLtrs.pdf","cats":["CMC","EFF","NCL"],"cat_source":"rule","rule_cats":["CMC","EFF","NCL"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA206976_20170324:p1:s21","page":1,"text":"Conduct at least one adequate and well-controlled clinical efficacy trial to demonstrate the safety and effectiveness of the to-be-marketed product manufactured at the proposed commercial manufacturing site, We recommend that you discuss the design of this study with the Division in advance."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"diclofenac epolamine","product_type":"not_classified","sponsor":"Institut Biochimique SA (IBSA)"},{"id":"CRL_NDA205394_20190328","program":"intelgenx","apps":["NDA205394"],"app":"NDA205394","date":"2019-03-28","file":"205394_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/205394_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"RizaFilm","product_type":"not_classified","sponsor":"RedHill Biopharma Ltd."},{"id":"CRL_NDA205394_20200324","program":"intelgenx","apps":["NDA205394"],"app":"NDA205394","date":"2020-03-24","file":"205394_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/205394_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA205394_20200324:p1:s37","page":1,"text":"Please note that that this information will be reviewed by the Agency during the review of the application and a follow up Pre approval inspection may be needed to verify that the facility has taken necessary corrective actions to ensure oral film product quality."}]},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"RizaFilm","product_type":"not_classified","sponsor":"RedHill Biopharma Ltd."},{"id":"CRL_NDA211363_20181212","program":"international_medication_systems","apps":["NDA211363"],"app":"NDA211363","date":"2018-12-12","file":"211363_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211363_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Epinephrine","product_type":"not_classified","sponsor":"International Medication Systems, Limited"},{"id":"CRL_BLA761311_20260629","program":"ipsen_biopharm","apps":["BLA761311"],"app":"BLA761311","date":"2026-06-29","file":"CRL_BLA761311_20260629_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761311_20260629_Redacted.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761311_20260629:p1:s20","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on FDA Form 483 prior to your complete response to your application."},{"sid":"CRL_BLA761311_20260629:p1:s21","page":1,"text":"Your complete response should include the date(s) of the facility's response to FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"relabotulinumtoxinA injection (Relfydess, Galderma; QM-1114)","product_type":"novel","sponsor":"Galderma R&D, LLC"},{"id":"CRL_NDA209311_20170728","program":"ironshore_pharmaceuticals_development","apps":["NDA209311"],"app":"NDA209311","date":"2017-07-28","file":"209311_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209311_2018_Orig1s000OtherActionLtrs.pdf","cats":["EFF","SAF"],"cat_source":"rule","rule_cats":["EFF","SAF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA209311_20170728:p1:s30","page":1,"text":"To obtain marketing authorization for this patient population, you would need to conduct an additional study to find a lower dose that is safe and effective."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Jornay PM Modified Release","product_type":"not_classified","sponsor":"Ironshore Pharmaceuticals & Development, Inc."},{"id":"CRL_NDA218705_20260807","program":"itm_solucin","apps":["NDA218705"],"app":"NDA218705","date":"2026-08-07","file":"CRL_NDA218705_20260807.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218705_20260807.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_NDA218705_20260807:p1:s22","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on FDA Form 483 prior to your complete response to your application."},{"sid":"CRL_NDA218705_20260807:p1:s21","page":1,"text":"3. Following a pre-approval inspection a listed in this application, conveyed deficiencies to the representative of the facility."},{"sid":"CRL_NDA218705_20260807:p1:s23","page":1,"text":"Your complete response should include the date(s) of the facility's response to FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"ITM-11, lutetium Lu 177 edotreotide (n.c.a.) injection","product_type":"novel","sponsor":"ITM Solucin GmbH"},{"id":"CRL_BLA761433_20241213","program":"janssen_biotech","apps":["BLA761433"],"app":"BLA761433","date":"2024-12-13","file":"CRL_BLA761433_20241213.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761433_20241213.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761433_20241213:p1:s17","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA Form 483 prior to resubmitting your application for amivantamab and hyaluronidase injection."},{"sid":"CRL_BLA761433_20241213:p1:s18","page":1,"text":"Your complete response addressing these deficiencies must include the date of the facility's response to the FDA Form 483. The assessment of the application approvability and the resolution of inspection deficiencies will be evaluated upon receipt of the complete response addressing the deficiencies and may include reinspection of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"amivantamab and hyaluronidase-lpuj (Rybrevant Faspro), subcutaneous","product_type":"other","sponsor":"Janssen Biotech, Inc."},{"id":"CRL_BLA761308_20240516","program":"jiangsu_hengrui_pharmaceuticals","apps":["BLA761308"],"app":"BLA761308","date":"2024-05-16","file":"CRL_BLA761308_20240516.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761308_20240516.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761308_20240516:p1:s19","page":1,"text":"Form 483. The assessment of the application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":3,"product":"SHR-1210, camrelizumab (anti-PD-1), with rivoceranib for 1L uHCC","product_type":"novel","sponsor":"Jiangsu Hengrui Pharmaceuticals Co., Ltd."},{"id":"CRL_BLA761308_20250320","program":"jiangsu_hengrui_pharmaceuticals","apps":["BLA761308"],"app":"BLA761308","date":"2025-03-20","file":"CRL_BLA761308_20250320.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761308_20250320.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761308_20250320:p1:s23","page":1,"text":"Your complete response should include the date(s) of the facility's response to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":2,"n_app":3,"product":"SHR-1210, camrelizumab (anti-PD-1), with rivoceranib for 1L uHCC","product_type":"novel","sponsor":"Jiangsu Hengrui Pharmaceuticals Co., Ltd."},{"id":"CRL_BLA761308_20260709","program":"jiangsu_hengrui_pharmaceuticals","apps":["BLA761308"],"app":"BLA761308","date":"2026-07-09","file":"CRL_BLA761308_20260709_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761308_20260709_Redacted.pdf","cats":["REG"],"cat_source":"coded","rule_cats":[],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":3,"n_app":3,"product":"SHR-1210, camrelizumab (anti-PD-1), with rivoceranib for 1L uHCC","product_type":"novel","sponsor":"Jiangsu Hengrui Pharmaceuticals Co., Ltd."},{"id":"CRL_NDA210933_20190807","program":"kala_pharmaceuticals","apps":["NDA210933"],"app":"NDA210933","date":"2019-08-07","file":"210933_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210933_2021_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Eysuvis","product_type":"not_classified","sponsor":"Kala Pharmaceuticals, Inc."},{"id":"CRL_BLA761082_20190611","program":"kashiv_biosciences","apps":["BLA761082"],"app":"BLA761082","date":"2019-06-11","file":"761082_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761082_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_BLA761082_20190611:p1:s40","page":1,"text":"To address this deficiency, identify an appropriately qualified, external third party to perform an independent and thorough audit of all the product quality data provided in your 351(k) BLA for accuracy and completeness."},{"sid":"CRL_BLA761082_20190611:p2:s2","page":2,"text":"The Agency will not be able to perform a meaningful review of your 351(k) BLA until the final audit report provides assurance that all analytical similarity and other product quality information provided in the 351(k) BLA application is accurate and complete."}]},"type":"original","era":"after_approval","cycle":2,"n_app":4,"product":"TPI-120","product_type":"not_classified","sponsor":"Adello Biologics, LLC"},{"id":"CRL_BLA761082_20201222","program":"kashiv_biosciences","apps":["BLA761082"],"app":"BLA761082","date":"2020-12-22","file":"761082_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761082_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_BLA761082_20201222:p5:s1","page":5,"text":"We acknowledge that you provided data to support that the removal of kanamycin in tel nae fermentation processes does not have an impact on manufacturing process and product quality."}]},"type":"original","era":"after_approval","cycle":3,"n_app":4,"product":"TPI-120","product_type":"not_classified","sponsor":"Adello Biologics, LLC"},{"id":"CRL_BLA761082_20210802","program":"kashiv_biosciences","apps":["BLA761082"],"app":"BLA761082","date":"2021-08-02","file":"761082_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761082_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":4,"n_app":4,"product":"TPI-120","product_type":"not_classified","sponsor":"Adello Biologics, LLC"},{"id":"CRL_BLA761084_20210811","program":"kashiv_biosciences","apps":["BLA761084"],"app":"BLA761084","date":"2021-08-11","file":"761084_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761084_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC","DEV","FAC"],"cat_source":"rule","rule_cats":["CMC","DEV","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"TPI-120","product_type":"not_classified","sponsor":"Kashiv BioSciences, LLC"},{"id":"CRL_NDA022377_20090515","program":"king_pharmaceuticals","apps":["NDA022377"],"app":"NDA022377","date":"2009-05-15","file":"CRL_NDA022377_20090515.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA022377_20090515.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sumatriptan","product_type":"not_classified","sponsor":"King Pharmaceuticals, Inc."},{"id":"CRL_NDA022075_20080225","program":"kyowa_pharmaceutical","apps":["NDA022075"],"app":"NDA022075","date":"2008-02-25","file":"022075Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/022075Orig1s000OtherActionLtrs.pdf","cats":["CLP","NCL"],"cat_source":"rule","rule_cats":["CLP","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"istradefylline","product_type":"not_classified","sponsor":"Kyowa Pharmaceutical, Inc."},{"id":"CRL_NDA214835_20210924","program":"laboratorios_farmaceuticos_rovi","apps":["NDA214835"],"app":"NDA214835","date":"2021-09-24","file":"Pages from 214835Orig1s000_ORIGINAL_APPROVAL_PACKAGE.pdf","url":"https://download.open.fda.gov/crl/Pages%20from%20214835Orig1s000_ORIGINAL_APPROVAL_PACKAGE.pdf","cats":["CLP","CMC","DEV","FAC"],"cat_source":"rule","rule_cats":["CLP","CMC","DEV","FAC"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA214835_20210924:p2:s27","page":2,"text":"PBBM, etc. For an established safe space, the acceptable dissolution specifications should ensure bioequivalence/clinical relevance of future batches with dissolution profiles falling between the identified extreme ranges within the limits."}],"DEV":[{"sid":"CRL_NDA214835_20210924:p1:s24","page":1,"text":"The results of your human factors (HF) validation study indicated the need for further revisions to your user interface in order to mitigate residual risk."},{"sid":"CRL_NDA214835_20210924:p1:s33","page":1,"text":"Any product redesign will require an additional human factors validation study to demonstrate that the design mitigations were effective."},{"sid":"CRL_NDA214835_20210924:p1:s25","page":1,"text":"In particular, we are concerned that your intended users may have difficulty injecting the full dose of medication due to the viscosity of the product, as evidenced by use difficulties and use errors in your human factors validation study."}]},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"Risvan","product_type":"not_classified","sponsor":"Laboratorios Farmacéuticos ROVI, S.A."},{"id":"CRL_NDA214835_20220715","program":"laboratorios_farmaceuticos_rovi","apps":["NDA214835"],"app":"NDA214835","date":"2022-07-15","file":"Pages from 214835Orig1s000_ORIGINAL_APPROVAL_PACKAGE.pdf","url":"https://download.open.fda.gov/crl/Pages%20from%20214835Orig1s000_ORIGINAL_APPROVAL_PACKAGE.pdf","cats":["CMC","DEV","FAC"],"cat_source":"rule","rule_cats":["CMC","DEV","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"Risvan","product_type":"not_classified","sponsor":"Laboratorios Farmacéuticos ROVI, S.A."},{"id":"CRL_NDA214835_20230727","program":"laboratorios_farmaceuticos_rovi","apps":["NDA214835"],"app":"NDA214835","date":"2023-07-27","file":"Pages from 214835Orig1s000_ORIGINAL_APPROVAL_PACKAGE.pdf","url":"https://download.open.fda.gov/crl/Pages%20from%20214835Orig1s000_ORIGINAL_APPROVAL_PACKAGE.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"Risvan","product_type":"not_classified","sponsor":"Laboratorios Farmacéuticos ROVI, S.A."},{"id":"CRL_NDA209575_20180720","program":"lannett_holdings","apps":["NDA209575"],"app":"NDA209575","date":"2018-07-20","file":"209575_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209575_2020_Orig1s000OtherActionLtrs.pdf","cats":["CLP","NCL"],"cat_source":"rule","rule_cats":["CLP","NCL"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA209575_20180720:p2:s4","page":2,"text":"In addition, you must establish a \"bridge\" (e.g., via comparative bioavailability data) between your proposed drug product and each listed drug upon which you propose to rely to demonstrate that such reliance is scientifically justified."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Cocaine Hydrochloride","product_type":"not_classified","sponsor":"Lannett Holdings, Inc."},{"id":"CRL_NDA217719_20250310","program":"laurus_generics","apps":["NDA217719"],"app":"NDA217719","date":"2025-03-10","file":"CRL_NDA217719_20250310.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA217719_20250310.pdf","cats":["CMC"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"darunavir/ritonavir fixed-dose tablets (Laurus, PEPFAR)","product_type":"505b2_new_formulation","sponsor":"Laurus Generics, Inc."},{"id":"CRL_BLA761180_20210423","program":"leo_pharma_a_s","apps":["BLA761180"],"app":"BLA761180","date":"2021-04-23","file":"761180_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761180_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"tralokinumab","product_type":"not_classified","sponsor":"LEO Pharma A/S"},{"id":"CRL_NDA210934_20241220","program":"lexicon_pharmaceuticals","apps":["NDA210934"],"app":"NDA210934","date":"2024-12-20","file":"CRL_NDA210934_20241220.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA210934_20241220.pdf","cats":["EFF","SAF"],"cat_source":"coded","rule_cats":["EFF","SAF"],"new_trial":"unclear","passages":{"EFF":[{"sid":"CRL_NDA210934_20241220:p1:s27","page":1,"text":"We acknowledge that substantial evidence of effectiveness (SEE) for a glycemic control indication was demonstrated in the overall Tandem population, based on the primary analyses of the change-from-baseline (CFB) hemoglobin A1c (A1C) endpoint, during the review of the original NDA submission."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"sotagliflozin (Zynquista) for type 1 diabetes","product_type":"other","sponsor":"Lexicon Pharmaceuticals, Inc."},{"id":"CRL_BLA761427_20251212","program":"lib_therapeutics","apps":["BLA761427"],"app":"BLA761427","date":"2025-12-12","file":"CRL_BLA761427_20251212.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761427_20251212.pdf","cats":["EFF"],"cat_source":"coded","rule_cats":["EFF"],"new_trial":"unclear","passages":{"EFF":[{"sid":"CRL_BLA761427_20251212:p1:s30","page":1,"text":"Given concerns for the cross-over design of the trial, an additional analysis of the primary efficacy endpoint for Period A only was performed."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Lerochol","product_type":"not_classified","sponsor":"LIB Therapeutics, Inc."},{"id":"CRL_NDA216482_20230106","program":"liqmeds_worldwide","apps":["NDA216482"],"app":"NDA216482","date":"2023-01-06","file":"216482_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/216482_2024_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"mycophenolate mofetil","product_type":"not_classified","sponsor":"Liqmeds Worldwide Limited"},{"id":"CRL_NDA215559_20221223","program":"lpsen_biopharmaceuticals","apps":["NDA215559"],"app":"NDA215559","date":"2022-12-23","file":"215559_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215559_2023_Orig1s000OtherActionLtrs.pdf","cats":["EFF","SAF"],"cat_source":"rule","rule_cats":["EFF","SAF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA215559_20221223:p1:s18","page":1,"text":"You have not provided adequate support for the efficacy of palovarotene, thus the anticipated clinical benefit in the treatment of pediatric and adult patients with ibrodysplasia ossificans progressiva (FOP), specifically a benefit of palovarotene to prevent the formation of new heterotopic ossification (HO) (the proposed indication), has not been established."},{"sid":"CRL_NDA215559_20221223:p1:s35","page":1,"text":"Effectiveness for Human Drug and Biological Products, e.g., if you intend to rely on a single adequate and well controlled trial, you will need to provide confirmatory evidence of effectiveness."}],"SAF":[{"sid":"CRL_NDA215559_20221223:p5:s26","page":5,"text":"Because the benefits of palovarotene for treatment of patients with FOP have not been established, we are unable to conduct a meaningful benefit risk assessment."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"palovarotene","product_type":"not_classified","sponsor":"lpsen Biopharmaceuticals Inc."},{"id":"CRL_NDA213972_20210723","program":"lterum_therapeutics_us","apps":["NDA213972"],"app":"NDA213972","date":"2021-07-23","file":"213972_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213972_2024_Orig1s000OtherActionLtrs.pdf","cats":["EFF"],"cat_source":"rule","rule_cats":["EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA213972_20210723:p1:s17","page":1,"text":"There is a lack of substantial evidence consisting of adequate and well-controlled investigations, as defined in 21CFR §314.126, that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling (21 CFR §314.125(b)(5))."},{"sid":"CRL_NDA213972_20210723:p1:s18","page":1,"text":"The clinical data submitted from Study 301 do not provide substantial evidence of effectiveness of sulopenem etzadroxil and probenecid tablets for the proposed indication of treatment of adult women with uncomplicated urinary tract infections (uUT1) caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone."},{"sid":"CRL_NDA213972_20210723:p1:s21","page":1,"text":"2. The other trials conducted with sulopenem failed to meet their primary endpoint, and therefore, could not provide evidence of effectiveness."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sulopenem etzadroxil","product_type":"not_classified","sponsor":"lterum Therapeutics U.S. Ltd."},{"id":"CRL_BLA761212_20241114","program":"lupin_biotech_division","apps":["BLA761212"],"app":"BLA761212","date":"2024-11-14","file":"CRL_BLA761212_20241114.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761212_20241114.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761212_20241114:p1:s21","page":1,"text":"Your complete response should include the date of the facility's response to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Armlupeg (pegfilgrastim-unne, LUBT004), pegfilgrastim biosimilar","product_type":"biosimilar","sponsor":"Lupin Limited (Biotech Division)"},{"id":"CRL_NDA215455_20240808","program":"lykos_therapeutics","apps":["NDA215455"],"app":"NDA215455","date":"2024-08-08","file":"CRL_NDA215455_20240808.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA215455_20240808.pdf","cats":["EFF","SAF"],"cat_source":"coded","rule_cats":["EFF"],"new_trial":"yes","passages":{"EFF":[{"sid":"CRL_NDA215455_20240808:p1:s17","page":1,"text":"We have concluded that your application does not provide substantial evidence of effectiveness or establish the safety of your product to support the approval of midomafetamine for the treatment of posttraumatic stress disorder (PTSD)."},{"sid":"CRL_NDA215455_20240808:p3:s7","page":3,"text":"These limitations impact the interpretability of MAPP1 and MAPP2 and, together with failure of MPLONG to provide evidence of a durable treatment effect, preclude the ability to establish substantial evidence of effectiveness."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"midomafetamine (MDMA) capsules, for MDMA-assisted therapy of PTSD","product_type":"novel","sponsor":"Lykos Therapeutics"},{"id":"CRL_NDA022231_20200911","program":"mallinckrodt_hospital_products_ip","apps":["NDA022231"],"app":"NDA022231","date":"2020-09-11","file":"022231Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/022231Orig1s000OtherActionLtrs.pdf","cats":["EFF","SAF"],"cat_source":"rule","rule_cats":["EFF","SAF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA022231_20200911:p1:s21","page":1,"text":"In order to be counted in the primary endpoint, patients also needed to be alive without renal replacement therapy for at least 10 days after achieving verified HRS reversal."},{"sid":"CRL_NDA022231_20200911:p1:s29","page":1,"text":"The primary endpoint and analytic plan should be discussed with and agreed upon by the FDA prior to initiation."}],"SAF":[{"sid":"CRL_NDA022231_20200911:p1:s28","page":1,"text":"To address this issue, you will need to conduct an adequate and well-controlled study that demonstrates an acceptable risk-benefit profile, perhaps utilizing the proposed risk mitigation strategy."}]},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"terlipressin","product_type":"not_classified","sponsor":"Orphan Therapeutics, LLC"},{"id":"CRL_NDA022231_20220218","program":"mallinckrodt_pharmaceuticals_ireland","apps":["NDA022231"],"app":"NDA022231","date":"2022-02-18","file":"022231Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/022231Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"terlipressin","product_type":"not_classified","sponsor":"Orphan Therapeutics, LLC"},{"id":"CRL_NDA218223_20240308","program":"mapi_pharma","apps":["NDA218223"],"app":"NDA218223","date":"2024-03-08","file":"CRL_NDA218223_20240308.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218223_20240308.pdf","cats":["CLP","CMC","EFF","FAC","NCL","SAF"],"cat_source":"coded","rule_cats":["CLP","CMC","DEV","EFF","FAC"],"new_trial":"yes","passages":{"EFF":[{"sid":"CRL_NDA218223_20240308:p2:s2","page":2,"text":"We strongly recommend that you seek the Division's feedback on any protocol for a future study intended to provide substantial evidence of effectiveness."},{"sid":"CRL_NDA218223_20240308:p3:s13","page":3,"text":"Since the reason for study discontinuation may be related to the treatment assignment (i.e., perceived lack of efficacy or an adverse event) or the primary endpoint (i.e., a relapse), the loss of these data may lead to bias in the estimated treatment effect."},{"sid":"CRL_NDA218223_20240308:p2:s1","page":2,"text":"These concerns would need to be addressed in a new adequate and well-controlled study demonstrating a significant treatment effect on a rigorously measured primary outcome."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"GA Depot (glatiramer acetate extended-release depot injection, monthly)","product_type":"505b2_new_formulation","sponsor":"Mapi Pharma Ltd."},{"id":"CRL_NDA213953_20211022","program":"marius_pharmaceuticals","apps":["NDA213953"],"app":"NDA213953","date":"2021-10-22","file":"213953_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213953_2022_Orig1s000OtherActionLtrs.pdf","cats":["EFF"],"cat_source":"rule","rule_cats":["EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA213953_20211022:p1:s31","page":1,"text":"As the integrity and reliability of the PK data from MRS-TU-2019EXT cannot be assured, we cannot conclude that MRS-TU-2019EXT provides substantial evidence of effectiveness for your product."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"testosterone undecanoate","product_type":"not_classified","sponsor":"Marius Pharmaceuticals, LLC"},{"id":"CRL_NDA214759_20210730","program":"medac_gesellschaft_fur_klinische_spezialpraparate_mbh","apps":["NDA214759"],"app":"NDA214759","date":"2021-07-30","file":"214759_2025_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214759_2025_Orig1s000OtherActionLtrs.pdf","cats":["CLP","EFF","NCL"],"cat_source":"rule","rule_cats":["CLP","EFF","NCL"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA214759_20210730:p1:s17","page":1,"text":"1. You have not provided substantial evidence of effectiveness of treosulfan as a part of a preparative regimen for allogeneic hematopoietic stem cell transplantation for adult and pediatric patients with AML or MDS for the following reasons:"},{"sid":"CRL_NDA214759_20210730:p2:s33","page":2,"text":"In order to obtain approval for both indications, you would need to demonstrate substantial evidence of effectiveness for each individually."},{"sid":"CRL_NDA214759_20210730:p1:s19","page":1,"text":"Because all complete blood cell (CBC) and marrow results were not submitted, we were unable to independently confirm the results of the analysis of the primary endpoint of EFS for Study MC-FLudT-14/L Trial Il."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Grafapex","product_type":"not_classified","sponsor":"medac Gesellschaft fur klinische Spezialpraparate mbH"},{"id":"CRL_NDA220184_20251222","program":"medicasafe","apps":["NDA220184"],"app":"NDA220184","date":"2025-12-22","file":"CRL_NDA220184_20251222.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA220184_20251222.pdf","cats":["CMC","DEV","REG"],"cat_source":"coded","rule_cats":["CMC","DEV"],"new_trial":"no","passages":{"DEV":[{"sid":"CRL_NDA220184_20251222:p2:s8","page":2,"text":"Based on our review of your Human Factors (HF) Validation Study, we have the following recommendation:"},{"sid":"CRL_NDA220184_20251222:p2:s21","page":2,"text":"Based on the use-related risk analysis (URRA), if the user uses an improper technique while interacting with the product (7 Mi), cartridge), there is risk of opioid withdrawal symptoms."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"MedicaSafe buprenorphine/naloxone cartridges + SmartKey dispensing device (drug-device combination)","product_type":"other","sponsor":"MedicaSafe, Inc."},{"id":"CRL_BLA761192_20210625","program":"mediwound","apps":["BLA761192"],"app":"BLA761192","date":"2021-06-25","file":"761192_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761192_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":null,"product_type":"not_classified","sponsor":"MediWound, Ltd."},{"id":"CRL_NDA215029_20240711","program":"medrx_usa","apps":["NDA215029"],"app":"NDA215029","date":"2024-07-11","file":"CRL_NDA215029_20240711.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA215029_20240711.pdf","cats":["NCL"],"cat_source":"coded","rule_cats":["NCL"],"new_trial":"unclear","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Bondlido (lidocaine topical system 10%)","product_type":"505b2_new_formulation","sponsor":"MEDRx USA, Inc."},{"id":"CRL_NDA212271_20241211","program":"meitheal_pharmaceuticals","apps":["NDA212271"],"app":"NDA212271","date":"2024-12-11","file":"CRL_NDA212271_20241211.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA212271_20241211.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Contepo (fosfomycin disodium for injection), IV fosfomycin","product_type":"505b2_new_formulation","sponsor":"Meitheal Pharmaceuticals Inc."},{"id":"CRL_NDA204569_20130628","program":"merck","apps":["NDA204569"],"app":"NDA204569","date":"2013-06-28","file":"CRL_NDA204569_20130628.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA204569_20130628.pdf","cats":["EFF","SAF"],"cat_source":"rule","rule_cats":["EFF","SAF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA204569_20130628:p1:s23","page":1,"text":"We have concluded that you have submitted substantial evidence of effectiveness for suvorexant for the treatment of insomnia characterized by difficulty with sleep onset and/or sleep maintenance, at doses of 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, and 80 mg."},{"sid":"CRL_NDA204569_20130628:p2:s27","page":2,"text":"We are also concerned that hallucinations and sleep paralysis, which were reported more frequently in patients taking suvorexant than placebo, can cause clinically meaningful psychological harm in patients with insomnia."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Suvorexant","product_type":"not_classified","sponsor":"Merck & Co., Inc."},{"id":"CRL_UNKNOWN_20230801","program":"mesoblast","apps":["BLA125706"],"app":"BLA125706","date":"2023-08-01","file":"CRL_BLA125706_20230801.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125706_20230801.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_UNKNOWN_20230801:p3:s20","page":3,"text":"In Section 6.5.3 of your BLA resubmission (Module 1.11.4, SNO065), you describe accelerated stability studies conducted to demonstrate that the inhibition of IL-2Ra assay is stability indicating for (6) (4) (Study SP-019) and DP (Study SP-018) to address additional CMC comment #3 from the CRL (dated September 30, 2020)."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":null,"product_type":"not_classified","sponsor":"Mesoblast, Inc."},{"id":"CRL_NDA208193_20170111","program":"metacel_pharmaceuticals","apps":["NDA208193"],"app":"NDA208193","date":"2017-01-11","file":"208193_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208193_2019_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Ozobax","product_type":"not_classified","sponsor":"Metacel Pharmaceuticals, LLC"},{"id":"CRL_NDA208193_20180625","program":"metacel_pharmaceuticals","apps":["NDA208193"],"app":"NDA208193","date":"2018-06-25","file":"208193_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208193_2019_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"Ozobax","product_type":"not_classified","sponsor":"Metacel Pharmaceuticals, LLC"},{"id":"CRL_NDA218571_20250327","program":"milestone_pharmaceuticals_usa","apps":["NDA218571"],"app":"NDA218571","date":"2025-03-27","file":"CRL_NDA218571_20250327.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218571_20250327.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"etripamil nasal spray (Cardamyst)","product_type":"novel","sponsor":"Milestone Pharmaceuticals USA, Inc."},{"id":"CRL_NDA217002_20240226","program":"minerva_neurosciences","apps":["NDA217002"],"app":"NDA217002","date":"2024-02-26","file":"CRL_NDA217002_20240226.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA217002_20240226.pdf","cats":["CLP","CMC","EFF","NCL","SAF"],"cat_source":"coded","rule_cats":["CLP","CMC","EFF","NCL","SAF"],"new_trial":"yes","passages":{"EFF":[{"sid":"CRL_NDA217002_20240226:p1:s23","page":1,"text":"(1) You have not established substantial evidence of effectiveness (SEE) for the effects of roluperidone on the negative symptoms of schizophrenia."},{"sid":"CRL_NDA217002_20240226:p1:s24","page":1,"text":"Study MINI-101C03 (Study C03) demonstrated statistical significance on the primary efficacy endpoint."},{"sid":"CRL_NDA217002_20240226:p2:s20","page":2,"text":"You must provide additional data to demonstrate the safety and efficacy of roluperidone coadministered with antipsychotic medications, to support that observed effect on negative symptoms with roluperidone treatment corresponds to a clinically meaningful change, and to demonstrate the long-term safety of the proposed dose."}],"SAF":[{"sid":"CRL_NDA217002_20240226:p2:s20","page":2,"text":"You must provide additional data to demonstrate the safety and efficacy of roluperidone coadministered with antipsychotic medications, to support that observed effect on negative symptoms with roluperidone treatment corresponds to a clinically meaningful change, and to demonstrate the long-term safety of the proposed dose."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Roluperidone, for negative symptoms of schizophrenia","product_type":"novel","sponsor":"Minerva Neurosciences, Inc"},{"id":"CRL_NDA210605_20180517","program":"mylan","apps":["NDA210605"],"app":"NDA210605","date":"2018-05-17","file":"210605_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210605_2020_Orig1s000OtherActionLtrs.pdf","cats":["CMC","DEV"],"cat_source":"rule","rule_cats":["CMC","DEV"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA210605_20180517:p1:s40","page":1,"text":"CMC microbiology review noted the following deficiencies:"}],"DEV":[{"sid":"CRL_NDA210605_20180517:p2:s13","page":2,"text":"Once you finalize your proposed to-be-marketed IFU, you should conduct an additional human factors validation study with 15 untrained injection naive pediatric patients."}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"insulin glargine","product_type":"not_classified","sponsor":"Mylan GmbH"},{"id":"CRL_NDA210605_20190828","program":"mylan","apps":["NDA210605"],"app":"NDA210605","date":"2019-08-28","file":"210605_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210605_2020_Orig1s000OtherActionLtrs.pdf","cats":["DEV","FAC"],"cat_source":"rule","rule_cats":["DEV","FAC"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA210605_20190828:p1:s46","page":1,"text":"Therefore, please revert to the prior sub-bullet letter designations (A, B, C, etc.) under each numbered step that were used in the Human Factors study."},{"sid":"CRL_NDA210605_20190828:p1:s45","page":1,"text":"Please note that we consider this to be a major change to the IFU, which was validated by the Human Factors study."}]},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"insulin glargine","product_type":"not_classified","sponsor":"Mylan GmbH"},{"id":"CRL_NDA206610_20160310","program":"mylan_laboratories","apps":["NDA206610"],"app":"NDA206610","date":"2016-03-10","file":"206610_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206610_2021_Orig1s000OtherActionLtrs.pdf","cats":["NCL"],"cat_source":"rule","rule_cats":["NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":5,"product":"Acetaminophen ©","product_type":"not_classified","sponsor":"Mylan Pharmaceuticals Inc."},{"id":"CRL_NDA206610_20170201","program":"mylan_laboratories","apps":["NDA206610"],"app":"NDA206610","date":"2017-02-01","file":"206610_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206610_2021_Orig1s000OtherActionLtrs.pdf","cats":["NCL"],"cat_source":"rule","rule_cats":["NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":5,"product":"Acetaminophen ©","product_type":"not_classified","sponsor":"Mylan Pharmaceuticals Inc."},{"id":"CRL_NDA206610_20171206","program":"mylan_laboratories","apps":["NDA206610"],"app":"NDA206610","date":"2017-12-06","file":"206610_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206610_2021_Orig1s000OtherActionLtrs.pdf","cats":["NCL"],"cat_source":"rule","rule_cats":["NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":4,"n_app":5,"product":"Acetaminophen ©","product_type":"not_classified","sponsor":"Mylan Pharmaceuticals Inc."},{"id":"CRL_NDA206610_20190606","program":"mylan_laboratories","apps":["NDA206610"],"app":"NDA206610","date":"2019-06-06","file":"206610_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206610_2021_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":5,"n_app":5,"product":"Acetaminophen ©","product_type":"not_classified","sponsor":"Mylan Pharmaceuticals Inc."},{"id":"CRL_NDA204311_20141023","program":"mylan_pharmaceuticals","apps":["NDA204311"],"app":"NDA204311","date":"2014-10-23","file":"204311_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/204311_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA204311_20141023:p1:s32","page":1,"text":"Your amendment should include updated labeling, chemistry, manufacturing and controls data, and a safety update."}]},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":null,"product_type":"not_classified","sponsor":"Mylan Pharmaceuticals Inc."},{"id":"CRL_NDA206610_20150227","program":"mylan_pharmaceuticals","apps":["NDA206610"],"app":"NDA206610","date":"2015-02-27","file":"206610_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206610_2021_Orig1s000OtherActionLtrs.pdf","cats":["FAC","NCL"],"cat_source":"rule","rule_cats":["FAC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":5,"product":"Acetaminophen ©","product_type":"not_classified","sponsor":"Mylan Pharmaceuticals Inc."},{"id":"CRL_NDA204311_20190806","program":"mylan_pharmaceuticals","apps":["NDA204311"],"app":"NDA204311","date":"2019-08-06","file":"204311_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/204311_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":null,"product_type":"not_classified","sponsor":"Mylan Pharmaceuticals Inc."},{"id":"CRL_NDA204311_20230113","program":"mylan_pharmaceuticals_a_viatris","apps":["NDA204311"],"app":"NDA204311","date":"2023-01-13","file":"204311_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/204311_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":null,"product_type":"not_classified","sponsor":"Mylan Pharmaceuticals Inc."},{"id":"CRL_NDA217379_20240614","program":"nanocopoeia","apps":["NDA217379"],"app":"NDA217379","date":"2024-06-14","file":"CRL_NDA217379_20240614.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA217379_20240614.pdf","cats":["CLP","FAC","SAF"],"cat_source":"coded","rule_cats":["CLP","FAC"],"new_trial":"yes","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Cavhanza (nilotinib tablets), new nilotinib formulation","product_type":"505b2_new_formulation","sponsor":"Nanocopoeia, LLC"},{"id":"CRL_NDA218317_20240524","program":"neuroderm","apps":["NDA218317"],"app":"NDA218317","date":"2024-05-24","file":"CRL_NDA218317_20240524.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218317_20240524.pdf","cats":["CLP","CMC","DEV","FAC","NCL"],"cat_source":"coded","rule_cats":["CLP","CMC","DEV","FAC"],"new_trial":"yes","passages":{"CLP":[{"sid":"CRL_NDA218317_20240524:p1:s17","page":1,"text":"(1) Based on results from the relative bioavailability study, ND0612-115, an adequate scientific bridge to levodopa based on pharmacokinetic (PK) exposure was established; however, an adequate scientific bridge was not established for the carbidopa PK exposure between Engolce and the reliedupon listed drug, Sinemet, at the highest proposed dosage regimen of Engolce."}],"DEV":[{"sid":"CRL_NDA218317_20240524:p3:s0","page":3,"text":"3. The comments in this section are not intended to convey human factors (HF)"}]},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"ND0612 (carbidopa/levodopa continuous subcutaneous infusion)","product_type":"505b2_new_formulation","sponsor":"NeuroDerm, Ltd."},{"id":"CRL_NDA218317_20251021","program":"neuroderm","apps":["NDA218317"],"app":"NDA218317","date":"2025-10-21","file":"CRL_NDA218317_20251021.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218317_20251021.pdf","cats":["FAC","NCL"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"unclear","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"ND0612 (carbidopa/levodopa continuous subcutaneous infusion)","product_type":"505b2_new_formulation","sponsor":"NeuroDerm, Ltd."},{"id":"CRL_NDA214628_20210614","program":"nevakar","apps":["NDA214628"],"app":"NDA214628","date":"2021-06-14","file":"214628_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214628_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Norepinephrine Bitartrate","product_type":"not_classified","sponsor":"Nevakar, Inc."},{"id":"CRL_NDA206968_20150227","program":"nnopharma_licensing","apps":["NDA206968"],"app":"NDA206968","date":"2015-02-27","file":"206968_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206968_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC","NCL"],"cat_source":"rule","rule_cats":["CMC","FAC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":4,"product":"Acetaminophen","product_type":"not_classified","sponsor":"nnoPharma Licensing LLC"},{"id":"CRL_NDA213478_20200813","program":"nobelpharma","apps":["NDA213478"],"app":"NDA213478","date":"2020-08-13","file":"213478_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213478_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"sirolimus","product_type":"not_classified","sponsor":"Nobelpharma Co., Ltd."},{"id":"CRL_NDA202158_20131104","program":"northstar_medical_radioisotopes","apps":["NDA202158"],"app":"NDA202158","date":"2013-11-04","file":"202158_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/202158_2018_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA202158_20131104:p3:s20","page":3,"text":"Be advised that any change would require submission of complete chemistry, manufacturing and controls information (including the stability data) for that solution."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"TechneGen Generator","product_type":"not_classified","sponsor":"NorthStar Medical Radioisotopes, LLC"},{"id":"CRL_NDA214012_20201218","program":"novartis_pharmaceuticals","apps":["NDA214012"],"app":"NDA214012","date":"2020-12-18","file":"214012_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214012_2022_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"inclisiran","product_type":"not_classified","sponsor":"Novartis Pharmaceuticals Corporation"},{"id":"CRL_NDA214581_20210212","program":"novitium_pharma","apps":["NDA214581"],"app":"NDA214581","date":"2021-02-12","file":"214581_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214581_2022_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC"],"cat_source":"rule","rule_cats":["CLP","CMC"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA214581_20210212:p1:s23","page":1,"text":", of (2) conduct appropriate in vivo bioavailability or bioequivalence studies to bridge your proposed drug product to the listed drug."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Hydroxychloroquine Sulfate","product_type":"not_classified","sponsor":"Novitium Pharma LLC"},{"id":"CRL_BLA761315_20230424","program":"novo_nordisk","apps":["BLA761315"],"app":"BLA761315","date":"2023-04-24","file":"761315_2025_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761315_2025_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC","DEV","FAC"],"cat_source":"rule","rule_cats":["CLP","CMC","DEV","FAC"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_BLA761315_20230424:p8:s6","page":8,"text":"The comments in this section are not intended to convey human factors (HF) approvability issues with your proposed product; however, it will be necessary for you to consider how any revisions to your proposed product to address the deficiencies outlined above will impact your user interface."},{"sid":"CRL_BLA761315_20230424:p8:s7","page":8,"text":"If your user interface is revised in response to the complete response, you should update your use-related risk analysis (URRA) to determine whether any new risks, including new critical tasks or failure modes are introduced by the changes."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"NNC0148-0287","product_type":"not_classified","sponsor":"Novo Nordisk"},{"id":"CRL_BLA761326_20240710","program":"novo_nordisk","apps":["BLA761326"],"app":"BLA761326","date":"2024-07-10","file":"CRL_BLA761326_20240710.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761326_20240710.pdf","cats":["CMC","FAC","SAF"],"cat_source":"coded","rule_cats":["CMC","EFF","FAC","NCL","SAF"],"new_trial":"yes","passages":{"FAC":[{"sid":"CRL_BLA761326_20240710:p1:s31","page":1,"text":"Your complete response should include the date(s) of the facility's response to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies will be evaluated upon receipt of the complete response and may include re-inspection of the facility."}],"SAF":[{"sid":"CRL_BLA761326_20240710:p2:s11","page":2,"text":"As a path forward, provide new clinical data to demonstrate favorable benefit-risk for NNC0148-0287 in subjects with type 1 diabetes."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"insulin icodec (Awiqli FlexTouch)","product_type":"novel","sponsor":"Novo Nordisk"},{"id":"CRL_NDA208742_20160721","program":"ocular_therapeutix","apps":["NDA208742"],"app":"NDA208742","date":"2016-07-21","file":"208742_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208742_2018_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"DEXTENZA","product_type":"not_classified","sponsor":"Ocular Therapeutix, Inc."},{"id":"CRL_NDA208742_20170710","program":"ocular_therapeutix","apps":["NDA208742"],"app":"NDA208742","date":"2017-07-10","file":"208742_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208742_2018_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"DEXTENZA","product_type":"not_classified","sponsor":"Ocular Therapeutix, Inc."},{"id":"CRL_NDA217363_20260515","program":"ocuvex_therapeutics","apps":["NDA217363"],"app":"NDA217363","date":"2026-05-15","file":"CRL_NDA217363_20260515_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA217363_20260515_Redacted.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"PDP-716 (brimonidine tartrate ophthalmic suspension 0.35%, once daily)","product_type":"505b2_new_formulation","sponsor":"Ocuvex Therapeutics, Inc."},{"id":"CRL_BLA761152_20211015","program":"omeros","apps":["BLA761152"],"app":"BLA761152","date":"2021-10-15","file":"CRL_BLA761152_20211015.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761152_20211015.pdf","cats":["EFF"],"cat_source":"rule","rule_cats":["EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_BLA761152_20211015:p1:s18","page":1,"text":"The data presented in BLA 761152 fails to demonstrate substantial evidence of effectiveness for OMS721 for the treatment of hematopoietic stem cell transplantationthrombotic microangiopathy (HSCT-TMA)."},{"sid":"CRL_BLA761152_20211015:p1:s20","page":1,"text":"It appears you are attempting to establish substantial evidence of effectiveness by proposing a single adequate and well-controlled trial plus confirmatory evidence, instead of two adequate and well-controlled trials."},{"sid":"CRL_BLA761152_20211015:p2:s23","page":2,"text":"Although there appears to be partial attenuation of complement activation and a delay in thrombotic onset by OMS721 in animal and in vitro models, you have not shown evidence that this translates into a measurable clinical benefit, either directly or indirectly."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"OMS721","product_type":"not_classified","sponsor":"Omeros Corporation"},{"id":"CRL_NDA217433_20240715","program":"orexo","apps":["NDA217433"],"app":"NDA217433","date":"2024-07-15","file":"CRL_NDA217433_20240715.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA217433_20240715.pdf","cats":["CMC","DEV"],"cat_source":"coded","rule_cats":["CMC","DEV"],"new_trial":"no","passages":{"DEV":[{"sid":"CRL_NDA217433_20240715:p1:s33","page":1,"text":"(3) Based on the evaluation of the human factors (HF) validation study results, the user interface does not support the safe and effective use of the proposed product."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"OX124, high-dose naloxone hydrochloride nasal powder","product_type":"505b2_new_formulation","sponsor":"Orexo AB"},{"id":"CRL_NDA021164_20020315","program":"organon","apps":["NDA021164"],"app":"NDA021164","date":"2002-03-15","file":"021164Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/021164Orig1s000OtherActionLtrs.pdf","cats":["CLP","EFF","NCL","SAF"],"cat_source":"rule","rule_cats":["CLP","EFF","NCL","SAF"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA021164_20020315:p6:s24","page":6,"text":"2. In the food effect study, the data showed that food has a significant effect on gepirone bioavailability (increase in Cmax approximately of 62%)."}],"EFF":[{"sid":"CRL_NDA021164_20020315:p1:s23","page":1,"text":"You have not provided substantial evidence of effectiveness for the claim of short-term efficacy for gepirone ER in major depressive disorder (MDD)."},{"sid":"CRL_NDA021164_20020315:p3:s23","page":3,"text":"While we have concluded that you have not provided substantial evidence of effectiveness for any dose, it is likely that, if the drug is effective, the effective dose is likely to be at least 40 mg/day."},{"sid":"CRL_NDA021164_20020315:p2:s37","page":2,"text":"Although none of the 6 definitions would have been rejected as unreasonable primary endpoints, their post-facto identification, together with failure to show an effect on the primary endpoints, leaves Study 03A7-002 unable to provide primary support for the claim of efficacy of gepirone IR in MDD."}],"SAF":[{"sid":"CRL_NDA021164_20020315:p1:s16","page":1,"text":"The critical deficiency that is the basis of this nonapproval action is the lack of adequate efficacy data to support a claim in major depressive disorder as well as the inadequate amount of long-term safety data."},{"sid":"CRL_NDA021164_20020315:p3:s25","page":3,"text":"At a minimum, you will need to augment this safety database to meet the ICH guidelines for longterm safety data exposure at clinically effective doses as described above."}]},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"Gepirone Hydrochloride Extended Release","product_type":"not_classified","sponsor":"Organon, Inc."},{"id":"CRL_NDA021164_20040623","program":"organon","apps":["NDA021164"],"app":"NDA021164","date":"2004-06-23","file":"021164Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/021164Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"Gepirone Hydrochloride Extended Release","product_type":"not_classified","sponsor":"Organon, Inc."},{"id":"CRL_NDA022231_20091104","program":"orphan_therapeutics","apps":["NDA022231"],"app":"NDA022231","date":"2009-11-04","file":"022231Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/022231Orig1s000OtherActionLtrs.pdf","cats":["CMC","EFF","FAC"],"cat_source":"rule","rule_cats":["CMC","EFF","FAC"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA022231_20091104:p1:s22","page":1,"text":"The smaller, open-label TAHRS also failed on its pre-specified primary endpoint and failed to show a sustained effect on serum creatinine."}]},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"terlipressin","product_type":"not_classified","sponsor":"Orphan Therapeutics, LLC"},{"id":"CRL_NDA214927_20210617","program":"orphazyme_a_s","apps":["NDA214927"],"app":"NDA214927","date":"2021-06-17","file":"214927_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214927_2024_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"arimoclomol","product_type":"not_classified","sponsor":"Orphazyme A/S"},{"id":"CRL_NDA202971_20120726","program":"otsuka_pharmaceutical","apps":["NDA202971"],"app":"NDA202971","date":"2012-07-26","file":"CRL_NDA202971_20120726.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA202971_20120726.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"ABILIFY MAINTENA","product_type":"not_classified","sponsor":"Otsuka Pharmaceutical Company, Ltd."},{"id":"CRL_BLA761320_20250827","program":"outlook_therapeutics","apps":["BLA761320"],"app":"BLA761320","date":"2025-08-27","file":"CRL_BLA761320_20250827.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761320_20250827.pdf","cats":["EFF"],"cat_source":"coded","rule_cats":[],"new_trial":"unclear","passages":{},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"Lytenava (bevacizumab-vikg, ONS-5010), ophthalmic bevacizumab for wet AMD","product_type":"novel","sponsor":"Outlook Therapeutics, Inc."},{"id":"CRL_BLA761320_20251230","program":"outlook_therapeutics","apps":["BLA761320"],"app":"BLA761320","date":"2025-12-30","file":"CRL_BLA761320_20251230.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761320_20251230.pdf","cats":["EFF"],"cat_source":"coded","rule_cats":[],"new_trial":"unclear","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"Lytenava (bevacizumab-vikg, ONS-5010), ophthalmic bevacizumab for wet AMD","product_type":"novel","sponsor":"Outlook Therapeutics, Inc."},{"id":"CRL_NDA218879_20250103","program":"owp_pharmaceuticals","apps":["NDA218879"],"app":"NDA218879","date":"2025-01-03","file":"CRL_NDA218879_20250103.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218879_20250103.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC","NCL"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"SUBVENITE (lamotrigine) oral suspension","product_type":"505b2_new_formulation","sponsor":"OWP Pharmaceuticals, Inc."},{"id":"CRL_NDA212156_20200518","program":"par_sterile_products","apps":["NDA212156"],"app":"NDA212156","date":"2020-05-18","file":"212156_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212156_2021_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC","NCL"],"cat_source":"rule","rule_cats":["CMC","FAC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Micafungin","product_type":"not_classified","sponsor":"Par Sterile Products, LLC"},{"id":"CRL_BLA761081_20180420","program":"pfizer","apps":["BLA761081"],"app":"BLA761081","date":"2018-04-20","file":"761081_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761081_2019_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Trazimera","product_type":"not_classified","sponsor":"Pfizer Inc."},{"id":"CRL_BLA761184_20220121","program":"pfizer_ireland_pharmaceuticals","apps":["BLA761184"],"app":"BLA761184","date":"2022-01-21","file":"761184_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761184_2023_Orig1s000OtherActionLtrs.pdf","cats":["FAC","SAF"],"cat_source":"rule","rule_cats":["FAC","SAF"],"new_trial":null,"passages":{"SAF":[{"sid":"CRL_BLA761184_20220121:p1:s34","page":1,"text":"Given the availability of other hGH replacement therapies that have similar efficacy and that do not carry this risk, MOD-4023 does not appear to address any identifiable unmet need that would justify its approval in light of this uncertainty, and we have concluded that the benefit-risk profile for MOD-4023 is unfavorable at this time."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"MOD-4023","product_type":"not_classified","sponsor":"Pfizer Ireland Pharmaceuticals"},{"id":"CRL_NDA210649_20180313","program":"pharmaceuticals","apps":["NDA210649"],"app":"NDA210649","date":"2018-03-13","file":"210649_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210649_2019_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":null,"product_type":"not_classified","sponsor":"AB Pharmaceuticals, LLC"},{"id":"CRL_NDA210649_20180912","program":"pharmaceuticals","apps":["NDA210649"],"app":"NDA210649","date":"2018-09-12","file":"210649_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210649_2019_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":null,"product_type":"not_classified","sponsor":"AB Pharmaceuticals, LLC"},{"id":"CRL_BLA761166_20210312","program":"pharmaessentia","apps":["BLA761166"],"app":"BLA761166","date":"2021-03-12","file":"761166_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761166_2021_Orig1s000OtherActionLtrs.pdf","cats":["DEV","FAC"],"cat_source":"rule","rule_cats":["DEV","FAC"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_BLA761166_20210312:p1:s15","page":1,"text":"Based on the results of the human factors (HF) validation study data, root cause analysis, and participants' subjective feedback, the proposed product design and user interface do not support safe and effective use of the product, as previously communicated to you in our October 15, 2020, correspondence regarding our review of your HF study results report."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"P1101","product_type":"not_classified","sponsor":"PharmaEssentia Corporation"},{"id":"CRL_NDA202049_20130318","program":"pharmaxis","apps":["NDA202049"],"app":"NDA202049","date":"2013-03-18","file":"202049_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/202049_2021_Orig1s000OtherActionLtrs.pdf","cats":["CMC","EFF","FAC","SAF"],"cat_source":"rule","rule_cats":["CMC","EFF","FAC","SAF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA202049_20130318:p1:s23","page":1,"text":"The determination of efficacy based on the two submitted trials are not adequate because of the treatment-related frequent early dropouts in trial 301 for which the primary statistical analyses did not account and the lack of statistical significance in trial 302 for the primary endpoint."}],"SAF":[{"sid":"CRL_NDA202049_20130318:p1:s22","page":1,"text":"The submitted data do not provide a favorable benefit-risk balance to support the use of inhaled mannitol in patients with cystic fibrosis 6 years of age and older."}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"PRX-102","product_type":"not_classified","sponsor":"Pharmaxis Ltd."},{"id":"CRL_NDA215151_20230207","program":"phathom_pharmaceuticals","apps":["NDA215151"],"app":"NDA215151","date":"2023-02-07","file":"215151_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215151_2024_Orig1s000OtherActionLtrs.pdf","cats":["CLP"],"cat_source":"rule","rule_cats":["CLP"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA215151_20230207:p1:s15","page":1,"text":"The methods to be used in, and the facilities and controls used for, the manufacture, processing, packing, or holding of the drug substance or the drug product are inadequate to preserve its identity, strength, quality, purity, stability, and bioavailability (21 CFR 314.125(b)(1))."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Voquezna","product_type":"not_classified","sponsor":"Phathom Pharmaceuticals, Inc."},{"id":"CRL_UNKNOWN_20260109","program":"pierre_fabre_pharmaceuticals","apps":["BLA125745"],"app":"BLA125745","date":"2026-01-09","file":"CRL_BLA125745_20260109.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125745_20260109.pdf","cats":["EFF"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"unclear","passages":{"EFF":[{"sid":"CRL_UNKNOWN_20260109:p1:s18","page":1,"text":"For these reasons, the data from the ALLELE study are insufficient to demonstrate substantial evidence of effectiveness of tabelecleuce ®) ) to treat relapsed or refractory EBV+ PTLD."}]},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"tabelecleucel (Ebvallo), allogeneic EBV-specific T-cell therapy","product_type":"novel","sponsor":"Atara Biotherapeutics, Inc."},{"id":"CRL_NDA214375_20211005","program":"polarean","apps":["NDA214375"],"app":"NDA214375","date":"2021-10-05","file":"214375_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214375_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Xenoview","product_type":"not_classified","sponsor":"Polarean Inc."},{"id":"CRL_BLA761183_20210702","program":"provention_bio","apps":["BLA761183"],"app":"BLA761183","date":"2021-07-02","file":"761183_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761183_2023_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC","EFF","FAC"],"cat_source":"rule","rule_cats":["CLP","CMC","EFF","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"PRV-031","product_type":"not_classified","sponsor":"Provention Bio, Inc."},{"id":"CRL_NDA211321_20190329","program":"proximagen","apps":["NDA211321"],"app":"NDA211321","date":"2019-03-29","file":"211321_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211321_2019_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Nayzilam","product_type":"not_classified","sponsor":"Proximagen, LLC"},{"id":"CRL_NDA220049_20250818","program":"ptc_therapeutics","apps":["NDA220049"],"app":"NDA220049","date":"2025-08-18","file":"CRL_NDA220049_20250818.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA220049_20250818.pdf","cats":["CMC","EFF","NCL"],"cat_source":"coded","rule_cats":["CMC","EFF","NCL"],"new_trial":"yes","passages":{"EFF":[{"sid":"CRL_NDA220049_20250818:p1:s15","page":1,"text":"1. After a detailed review of your application, we have concluded that the data do not demonstrate substantial evidence of effectiveness (SEE) for vatiquinone in the treatment of Friedreich's Ataxia (FA)."},{"sid":"CRL_NDA220049_20250818:p1:s28","page":1,"text":"The clinical meaningfulness of the treatment difference is uncertain."},{"sid":"CRL_NDA220049_20250818:p2:s15","page":2,"text":"The overall persuasiveness of the findings on the USS, a nominally significant exploratory endpoint, in the setting of negative results on an acceptable clinically meaningful primary endpoint and key secondary endpoints are not sufficient to establish the effectiveness of vatiquinone for the treatment of FA."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"vatiquinone, 15-LO inhibitor for Friedreich ataxia","product_type":"novel","sponsor":"PTC Therapeutics, Inc."},{"id":"CRL_NDA217338_20240726","program":"rb_health_us","apps":["NDA217338"],"app":"NDA217338","date":"2024-07-26","file":"CRL_NDA217338_20240726.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA217338_20240726.pdf","cats":["CLP","EFF"],"cat_source":"coded","rule_cats":["CLP","EFF"],"new_trial":"unclear","passages":{"EFF":[{"sid":"CRL_NDA217338_20240726:p1:s30","page":1,"text":"Therefore, we conclude that the submitted material do not provide substantial evidence of efficacy to support the proposed 12-hour duration of action and dosing regimen."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"naproxen sodium / dextromethorphan HBr / guaifenesin ER tablet (Mucinex 12HR Cold & Fever Multi-Symptom, OTC)","product_type":"505b2_new_formulation","sponsor":"RB Health (US) LLC"},{"id":"CRL_NDA211302_20200128","program":"recordati_rare_diseases","apps":["NDA211302"],"app":"NDA211302","date":"2020-01-28","file":"211302_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211302_2020_Orig1s000OtherActionLtrs.pdf","cats":["CLP"],"cat_source":"rule","rule_cats":["CLP"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA211302_20200128:p1:s19","page":1,"text":"2. The methods to be used in, and the facilities and controls used for the manufacture, processing, packing and holding of the drug product are inadequate to preserve its identity, strength, quality, purity, stability or bioavailability."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Cystadrops","product_type":"not_classified","sponsor":"Recordati Rare Diseases Inc."},{"id":"CRL_NDA210583_20180523","program":"recro_pharma","apps":["NDA210583"],"app":"NDA210583","date":"2018-05-23","file":"210583_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210583_2020_Orig1s000OtherActionLtrs.pdf","cats":["CMC","EFF","NCL"],"cat_source":"rule","rule_cats":["CMC","EFF","NCL"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA210583_20180523:p1:s18","page":1,"text":"1. Although you have demonstrated a statistically significant difference between ANJESO and placebo on the primary endpoint in Studies REC-15-015 and REC-15-016, the results of the secondary analyses, including pain intensity difference over time curves, SPID1824, and SPID42-48, indicate that the analgesic effect does not persist through the dosing interval."}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Meloxicam","product_type":"not_classified","sponsor":"Recro Pharma Inc."},{"id":"CRL_NDA210583_20190322","program":"recro_pharma","apps":["NDA210583"],"app":"NDA210583","date":"2019-03-22","file":"210583_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210583_2020_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"Meloxicam","product_type":"not_classified","sponsor":"Recro Pharma Inc."},{"id":"CRL_NDA205394_20140131","program":"redhill_biopharma","apps":["NDA205394"],"app":"NDA205394","date":"2014-01-31","file":"205394_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/205394_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"RizaFilm","product_type":"not_classified","sponsor":"RedHill Biopharma Ltd."},{"id":"CRL_BLA761355_20230627","program":"regeneron_pharmaceuticals","apps":["BLA761355"],"app":"BLA761355","date":"2023-06-27","file":"761355_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761355_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"BLA","product_type":"not_classified","sponsor":"Regeneron Pharmaceuticals, Inc."},{"id":"CRL_BLA761303_20240322","program":"regeneron_pharmaceuticals","apps":["BLA761303"],"app":"BLA761303","date":"2024-03-22","file":"CRL_BLA761303Original1_20240322.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761303Original1_20240322.pdf","cats":["AAP"],"cat_source":"coded","rule_cats":["AAP","CMC"],"new_trial":"no","passages":{"AAP":[{"sid":"CRL_BLA761303_20240322:p1:s28","page":1,"text":"After enrollment and analysis of Part 1 (safety run-in or dose-finding) is completed for your intended confirmatory trial(s) in follicular lymphoma, we recommend you request a meeting with the Agency to discuss trial benchmarks (e.g., enrollment goals, site activation, proportion of primary endpoint events accrued, trial completion date) to allow measurement of the progress of the trial(s)."},{"sid":"CRL_BLA761303_20240322:p1:s29","page":1,"text":"You should demonstrate in your submission that your milestones are appropriate and that, prior to approval, you will demonstrate sufficient progress in the conduct of the confirmatory portion of the confirmatory trial(s) to provide sufficient assurance of timely completion of the trial(s)."}]},"type":"original","era":"issued","cycle":1,"n_app":3,"product":"odronextamab (Ordspono), CD20xCD3 bispecific antibody (R/R follicular lymphoma)","product_type":"novel","sponsor":"Regeneron Pharmaceuticals, Inc."},{"id":"CRL_BLA761303_20240322_2","program":"regeneron_pharmaceuticals","apps":["BLA761303"],"app":"BLA761303","date":"2024-03-22","file":"CRL_BLA761303Original2_20240322.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761303Original2_20240322.pdf","cats":["AAP"],"cat_source":"coded","rule_cats":["AAP","CMC"],"new_trial":"no","passages":{"AAP":[{"sid":"CRL_BLA761303_20240322_2:p1:s30","page":1,"text":"You should demonstrate in your submission that your milestones are appropriate and hat, prior to approval, you will demonstrate sufficient progress in the conduct of he confirmatory portion of the confirmatory trial to provide sufficient assurance of imely completion of the trial."}]},"type":"original","era":"issued","cycle":2,"n_app":3,"product":"odronextamab (Ordspono), CD20xCD3 bispecific antibody (R/R follicular lymphoma)","product_type":"novel","sponsor":"Regeneron Pharmaceuticals, Inc."},{"id":"CRL_BLA761400_20240820","program":"regeneron_pharmaceuticals","apps":["BLA761400"],"app":"BLA761400","date":"2024-08-20","file":"CRL_BLA761400_20240820.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761400_20240820.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC","NCL"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Lynozyfic (linvoseltamab-gcpt), BCMAxCD3 bispecific antibody","product_type":"novel","sponsor":"Regeneron Pharmaceuticals, Inc."},{"id":"CRL_BLA761303_20250730","program":"regeneron_pharmaceuticals","apps":["BLA761303"],"app":"BLA761303","date":"2025-07-30","file":"CRL_BLA761303_20250730.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761303_20250730.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":3,"n_app":3,"product":"odronextamab (Ordspono), CD20xCD3 bispecific antibody (R/R follicular lymphoma)","product_type":"novel","sponsor":"Regeneron Pharmaceuticals, Inc."},{"id":"CRL_UNKNOWN_20260207","program":"regenxbio","apps":["BLA125840"],"app":"BLA125840","date":"2026-02-07","file":"CRL_BLA125840_20260207.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125840_20260207.pdf","cats":["AAP","EFF"],"cat_source":"coded","rule_cats":["AAP","SAF"],"new_trial":"unclear","passages":{"EFF":[{"sid":"CRL_UNKNOWN_20260207:p2:s1","page":2,"text":"As communicated during the Late Cycle Meeting (1b) (4) ), the data from the RGX-121-101 Part 2 study are insufficient to provide substantial evidence of effectiveness to support approval of clemidsogene lanparvovec for the proposed indication of treatment of patients with MPS II, or for the narrower indication of neuronopathic MPS II pursued during clinical development."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"RGX-121 (clemidsogene lanparvovec), AAV gene therapy for MPS II","product_type":"novel","sponsor":"REGENXBIO, Inc."},{"id":"CRL_UNKNOWN_20250721","program":"replimune","apps":["BLA125827"],"app":"BLA125827","date":"2025-07-21","file":"CRL_BLA125827_20250721.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125827_20250721.pdf","cats":["EFF"],"cat_source":"coded","rule_cats":["CMC","EFF"],"new_trial":"yes","passages":{"EFF":[{"sid":"CRL_UNKNOWN_20250721:p1:s26","page":1,"text":"To address this deficiency, you must conduct and provide the results from adequate and well-controlled clinical trial(s) which demonstrate substantial evidence of effectiveness."},{"sid":"CRL_UNKNOWN_20250721:p1:s35","page":1,"text":"We recommend you submit a revised study protocol that assesses the individual contribution of vusolimogene oderparepvec to the observed ORR and provide a detailed justification for the statistical assumptions that support your primary efficacy endpoints."}]},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"RP1, vusolimogene oderparepvec (Tudriqev), oncolytic HSV-1","product_type":"novel","sponsor":"Replimune, Inc."},{"id":"CRL_UNKNOWN_20260410","program":"replimune","apps":["BLA125827"],"app":"BLA125827","date":"2026-04-10","file":"CRL_BLA125827_20260410.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125827_20260410.pdf","cats":["AAP","EFF"],"cat_source":"coded","rule_cats":["AAP","EFF"],"new_trial":"yes","passages":{"AAP":[{"sid":"CRL_UNKNOWN_20260410:p3:s5","page":3,"text":"FDA provided recommendations regarding use of data from the ongoing Phase 3 trial to potentially support Accelerated Approval."}],"EFF":[{"sid":"CRL_UNKNOWN_20260410:p4:s5","page":4,"text":"Therefore, RPL-001-16 is not considered to be an adequate and well controlled clinical investigation that provides substantial evidence of effectiveness and the FDA review team cannot conclude that the reported results are clinically meaningful."}]},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"RP1, vusolimogene oderparepvec (Tudriqev), oncolytic HSV-1","product_type":"novel","sponsor":"Replimune, Inc."},{"id":"CRL_NDA217382_20250602","program":"resq_pharma","apps":["NDA217382"],"app":"NDA217382","date":"2025-06-02","file":"CRL_NDA217382_20250602.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA217382_20250602.pdf","cats":["CLP","DEV","NCL"],"cat_source":"coded","rule_cats":["CLP","DEV","NCL"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Nutrilipid 20% soybean oil emulsion in kit (LipidRescue) for local anesthetic systemic toxicity","product_type":"other","sponsor":"ResQ Pharma"},{"id":"CRL_BLA761127_20211014","program":"revance_therapeutics","apps":["BLA761127"],"app":"BLA761127","date":"2021-10-14","file":"761127_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761127_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"daxibotulinumtoxinA","product_type":"not_classified","sponsor":"Revance Therapeutics, Inc."},{"id":"CRL_NDA212501_20190718","program":"ricon_pharma","apps":["NDA212501"],"app":"NDA212501","date":"2019-07-18","file":"212501_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212501_2021_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Cyclophosphamide","product_type":"not_classified","sponsor":"Ricon Pharma, LLC"},{"id":"CRL_UNKNOWN_20240614","program":"rocket_pharmaceuticals","apps":["BLA125806"],"app":"BLA125806","date":"2024-06-14","file":"CRL_BLA125806_20240614.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125806_20240614.pdf","cats":["CMC"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"unclear","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"KRESLADI (marnetegragene autotemcel), lentiviral gene therapy for severe LAD-I","product_type":"novel","sponsor":"Rocket Pharmaceuticals, Inc."},{"id":"CRL_NDA220140_20260305","program":"rosemont_pharmaceuticals_holdings","apps":["NDA220140"],"app":"NDA220140","date":"2026-03-05","file":"CRL_NDA220140_20260305.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA220140_20260305.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Valacyclovir for oral suspension (Hyloris; Rosemont commercial partner)","product_type":"505b2_new_formulation","sponsor":"Rosemont Pharmaceuticals Holdings, Inc."},{"id":"CRL_NDA203856_20130503","program":"roxane_laboratories","apps":["NDA203856"],"app":"NDA203856","date":"2013-05-03","file":"CRL_NDA203856_20130503.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA203856_20130503.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Cyclophosphamide","product_type":"not_classified","sponsor":"Roxane Laboratories, Inc."},{"id":"CRL_NDA208647_20160622","program":"salamandra","apps":["NDA208647"],"app":"NDA208647","date":"2016-06-22","file":"208647_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208647_2018_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"rosuvastatin","product_type":"not_classified","sponsor":"Salamandra, LLC"},{"id":"CRL_BLA761066_20180323","program":"samsung_bioepis","apps":["BLA761066"],"app":"BLA761066","date":"2018-03-23","file":"761066_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761066_2019_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Pyzchiva","product_type":"not_classified","sponsor":"Samsung Bioepis Co., Ltd."},{"id":"CRL_BLA761373_20240704","program":"samsung_bioepis","apps":["BLA761373"],"app":"BLA761373","date":"2024-07-04","file":"761373Orig2s000_761425Orig2s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761373Orig2s000_761425Orig2s000OtherActionLtrs.pdf","cats":["REG"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Pyzchiva","product_type":"not_classified","sponsor":"Samsung Bioepis Co., Ltd."},{"id":"CRL_BLA761045_20160624","program":"sandoz","apps":["BLA761045"],"app":"BLA761045","date":"2016-06-24","file":"761045_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761045_2019_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC","DEV","EFF"],"cat_source":"rule","rule_cats":["CLP","CMC","DEV","EFF"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_BLA761045_20160624:p3:s23","page":3,"text":"The proposed presentation(s) may need Human Factors studies to demonstrate that users can accurately measure the doses."}],"EFF":[{"sid":"CRL_BLA761045_20160624:p1:s28","page":1,"text":"In the absence of an adequate scientific bridge, there is insufficient data to support a demonstration of no clinically meaningful differences between LA-EP2006 and US-licensed Neulasta."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"EG12014","product_type":"not_classified","sponsor":"Sandoz Inc."},{"id":"CRL_BLA761271_20241205","program":"sandoz","apps":["BLA761271"],"app":"BLA761271","date":"2024-12-05","file":"CRL_BLA761271_20241205.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761271_20241205.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"EG12014, trastuzumab biosimilar (Herwenda in EU; EirGenix/Sandoz)","product_type":"biosimilar","sponsor":"Sandoz Inc."},{"id":"CRL_BLA761271_20251209","program":"sandoz","apps":["BLA761271"],"app":"BLA761271","date":"2025-12-09","file":"CRL_BLA761271_20251209.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761271_20251209.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"EG12014, trastuzumab biosimilar (Herwenda in EU; EirGenix/Sandoz)","product_type":"biosimilar","sponsor":"Sandoz Inc."},{"id":"CRL_NDA214429_20201112","program":"sanofi_aventis_us","apps":["NDA214429"],"app":"NDA214429","date":"2020-11-12","file":"214429_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214429_2021_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Fexinidazole","product_type":"not_classified","sponsor":"sanofi-aventis U.S. LLC"},{"id":"CRL_NDA215092_20211109","program":"santen","apps":["NDA215092"],"app":"NDA215092","date":"2021-11-09","file":"215092_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215092_2022_Orig1s000OtherActionLtrs.pdf","cats":["CLP"],"cat_source":"rule","rule_cats":["CLP"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA215092_20211109:p1:s16","page":1,"text":"211, and the methods to be used in, and the facilities and controls used for, the manufacture, processing, packing, or holding of the drug substance or the drug product are inadequate to preserve its identity, strength, quality, purity, stability, and bioavailability."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Omlonti","product_type":"not_classified","sponsor":"Santen, Inc."},{"id":"CRL_NDA218679_20250827","program":"saol_international_development","apps":["NDA218679"],"app":"NDA218679","date":"2025-08-27","file":"CRL_NDA218679_20250827.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf","cats":["CLP","EFF","NCL"],"cat_source":"coded","rule_cats":["AAP","EFF","SAF"],"new_trial":"yes","passages":{"EFF":[{"sid":"CRL_NDA218679_20250827:p1:s19","page":1,"text":"The data presented in NDA 218679 failed to demonstrate substantial evidence of effectiveness for sodium dichloroacetate (DCA) for the treatment of pyruvate dehydrogenase complex deficiency (PDCD)."},{"sid":"CRL_NDA218679_20250827:p2:s10","page":2,"text":"As substantial evidence of effectiveness of DCA for the treatment of PDCD was not established in this application, we cannot conclude that the known and potential risks with DCA in your application are outweighed by its benefit(s)."},{"sid":"CRL_NDA218679_20250827:p2:s8","page":2,"text":"If you intend to demonstrate substantial evidence of effectiveness based on a single adequate and well controlled trial, you will also need to provide adequate confirmatory evidence substantiating the results of your adequate and well controlled trial."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"SL1009, sodium dichloroacetate oral solution, for PDC deficiency","product_type":"novel","sponsor":"Saol International Development Limited"},{"id":"CRL_NDA211970_20190819","program":"sarepta_therapeutics","apps":["NDA211970"],"app":"NDA211970","date":"2019-08-19","file":"211970_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211970_2019_Orig1s000OtherActionLtrs.pdf","cats":["AAP","EFF","SAF"],"cat_source":"rule","rule_cats":["AAP","EFF","SAF"],"new_trial":null,"passages":{"AAP":[{"sid":"CRL_NDA211970_20190819:p5:s27","page":5,"text":"\"Thus, | am confident that this unique situation will not set a general precedent for drug approvals under the accelerated approval pathway, as the statute and regulations are clear that each situation must be evaluated on its own merits based on the totality of data and information.\""},{"sid":"CRL_NDA211970_20190819:p6:s0","page":6,"text":"First, considering the Center Director's 2016 decision on the accelerated approval of eteplirsen, there would have been support for granting accelerated approval to golodirsen - assuming other important aspects of the two drugs were equal."},{"sid":"CRL_NDA211970_20190819:p1:s17","page":1,"text":"\"reasonably likely\" to predict clinical benefit."}],"SAF":[{"sid":"CRL_NDA211970_20190819:p4:s35","page":4,"text":"/mportanily, therefore, the possibility of infections did not figure into eteplirsen's risk-benefit calculus at the time of its approval."},{"sid":"CRL_NDA211970_20190819:p6:s19","page":6,"text":"The important point here is that the benefit-risk balance with golodirsen differs from the benefit-risk balance that was known for eteplirsen at the time of its accelerated approval."},{"sid":"CRL_NDA211970_20190819:p6:s24","page":6,"text":"The risk-benefit profile for eteplirsen was quite different when it was given accelerated approval in 2016, as no risks were evident."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Vyondys","product_type":"not_classified","sponsor":"Sarepta Therapeutics, Inc."},{"id":"CRL_NDA213218_20200110","program":"sarfez_pharmaceuticals","apps":["NDA213218"],"app":"NDA213218","date":"2020-01-10","file":"213218_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213218_2022_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"pd Pe or to section","product_type":"not_classified","sponsor":"Sarfez Pharmaceuticals Inc."},{"id":"CRL_BLA761463_20250922","program":"scholar_rock","apps":["BLA761463"],"app":"BLA761463","date":"2025-09-22","file":"CRL_BLA761463_20250922.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761463_20250922.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"ISEMBYLD (apitegromab-mstn)","product_type":"novel","sponsor":"Scholar Rock, Inc."},{"id":"CRL_NDA218772_20240819","program":"scienture","apps":["NDA218772"],"app":"NDA218772","date":"2024-08-19","file":"218772_2025_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/218772_2025_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"coded","rule_cats":["CLP","CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Arbli (losartan potassium oral suspension 10 mg/mL)","product_type":"505b2_new_formulation","sponsor":"Scienture Inc."},{"id":"CRL_NDA207962_20160510","program":"scilex_pharmaceuticals","apps":["NDA207962"],"app":"NDA207962","date":"2016-05-10","file":"207962_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/207962_2018_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC","FAC","NCL","SAF"],"cat_source":"rule","rule_cats":["CLP","CMC","FAC","NCL","SAF"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA207962_20160510:p2:s14","page":2,"text":"To address this deficiency, conduct a new adequately-designed comparative bioavailability study to demonstrate equivalent systemic exposure to Lidoderm patch 5%."}],"SAF":[{"sid":"CRL_NDA207962_20160510:p6:s28","page":6,"text":"Provide a risk-benefit analysis addressing the potential benefits of ZTlido that would offset concerns about the dermal safety profile."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"ZTlido","product_type":"not_classified","sponsor":"Scilex Pharmaceuticals, Inc."},{"id":"CRL_NDA209988_20180611","program":"scpharmaceuticals","apps":["NDA209988"],"app":"NDA209988","date":"2018-06-11","file":"209988_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209988_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","DEV","EFF"],"cat_source":"rule","rule_cats":["CMC","DEV","EFF"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA209988_20180611:p7:s32","page":7,"text":"27. The human factors (HF) data do not support a conclusion that your proposed product can be used safely and effectively by the intended users for its intended uses and use environments."},{"sid":"CRL_NDA209988_20180611:p8:s1","page":8,"text":"We recommend that you submit your updated use-related risk analysis and human factors validation study protocol for review prior to commencing the study."},{"sid":"CRL_NDA209988_20180611:p8:s4","page":8,"text":"29. We recommend you consider the following as you update your use-related risk analysis and design your HF protocol methodology:"}],"EFF":[{"sid":"CRL_NDA209988_20180611:p7:s10","page":7,"text":"25. The Furoscix Infusor Product Design Clinical Validation Study (PDCV), Study CP-00001 did not meet its primary endpoint, \"Absence of Major Product Failure."}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Furoscix™ “","product_type":"not_classified","sponsor":"scPharmaceuticals, Inc."},{"id":"CRL_NDA209988_20201203","program":"scpharmaceuticals_services","apps":["NDA209988"],"app":"NDA209988","date":"2020-12-03","file":"209988_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/209988_2023_Orig1s000OtherActionLtrs.pdf","cats":["DEV","FAC"],"cat_source":"rule","rule_cats":["DEV","FAC"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA209988_20201203:p4:s14","page":4,"text":"Based on the aforementioned information and data, you should determine whether you need to submit the results of another human factors (HF) validation study conducted under simulated use conditions with representative users performing necessary tasks to demonstrate safe and effective use of the product."},{"sid":"CRL_NDA209988_20201203:p4:s6","page":4,"text":"We recommend you update your comprehensive use-related risk analysis taking into consideration the device modifications."},{"sid":"CRL_NDA209988_20201203:p3:s31","page":3,"text":"However, we note that your human factors/usability use-related risk analysis does not assess the risk of a patient applying the infusor if they have the characteristics listed in items 1 through 6 above."}],"FAC":[{"sid":"CRL_NDA209988_20201203:p10:s13","page":10,"text":"Comments about Facility Inspection Not Completed Due to Travel Restrictions:"}]},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"Furoscix™ “","product_type":"not_classified","sponsor":"scPharmaceuticals, Inc."},{"id":"CRL_NDA210864_20190322","program":"sedor_pharmaceuticals","apps":["NDA210864"],"app":"NDA210864","date":"2019-03-22","file":"210864_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210864_2021_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Sesquient","product_type":"not_classified","sponsor":"Sedor Pharmaceuticals, LLC"},{"id":"CRL_NDA210864_20191220","program":"sedor_pharmaceuticals","apps":["NDA210864"],"app":"NDA210864","date":"2019-12-20","file":"210864_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210864_2021_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"Sesquient","product_type":"not_classified","sponsor":"Sedor Pharmaceuticals, LLC"},{"id":"CRL_BLA761393_20250311","program":"seikagaku","apps":["BLA761393"],"app":"BLA761393","date":"2025-03-11","file":"CRL_BLA761393_20250311.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761393_20250311.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761393_20250311:p1:s16","page":1,"text":"1. Following pre-license inspection of isted in this application, conveyed leficiencies to the representative of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"SI-6603 (condoliase) injection, for lumbar disc herniation","product_type":"novel","sponsor":"Seikagaku Corporation"},{"id":"CRL_NDA211241_20250930","program":"sentynl_therapeutics","apps":["NDA211241"],"app":"NDA211241","date":"2025-09-30","file":"CRL_NDA211241_20250930.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA211241_20250930.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"ZYCUBO (copper histidinate) injection, for Menkes disease","product_type":"novel","sponsor":"Sentynl Therapeutics, Inc."},{"id":"CRL_BLA761290_20250131","program":"sfj_pharmaceuticals","apps":["BLA761290"],"app":"BLA761290","date":"2025-01-31","file":"CRL_BLA761290_20250131.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761290_20250131.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761290_20250131:p1:s41","page":1,"text":"Your complete response should include the date(s) of the facility's response(s) to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facilities."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"unknown (probably bentracimab, ticagrelor reversal agent)","product_type":"unknown","sponsor":"SFJ Pharmaceuticals, Inc."},{"id":"CRL_NDA212849_20200128","program":"shandong_luye_pharmaceutical","apps":["NDA212849"],"app":"NDA212849","date":"2020-01-28","file":"212849_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212849_2024_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC","DEV","FAC"],"cat_source":"rule","rule_cats":["CLP","CMC","DEV","FAC"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA212849_20200128:p1:s17","page":1,"text":"Your NDA submission provides adequate pharmacokinetic bridging (via the bioequivalence at steady-state) to the listed drug, Risperdal CONSTA."}],"CMC":[{"sid":"CRL_NDA212849_20200128:p1:s33","page":1,"text":"The following product quality deficiencies will need to be adequately addressed before this application can be approved:"},{"sid":"CRL_NDA212849_20200128:p3:s3","page":3,"text":"After resolving the Clinical, Clinical Pharmacology, and Product Quality deficiencies noted above, you must conduct a use-related risk analysis and determine whether a human factors validation study is necessary."}],"DEV":[{"sid":"CRL_NDA212849_20200128:p3:s12","page":3,"text":"Applications' for the content of a human factors validation study protocol submission."}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Rykindo","product_type":"not_classified","sponsor":"Shandong Luye Pharmaceutical Co., Ltd."},{"id":"CRL_NDA212849_20220218","program":"shandong_luye_pharmaceutical","apps":["NDA212849"],"app":"NDA212849","date":"2022-02-18","file":"212849_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212849_2024_Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC"],"cat_source":"rule","rule_cats":["CLP","CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"Rykindo","product_type":"not_classified","sponsor":"Shandong Luye Pharmaceutical Co., Ltd."},{"id":"CRL_NDA219846_20251023","program":"shanghai_auzone_biological_technology","apps":["NDA219846"],"app":"NDA219846","date":"2025-10-23","file":"CRL_NDA219846_20251023.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA219846_20251023.pdf","cats":["CMC","NCL"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"edaravone oral tablet (Auzone), for ALS","product_type":"505b2_new_formulation","sponsor":"Shanghai Auzone Biological Technology Co., Ltd."},{"id":"CRL_NDA212782_20200310","program":"shilpa_medicare","apps":["NDA212782"],"app":"NDA212782","date":"2020-03-10","file":"212782Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212782Orig1s000OtherActionLtrs.pdf","cats":["CLP","CMC"],"cat_source":"rule","rule_cats":["CLP","CMC"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA212782_20200310:p1:s28","page":1,"text":"(a) Conduct clinical studies to demonstrate the comparable bioavailability/bioequivalence and safety of your drug product."}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"bortezomib","product_type":"not_classified","sponsor":"Shilpa Medicare Limited"},{"id":"CRL_NDA215179_20210624","program":"shilpa_medicare","apps":["NDA215179"],"app":"NDA215179","date":"2021-06-24","file":"215179_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215179_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"bortezomib","product_type":"not_classified","sponsor":"Shilpa Medicare Limited"},{"id":"CRL_NDA215179_20220414","program":"shilpa_medicare","apps":["NDA215179"],"app":"NDA215179","date":"2022-04-14","file":"215179_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/215179_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"bortezomib","product_type":"not_classified","sponsor":"Shilpa Medicare Limited"},{"id":"CRL_NDA212782_20230801","program":"shilpa_medicare","apps":["NDA212782"],"app":"NDA212782","date":"2023-08-01","file":"212782Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212782Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"bortezomib","product_type":"not_classified","sponsor":"Shilpa Medicare Limited"},{"id":"CRL_BLA761148_20210803","program":"spectrum_pharmaceuticals","apps":["BLA761148"],"app":"BLA761148","date":"2021-08-03","file":"761148_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761148_2022_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"SPI-2012","product_type":"not_classified","sponsor":"Spectrum Pharmaceuticals, Inc."},{"id":"CRL_NDA216686_20221019","program":"spes_pharmaceuticals","apps":["NDA216686"],"app":"NDA216686","date":"2022-10-19","file":"216686_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/216686_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"fosaprepitant","product_type":"not_classified","sponsor":"Spes Pharmaceuticals Inc."},{"id":"CRL_NDA217294_20240112","program":"sq_innovation","apps":["NDA217294"],"app":"NDA217294","date":"2024-01-12","file":"CRL_NDA217294_20240112.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA217294_20240112.pdf","cats":["CMC","DEV"],"cat_source":"coded","rule_cats":["CMC","DEV"],"new_trial":"no","passages":{"DEV":[{"sid":"CRL_NDA217294_20240112:p2:s13","page":2,"text":"If your user interface is revised in response to the Complete Response, additional human factors considerations may apply."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Lasix ONYU (furosemide subcutaneous injection, on-body)","product_type":"505b2_new_formulation","sponsor":"SQ Innovation, Inc."},{"id":"CRL_NDA215244_20250515","program":"stealth_biotherapeutics","apps":["NDA215244"],"app":"NDA215244","date":"2025-05-15","file":"CRL_NDA215244_20250515.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA215244_20250515.pdf","cats":["AAP","EFF","FAC"],"cat_source":"coded","rule_cats":["AAP","EFF","FAC"],"new_trial":"unclear","passages":{"AAP":[{"sid":"CRL_NDA215244_20250515:p1:s20","page":1,"text":"For the reasons described below, we are unable to conclude that these approaches establish the effectiveness of elamipretide for traditional or accelerated approval, even when applying regulatory flexibility for this rare, serious disease."},{"sid":"CRL_NDA215244_20250515:p4:s0","page":4,"text":"FDA is considering the endpoint on muscle strength of the knee extensors assessed using handheld dynamometry in SPIBA-201, Part 2, as a potential intermediate clinical endpoint for accelerated approval of elamipretide, if it is reasonably likely to predict a clinical benefit in BTHS."},{"sid":"CRL_NDA215244_20250515:p1:s21","page":1,"text":"However, one of the endpoints in SPIBA-201, Part 2 - muscle strength of the knee extensors assessed using handheld dynamometry - could be reasonable as an intermediate clinical endpoint for accelerated approval."}],"EFF":[{"sid":"CRL_NDA215244_20250515:p1:s33","page":1,"text":"SPIBA-201, Part 1, the only randomized, placebo-controlled, study of elamipretide in patients with BTHS, did not show superiority of elamipretide to placebo on the primary endpoint family of distance walked on 6-minute walk test (6MWT) (p=0.97) and total fatigue score (TFS) on the Barth syndrome symptom assessment (p=0.89) at the end of the 12-week treatment period."},{"sid":"CRL_NDA215244_20250515:p4:s0","page":4,"text":"FDA is considering the endpoint on muscle strength of the knee extensors assessed using handheld dynamometry in SPIBA-201, Part 2, as a potential intermediate clinical endpoint for accelerated approval of elamipretide, if it is reasonably likely to predict a clinical benefit in BTHS."},{"sid":"CRL_NDA215244_20250515:p1:s17","page":1,"text":"We extensively evaluated whether the evidence for the endpoints that directly assessed clinical benefit (i.e., how patients feel, function, or survive) in your studies could establish the effectiveness of elamipretide for traditional approval."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"elamipretide (Forzinity)","product_type":"novel","sponsor":"Stealth BioTherapeutics Inc."},{"id":"CRL_UNKNOWN_20230120","program":"stemcyte","apps":["BLA125764"],"app":"BLA125764","date":"2023-01-20","file":"CRL_BLA125764_20230120.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125764_20230120.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"FAC":[{"sid":"CRL_UNKNOWN_20230120:p8:s13","page":8,"text":"Outstanding inspectional issues relating to the pre-license inspection (PLI) performed at your Baldwin Park, CA facility from August 29 to September 2, 2022:"}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Hematopoietic Progenitor Cells","product_type":"not_classified","sponsor":"StemCyte, Inc."},{"id":"CRL_NDA206185_20141124","program":"sun_pharma_advanced_research","apps":["NDA206185"],"app":"NDA206185","date":"2014-11-24","file":"206185_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206185_2018_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"Elepsia XR","product_type":"not_classified","sponsor":"Sun Pharma Advanced Research Company Limited"},{"id":"CRL_NDA206185_20150730","program":"sun_pharma_advanced_research","apps":["NDA206185"],"app":"NDA206185","date":"2015-07-30","file":"206185_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206185_2018_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"Elepsia XR","product_type":"not_classified","sponsor":"Sun Pharma Advanced Research Company Limited"},{"id":"CRL_NDA204417_20150923","program":"sun_pharma_advanced_research","apps":["NDA204417"],"app":"NDA204417","date":"2015-09-23","file":"204417Orig1s000OtherActionLtr.pdf","url":"https://download.open.fda.gov/crl/204417Orig1s000OtherActionLtr.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"Elepsia XR","product_type":"not_classified","sponsor":"Sun Pharma Global FZE"},{"id":"CRL_NDA206185_20161219","program":"sun_pharma_advanced_research","apps":["NDA206185"],"app":"NDA206185","date":"2016-12-19","file":"206185_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/206185_2018_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"Elepsia XR","product_type":"not_classified","sponsor":"Sun Pharma Advanced Research Company Limited"},{"id":"CRL_NDA204417_20170322","program":"sun_pharma_advanced_research","apps":["NDA204417"],"app":"NDA204417","date":"2017-03-22","file":"204417Orig1s000OtherActionLtr.pdf","url":"https://download.open.fda.gov/crl/204417Orig1s000OtherActionLtr.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"Elepsia XR","product_type":"not_classified","sponsor":"Sun Pharma Global FZE"},{"id":"CRL_NDA204417_20130329","program":"sun_pharma_global_fze","apps":["NDA204417"],"app":"NDA204417","date":"2013-03-29","file":"204417Orig1s000OtherActionLtr.pdf","url":"https://download.open.fda.gov/crl/204417Orig1s000OtherActionLtr.pdf","cats":["CLP"],"cat_source":"rule","rule_cats":["CLP"],"new_trial":null,"passages":{"CLP":[{"sid":"CRL_NDA204417_20130329:p1:s23","page":1,"text":"We acknowledge that the data from your bioequivalence (BE) studies establish that your product is bioequivalent to Keppra XR in the fasted state."},{"sid":"CRL_NDA204417_20130329:p1:s42","page":1,"text":"XR, we cannot approve your 1000 mg tablet based on a waiver of the bioequivalence requirement for that strength."}]},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"Elepsia XR","product_type":"not_classified","sponsor":"Sun Pharma Global FZE"},{"id":"CRL_NDA208313_20151124","program":"sun_pharmaceutical_industries","apps":["NDA208313"],"app":"NDA208313","date":"2015-11-24","file":"208313_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208313_2018_Orig1s000OtherActionLtrs.pdf","cats":["DEV","FAC"],"cat_source":"rule","rule_cats":["DEV","FAC"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA208313_20151124:p1:s31","page":1,"text":"We recommend the following comments be implemented prior to commencing the gemcitabine hydrochloride in sodium chloride injection summative human factors study."}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"nilotinib","product_type":"not_classified","sponsor":"Sun Pharmaceutical Industries Limited"},{"id":"CRL_NDA208313_20170523","program":"sun_pharmaceutical_industries","apps":["NDA208313"],"app":"NDA208313","date":"2017-05-23","file":"208313_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208313_2018_Orig1s000OtherActionLtrs.pdf","cats":["FAC","NCL"],"cat_source":"rule","rule_cats":["FAC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"nilotinib","product_type":"not_classified","sponsor":"Sun Pharmaceutical Industries Limited"},{"id":"CRL_NDA215644_20241025","program":"sun_pharmaceutical_industries","apps":["NDA215644"],"app":"NDA215644","date":"2024-10-25","file":"CRL_NDA215644_20241025.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA215644_20241025.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC","NCL"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_NDA215644_20241025:p1:s58","page":1,"text":"FDA may determine that a CGMP reinspection and/or additional pre-approval inspection (PAI) is needed to confirm satisfactory resolution of inspection deficiencies before this application can be approved."}]},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"nilotinib capsules (Sun Pharma)","product_type":"unknown","sponsor":"Sun Pharmaceutical Industries Limited"},{"id":"CRL_NDA215644_20250625","program":"sun_pharmaceutical_industries","apps":["NDA215644"],"app":"NDA215644","date":"2025-06-25","file":"CRL_NDA215644_20250625.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA215644_20250625.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"nilotinib capsules (Sun Pharma)","product_type":"unknown","sponsor":"Sun Pharmaceutical Industries Limited"},{"id":"CRL_NDA210875_20190129","program":"sunovion_pharmaceuticals","apps":["NDA210875"],"app":"NDA210875","date":"2019-01-29","file":"210875_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210875_2020_Orig1s000OtherActionLtrs.pdf","cats":["CLP","DEV","SAF"],"cat_source":"rule","rule_cats":["CLP","DEV","SAF"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA210875_20190129:p1:s20","page":1,"text":"As communicated to you in a November 21, 2018, Discipline Review (DR) letter, the human factors (HF) validation study conducted for Kynmobi does not provide sufficient evidence to demonstrate that the proposed product can be used safely and effectively by intended users for its intended uses and use environments."},{"sid":"CRL_NDA210875_20190129:p1:s22","page":1,"text":"Additionally, you have not provided data to demonstrate that your proposed mitigations are effective and do not introduce new use-related risks."},{"sid":"CRL_NDA210875_20190129:p2:s4","page":2,"text":"A human factors validation study using the intend-to-market user interface (i.e., oe packaging) is needed to demonstrate that the mitigations are effective and do not introduce new risks."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Kynmobi","product_type":"not_classified","sponsor":"Sunovion Pharmaceuticals Inc."},{"id":"CRL_NDA211964_20201106","program":"supernus_pharmaceuticals","apps":["NDA211964"],"app":"NDA211964","date":"2020-11-06","file":"211964_2021_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211964_2021_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"viloxazine hydrochloride","product_type":"not_classified","sponsor":"Supernus Pharmaceuticals, Inc."},{"id":"CRL_BLA761438_20260626","program":"swedish_orphan_biovitrum_publ","apps":["BLA761438"],"app":"BLA761438","date":"2026-06-26","file":"CRL_BLA761438_20260626_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761438_20260626_Redacted.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761438_20260626:p1:s68","page":1,"text":"Following a CGMP inspection and pre-license inspection 0 conveyed deficiencies to the representative of the facility."},{"sid":"CRL_BLA761438_20260626:p1:s75","page":1,"text":"FDA may determine that a CGMP reinspection and/or additional pre-license inspection (PLI) is needed to confirm satisfactory resolution of inspection deficiencies before this application can be approved."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"NASP / SEL-212 (pegadricase-sogo + nanoencapsulated sirolimus), for uncontrolled gout","product_type":"novel","sponsor":"Swedish Orphan Biovitrum AB (publ)"},{"id":"CRL_NDA219694_20251022","program":"sydnexis","apps":["NDA219694"],"app":"NDA219694","date":"2025-10-22","file":"CRL_NDA219694_20251022.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA219694_20251022.pdf","cats":["EFF"],"cat_source":"coded","rule_cats":["EFF"],"new_trial":"unclear","passages":{"EFF":[{"sid":"CRL_NDA219694_20251022:p1:s17","page":1,"text":"There is a lack of substantial evidence consisting of adequate and well-controlled investigations, as defined in 21 CFR 314.126, that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling."},{"sid":"CRL_NDA219694_20251022:p1:s19","page":1,"text":"In Study SYD-101-001, the atropine 0.01% dose but not the atropine 0.03% dose met the primary endpoint."},{"sid":"CRL_NDA219694_20251022:p2:s27","page":2,"text":"While Study SYD-101-001 achieved its prespecified primary endpoint, multiple factors raise significant concerns regarding the robustness and clinical meaningfulness of the observed treatment effect:"}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"SYD-101, atropine sulfate ophthalmic 0.01% for pediatric myopia","product_type":"505b2_new_formulation","sponsor":"SYDNEXIS Inc."},{"id":"CRL_BLA761133_20191217","program":"takeda_pharmaceuticals_usa","apps":["BLA761133"],"app":"BLA761133","date":"2019-12-17","file":"761133_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761133_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","DEV","FAC"],"cat_source":"rule","rule_cats":["CMC","DEV","FAC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_BLA761133_20191217:p4:s30","page":4,"text":"1. Reference is made to the deficiencies related to product quality (i.e., for device design, control and performance) and the recommended resolution to these deficiencies as conveyed above."},{"sid":"CRL_BLA761133_20191217:p5:s1","page":5,"text":"Therefore, the Chemistry, Manufacturing and Control (CMC) information and data provided are considered inadequate to support the intended performance of the proposed combination products from a biologic product quality perspective."},{"sid":"CRL_BLA761133_20191217:p5:s5","page":5,"text":"CMC changes and/or the manufacture of vedolizumab, device, and final combination product(s) in the resubmission, provide appropriate justification to support the relevance of the information and data."}],"DEV":[{"sid":"CRL_BLA761133_20191217:p1:s28","page":1,"text":"We recommend that you implement these revisions along with additional mitigations that you determine to be necessary to address these use-related issues and conduct and submit results of another human factors validation study to demonstrate that the mitigations are effective and do not introduce new risks."},{"sid":"CRL_BLA761133_20191217:p1:s21","page":1,"text":"(5) The human factors (HF) validation study results for your Entyvio prefilled pen submitted on March 7, 2019 identified several use errors, close calls, and use difficulties with critical and non-critical tasks."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Eohilia","product_type":"not_classified","sponsor":"Takeda Pharmaceuticals U.S.A., Inc."},{"id":"CRL_NDA213976_20211217","program":"takeda_pharmaceuticals_usa","apps":["NDA213976"],"app":"NDA213976","date":"2021-12-17","file":"213976_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213976_2024_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Eohilia","product_type":"not_classified","sponsor":"Takeda Pharmaceuticals U.S.A., Inc."},{"id":"CRL_BLA761126_20190924","program":"tanvex_biopharma_usa","apps":["BLA761126"],"app":"BLA761126","date":"2019-09-24","file":"761126_2025_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761126_2025_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_BLA761126_20190924:p5:s35","page":5,"text":"In addition, provide a risk assessment and supporting data to address the potential leachables derived from the drug substance manufacturing process and their potential impact on product quality and patient safety."}]},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"TX05","product_type":"not_classified","sponsor":"Tanvex BioPharma USA, Inc."},{"id":"CRL_BLA761126_20210520","program":"tanvex_biopharma_usa","apps":["BLA761126"],"app":"BLA761126","date":"2021-05-20","file":"761126_2025_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761126_2025_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"TX05","product_type":"not_classified","sponsor":"Tanvex BioPharma USA, Inc."},{"id":"CRL_BLA761126_20230214","program":"tanvex_biopharma_usa","apps":["BLA761126"],"app":"BLA761126","date":"2023-02-14","file":"761126_2025_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761126_2025_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"TX05","product_type":"not_classified","sponsor":"Tanvex BioPharma USA, Inc."},{"id":"CRL_BLA761266_20250103","program":"tanvex_biopharma_usa","apps":["BLA761266"],"app":"BLA761266","date":"2025-01-03","file":"CRL_BLA761266_20250103.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761266_20250103.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"TX05, trastuzumab biosimilar (Herceptin)","product_type":"biosimilar","sponsor":"Tanvex BioPharma USA, Inc."},{"id":"CRL_BLA761266_20260623","program":"tanvex_biopharma_usa","apps":["BLA761266"],"app":"BLA761266","date":"2026-06-23","file":"CRL_BLA761266_20260623_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761266_20260623_Redacted.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"TX05, trastuzumab biosimilar (Herceptin)","product_type":"biosimilar","sponsor":"Tanvex BioPharma USA, Inc."},{"id":"CRL_NDA218592_20250425","program":"telix_pharmaceuticals_us","apps":["NDA218592"],"app":"NDA218592","date":"2025-04-25","file":"CRL_NDA218592_20250425.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218592_20250425.pdf","cats":["CMC","EFF"],"cat_source":"coded","rule_cats":["CMC","EFF"],"new_trial":"unclear","passages":{"EFF":[{"sid":"CRL_NDA218592_20250425:p1:s19","page":1,"text":"Evidence provided as confirmatory evidence of effectiveness was not sufficiently strong to complement study 18F-TLX101-CDx-203. Four studies were examined as confirmatory evidence, including one re-read of images obtained from expanded access use of floretyrosine F 18, GBM-RET-01, and three published retrospective studies."},{"sid":"CRL_NDA218592_20250425:p1:s24","page":1,"text":"To address these issues, a second adequate and well-controlled efficacy study, which could be conducted in the same patient population or a closely related condition, or other robust confirmatory evidence of efficacy is necessary."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"PIXCLARA (floretyrosine F 18; TLX101-CDx), FET PET agent for glioma","product_type":"novel","sponsor":"Telix Pharmaceuticals (US) Inc."},{"id":"CRL_BLA761401_20260410","program":"telix_pharmaceuticals_us","apps":["BLA761401"],"app":"BLA761401","date":"2026-04-10","file":"CRL_BLA761401_20260410.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761401_20260410.pdf","cats":["CLP","CMC","FAC"],"cat_source":"coded","rule_cats":["CLP","CMC","FAC"],"new_trial":"yes","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"TLX250-CDx, 89Zr-girentuximab (Zircaix), PET imaging agent","product_type":"novel","sponsor":"Telix Pharmaceuticals (US) Inc."},{"id":"CRL_NDA213586_20220415","program":"teva_neuroscience","apps":["NDA213586"],"app":"NDA213586","date":"2022-04-15","file":"213586_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213586_2024_Orig1s000OtherActionLtrs.pdf","cats":["EFF"],"cat_source":"rule","rule_cats":["EFF"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"risperidone","product_type":"not_classified","sponsor":"Teva Neuroscience, Inc."},{"id":"CRL_NDA208082_20160527","program":"teva_pharmaceuticals","apps":["NDA208082"],"app":"NDA208082","date":"2016-05-27","file":"CRL_NDA208082_20160527.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA208082_20160527.pdf","cats":["CLP","CMC","NCL"],"cat_source":"rule","rule_cats":["CLP","CMC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"TVB-009","product_type":"not_classified","sponsor":"Teva Pharmaceuticals, Inc."},{"id":"CRL_BLA761385_20250730","program":"teva_pharmaceuticals","apps":["BLA761385"],"app":"BLA761385","date":"2025-07-30","file":"CRL_BLA761385_20250730.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761385_20250730.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761385_20250730:p1:s20","page":1,"text":"FDA may need to perform an onsite pre-license inspection (PLI) before this application may be approved."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"TVB-009, denosumab-adet (Ponlimsi), Prolia biosimilar","product_type":"biosimilar","sponsor":"Teva Pharmaceuticals, Inc."},{"id":"CRL_NDA208574_20160601","program":"teva_pharmaceuticals_usa","apps":["NDA208574"],"app":"NDA208574","date":"2016-06-01","file":"208574Orig1s000,Orig2s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208574Orig1s000%2COrig2s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"Romidepsin","product_type":"not_classified","sponsor":"Teva Pharmaceuticals USA"},{"id":"CRL_NDA208042_20160930","program":"teva_pharmaceuticals_usa","apps":["NDA208042"],"app":"NDA208042","date":"2016-09-30","file":"208042_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208042_2018_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Fulvestrant","product_type":"not_classified","sponsor":"Teva Pharmaceuticals USA"},{"id":"CRL_NDA208574_20170602","program":"teva_pharmaceuticals_usa","apps":["NDA208574"],"app":"NDA208574","date":"2017-06-02","file":"208574Orig1s000,Orig2s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208574Orig1s000%2COrig2s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"Romidepsin","product_type":"not_classified","sponsor":"Teva Pharmaceuticals USA"},{"id":"CRL_NDA210063_20171026","program":"teva_pharmaceuticals_usa","apps":["NDA210063"],"app":"NDA210063","date":"2017-10-26","file":"210063_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210063_2019_Orig1s000OtherActionLtrs.pdf","cats":["CMC","DEV","NCL"],"cat_source":"rule","rule_cats":["CMC","DEV","NCL"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA210063_20171026:p4:s0","page":4,"text":"We recommend you conduct a comprehensive use-related risk analysis if you have not already completed one."},{"sid":"CRL_NDA210063_20171026:p3:s30","page":3,"text":"1. We note that you have not submitted a comprehensive risk analysis or your justification for not conducting a Human Factors (HF) validation study."},{"sid":"CRL_NDA210063_20171026:p4:s1","page":4,"text":"The comprehensive use-related risk analysis should include a comprehensive and systematic evaluation of all the steps involved in using your product (e.g., based on a task analysis) the errors that users might commit or the tasks they might fail to perform and the potential negative clinical consequences of use errors and task failures."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Fulvestrant","product_type":"not_classified","sponsor":"Teva Pharmaceuticals USA"},{"id":"CRL_NDA201110_20110228","program":"teva_womens_health","apps":["NDA201110"],"app":"NDA201110","date":"2011-02-28","file":"201110_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/201110_2020_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"progesterone","product_type":"not_classified","sponsor":"Teva Women’s Health, Inc."},{"id":"CRL_NDA212479_20211222","program":"therakind","apps":["NDA212479"],"app":"NDA212479","date":"2021-12-22","file":"212479Orig1,Orig2,Orig3,Orig4s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212479Orig1%2COrig2%2COrig3%2COrig4s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Jylamvo","product_type":"not_classified","sponsor":"Therakind Limited"},{"id":"CRL_NDA208564_20170505","program":"therapeuticsmd","apps":["NDA208564"],"app":"NDA208564","date":"2017-05-05","file":"208564_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208564_2018_Orig1s000OtherActionLtrs.pdf","cats":["CMC","SAF"],"cat_source":"rule","rule_cats":["CMC","SAF"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"estradiol","product_type":"not_classified","sponsor":"TherapeuticsMD, Inc."},{"id":"CRL_NDA200655_20131022","program":"thomas_chaly_phd_faic","apps":["NDA200655"],"app":"NDA200655","date":"2013-10-22","file":"200655_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/200655_2019_Orig1s000OtherActionLtrs.pdf","cats":["CMC","EFF"],"cat_source":"rule","rule_cats":["CMC","EFF"],"new_trial":null,"passages":{"EFF":[{"sid":"CRL_NDA200655_20131022:p2:s1","page":2,"text":"However, Study #21 does not provide substantial evidence of efficacy for the following reasons:"}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Fluorodopa F","product_type":"not_classified","sponsor":"Thomas Chaly, Ph.D., FAIC"},{"id":"CRL_NDA210730_20181102","program":"trevena","apps":["NDA210730"],"app":"NDA210730","date":"2018-11-02","file":"210730_2020_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210730_2020_Orig1s000OtherActionLtrs.pdf","cats":["CMC","NCL","SAF"],"cat_source":"rule","rule_cats":["CMC","NCL","SAF"],"new_trial":null,"passages":{"SAF":[{"sid":"CRL_NDA210730_20181102:p2:s2","page":2,"text":"Specifically, the safety database must include at least 350 patients exposed to the highest dose proposed for the longest duration of use indicated in the labeling."},{"sid":"CRL_NDA210730_20181102:p1:s43","page":1,"text":"You have proposed a maximum daily dose of 40 mg ™® You were advised at the End-ofPhase 2 and pre-NDA meetings that the safety database needed to include at least 350 patients exposed to the highest doses for the longest duration of use."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Oliceridine","product_type":"not_classified","sponsor":"Trevena, Inc."},{"id":"CRL_NDA210526_20180725","program":"tris_pharma","apps":["NDA210526"],"app":"NDA210526","date":"2018-07-25","file":"210526_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210526_2022_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"Dyanavel XR","product_type":"not_classified","sponsor":"Tris Pharma, Inc."},{"id":"CRL_NDA220138_20260615","program":"tris_pharma","apps":["NDA220138"],"app":"NDA220138","date":"2026-06-15","file":"CRL_NDA220138_20260615_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA220138_20260615_Redacted.pdf","cats":["CLP","CMC","EFF","NCL"],"cat_source":"coded","rule_cats":["CLP","CMC","DEV","EFF","NCL"],"new_trial":"yes","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"TRN-257, low-sodium once-nightly oxybate ER oral suspension","product_type":"505b2_new_formulation","sponsor":"Tris Pharma, Inc."},{"id":"CRL_BLA761151_20220512","program":"ugb","apps":["BLA761151"],"app":"BLA761151","date":"2022-05-12","file":"761151_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/761151_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"UCB4940","product_type":"not_classified","sponsor":"UGB, Inc."},{"id":"CRL_UNKNOWN_20250707","program":"ultragenyx_pharmaceutical","apps":["BLA125845"],"app":"BLA125845","date":"2025-07-07","file":"CRL_BLA125845_20250707.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA125845_20250707.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"UX111, rebisufligene etisparvovec (Fayuvi), AAV9 gene therapy for MPS IIIA","product_type":"novel","sponsor":"Ultragenyx Pharmaceutical Inc."},{"id":"CRL_NDA218607_20250627","program":"unicycive_therapeutics","apps":["NDA218607"],"app":"NDA218607","date":"2025-06-27","file":"CRL_NDA218607_20250627.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218607_20250627.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_NDA218607_20250627:p1:s17","page":1,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA Form 483 prior to your complete response to your application."}]},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"oxylanthanum carbonate (OLC) tablets","product_type":"505b2_new_formulation","sponsor":"Unicycive Therapeutics Inc."},{"id":"CRL_NDA218607_20260629","program":"unicycive_therapeutics","apps":["NDA218607"],"app":"NDA218607","date":"2026-06-29","file":"CRL_NDA218607_20260629.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218607_20260629.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_NDA218607_20260629:p1:s18","page":1,"text":"The facility should provide satisfactory responses to hese deficiencies to the FDA office indicated on the FDA Form 483 prior to your complete response."}]},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"oxylanthanum carbonate (OLC) tablets","product_type":"505b2_new_formulation","sponsor":"Unicycive Therapeutics Inc."},{"id":"CRL_NDA208276_20161007","program":"united_therapeutics","apps":["NDA208276"],"app":"NDA208276","date":"2016-10-07","file":"208276_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208276_2018_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"treprostinil","product_type":"not_classified","sponsor":"United Therapeutics Corporation"},{"id":"CRL_NDA208276_20170602","program":"united_therapeutics","apps":["NDA208276"],"app":"NDA208276","date":"2017-06-02","file":"208276_2018_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/208276_2018_Orig1s000OtherActionLtrs.pdf","cats":["DEV"],"cat_source":"rule","rule_cats":["DEV"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"treprostinil","product_type":"not_classified","sponsor":"United Therapeutics Corporation"},{"id":"CRL_NDA214324_20211015","program":"united_therapeutics","apps":["NDA214324"],"app":"NDA214324","date":"2021-10-15","file":"214324_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/214324_2022_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"treprostinil","product_type":"not_classified","sponsor":"United Therapeutics Corporation"},{"id":"CRL_NDA218353_20250425","program":"university_california_san_francisco","apps":["NDA218353"],"app":"NDA218353","date":"2025-04-25","file":"CRL_NDA218353_20250425.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218353_20250425.pdf","cats":["EFF"],"cat_source":"coded","rule_cats":["EFF"],"new_trial":"unclear","passages":{"EFF":[{"sid":"CRL_NDA218353_20250425:p1:s18","page":1,"text":"Evidence provided as confirmatory evidence of effectiveness was not sufficiently strong to complement study 18F-TLX101-CDx-203. Four studies were examined as confirmatory evidence, including one re-read of images obtained from expanded access use of floretyrosine F 18, GBM-RET-01, and three published retrospective studies."},{"sid":"CRL_NDA218353_20250425:p1:s23","page":1,"text":"To address these issues, a second adequate and well-controlled efficacy study, which could be conducted in the same patient population or a closely related condition, or other robust confirmatory evidence of efficacy is necessary."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"[18F]floretyrosine (FET) PET, UCSF academic NDA","product_type":"novel","sponsor":"University of California San Francisco"},{"id":"CRL_NDA210821_20181120","program":"valeant_pharmaceuticals_ireland","apps":["NDA210821"],"app":"NDA210821","date":"2018-11-20","file":"210821_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210821_2019_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"tetracaine hydrochloride","product_type":"not_classified","sponsor":"Valeant Pharmaceuticals Ireland"},{"id":"CRL_NDA217556_20240222","program":"venatorx_pharmaceuticals","apps":["NDA217556"],"app":"NDA217556","date":"2024-02-22","file":"CRL_NDA217556_20240222.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA217556_20240222.pdf","cats":["CMC","NCL"],"cat_source":"coded","rule_cats":["CLP","CMC","NCL"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"cefepime-taniborbactam (IV), beta-lactam/beta-lactamase inhibitor for cUTI","product_type":"novel","sponsor":"Venatorx Pharmaceuticals, Inc."},{"id":"CRL_NDA202860_20190123","program":"vero_biotech","apps":["NDA202860"],"app":"NDA202860","date":"2019-01-23","file":"202860_2019_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/202860_2019_Orig1s000OtherActionLtrs.pdf","cats":["DEV","FAC"],"cat_source":"rule","rule_cats":["DEV","FAC"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA202860_20190123:p2:s30","page":2,"text":"The human factors (HF) validation study, submitted on July 23, 2018, does not provide sufficient evidence to demonstrate that your proposed product can be used safely and effectively by the intended users for its intended uses and use environments."},{"sid":"CRL_NDA202860_20190123:p3:s16","page":3,"text":"You state that none of the changes made as part of the mitigation strategy altered the user interface or modes of use and thus no additional human factors testing is required."},{"sid":"CRL_NDA202860_20190123:p3:s21","page":3,"text":"We expect user performance to be evaluated using all components of the final intend-to-market user interface, including the QRG, OM, and training program, for the final intend-to-market device to provide the data to demonstrate that the mitigation strategies are effective and do not introduce new use-related risks."}]},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"GENOsyl® © Delivery","product_type":"not_classified","sponsor":"GeNO LLC"},{"id":"CRL_NDA212905_20200713","program":"verrica_pharmaceuticals","apps":["NDA212905"],"app":"NDA212905","date":"2020-07-13","file":"212905_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212905_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","DEV"],"cat_source":"rule","rule_cats":["CMC","DEV"],"new_trial":null,"passages":{"DEV":[{"sid":"CRL_NDA212905_20200713:p3:s3","page":3,"text":"As you further develop your proposed product and prepare your next human factors study protocol to address the above concerns, we have the following additional recommendations:"}]},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"cantharidin","product_type":"not_classified","sponsor":"Verrica Pharmaceuticals Inc."},{"id":"CRL_NDA212905_20210916","program":"verrica_pharmaceuticals","apps":["NDA212905"],"app":"NDA212905","date":"2021-09-16","file":"212905_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212905_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"cantharidin","product_type":"not_classified","sponsor":"Verrica Pharmaceuticals Inc."},{"id":"CRL_NDA212905_20220523","program":"verrica_pharmaceuticals","apps":["NDA212905"],"app":"NDA212905","date":"2022-05-23","file":"212905_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212905_2024_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"cantharidin","product_type":"not_classified","sponsor":"Verrica Pharmaceuticals Inc."},{"id":"CRL_NDA212888_20191219","program":"viiv_healthcare","apps":["NDA212888"],"app":"NDA212888","date":"2019-12-19","file":"212887Orig1s000,212888Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212887Orig1s000%2C212888Orig1s000OtherActionLtrs.pdf","cats":["CMC","FAC"],"cat_source":"rule","rule_cats":["CMC","FAC"],"new_trial":null,"passages":{"FAC":[{"sid":"CRL_NDA212888_20191219:p1:s21","page":1,"text":"Note that as a follow-up to the pre-approval inspection, a Post-Action Memorandum with outstanding concerns will be sent to the inspected drug product facility."}]},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"CABENUVA®","product_type":"not_classified","sponsor":"ViiV Healthcare Company"},{"id":"CRL_NDA212887_20191219","program":"viiv_healthcare","apps":["NDA212887"],"app":"NDA212887","date":"2019-12-19","file":"212887Orig1s000,212888Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212887Orig1s000%2C212888Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"CABENUVA®","product_type":"not_classified","sponsor":"ViiV Healthcare Company"},{"id":"CRL_NDA217711_20250827","program":"vyluma","apps":["NDA217711"],"app":"NDA217711","date":"2025-08-27","file":"CRL_NDA 217711_20250827.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA%20217711_20250827.pdf","cats":["EFF","FAC"],"cat_source":"coded","rule_cats":["EFF","FAC"],"new_trial":"unclear","passages":{"EFF":[{"sid":"CRL_NDA217711_20250827:p1:s39","page":1,"text":"Second, the study suffered from substantial and imbalanced missing data that creates a significant potential for bias, with the 0.01% arm exhibiting 25% missing data at the primary endpoint compared to 11% in the placebo arm and 14% in the 0.02% arm."},{"sid":"CRL_NDA217711_20250827:p1:s48","page":1,"text":"These post-hoc analyses increase the risk of a type 1 error and thus increase the risk of finding a treatment effect when one does not exist."}],"FAC":[{"sid":"CRL_NDA217711_20250827:p2:s33","page":2,"text":"The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA Form 483 prior to your complete response."},{"sid":"CRL_NDA217711_20250827:p2:s39","page":2,"text":"Following resolution of the CGMP inspection, FDA may need to conduct a Pre-Approval Inspection (PAI) of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"NVK002, atropine sulfate ophthalmic solution 0.01% for pediatric myopia","product_type":"505b2_new_formulation","sponsor":"Vyluma, Inc."},{"id":"CRL_BLA761187_20240419","program":"xbrane_biopharma","apps":["BLA761187"],"app":"BLA761187","date":"2024-04-19","file":"CRL_BLA761187_20240419.pdf","url":"https://download.open.fda.gov/crl/CRL_BLA761187_20240419.pdf","cats":["CMC","FAC"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_BLA761187_20240419:p1:s22","page":1,"text":"Your complete response should include the date(s) of the facility's response to the FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."},{"sid":"CRL_BLA761187_20240419:p1:s29","page":1,"text":"FDA Form 483. The assessment of application approvability and the resolution of inspection deficiencies would be evaluated upon receipt of the complete response and may include re-inspection of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Xlucane / Ximluci, ranibizumab biosimilar","product_type":"biosimilar","sponsor":"Xbrane Biopharma AB"},{"id":"CRL_NDA213895_20200320","program":"xellia_pharmaceuticals_aps","apps":["NDA213895"],"app":"NDA213895","date":"2020-03-20","file":"213895_2022_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/213895_2022_Orig1s000OtherActionLtrs.pdf","cats":[],"cat_source":"rule","rule_cats":[],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":1,"product":"Vancomycin","product_type":"not_classified","sponsor":"Xellia Pharmaceuticals, ApS"},{"id":"CRL_NDA212097_20240209","program":"xeris_pharmaceuticals","apps":["NDA212097"],"app":"NDA212097","date":"2024-02-09","file":"212097-s012_OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/212097-s012_OtherActionLtrs.pdf","cats":["CLP","CMC"],"cat_source":"coded","rule_cats":["CLP","CMC"],"new_trial":"unclear","passages":{"CLP":[{"sid":"CRL_NDA212097_20240209:p1:s28","page":1,"text":"You may establish an adequate scientific bridge by conducting a new a pharmacokinetics (PK) study in humans that demonstrates comparable bioavailability of your proposed product and the relied-upon listed drug for IV administration."}]},"type":"supplement","era":"issued","cycle":1,"n_app":1,"product":"Gvoke","product_type":"not_classified","sponsor":"Xeris Pharmaceuticals, Inc."},{"id":"CRL_NDA216195_20240725","program":"xspray_pharma","apps":["NDA216195"],"app":"NDA216195","date":"2024-07-25","file":"CRL_NDA216195_20240725.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA216195_20240725.pdf","cats":["CMC","FAC","REG"],"cat_source":"coded","rule_cats":["CMC","FAC"],"new_trial":"unclear","passages":{"FAC":[{"sid":"CRL_NDA216195_20240725:p2:s11","page":2,"text":"FDA Form 483. If the FDA determines the deficiencies resolved following a full review of the inspection and 483 responses after this Complete Response Letter, the facility will be informed."}]},"type":"original","era":"issued","cycle":1,"n_app":2,"product":"DASYNOC (dasatinib, HyNap amorphous formulation)","product_type":"505b2_new_formulation","sponsor":"Xspray Pharma AB"},{"id":"CRL_NDA216195_20251007","program":"xspray_pharma","apps":["NDA216195"],"app":"NDA216195","date":"2025-10-07","file":"CRL_NDA216195_20251007.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA216195_20251007.pdf","cats":["CMC","FAC","REG"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"unclear","passages":{},"type":"original","era":"issued","cycle":2,"n_app":2,"product":"DASYNOC (dasatinib, HyNap amorphous formulation)","product_type":"505b2_new_formulation","sponsor":"Xspray Pharma AB"},{"id":"CRL_NDA217644_20260604","program":"xspray_pharma","apps":["NDA217644"],"app":"NDA217644","date":"2026-06-04","file":"CRL_NDA217644_20260604_Redacted.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA217644_20260604_Redacted.pdf","cats":["CLP","CMC","FAC"],"cat_source":"coded","rule_cats":["CLP","CMC","FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_NDA217644_20260604:p1:s37","page":1,"text":"Following resolution of the CGMP inspection, FDA may need to conduct a pre-approval inspection (PAI) of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"XS003, nilotinib amorphous solid dispersion capsules (Nilopki)","product_type":"505b2_new_formulation","sponsor":"Xspray Pharma AB"},{"id":"CRL_NDA218698_20240612","program":"xtm_consulting","apps":["NDA218698"],"app":"NDA218698","date":"2024-06-12","file":"CRL_NDA218698_20240612.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218698_20240612.pdf","cats":["CMC"],"cat_source":"coded","rule_cats":["CMC"],"new_trial":"no","passages":{},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"Lopressor (metoprolol tartrate) 12.5 mg tablets","product_type":"505b2_new_formulation","sponsor":"XTM Consulting LLC"},{"id":"CRL_NDA217724_20241008","program":"zealand_pharma_us","apps":["NDA217724"],"app":"NDA217724","date":"2024-10-08","file":"CRL_NDA217724_20241008.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA217724_20241008.pdf","cats":["FAC"],"cat_source":"coded","rule_cats":["FAC"],"new_trial":"no","passages":{"FAC":[{"sid":"CRL_NDA217724_20241008:p1:s35","page":1,"text":"FDA may need to conduct a pre-approval inspection (PAI) of the facility."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"dasiglucagon injection for congenital hyperinsulinism (Zegalogue molecule)","product_type":"other","sponsor":"Zealand Pharma US, Inc."},{"id":"CRL_NDA218828_20241219","program":"zealand_pharma_us","apps":["NDA218828"],"app":"NDA218828","date":"2024-12-19","file":"CRL_NDA218828_20241219.pdf","url":"https://download.open.fda.gov/crl/CRL_NDA218828_20241219.pdf","cats":["CLP","EFF","FAC","SAF"],"cat_source":"coded","rule_cats":["FAC","SAF"],"new_trial":"yes","passages":{"EFF":[{"sid":"CRL_NDA218828_20241219:p1:s13","page":1,"text":"In situations such as this, we recognize the need to incorporate regulatory flexibility, while still ensuring that substantial evidence of effectiveness is demonstrated."},{"sid":"CRL_NDA218828_20241219:p1:s15","page":1,"text":"Based upon our review of your submitted data, we are unable to conclude that there is substantial evidence of effectiveness (SEE), nor that the benefits outweigh the known and anticipated risks."},{"sid":"CRL_NDA218828_20241219:p3:s1","page":3,"text":"TW) were not evaluated in your phase 2 studies wherein you evaluated 0.1 mg, 1 mg, and 10 mg daily regimen for 3 weeks, using different endpoints than those evaluated in EASE-1. Although an apparent dose-response relationship was observed in EASE-1, exposure response analyses suggested a lack of relationship between observed glepaglutide exposure and the primary efficacy endpoint."}],"FAC":[{"sid":"CRL_NDA218828_20241219:p5:s19","page":5,"text":"FDA may need to conduct a pre-approval inspection/pre-licensing inspection (PAI/PLI) of the facility."}],"SAF":[{"sid":"CRL_NDA218828_20241219:p3:s24","page":3,"text":"However, we generally recommend a safety database that includes at least ~100 subjects treated with the TBM dosage for at least 1 year, to inform the safety profile of a new drug intended for chronic use."},{"sid":"CRL_NDA218828_20241219:p3:s23","page":3,"text":"We acknowledge that your 120-day safety update report included additional safety information available for the TBM dosage, providing a total of |{i}) subjects who received the TBM dosage for at least 1 year in your safety database."},{"sid":"CRL_NDA218828_20241219:p3:s25","page":3,"text":"Multiple safety concerns, including potential drug-induced liver injury, cancers (gastric neuroendocrine carcinoma, basal cell carcinoma of skin and basosquamous carcinoma of skin), and gastric polyps were identified within this limited safety database."}]},"type":"original","era":"issued","cycle":1,"n_app":1,"product":"glepaglutide injection (GLP-2 analog) for short bowel syndrome","product_type":"novel","sponsor":"Zealand Pharma US, Inc."},{"id":"CRL_NDA210274_20180615","program":"zhejiang_novus_pharmaceuticals","apps":["NDA210274"],"app":"NDA210274","date":"2018-06-15","file":"210274_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210274_2023_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":1,"n_app":3,"product":"Vancomycin Hydrochloride","product_type":"not_classified","sponsor":"Zhejiang Novus Pharmaceuticals Co. Ltd."},{"id":"CRL_NDA210274_20201127","program":"zhejiang_novus_pharmaceuticals","apps":["NDA210274"],"app":"NDA210274","date":"2020-11-27","file":"210274_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210274_2023_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":3,"product":"Vancomycin Hydrochloride","product_type":"not_classified","sponsor":"Zhejiang Novus Pharmaceuticals Co. Ltd."},{"id":"CRL_NDA210274_20210825","program":"zhejiang_novus_pharmaceuticals","apps":["NDA210274"],"app":"NDA210274","date":"2021-08-25","file":"210274_2023_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/210274_2023_Orig1s000OtherActionLtrs.pdf","cats":["FAC"],"cat_source":"rule","rule_cats":["FAC"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":3,"n_app":3,"product":"Vancomycin Hydrochloride","product_type":"not_classified","sponsor":"Zhejiang Novus Pharmaceuticals Co. Ltd."},{"id":"CRL_NDA211566_20210902","program":"zydus_worldwide_dmcc","apps":["NDA211566"],"app":"NDA211566","date":"2021-09-02","file":"211566_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211566_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC"],"cat_source":"rule","rule_cats":["CMC"],"new_trial":null,"passages":{"CMC":[{"sid":"CRL_NDA211566_20210902:p2:s3","page":2,"text":"In addition to a safety update, the amendment should also identify changes, if any, in the conditions under which your product was entatively approved, i.e., updated labeling; chemistry, manufacturing, and controls data;"}]},"type":"original","era":"after_approval","cycle":1,"n_app":2,"product":"sitagliptin","product_type":"not_classified","sponsor":"Zydus Worldwide DMCC"},{"id":"CRL_NDA211566_20230303","program":"zydus_worldwide_dmcc","apps":["NDA211566"],"app":"NDA211566","date":"2023-03-03","file":"211566_2024_Orig1s000OtherActionLtrs.pdf","url":"https://download.open.fda.gov/crl/211566_2024_Orig1s000OtherActionLtrs.pdf","cats":["CMC","NCL"],"cat_source":"rule","rule_cats":["CMC","NCL"],"new_trial":null,"passages":{},"type":"original","era":"after_approval","cycle":2,"n_app":2,"product":"sitagliptin","product_type":"not_classified","sponsor":"Zydus Worldwide DMCC"}],"applications":[{"app":"BLA125522","kind":"BLA","program":"amgen","sponsor":"Amgen Inc.","tickers":["AMGN"],"sec_filer":true,"product":"Kanjinti","product_type":"not_classified","product_sources":[],"first":"2015-08-27","last":"2015-08-27","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-02-26","tentative":[],"t":2010,"censored":false,"letters":["CRL_BLA125522_20150827"]},{"app":"BLA125706","kind":"BLA","program":"mesoblast","sponsor":"Mesoblast, Inc.","tickers":["MESO","MEOBF"],"sec_filer":true,"product":null,"product_type":"not_classified","product_sources":[],"first":"2023-08-01","last":"2023-08-01","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"not_covered","approved":null,"tentative":[],"t":1165,"censored":true,"letters":["CRL_UNKNOWN_20230801"]},{"app":"BLA125713","kind":"BLA","program":"dbv_technologies","sponsor":"DBV Technologies S.A.","tickers":["DBVT","DBVTF"],"sec_filer":true,"product":null,"product_type":"not_classified","product_sources":[],"first":"2020-08-03","last":"2020-08-03","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"not_covered","approved":null,"tentative":[],"t":2258,"censored":true,"letters":["CRL_UNKNOWN_20200803"]},{"app":"BLA125734","kind":"BLA","program":"celltrans","sponsor":"CellTrans Inc.","tickers":[],"sec_filer":false,"product":null,"product_type":"not_classified","product_sources":[],"first":"2021-08-18","last":"2021-08-18","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"not_covered","approved":null,"tentative":[],"t":1878,"censored":true,"letters":["CRL_UNKNOWN_20210818"]},{"app":"BLA125743","kind":"BLA","program":"green_cross","sponsor":"Green Cross Corporation","tickers":[],"sec_filer":false,"product":"immune globulin","product_type":"not_classified","product_sources":[],"first":"2022-02-25","last":"2022-02-25","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"not_covered","approved":null,"tentative":[],"t":1687,"censored":true,"letters":["CRL_UNKNOWN_20220225"]},{"app":"BLA125745","kind":"BLA","program":"atara_biotherapeutics","sponsor":"Atara Biotherapeutics, Inc.","tickers":["ATRA"],"sec_filer":true,"product":"tabelecleucel (Ebvallo), allogeneic EBV-specific T-cell therapy","product_type":"novel","product_sources":["https://www.cgtlive.com/view/fda-hits-atara-biotherapeutics-t-cell-immunotherapy-tabelecleucel-ebv-ptld-second-crl","https://www.cancernetwork.com/view/tabelecleucel-bla-resubmitted-to-fda-for-ebv-positive-ptld"],"first":"2025-01-15","last":"2026-01-09","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"not_covered","approved":null,"tentative":[],"t":632,"censored":true,"letters":["CRL_UNKNOWN_20250115","CRL_UNKNOWN_20260109"]},{"app":"BLA125764","kind":"BLA","program":"stemcyte","sponsor":"StemCyte, Inc.","tickers":[],"sec_filer":false,"product":"Hematopoietic Progenitor Cells","product_type":"not_classified","product_sources":[],"first":"2023-01-20","last":"2023-01-20","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"not_covered","approved":null,"tentative":[],"t":1358,"censored":true,"letters":["CRL_UNKNOWN_20230120"]},{"app":"BLA125806","kind":"BLA","program":"rocket_pharmaceuticals","sponsor":"Rocket Pharmaceuticals, Inc.","tickers":["RCKT"],"sec_filer":true,"product":"KRESLADI (marnetegragene autotemcel), lentiviral gene therapy for severe LAD-I","product_type":"novel","product_sources":["https://www.barchart.com/story/news/1001694/rocket-pharmaceuticals-announces-fda-approval-of-kresladi-for-pediatric-patients-with-severe-leukocyte-adhesion-deficiency-i-lad-i","https://biocentury.com/article/659029/rocket-gene-therapy-among-fda-s-march-approvals-earns-prv"],"first":"2024-06-14","last":"2024-06-14","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"not_covered","approved":null,"tentative":[],"t":847,"censored":true,"letters":["CRL_UNKNOWN_20240614"]},{"app":"BLA125807","kind":"BLA","program":"abeona_therapeutics","sponsor":"Abeona Therapeutics, Inc.","tickers":["ABEO"],"sec_filer":true,"product":"Zevaskyn (prademagene zamikeracel), autologous gene-modified cell sheets for RDEB","product_type":"novel","product_sources":["https://www.sec.gov/Archives/edgar/data/318306/000164117225006548/form8-k.htm","https://www.cgtlive.com/view/fda-approves-abeona-therapeutics-epidermolysis-bullosa-gene-therapy-pz-cel"],"first":"2024-04-16","last":"2024-04-16","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"not_covered","approved":null,"tentative":[],"t":906,"censored":true,"letters":["CRL_UNKNOWN_20240416"]},{"app":"BLA125827","kind":"BLA","program":"replimune","sponsor":"Replimune, Inc.","tickers":["REPL"],"sec_filer":true,"product":"RP1, vusolimogene oderparepvec (Tudriqev), oncolytic HSV-1","product_type":"novel","product_sources":["https://www.ajmc.com/view/after-wild-ride-fda-grants-accelerated-approval-for-replimune-s-rp1-plus-nivolumab-in-advanced-melanoma","https://cancerletter.com/regulatory-news/20260807_2/"],"first":"2025-07-21","last":"2026-04-10","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"not_covered","approved":null,"tentative":[],"t":445,"censored":true,"letters":["CRL_UNKNOWN_20250721","CRL_UNKNOWN_20260410"]},{"app":"BLA125840","kind":"BLA","program":"regenxbio","sponsor":"REGENXBIO, Inc.","tickers":["RGNX"],"sec_filer":true,"product":"RGX-121 (clemidsogene lanparvovec), AAV gene therapy for MPS II","product_type":"novel","product_sources":["https://www.sec.gov/Archives/edgar/data/1590877/000119312526043342/rgnx-ex99_1.htm","https://www.sec.gov/Archives/edgar/data/0001590877/000119312526363786/rgnx-20260824.htm"],"first":"2026-02-07","last":"2026-02-07","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"not_covered","approved":null,"tentative":[],"t":244,"censored":true,"letters":["CRL_UNKNOWN_20260207"]},{"app":"BLA125842","kind":"BLA","program":"capricor","sponsor":"Capricor, Inc.","tickers":["CAPR"],"sec_filer":true,"product":"deramiocel (CAP-1002), allogeneic cardiosphere-derived cell therapy for DMD cardiomyopathy","product_type":"novel","product_sources":["https://www.cgtlive.com/view/fda-peels-back-crl-capricor-dmd-cardiomyopathy-cell-therapy-deramiocel","https://www.boardroomalpha.com/sec/capr-8-k-2026-08-24-0001104659-26-100071"],"first":"2025-07-09","last":"2025-07-09","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"not_covered","approved":null,"tentative":[],"t":457,"censored":true,"letters":["CRL_UNKNOWN_20250709"]},{"app":"BLA125845","kind":"BLA","program":"ultragenyx_pharmaceutical","sponsor":"Ultragenyx Pharmaceutical Inc.","tickers":["RARE"],"sec_filer":true,"product":"UX111, rebisufligene etisparvovec (Fayuvi), AAV9 gene therapy for MPS IIIA","product_type":"novel","product_sources":["https://www.neurologylive.com/view/fda-approves-ux111-first-gene-therapy-sanfilippo-syndrome-type-a","https://www.biospace.com/press-releases/ultragenyx-announces-u-s-fda-acceptance-of-bla-resubmission-for-ux111-aav-gene-therapy-to-treat-sanfilippo-syndrome-type-a-mps-iiia"],"first":"2025-07-07","last":"2025-07-07","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"not_covered","approved":null,"tentative":[],"t":459,"censored":true,"letters":["CRL_UNKNOWN_20250707"]},{"app":"BLA761027","kind":"BLA","program":"accord_biopharma","sponsor":"Accord BioPharma Inc.","tickers":[],"sec_filer":false,"product":"FILKRI (filgrastim-laha), filgrastim biosimilar","product_type":"biosimilar","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA761027","https://www.assyro.com/tools/fda-purple-book/product/filkri-761027"],"first":"2025-06-26","last":"2025-06-26","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2026-01-15","tentative":[],"t":203,"censored":false,"letters":["CRL_BLA761027_20250626"]},{"app":"BLA761039","kind":"BLA","program":"coherus_biosciences","sponsor":"Coherus BioSciences, Inc.","tickers":[],"sec_filer":false,"product":"toripalimab-tpzi","product_type":"not_classified","product_sources":[],"first":"2017-06-09","last":"2017-06-09","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-11-02","tentative":[],"t":511,"censored":false,"letters":["CRL_BLA761039_20170609"]},{"app":"BLA761045","kind":"BLA","program":"sandoz","sponsor":"Sandoz Inc.","tickers":[],"sec_filer":false,"product":"EG12014","product_type":"not_classified","product_sources":[],"first":"2016-06-24","last":"2016-06-24","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-11-04","tentative":[],"t":1228,"censored":false,"letters":["CRL_BLA761045_20160624"]},{"app":"BLA761062","kind":"BLA","program":"amgen","sponsor":"Amgen Inc.","tickers":["AMGN"],"sec_filer":true,"product":"Kanjinti","product_type":"not_classified","product_sources":[],"first":"2017-07-13","last":"2017-07-13","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-04-09","tentative":[],"t":635,"censored":false,"letters":["CRL_BLA761062_20170713"]},{"app":"BLA761066","kind":"BLA","program":"samsung_bioepis","sponsor":"Samsung Bioepis Co., Ltd.","tickers":[],"sec_filer":false,"product":"Pyzchiva","product_type":"not_classified","product_sources":[],"first":"2018-03-23","last":"2018-03-23","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-04-25","tentative":[],"t":398,"censored":false,"letters":["CRL_BLA761066_20180323"]},{"app":"BLA761073","kind":"BLA","program":"amgen","sponsor":"Amgen Inc.","tickers":["AMGN"],"sec_filer":true,"product":"Kanjinti","product_type":"not_classified","product_sources":[],"first":"2018-05-25","last":"2018-05-25","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-06-13","tentative":[],"t":384,"censored":false,"letters":["CRL_BLA761073_20180525"]},{"app":"BLA761081","kind":"BLA","program":"pfizer","sponsor":"Pfizer Inc.","tickers":["PFE"],"sec_filer":true,"product":"Trazimera","product_type":"not_classified","product_sources":[],"first":"2018-04-20","last":"2018-04-20","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-03-11","tentative":[],"t":325,"censored":false,"letters":["CRL_BLA761081_20180420"]},{"app":"BLA761082","kind":"BLA","program":"adello_biologics","sponsor":"Adello Biologics, LLC","tickers":[],"sec_filer":false,"product":"TPI-120","product_type":"not_classified","product_sources":[],"first":"2018-05-10","last":"2021-08-02","n":4,"n_orig":4,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-02-25","tentative":[],"t":1387,"censored":false,"letters":["CRL_BLA761082_20180510","CRL_BLA761082_20190611","CRL_BLA761082_20201222","CRL_BLA761082_20210802"]},{"app":"BLA761084","kind":"BLA","program":"kashiv_biosciences","sponsor":"Kashiv BioSciences, LLC","tickers":[],"sec_filer":false,"product":"TPI-120","product_type":"not_classified","product_sources":[],"first":"2021-08-11","last":"2021-08-11","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-05-26","tentative":[],"t":288,"censored":false,"letters":["CRL_BLA761084_20210811"]},{"app":"BLA761085","kind":"BLA","program":"evolus","sponsor":"Evolus, Inc.","tickers":["EOLS"],"sec_filer":true,"product":"otulinum toxin Type A","product_type":"not_classified","product_sources":[],"first":"2018-05-15","last":"2018-05-15","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-02-01","tentative":[],"t":262,"censored":false,"letters":["CRL_BLA761085_20180515"]},{"app":"BLA761088","kind":"BLA","program":"celltrion","sponsor":"CELLTRION, Inc.","tickers":[],"sec_filer":false,"product":"Steqeyma","product_type":"not_classified","product_sources":[],"first":"2018-02-28","last":"2018-02-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-11-28","tentative":[],"t":273,"censored":false,"letters":["CRL_BLA761088_20180228"]},{"app":"BLA761091","kind":"BLA","program":"celltrion","sponsor":"CELLTRION, Inc.","tickers":[],"sec_filer":false,"product":"Steqeyma","product_type":"not_classified","product_sources":[],"first":"2018-03-30","last":"2018-03-30","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-12-14","tentative":[],"t":259,"censored":false,"letters":["CRL_BLA761091_20180330"]},{"app":"BLA761115","kind":"BLA","program":"immunomedics","sponsor":"Immunomedics, Inc","tickers":[],"sec_filer":false,"product":"sacituzumab govitecan","product_type":"not_classified","product_sources":[],"first":"2019-01-17","last":"2019-01-17","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-04-22","tentative":[],"t":461,"censored":false,"letters":["CRL_BLA761115_20190117"]},{"app":"BLA761126","kind":"BLA","program":"tanvex_biopharma_usa","sponsor":"Tanvex BioPharma USA, Inc.","tickers":[],"sec_filer":false,"product":"TX05","product_type":"not_classified","product_sources":[],"first":"2019-09-24","last":"2023-02-14","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-06-28","tentative":[],"t":1739,"censored":false,"letters":["CRL_BLA761126_20190924","CRL_BLA761126_20210520","CRL_BLA761126_20230214"]},{"app":"BLA761127","kind":"BLA","program":"revance_therapeutics","sponsor":"Revance Therapeutics, Inc.","tickers":[],"sec_filer":false,"product":"daxibotulinumtoxinA","product_type":"not_classified","product_sources":[],"first":"2021-10-14","last":"2021-10-14","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-09-07","tentative":[],"t":328,"censored":false,"letters":["CRL_BLA761127_20211014"]},{"app":"BLA761133","kind":"BLA","program":"takeda_pharmaceuticals_usa","sponsor":"Takeda Pharmaceuticals U.S.A., Inc.","tickers":[],"sec_filer":false,"product":"Eohilia","product_type":"not_classified","product_sources":[],"first":"2019-12-17","last":"2019-12-17","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-09-27","tentative":[],"t":1380,"censored":false,"letters":["CRL_BLA761133_20191217"]},{"app":"BLA761147","kind":"BLA","program":"accord_biopharma","sponsor":"Accord BioPharma Inc.","tickers":[],"sec_filer":false,"product":"Ennumo (pegfilgrastim-pccg), pegfilgrastim biosimilar","product_type":"biosimilar","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761147"],"first":"2024-04-05","last":"2025-08-05","n":3,"n_orig":3,"era":"issued","track":"original","outcome":"approved","approved":"2026-05-07","tentative":[],"t":762,"censored":false,"letters":["CRL_BLA761147_20240405","CRL_BLA761147_20241029","CRL_BLA761147_20250805"]},{"app":"BLA761148","kind":"BLA","program":"spectrum_pharmaceuticals","sponsor":"Spectrum Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"SPI-2012","product_type":"not_classified","product_sources":[],"first":"2021-08-03","last":"2021-08-03","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-09-09","tentative":[],"t":402,"censored":false,"letters":["CRL_BLA761148_20210803"]},{"app":"BLA761151","kind":"BLA","program":"ugb","sponsor":"UGB, Inc.","tickers":[],"sec_filer":false,"product":"UCB4940","product_type":"not_classified","product_sources":[],"first":"2022-05-12","last":"2022-05-12","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-10-17","tentative":[],"t":523,"censored":false,"letters":["CRL_BLA761151_20220512"]},{"app":"BLA761152","kind":"BLA","program":"omeros","sponsor":"Omeros Corporation","tickers":["OMER"],"sec_filer":true,"product":"OMS721","product_type":"not_classified","product_sources":[],"first":"2021-10-15","last":"2021-10-15","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2025-12-23","tentative":[],"t":1530,"censored":false,"letters":["CRL_BLA761152_20211015"]},{"app":"BLA761161","kind":"BLA","program":"chiesi_usa","sponsor":"Chiesi USA, Inc.","tickers":[],"sec_filer":false,"product":"PRX-102","product_type":"not_classified","product_sources":[],"first":"2021-04-27","last":"2021-04-27","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-05-09","tentative":[],"t":742,"censored":false,"letters":["CRL_BLA761161_20210427"]},{"app":"BLA761164","kind":"BLA","program":"bioverativ_usa","sponsor":"Bioverativ USA, Inc.","tickers":[],"sec_filer":false,"product":"sutimlimab","product_type":"not_classified","product_sources":[],"first":"2020-11-13","last":"2020-11-13","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-02-04","tentative":[],"t":448,"censored":false,"letters":["CRL_BLA761164_20201113"]},{"app":"BLA761166","kind":"BLA","program":"pharmaessentia","sponsor":"PharmaEssentia Corporation","tickers":[],"sec_filer":false,"product":"P1101","product_type":"not_classified","product_sources":[],"first":"2021-03-12","last":"2021-03-12","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-11-12","tentative":[],"t":245,"censored":false,"letters":["CRL_BLA761166_20210312"]},{"app":"BLA761180","kind":"BLA","program":"leo_pharma_a_s","sponsor":"LEO Pharma A/S","tickers":[],"sec_filer":false,"product":"tralokinumab","product_type":"not_classified","product_sources":[],"first":"2021-04-23","last":"2021-04-23","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-12-27","tentative":[],"t":248,"censored":false,"letters":["CRL_BLA761180_20210423"]},{"app":"BLA761183","kind":"BLA","program":"provention_bio","sponsor":"Provention Bio, Inc.","tickers":[],"sec_filer":false,"product":"PRV-031","product_type":"not_classified","product_sources":[],"first":"2021-07-02","last":"2021-07-02","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-11-17","tentative":[],"t":503,"censored":false,"letters":["CRL_BLA761183_20210702"]},{"app":"BLA761184","kind":"BLA","program":"pfizer_ireland_pharmaceuticals","sponsor":"Pfizer Ireland Pharmaceuticals","tickers":[],"sec_filer":false,"product":"MOD-4023","product_type":"not_classified","product_sources":[],"first":"2022-01-21","last":"2022-01-21","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-06-27","tentative":[],"t":522,"censored":false,"letters":["CRL_BLA761184_20220121"]},{"app":"BLA761187","kind":"BLA","program":"xbrane_biopharma","sponsor":"Xbrane Biopharma AB","tickers":[],"sec_filer":false,"product":"Xlucane / Ximluci, ranibizumab biosimilar","product_type":"biosimilar","product_sources":["https://www.inderes.se/en/releases/xbrane-biopharma-ab-publ-xbrane-or-the-company-nasdaq-stockholm-xbrane-receives-fda-bsufa-date-of-october-29-2026-for-its-investigational-biosimilar-candidate-to-lucentisr-ranibizumab"],"first":"2024-04-19","last":"2024-04-19","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"resubmitted","approved":null,"tentative":[],"t":903,"censored":true,"letters":["CRL_BLA761187_20240419"]},{"app":"BLA761192","kind":"BLA","program":"mediwound","sponsor":"MediWound, Ltd.","tickers":["MDWD"],"sec_filer":true,"product":null,"product_type":"not_classified","product_sources":[],"first":"2021-06-25","last":"2021-06-25","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-12-28","tentative":[],"t":551,"censored":false,"letters":["CRL_BLA761192_20210625"]},{"app":"BLA761198","kind":"BLA","program":"bio_thera_solutions","sponsor":"Bio-Thera Solutions Ltd.","tickers":[],"sec_filer":false,"product":"BAT1706","product_type":"not_classified","product_sources":[],"first":"2021-11-19","last":"2021-11-19","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-12-06","tentative":[],"t":747,"censored":false,"letters":["CRL_BLA761198_20211119"]},{"app":"BLA761211","kind":"BLA","program":"immedica_pharma","sponsor":"Immedica Pharma AB","tickers":[],"sec_filer":false,"product":"LOARGYS (pegzilarginase-nbln)","product_type":"novel","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA761211","https://www.assyro.com/tools/fda-purple-book/product/loargys-761211"],"first":"2025-08-06","last":"2025-08-06","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2026-02-23","tentative":[],"t":201,"censored":false,"letters":["CRL_BLA761211_20250806"]},{"app":"BLA761212","kind":"BLA","program":"lupin_biotech_division","sponsor":"Lupin Limited (Biotech Division)","tickers":[],"sec_filer":false,"product":"Armlupeg (pegfilgrastim-unne, LUBT004), pegfilgrastim biosimilar","product_type":"biosimilar","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761212","https://www.fda.gov/media/191513/download"],"first":"2024-11-14","last":"2024-11-14","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-11-28","tentative":[],"t":379,"censored":false,"letters":["CRL_BLA761212_20241114"]},{"app":"BLA761215","kind":"BLA","program":"eli_lilly","sponsor":"Eli Lilly and Company","tickers":["LLY"],"sec_filer":true,"product":"lebrikizumab","product_type":"not_classified","product_sources":[],"first":"2021-12-17","last":"2021-12-17","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-11-16","tentative":[],"t":334,"censored":false,"letters":["CRL_BLA761215_20211217","CRL_BLA761215_20211217_2"]},{"app":"BLA761219","kind":"BLA","program":"celitrion","sponsor":"Celitrion, Inc.","tickers":[],"sec_filer":false,"product":"CT-P17","product_type":"not_classified","product_sources":[],"first":"2021-11-24","last":"2022-11-23","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-05-23","tentative":[],"t":545,"censored":false,"letters":["CRL_BLA761219_20211124","CRL_BLA761219_20221123"]},{"app":"BLA761225","kind":"BLA","program":"hugel","sponsor":"Hugel, Inc","tickers":[],"sec_filer":false,"product":"letibotulinumtoxinA","product_type":"not_classified","product_sources":[],"first":"2022-03-31","last":"2023-04-12","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-02-29","tentative":[],"t":700,"censored":false,"letters":["CRL_BLA761225_20220331","CRL_BLA761225_20230412"]},{"app":"BLA761240","kind":"BLA","program":"coherus_biosciences","sponsor":"Coherus BioSciences, Inc.","tickers":[],"sec_filer":false,"product":"toripalimab-tpzi","product_type":"not_classified","product_sources":[],"first":"2022-04-29","last":"2022-04-29","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-10-27","tentative":[],"t":546,"censored":false,"letters":["CRL_BLA761240_20220429"]},{"app":"BLA761248","kind":"BLA","program":"eli_lilly","sponsor":"Eli Lilly and Company","tickers":["LLY"],"sec_filer":true,"product":"lebrikizumab","product_type":"not_classified","product_sources":[],"first":"2023-01-18","last":"2023-01-18","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-07-02","tentative":[],"t":531,"censored":false,"letters":["CRL_BLA761248_20230118"]},{"app":"BLA761253","kind":"BLA","program":"ferring_pharmaceuticals","sponsor":"Ferring Pharmaceuticals Inc.","tickers":[],"sec_filer":false,"product":"FE 999049, follitropin delta (Rekovelle in EU/Canada)","product_type":"novel","product_sources":["https://download.open.fda.gov/crl/CRL_BLA761253_20260227.pdf"],"first":"2026-02-27","last":"2026-02-27","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":224,"censored":true,"letters":["CRL_BLA761253_20260227"]},{"app":"BLA761258","kind":"BLA","program":"akeso_biopharma","sponsor":"Akeso Biopharma Co., Ltd.","tickers":[],"sec_filer":false,"product":"Penpulimab-kcqx (AK105), anti-PD-1 antibody","product_type":"novel","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA761258"],"first":"2024-01-19","last":"2024-01-19","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-04-23","tentative":[],"t":460,"censored":false,"letters":["CRL_BLA761258_20240119"]},{"app":"BLA761266","kind":"BLA","program":"tanvex_biopharma_usa","sponsor":"Tanvex BioPharma USA, Inc.","tickers":[],"sec_filer":false,"product":"TX05, trastuzumab biosimilar (Herceptin)","product_type":"biosimilar","product_sources":["https://www.bioworld.com/articles/716017-taiwans-tanvex-receives-second-crl-for-herceptin-biosimilar","https://www.nstock.tw/news/article_m?id=512418"],"first":"2025-01-03","last":"2026-06-23","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"resubmitted","approved":null,"tentative":[],"t":644,"censored":true,"letters":["CRL_BLA761266_20250103","CRL_BLA761266_20260623"]},{"app":"BLA761271","kind":"BLA","program":"sandoz","sponsor":"Sandoz Inc.","tickers":[],"sec_filer":false,"product":"EG12014, trastuzumab biosimilar (Herwenda in EU; EirGenix/Sandoz)","product_type":"biosimilar","product_sources":["https://onclive.com/view/fda-approval-sought-for-eirgenix-trastuzumab-biosimilar-for-her2-breast-and-gastric-cancers","https://download.open.fda.gov/crl/CRL_BLA761271_20241205.pdf"],"first":"2024-12-05","last":"2025-12-09","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":673,"censored":true,"letters":["CRL_BLA761271_20241205","CRL_BLA761271_20251209"]},{"app":"BLA761275","kind":"BLA","program":"fresenius_kabi_usa","sponsor":"Fresenius Kabi USA, LLC","tickers":[],"sec_filer":false,"product":"MSB11456","product_type":"not_classified","product_sources":[],"first":"2023-05-31","last":"2023-05-31","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-03-05","tentative":[],"t":279,"censored":false,"letters":["CRL_BLA761275_20230531"]},{"app":"BLA761279","kind":"BLA","program":"eli_lilly","sponsor":"Eli Lilly and Company","tickers":["LLY"],"sec_filer":true,"product":"lebrikizumab","product_type":"not_classified","product_sources":[],"first":"2023-03-30","last":"2023-03-30","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-10-26","tentative":[],"t":210,"censored":false,"letters":["CRL_BLA761279_20230330"]},{"app":"BLA761290","kind":"BLA","program":"sfj_pharmaceuticals","sponsor":"SFJ Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"unknown (probably bentracimab, ticagrelor reversal agent)","product_type":"unknown","product_sources":["https://www.pharmaceutical-technology.com/news/fda-sfj-serb-bentracimab/"],"first":"2025-01-31","last":"2025-01-31","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":616,"censored":true,"letters":["CRL_BLA761290_20250131"]},{"app":"BLA761297","kind":"BLA","program":"checkpoint_therapeutics","sponsor":"Checkpoint Therapeutics, Incorporated","tickers":[],"sec_filer":false,"product":"cosibelimab","product_type":"not_classified","product_sources":[],"first":"2023-12-15","last":"2023-12-15","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-12-13","tentative":[],"t":364,"censored":false,"letters":["CRL_BLA761297_20231215"]},{"app":"BLA761299","kind":"BLA","program":"alvotech_usa","sponsor":"Alvotech USA Inc.","tickers":["ALVO","ALVOW"],"sec_filer":true,"product":"AVTO5","product_type":"not_classified","product_sources":[],"first":"2022-12-20","last":"2023-06-28","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-02-23","tentative":[],"t":430,"censored":false,"letters":["CRL_BLA761299_20221220","CRL_BLA761299_20230628"]},{"app":"BLA761303","kind":"BLA","program":"regeneron_pharmaceuticals","sponsor":"Regeneron Pharmaceuticals, Inc.","tickers":["REGN"],"sec_filer":true,"product":"odronextamab (Ordspono), CD20xCD3 bispecific antibody (R/R follicular lymphoma)","product_type":"novel","product_sources":["https://www.cancernetwork.com/view/fda-accepts-odronextamab-bla-resubmission-for-r-r-follicular-lymphoma","https://www.pharmexec.com/view/regeneron-fda-crl-odronextamab-eylea","https://api.fda.gov/transparency/crl.json?search=application_number:%22BLA%20761303%22"],"first":"2024-03-22","last":"2025-07-30","n":3,"n_orig":3,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":931,"censored":true,"letters":["CRL_BLA761303_20240322","CRL_BLA761303_20240322_2","CRL_BLA761303_20250730"]},{"app":"BLA761306","kind":"BLA","program":"eli_lilly","sponsor":"Eli Lilly and Company","tickers":["LLY"],"sec_filer":true,"product":"lebrikizumab","product_type":"not_classified","product_sources":[],"first":"2023-09-28","last":"2023-09-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-09-13","tentative":[],"t":351,"censored":false,"letters":["CRL_BLA761306_20230928"]},{"app":"BLA761308","kind":"BLA","program":"jiangsu_hengrui_pharmaceuticals","sponsor":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","tickers":[],"sec_filer":false,"product":"SHR-1210, camrelizumab (anti-PD-1), with rivoceranib for 1L uHCC","product_type":"novel","product_sources":["https://www.fiercepharma.com/pharma/fda-rejects-hengrui-elevar-pd-1-liver-cancer-combo-3rd-time","https://www.onclive.com/view/fda-issues-third-crl-for-rivoceranib-plus-camrelizumab-in-first-line-hcc-over-additional-manufacturing-concerns"],"first":"2024-05-16","last":"2026-07-09","n":3,"n_orig":3,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":876,"censored":true,"letters":["CRL_BLA761308_20240516","CRL_BLA761308_20250320","CRL_BLA761308_20260709"]},{"app":"BLA761311","kind":"BLA","program":"galderma_r_d","sponsor":"Galderma R&D, LLC","tickers":[],"sec_filer":false,"product":"relabotulinumtoxinA injection (Relfydess, Galderma; QM-1114)","product_type":"novel","product_sources":["https://download.open.fda.gov/crl/CRL_BLA761311_20260629_Redacted.pdf","https://www.galderma.com/news/galderma-us-fda-acceptance-relabotulinumtoxina-application"],"first":"2023-09-29","last":"2026-06-29","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":1106,"censored":true,"letters":["CRL_BLA761311_20230929","CRL_BLA761311_20260629"]},{"app":"BLA761312","kind":"BLA","program":"citius_pharmaceuticals","sponsor":"Citius Pharmaceuticals, Inc.","tickers":["CTXR"],"sec_filer":true,"product":"Lymphir","product_type":"not_classified","product_sources":[],"first":"2023-07-28","last":"2023-07-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-08-07","tentative":[],"t":376,"censored":false,"letters":["CRL_BLA761312_20230728"]},{"app":"BLA761315","kind":"BLA","program":"novo_nordisk","sponsor":"Novo Nordisk","tickers":[],"sec_filer":false,"product":"NNC0148-0287","product_type":"not_classified","product_sources":[],"first":"2023-04-24","last":"2023-04-24","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-12-20","tentative":[],"t":606,"censored":false,"letters":["CRL_BLA761315_20230424"]},{"app":"BLA761320","kind":"BLA","program":"outlook_therapeutics","sponsor":"Outlook Therapeutics, Inc.","tickers":["OTLK"],"sec_filer":true,"product":"Lytenava (bevacizumab-vikg, ONS-5010), ophthalmic bevacizumab for wet AMD","product_type":"novel","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761320"],"first":"2025-08-27","last":"2025-12-30","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"approved","approved":"2026-07-24","tentative":[],"t":331,"censored":false,"letters":["CRL_BLA761320_20250827","CRL_BLA761320_20251230"]},{"app":"BLA761326","kind":"BLA","program":"novo_nordisk","sponsor":"Novo Nordisk","tickers":[],"sec_filer":false,"product":"insulin icodec (Awiqli FlexTouch)","product_type":"novel","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA761326"],"first":"2024-07-10","last":"2024-07-10","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2026-03-26","tentative":[],"t":624,"censored":false,"letters":["CRL_BLA761326_20240710"]},{"app":"BLA761338","kind":"BLA","program":"celltrion","sponsor":"CELLTRION, Inc.","tickers":[],"sec_filer":false,"product":"STEQEYMA (ustekinumab-stba; CT-P43), ustekinumab biosimilar","product_type":"biosimilar","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA761338"],"first":"2024-09-30","last":"2024-12-17","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"approved","approved":"2024-12-17","tentative":[],"t":78,"censored":false,"letters":["CRL_BLA761338_20240930","CRL_BLA761338_20241217"]},{"app":"BLA761343","kind":"BLA","program":"alvotech_usa","sponsor":"Alvotech USA Inc.","tickers":["ALVO","ALVOW"],"sec_filer":true,"product":"AVTO5","product_type":"not_classified","product_sources":[],"first":"2023-10-11","last":"2023-10-11","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-04-16","tentative":[],"t":188,"censored":false,"letters":["CRL_BLA761343_20231011"]},{"app":"BLA761355","kind":"BLA","program":"regeneron_pharmaceuticals","sponsor":"Regeneron Pharmaceuticals, Inc.","tickers":["REGN"],"sec_filer":true,"product":"BLA","product_type":"not_classified","product_sources":[],"first":"2023-06-27","last":"2023-06-27","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-08-18","tentative":[],"t":52,"censored":false,"letters":["CRL_BLA761355_20230627"]},{"app":"BLA761356","kind":"BLA","program":"gan_lee_pharmaceuticals","sponsor":"Gan & Lee Pharmaceuticals","tickers":[],"sec_filer":false,"product":"Gan & Lee insulin aspart, proposed insulin aspart biosimilar","product_type":"biosimilar","product_sources":["https://api.fda.gov/transparency/crl.json?search=application_number:%22BLA%20761356%22","https://www.thepharmaletter.com/biosimilars-news/sandoz-wins-ec-nod-for-two-insulin-biosimilars"],"first":"2024-04-12","last":"2024-04-12","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":910,"censored":true,"letters":["CRL_BLA761356_20240412"]},{"app":"BLA761357","kind":"BLA","program":"gan_lee_pharmaceuticals","sponsor":"Gan & Lee Pharmaceuticals","tickers":[],"sec_filer":false,"product":"Gan & Lee insulin lispro, proposed Humalog biosimilar","product_type":"biosimilar","product_sources":["https://download.open.fda.gov/crl/CRL_BLA761357_20240326.pdf","https://www.pearceip.law/2026/05/15/sandozs-insulin-lispro-and-insulin-aspart-biosimilars-eu-approved/"],"first":"2024-03-26","last":"2024-03-26","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":927,"censored":true,"letters":["CRL_BLA761357_20240326"]},{"app":"BLA761365","kind":"BLA","program":"astellas_pharma_us","sponsor":"Astellas Pharma US, Inc.","tickers":[],"sec_filer":false,"product":"VYLOY (zolbetuximab-clzb; IMAB362)","product_type":"novel","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA761365"],"first":"2024-01-04","last":"2024-01-04","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2024-10-18","tentative":[],"t":288,"censored":false,"letters":["CRL_BLA761365_20240104"]},{"app":"BLA761366","kind":"BLA","program":"daiichi_sankyo","sponsor":"Daiichi Sankyo, Inc.","tickers":[],"sec_filer":false,"product":"patritumab deruxtecan (HER3-DXd), HER3-directed ADC","product_type":"novel","product_sources":["https://www.merck.com/news/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer/","https://www.onclive.com/view/bla-is-withdrawn-for-patritumab-deruxtecan-in-egfr-mutated-nsclc"],"first":"2024-06-26","last":"2024-06-26","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"discontinued","approved":null,"tentative":[],"t":835,"censored":true,"letters":["CRL_BLA761366_20240626"]},{"app":"BLA761367","kind":"BLA","program":"csl_behring","sponsor":"CSL Behring LLC","tickers":[],"sec_filer":false,"product":"CSL312, garadacimab (Andembry)","product_type":"novel","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA761367"],"first":"2024-10-07","last":"2024-10-07","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-06-16","tentative":[],"t":252,"censored":false,"letters":["CRL_BLA761367_20241007"]},{"app":"BLA761373","kind":"BLA","program":"samsung_bioepis","sponsor":"Samsung Bioepis Co., Ltd.","tickers":[],"sec_filer":false,"product":"Pyzchiva","product_type":"not_classified","product_sources":[],"first":"2024-07-04","last":"2024-07-04","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-04-30","tentative":[],"t":300,"censored":false,"letters":["CRL_BLA761373_20240704"]},{"app":"BLA761376","kind":"BLA","program":"dr_reddys_laboratories","sponsor":"Dr. Reddy’s Laboratories, Inc.","tickers":["RDY"],"sec_filer":true,"product":"ZIMRIXBY (rituximab-cdxx; DRL_RI), rituximab biosimilar","product_type":"biosimilar","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA761376","https://www.pearceip.law/2024/04/20/dr-reddys-receives-complete-response-letter-for-biosimilar-rituximab-in-us/"],"first":"2024-04-19","last":"2025-10-16","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"approved","approved":"2026-07-31","tentative":[],"t":833,"censored":false,"letters":["CRL_BLA761376_20240419","CRL_BLA761376_20251016"]},{"app":"BLA761377","kind":"BLA","program":"celltrion","sponsor":"CELLTRION, Inc.","tickers":[],"sec_filer":false,"product":"Eydenzelt (aflibercept-boav, CT-P42), aflibercept biosimilar","product_type":"biosimilar","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761377"],"first":"2024-06-27","last":"2025-03-26","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"approved","approved":"2025-10-02","tentative":[],"t":462,"censored":false,"letters":["CRL_BLA761377_20240627","CRL_BLA761377_20250326"]},{"app":"BLA761385","kind":"BLA","program":"teva_pharmaceuticals","sponsor":"Teva Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"TVB-009, denosumab-adet (Ponlimsi), Prolia biosimilar","product_type":"biosimilar","product_sources":["https://www.pearceip.law/2026/03/30/tevas-biosimilar-denosumab-fda-approved-biosimilar-omalizumab-applications-accepted-for-review-in-us-eu/"],"first":"2025-07-30","last":"2025-07-30","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2026-03-27","tentative":[],"t":240,"censored":false,"letters":["CRL_BLA761385_20250730"]},{"app":"BLA761393","kind":"BLA","program":"seikagaku","sponsor":"Seikagaku Corporation","tickers":[],"sec_filer":false,"product":"SI-6603 (condoliase) injection, for lumbar disc herniation","product_type":"novel","product_sources":["https://thepharmaletter.com/fda-slaps-crl-on-seikagakus-bla-for-condoliase","https://www.bioworld.com/articles/733927-fda-issues-second-crl-to-seikagaku-for-condoliase-bla"],"first":"2025-03-11","last":"2025-03-11","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":577,"censored":true,"letters":["CRL_BLA761393_20250311"]},{"app":"BLA761400","kind":"BLA","program":"regeneron_pharmaceuticals","sponsor":"Regeneron Pharmaceuticals, Inc.","tickers":["REGN"],"sec_filer":true,"product":"Lynozyfic (linvoseltamab-gcpt), BCMAxCD3 bispecific antibody","product_type":"novel","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761400"],"first":"2024-08-20","last":"2024-08-20","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-07-02","tentative":[],"t":316,"censored":false,"letters":["CRL_BLA761400_20240820"]},{"app":"BLA761401","kind":"BLA","program":"telix_pharmaceuticals_us","sponsor":"Telix Pharmaceuticals (US) Inc.","tickers":["TLX","TLPPF"],"sec_filer":true,"product":"TLX250-CDx, 89Zr-girentuximab (Zircaix), PET imaging agent","product_type":"novel","product_sources":["https://www.sec.gov/Archives/edgar/data/0002007191/000200719125000065/zircprcrl.htm","https://download.open.fda.gov/crl/CRL_BLA761401_20260410.pdf"],"first":"2026-04-10","last":"2026-04-10","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":182,"censored":true,"letters":["CRL_BLA761401_20260410"]},{"app":"BLA761403","kind":"BLA","program":"amphastar_pharmaceuticals","sponsor":"Amphastar Pharmaceuticals, Inc.","tickers":["AMPH"],"sec_filer":true,"product":"Insulin aspart biosimilar to NovoLog (Amphastar)","product_type":"biosimilar","product_sources":["https://download.open.fda.gov/crl/CRL_BLA761403_20260226.pdf","https://www.marketbeat.com/instant-alerts/amphastar-pharmaceuticals-q2-earnings-call-highlights-2026-08-06/"],"first":"2026-02-26","last":"2026-02-26","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":225,"censored":true,"letters":["CRL_BLA761403_20260226"]},{"app":"BLA761424","kind":"BLA","program":"accord_biopharma","sponsor":"Accord BioPharma Inc.","tickers":[],"sec_filer":false,"product":"Jubereq / Osvyrti (denosumab-desu), denosumab biosimilars","product_type":"biosimilar","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761424"],"first":"2025-03-13","last":"2025-03-13","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-10-29","tentative":[],"t":230,"censored":false,"letters":["CRL_BLA761424_20250313"]},{"app":"BLA761427","kind":"BLA","program":"lib_therapeutics","sponsor":"LIB Therapeutics, Inc.","tickers":[],"sec_filer":false,"product":"Lerochol","product_type":"not_classified","product_sources":[],"first":"2025-12-12","last":"2025-12-12","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":301,"censored":true,"letters":["CRL_BLA761427_20251212"]},{"app":"BLA761433","kind":"BLA","program":"janssen_biotech","sponsor":"Janssen Biotech, Inc.","tickers":[],"sec_filer":false,"product":"amivantamab and hyaluronidase-lpuj (Rybrevant Faspro), subcutaneous","product_type":"other","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA761433"],"first":"2024-12-13","last":"2024-12-13","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-12-17","tentative":[],"t":369,"censored":false,"letters":["CRL_BLA761433_20241213"]},{"app":"BLA761435","kind":"BLA","program":"alvotech_usa","sponsor":"Alvotech USA Inc.","tickers":["ALVO","ALVOW"],"sec_filer":true,"product":"AVT06, aflibercept (Eylea) biosimilar","product_type":"biosimilar","product_sources":["https://www.biospace.com/press-releases/alvotech-announces-resubmission-of-u-s-biologics-license-applications-for-avt05-a-proposed-biosimilar-to-simponi-and-simponi-aria-and-avt06-a-proposed-biosimilar-to-eylea"],"first":"2025-11-24","last":"2025-11-24","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"resubmitted","approved":null,"tentative":[],"t":319,"censored":true,"letters":["CRL_BLA761435_20251124"]},{"app":"BLA761438","kind":"BLA","program":"swedish_orphan_biovitrum_publ","sponsor":"Swedish Orphan Biovitrum AB (publ)","tickers":[],"sec_filer":false,"product":"NASP / SEL-212 (pegadricase-sogo + nanoencapsulated sirolimus), for uncontrolled gout","product_type":"novel","product_sources":["https://api.fda.gov/transparency/crl.json?search=application_number:%22BLA%20761438%22","https://maestrodatabase.com/blog/sobi-receives-complete-response-letter-from-fda-for-nasp-nanoencapsulated-sirolimus-plus-pegadricase"],"first":"2026-06-26","last":"2026-06-26","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":105,"censored":true,"letters":["CRL_BLA761438_20260626"]},{"app":"BLA761440","kind":"BLA","program":"glaxosmithkline","sponsor":"GlaxoSmithKline LLC","tickers":[],"sec_filer":false,"product":"Exdensur lepemokimab-ulaa)","product_type":"not_classified","product_sources":[],"first":"2025-10-23","last":"2025-10-23","n":1,"n_orig":0,"era":"issued","track":"supplement","outcome":"supplement","approved":null,"tentative":[],"t":351,"censored":true,"letters":["CRL_BLA761440_20251023"]},{"app":"BLA761451","kind":"BLA","program":"astrazeneca_pharmaceuticals","sponsor":"AstraZeneca Pharmaceuticals LP","tickers":[],"sec_filer":false,"product":"anifrolumab-fnia (Saphnelo) subcutaneous","product_type":"other","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA761451"],"first":"2025-10-10","last":"2025-10-10","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2026-04-24","tentative":[],"t":196,"censored":false,"letters":["CRL_BLA761451_20251010"]},{"app":"BLA761458","kind":"BLA","program":"glaxosmithkline","sponsor":"GlaxoSmithKline LLC","tickers":[],"sec_filer":false,"product":"Exdensur lepemokimab-ulaa)","product_type":"not_classified","product_sources":[],"first":"2025-12-16","last":"2025-12-16","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":297,"censored":true,"letters":["CRL_BLA761458_20251216"]},{"app":"BLA761459","kind":"BLA","program":"abbvie","sponsor":"AbbVie Inc.","tickers":["ABBV"],"sec_filer":true,"product":"trenibotulinumtoxinE (TrenibotE; AGN-151586), botulinum toxin serotype E","product_type":"novel","product_sources":["https://news.abbvie.com/2026-04-23-AbbVie-Provides-Update-on-TrenibotulinumtoxinE-TrenibotE-Biologics-License-Application-in-the-U-S","https://www.biopharminternational.com/view/abbvie-receives-fda-complete-response-letter-for-trenibotulinumtoxine"],"first":"2026-04-22","last":"2026-04-22","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":170,"censored":true,"letters":["CRL_BLA761459_20260422"]},{"app":"BLA761461","kind":"BLA","program":"alvotech_usa","sponsor":"Alvotech USA Inc.","tickers":["ALVO","ALVOW"],"sec_filer":true,"product":"AVT05, golimumab biosimilar (Simponi/Simponi Aria)","product_type":"biosimilar","product_sources":["https://www.biospace.com/press-releases/alvotech-announces-resubmission-of-u-s-biologics-license-applications-for-avt05-a-proposed-biosimilar-to-simponi-and-simponi-aria-and-avt06-a-proposed-biosimilar-to-eylea"],"first":"2025-11-26","last":"2025-11-26","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"resubmitted","approved":null,"tentative":[],"t":317,"censored":true,"letters":["CRL_BLA761461_20251126"]},{"app":"BLA761462","kind":"BLA","program":"alvotech_usa","sponsor":"Alvotech USA Inc.","tickers":["ALVO","ALVOW"],"sec_filer":true,"product":"AVT05, golimumab biosimilar (Gobivaz ex-US)","product_type":"biosimilar","product_sources":["https://www.pearceip.law/2026/06/04/alvotech-resubmits-us-blas-for-aflibercept-golimumab-biosimilars/","https://www.pearceip.law/2025/11/02/fda-issues-crl-for-alvotechs-biosimilar-golimumab/"],"first":"2025-10-31","last":"2025-10-31","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"resubmitted","approved":null,"tentative":[],"t":343,"censored":true,"letters":["CRL_BLA761462_20251031"]},{"app":"BLA761463","kind":"BLA","program":"scholar_rock","sponsor":"Scholar Rock, Inc.","tickers":["SRRK"],"sec_filer":true,"product":"ISEMBYLD (apitegromab-mstn)","product_type":"novel","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA761463","https://seekingalpha.com/news/4588900-scholar-rock-anticipates-apitegromab-approval-by-september-30-as-fda-accepts-sma-bla-with-two"],"first":"2025-09-22","last":"2025-09-22","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2026-09-11","tentative":[],"t":354,"censored":false,"letters":["CRL_BLA761463_20250922"]},{"app":"BLA761471","kind":"BLA","program":"dr_reddys_laboratories","sponsor":"Dr. Reddy’s Laboratories, Inc.","tickers":["RDY"],"sec_filer":true,"product":"AVT03, denosumab biosimilar (Prolia/Xgeva), Alvotech/Dr. Reddy's","product_type":"biosimilar","product_sources":["https://www.pearceip.law/2026/01/01/fda-issues-crl-for-alvotech-dr-reddys-biosimilar-denosumab/"],"first":"2025-12-30","last":"2025-12-30","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":283,"censored":true,"letters":["CRL_BLA761471_20251230"]},{"app":"NDA018680","kind":"NDA","program":"coopersurgical","sponsor":"CooperSurgical, Inc.","tickers":[],"sec_filer":false,"product":"Paragard","product_type":"not_classified","product_sources":[],"first":"2023-12-18","last":"2023-12-18","n":1,"n_orig":0,"era":"after_approval","track":"supplement","outcome":"supplement","approved":null,"tentative":[],"t":1026,"censored":true,"letters":["CRL_NDA018680_20231218"]},{"app":"NDA021164","kind":"NDA","program":"organon","sponsor":"Organon, Inc.","tickers":["OGN"],"sec_filer":true,"product":"Gepirone Hydrochloride Extended Release","product_type":"not_classified","product_sources":[],"first":"2002-03-15","last":"2007-11-02","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-09-22","tentative":[],"t":7861,"censored":false,"letters":["CRL_NDA021164_20020315","CRL_NDA021164_20040623","CRL_NDA021164_20071102"]},{"app":"NDA022075","kind":"NDA","program":"kyowa_pharmaceutical","sponsor":"Kyowa Pharmaceutical, Inc.","tickers":[],"sec_filer":false,"product":"istradefylline","product_type":"not_classified","product_sources":[],"first":"2008-02-25","last":"2008-02-25","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-08-27","tentative":[],"t":4201,"censored":false,"letters":["CRL_NDA022075_20080225"]},{"app":"NDA022231","kind":"NDA","program":"orphan_therapeutics","sponsor":"Orphan Therapeutics, LLC","tickers":[],"sec_filer":false,"product":"terlipressin","product_type":"not_classified","product_sources":[],"first":"2009-11-04","last":"2022-02-18","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-09-14","tentative":[],"t":4697,"censored":false,"letters":["CRL_NDA022231_20091104","CRL_NDA022231_20200911","CRL_NDA022231_20220218"]},{"app":"NDA022335","kind":"NDA","program":"cyclomedica_australia","sponsor":"Cyclomedica Australia Pty Ltd.","tickers":[],"sec_filer":false,"product":null,"product_type":"not_classified","product_sources":[],"first":"2021-06-25","last":"2021-06-25","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-09-29","tentative":[],"t":826,"censored":false,"letters":["CRL_NDA022335_20210625"]},{"app":"NDA022377","kind":"NDA","program":"king_pharmaceuticals","sponsor":"King Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"sumatriptan","product_type":"not_classified","product_sources":[],"first":"2009-05-15","last":"2009-05-15","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2010-06-29","tentative":[],"t":410,"censored":false,"letters":["CRL_NDA022377_20090515"]},{"app":"NDA022450","kind":"NDA","program":"cadence_pharmaceuticals","sponsor":"Cadence Pharmaceuticals","tickers":[],"sec_filer":false,"product":"Ofirmev","product_type":"not_classified","product_sources":[],"first":"2010-02-10","last":"2010-02-10","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2010-11-02","tentative":[],"t":265,"censored":false,"letters":["CRL_NDA022450_20100210"]},{"app":"NDA022517","kind":"NDA","program":"ferring_pharmaceuticals","sponsor":"Ferring Pharmaceuticals Inc.","tickers":[],"sec_filer":false,"product":"progesterone","product_type":"not_classified","product_sources":[],"first":"2010-04-22","last":"2015-01-30","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-06-21","tentative":[],"t":2982,"censored":false,"letters":["CRL_NDA022517_20100422","CRL_NDA022517_20130130","CRL_NDA022517_20150130"]},{"app":"NDA022561","kind":"NDA","program":"emd_serono","sponsor":"EMD Serono, Inc.","tickers":[],"sec_filer":false,"product":"cladribine","product_type":"not_classified","product_sources":[],"first":"2011-02-28","last":"2011-02-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-03-29","tentative":[],"t":2951,"censored":false,"letters":["CRL_NDA022561_20110228"]},{"app":"NDA200655","kind":"NDA","program":"thomas_chaly_phd_faic","sponsor":"Thomas Chaly, Ph.D., FAIC","tickers":[],"sec_filer":false,"product":"Fluorodopa F","product_type":"not_classified","product_sources":[],"first":"2013-10-22","last":"2016-09-15","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-10-10","tentative":[],"t":2179,"censored":false,"letters":["CRL_NDA200655_20131022","CRL_NDA200655_20160915"]},{"app":"NDA201110","kind":"NDA","program":"teva_womens_health","sponsor":"Teva Women’s Health, Inc.","tickers":[],"sec_filer":false,"product":"progesterone","product_type":"not_classified","product_sources":[],"first":"2011-02-28","last":"2016-11-23","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-04-29","tentative":[],"t":3348,"censored":false,"letters":["CRL_NDA201110_20110228","CRL_NDA201110_20161123"]},{"app":"NDA201848","kind":"NDA","program":"delcath_systems","sponsor":"Delcath Systems, Incorporated","tickers":["DCTH"],"sec_filer":true,"product":"Melblez","product_type":"not_classified","product_sources":[],"first":"2013-09-12","last":"2013-09-12","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-08-14","tentative":[],"t":3623,"censored":false,"letters":["CRL_NDA201848_20130912"]},{"app":"NDA202049","kind":"NDA","program":"pharmaxis","sponsor":"Pharmaxis Ltd.","tickers":[],"sec_filer":false,"product":"PRX-102","product_type":"not_classified","product_sources":[],"first":"2013-03-18","last":"2019-06-19","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-10-30","tentative":[],"t":2783,"censored":false,"letters":["CRL_NDA202049_20130318","CRL_NDA202049_20190619"]},{"app":"NDA202158","kind":"NDA","program":"northstar_medical_radioisotopes","sponsor":"NorthStar Medical Radioisotopes, LLC","tickers":[],"sec_filer":false,"product":"TechneGen Generator","product_type":"not_classified","product_sources":[],"first":"2013-11-04","last":"2013-11-04","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-02-08","tentative":[],"t":1557,"censored":false,"letters":["CRL_NDA202158_20131104"]},{"app":"NDA202293","kind":"NDA","program":"bristol_myers_squibb","sponsor":"Bristol-Myers Squibb","tickers":["BMY","CELG-RI"],"sec_filer":true,"product":"dapagliflozin","product_type":"not_classified","product_sources":[],"first":"2012-01-17","last":"2012-01-17","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2014-01-08","tentative":[],"t":722,"censored":false,"letters":["CRL_NDA202293_20120117"]},{"app":"NDA202408","kind":"NDA","program":"fera_pharmaceuticals","sponsor":"Fera Pharmaceuticals, LLC","tickers":[],"sec_filer":false,"product":"Avaclyr","product_type":"not_classified","product_sources":[],"first":"2014-03-31","last":"2019-03-28","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-03-29","tentative":[],"t":1824,"censored":false,"letters":["CRL_NDA202408_20140331","CRL_NDA202408_20160624","CRL_NDA202408_20190328"]},{"app":"NDA202860","kind":"NDA","program":"geno","sponsor":"GeNO LLC","tickers":[],"sec_filer":false,"product":"GENOsyl® © Delivery","product_type":"not_classified","product_sources":[],"first":"2012-05-18","last":"2019-01-23","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-12-20","tentative":[],"t":2772,"censored":false,"letters":["CRL_NDA202860_20120518","CRL_NDA202860_20130628","CRL_NDA202860_20190123"]},{"app":"NDA202971","kind":"NDA","program":"otsuka_pharmaceutical","sponsor":"Otsuka Pharmaceutical Company, Ltd.","tickers":[],"sec_filer":false,"product":"ABILIFY MAINTENA","product_type":"not_classified","product_sources":[],"first":"2012-07-26","last":"2012-07-26","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2013-02-28","tentative":[],"t":217,"censored":false,"letters":["CRL_NDA202971_20120726"]},{"app":"NDA203202","kind":"NDA","program":"chelsea_therapeutics","sponsor":"Chelsea Therapeutics, Inc.","tickers":[],"sec_filer":false,"product":"NORTHERA","product_type":"not_classified","product_sources":[],"first":"2012-03-28","last":"2012-03-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2014-02-18","tentative":[],"t":692,"censored":false,"letters":["CRL_NDA203202_20120328"]},{"app":"NDA203856","kind":"NDA","program":"roxane_laboratories","sponsor":"Roxane Laboratories, Inc.","tickers":[],"sec_filer":false,"product":"Cyclophosphamide","product_type":"not_classified","product_sources":[],"first":"2013-05-03","last":"2013-05-03","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2013-09-16","tentative":[],"t":136,"censored":false,"letters":["CRL_NDA203856_20130503"]},{"app":"NDA204017","kind":"NDA","program":"agile_therapeutics","sponsor":"Agile Therapeutics, Inc.","tickers":[],"sec_filer":false,"product":"levonorgestrel/ethinyl estradiol","product_type":"not_classified","product_sources":[],"first":"2013-02-13","last":"2017-12-21","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-02-14","tentative":[],"t":2557,"censored":false,"letters":["CRL_NDA204017_20130213","CRL_NDA204017_20130717","CRL_NDA204017_20171221"]},{"app":"NDA204311","kind":"NDA","program":"mylan_pharmaceuticals","sponsor":"Mylan Pharmaceuticals Inc.","tickers":[],"sec_filer":false,"product":null,"product_type":"not_classified","product_sources":[],"first":"2014-10-23","last":"2023-01-13","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-12-22","tentative":[],"t":3347,"censored":false,"letters":["CRL_NDA204311_20141023","CRL_NDA204311_20190806","CRL_NDA204311_20230113"]},{"app":"NDA204408","kind":"NDA","program":"aveo_pharmaceuticals","sponsor":"AVEO Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"tivozanib hydrochloride","product_type":"not_classified","product_sources":[],"first":"2013-06-06","last":"2013-06-06","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":4873,"censored":true,"letters":["CRL_NDA204408_20130606"]},{"app":"NDA204417","kind":"NDA","program":"sun_pharma_global_fze","sponsor":"Sun Pharma Global FZE","tickers":[],"sec_filer":false,"product":"Elepsia XR","product_type":"not_classified","product_sources":[],"first":"2013-03-29","last":"2017-03-22","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-12-20","tentative":[],"t":2092,"censored":false,"letters":["CRL_NDA204417_20130329","CRL_NDA204417_20150923","CRL_NDA204417_20170322"]},{"app":"NDA204569","kind":"NDA","program":"merck","sponsor":"Merck & Co., Inc.","tickers":["MRK"],"sec_filer":true,"product":"Suvorexant","product_type":"not_classified","product_sources":[],"first":"2013-06-28","last":"2013-06-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2014-08-13","tentative":[],"t":411,"censored":false,"letters":["CRL_NDA204569_20130628"]},{"app":"NDA204803","kind":"NDA","program":"durect","sponsor":"DURECT Corporation","tickers":[],"sec_filer":false,"product":"POSIMIR","product_type":"not_classified","product_sources":[],"first":"2014-02-12","last":"2014-02-12","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-02-01","tentative":[],"t":2546,"censored":false,"letters":["CRL_NDA204803_20140212"]},{"app":"NDA204957","kind":"NDA","program":"b_braun_medical","sponsor":"B. Braun Medical, Inc.","tickers":[],"sec_filer":false,"product":"Acetaminophen","product_type":"not_classified","product_sources":[],"first":"2017-09-28","last":"2020-04-24","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-02-18","tentative":[],"t":1239,"censored":false,"letters":["CRL_NDA204957_20170928","CRL_NDA204957_20190327","CRL_NDA204957_20200424"]},{"app":"NDA205054","kind":"NDA","program":"elc_group","sponsor":"ELC Group","tickers":[],"sec_filer":false,"product":"Lutrate®","product_type":"not_classified","product_sources":[],"first":"2015-05-29","last":"2015-05-29","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-08-28","tentative":[],"t":1187,"censored":false,"letters":["CRL_NDA205054_20150529"]},{"app":"NDA205394","kind":"NDA","program":"redhill_biopharma","sponsor":"RedHill Biopharma Ltd.","tickers":["RDHL"],"sec_filer":true,"product":"RizaFilm","product_type":"not_classified","product_sources":[],"first":"2014-01-31","last":"2020-03-24","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-04-14","tentative":[],"t":3360,"censored":false,"letters":["CRL_NDA205394_20140131","CRL_NDA205394_20190328","CRL_NDA205394_20200324"]},{"app":"NDA205508","kind":"NDA","program":"heritage_pharmaceuticals_d_b_a_avet_pharmaceuticals","sponsor":"Heritage Pharmaceuticals Inc. d/b/a/ Avet Pharmaceuticals Inc.","tickers":[],"sec_filer":false,"product":"atazanavir sulfate and ritonavir tablets (fixed-dose combination)","product_type":"505b2_new_formulation","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA205508","https://download.open.fda.gov/crl/CRL_NDA205508_20250728.pdf"],"first":"2025-07-28","last":"2025-07-28","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":["2014-03-17"],"t":438,"censored":true,"letters":["CRL_NDA205508_20250728"]},{"app":"NDA205920","kind":"NDA","program":"armstrong_pharmaceuticals","sponsor":"Armstrong Pharmaceuticals","tickers":[],"sec_filer":false,"product":"Primatene Mist","product_type":"not_classified","product_sources":[],"first":"2014-05-22","last":"2016-12-23","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-11-07","tentative":[],"t":1630,"censored":false,"letters":["CRL_NDA205920_20140522","CRL_NDA205920_20161223"]},{"app":"NDA206089","kind":"NDA","program":"clarus_therapeutics","sponsor":"Clarus Therapeutics, Inc.","tickers":[],"sec_filer":false,"product":"testosterone undecanoate","product_type":"not_classified","product_sources":[],"first":"2014-11-03","last":"2018-03-22","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-03-27","tentative":[],"t":1605,"censored":false,"letters":["CRL_NDA206089_20141103","CRL_NDA206089_20180322"]},{"app":"NDA206185","kind":"NDA","program":"sun_pharma_advanced_research","sponsor":"Sun Pharma Advanced Research Company Limited","tickers":[],"sec_filer":false,"product":"Elepsia XR","product_type":"not_classified","product_sources":[],"first":"2014-11-24","last":"2016-12-19","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-09-12","tentative":[],"t":1388,"censored":false,"letters":["CRL_NDA206185_20141124","CRL_NDA206185_20150730","CRL_NDA206185_20161219"]},{"app":"NDA206610","kind":"NDA","program":"mylan_pharmaceuticals","sponsor":"Mylan Pharmaceuticals Inc.","tickers":[],"sec_filer":false,"product":"Acetaminophen ©","product_type":"not_classified","product_sources":[],"first":"2015-02-27","last":"2019-06-06","n":5,"n_orig":5,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-01-15","tentative":[],"t":2149,"censored":false,"letters":["CRL_NDA206610_20150227","CRL_NDA206610_20160310","CRL_NDA206610_20170201","CRL_NDA206610_20171206","CRL_NDA206610_20190606"]},{"app":"NDA206927","kind":"NDA","program":"dr_reddys_laboratories","sponsor":"Dr. Reddy’s Laboratories, Inc.","tickers":["RDY"],"sec_filer":true,"product":"AVT03","product_type":"not_classified","product_sources":[],"first":"2014-12-17","last":"2016-05-04","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-10-04","tentative":[],"t":1752,"censored":false,"letters":["CRL_NDA206927_20141217","CRL_NDA206927_20160504"]},{"app":"NDA206966","kind":"NDA","program":"dr_reddys_laboratories","sponsor":"Dr. Reddy’s Laboratories, Inc.","tickers":["RDY"],"sec_filer":true,"product":"AVT03","product_type":"not_classified","product_sources":[],"first":"2016-08-30","last":"2016-08-30","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-07-24","tentative":[],"t":1424,"censored":false,"letters":["CRL_NDA206966_20160830"]},{"app":"NDA206968","kind":"NDA","program":"nnopharma_licensing","sponsor":"nnoPharma Licensing LLC","tickers":[],"sec_filer":false,"product":"Acetaminophen","product_type":"not_classified","product_sources":[],"first":"2015-02-27","last":"2020-12-22","n":4,"n_orig":4,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-06-03","tentative":[],"t":2653,"censored":false,"letters":["CRL_NDA206968_20150227","CRL_NDA206968_20161115","CRL_NDA206968_20181109","CRL_NDA206968_20201222"]},{"app":"NDA206976","kind":"NDA","program":"institut_biochimique_ibsa","sponsor":"Institut Biochimique SA (IBSA)","tickers":[],"sec_filer":false,"product":"diclofenac epolamine","product_type":"not_classified","product_sources":[],"first":"2017-03-24","last":"2017-03-24","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-12-19","tentative":[],"t":635,"censored":false,"letters":["CRL_NDA206976_20170324"]},{"app":"NDA207962","kind":"NDA","program":"scilex_pharmaceuticals","sponsor":"Scilex Pharmaceuticals, Inc.","tickers":["SCLX","SCLXW"],"sec_filer":true,"product":"ZTlido","product_type":"not_classified","product_sources":[],"first":"2016-05-10","last":"2016-05-10","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-02-28","tentative":[],"t":659,"censored":false,"letters":["CRL_NDA207962_20160510"]},{"app":"NDA207987","kind":"NDA","program":"belcher_pharmaceuticals","sponsor":"Belcher Pharmaceuticals, LLC.","tickers":[],"sec_filer":false,"product":"Ablysinol","product_type":"not_classified","product_sources":[],"first":"2015-12-09","last":"2015-12-09","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-06-21","tentative":[],"t":925,"censored":false,"letters":["CRL_NDA207987_20151209"]},{"app":"NDA208042","kind":"NDA","program":"teva_pharmaceuticals_usa","sponsor":"Teva Pharmaceuticals USA","tickers":[],"sec_filer":false,"product":"Fulvestrant","product_type":"not_classified","product_sources":[],"first":"2016-09-30","last":"2016-09-30","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-09-07","tentative":[],"t":707,"censored":false,"letters":["CRL_NDA208042_20160930"]},{"app":"NDA208082","kind":"NDA","program":"teva_pharmaceuticals","sponsor":"Teva Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"TVB-009","product_type":"not_classified","product_sources":[],"first":"2016-05-27","last":"2016-05-27","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2017-04-03","tentative":[],"t":311,"censored":false,"letters":["CRL_NDA208082_20160527"]},{"app":"NDA208193","kind":"NDA","program":"metacel_pharmaceuticals","sponsor":"Metacel Pharmaceuticals, LLC","tickers":[],"sec_filer":false,"product":"Ozobax","product_type":"not_classified","product_sources":[],"first":"2017-01-11","last":"2018-06-25","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-09-18","tentative":[],"t":980,"censored":false,"letters":["CRL_NDA208193_20170111","CRL_NDA208193_20180625"]},{"app":"NDA208232","kind":"NDA","program":"camargo_pharmaceutical_services","sponsor":"Camargo Pharmaceutical Services","tickers":[],"sec_filer":false,"product":"Mycapssa","product_type":"not_classified","product_sources":[],"first":"2016-04-15","last":"2016-04-15","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-06-26","tentative":[],"t":1533,"censored":false,"letters":["CRL_NDA208232_20160415"]},{"app":"NDA208276","kind":"NDA","program":"united_therapeutics","sponsor":"United Therapeutics Corporation","tickers":["UTHR"],"sec_filer":true,"product":"treprostinil","product_type":"not_classified","product_sources":[],"first":"2016-10-07","last":"2017-06-02","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-07-30","tentative":[],"t":661,"censored":false,"letters":["CRL_NDA208276_20161007","CRL_NDA208276_20170602"]},{"app":"NDA208288","kind":"NDA","program":"3m_health_care_infection_prevention_division","sponsor":"3M Health Care (Infection Prevention Division)","tickers":[],"sec_filer":false,"product":"SoluPrep™","product_type":"not_classified","product_sources":[],"first":"2016-05-06","last":"2017-09-01","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-08-08","tentative":[],"t":824,"censored":false,"letters":["CRL_NDA208288_20160506","CRL_NDA208288_20170901"]},{"app":"NDA208313","kind":"NDA","program":"sun_pharmaceutical_industries","sponsor":"Sun Pharmaceutical Industries Limited","tickers":[],"sec_filer":false,"product":"nilotinib","product_type":"not_classified","product_sources":[],"first":"2015-11-24","last":"2017-05-23","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-07-16","tentative":[],"t":965,"censored":false,"letters":["CRL_NDA208313_20151124","CRL_NDA208313_20170523"]},{"app":"NDA208352","kind":"NDA","program":"evofem","sponsor":"Evofem, Inc.","tickers":["EVFM"],"sec_filer":true,"product":"Amphora","product_type":"not_classified","product_sources":[],"first":"2016-04-28","last":"2016-04-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-05-22","tentative":[],"t":1485,"censored":false,"letters":["CRL_NDA208352_20160428"]},{"app":"NDA208419","kind":"NDA","program":"actavis","sponsor":"Actavis, L.L.C.","tickers":[],"sec_filer":false,"product":"Pemetrexed","product_type":"not_classified","product_sources":[],"first":"2017-09-26","last":"2018-06-26","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-08-21","tentative":[],"t":1060,"censored":false,"letters":["CRL_NDA208419_20170926","CRL_NDA208419_20180626"]},{"app":"NDA208564","kind":"NDA","program":"therapeuticsmd","sponsor":"TherapeuticsMD, Inc.","tickers":["TXMD"],"sec_filer":true,"product":"estradiol","product_type":"not_classified","product_sources":[],"first":"2017-05-05","last":"2017-05-05","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-05-29","tentative":[],"t":389,"censored":false,"letters":["CRL_NDA208564_20170505"]},{"app":"NDA208574","kind":"NDA","program":"teva_pharmaceuticals_usa","sponsor":"Teva Pharmaceuticals USA","tickers":[],"sec_filer":false,"product":"Romidepsin","product_type":"not_classified","product_sources":[],"first":"2016-06-01","last":"2019-11-04","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-03-13","tentative":[],"t":1381,"censored":false,"letters":["CRL_NDA208574_20160601","CRL_NDA208574_20170602","CRL_NDA208574_20191104"]},{"app":"NDA208647","kind":"NDA","program":"salamandra","sponsor":"Salamandra, LLC","tickers":[],"sec_filer":false,"product":"rosuvastatin","product_type":"not_classified","product_sources":[],"first":"2016-06-22","last":"2016-06-22","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-12-18","tentative":[],"t":909,"censored":false,"letters":["CRL_NDA208647_20160622"]},{"app":"NDA208742","kind":"NDA","program":"ocular_therapeutix","sponsor":"Ocular Therapeutix, Inc.","tickers":["OCUL"],"sec_filer":true,"product":"DEXTENZA","product_type":"not_classified","product_sources":[],"first":"2016-07-21","last":"2017-07-10","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-11-30","tentative":[],"t":862,"censored":false,"letters":["CRL_NDA208742_20160721","CRL_NDA208742_20170710"]},{"app":"NDA208969","kind":"NDA","program":"amphastar_pharmaceuticals","sponsor":"Amphastar Pharmaceuticals, Inc.","tickers":["AMPH"],"sec_filer":true,"product":null,"product_type":"not_classified","product_sources":[],"first":"2017-02-17","last":"2017-02-17","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-03-07","tentative":[],"t":2209,"censored":false,"letters":["CRL_NDA208969_20170217"]},{"app":"NDA209128","kind":"NDA","program":"acelrx_pharmaceuticals","sponsor":"AcelRx Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"DSUVIA","product_type":"not_classified","product_sources":[],"first":"2017-10-11","last":"2017-10-11","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-11-02","tentative":[],"t":387,"censored":false,"letters":["CRL_NDA209128_20171011"]},{"app":"NDA209191","kind":"NDA","program":"hospira","sponsor":"Hospira, Inc.","tickers":[],"sec_filer":false,"product":"Daptomycin","product_type":"not_classified","product_sources":[],"first":"2017-04-26","last":"2018-02-22","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-05-02","tentative":[],"t":1832,"censored":false,"letters":["CRL_NDA209191_20170426","CRL_NDA209191_20171103","CRL_NDA209191_20180222"]},{"app":"NDA209311","kind":"NDA","program":"ironshore_pharmaceuticals_development","sponsor":"Ironshore Pharmaceuticals & Development, Inc.","tickers":[],"sec_filer":false,"product":"Jornay PM Modified Release","product_type":"not_classified","product_sources":[],"first":"2017-07-28","last":"2017-07-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-08-08","tentative":[],"t":376,"censored":false,"letters":["CRL_NDA209311_20170728"]},{"app":"NDA209354","kind":"NDA","program":"dow_pharmaceutical_sciences","sponsor":"Dow Pharmaceutical Sciences, Inc.","tickers":[],"sec_filer":false,"product":"halobetasol propionate","product_type":"not_classified","product_sources":[],"first":"2018-06-15","last":"2018-06-15","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-04-25","tentative":[],"t":314,"censored":false,"letters":["CRL_NDA209354_20180615"]},{"app":"NDA209388","kind":"NDA","program":"evoke_pharma","sponsor":"Evoke Pharma, Inc.","tickers":[],"sec_filer":false,"product":"Gimoti","product_type":"not_classified","product_sources":[],"first":"2019-04-01","last":"2019-04-01","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-06-19","tentative":[],"t":445,"censored":false,"letters":["CRL_NDA209388_20190401"]},{"app":"NDA209471","kind":"NDA","program":"aft_pharmaceuticals","sponsor":"AFT Pharmaceuticals Ltd.","tickers":[],"sec_filer":false,"product":"sirolimus","product_type":"not_classified","product_sources":[],"first":"2017-12-22","last":"2020-11-06","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-03-01","tentative":[],"t":1895,"censored":false,"letters":["CRL_NDA209471_20171222","CRL_NDA209471_20201106"]},{"app":"NDA209510","kind":"NDA","program":"acacia_pharma","sponsor":"Acacia Pharma Ltd","tickers":[],"sec_filer":false,"product":"Barhemsys","product_type":"not_classified","product_sources":[],"first":"2018-10-05","last":"2019-05-02","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-02-26","tentative":[],"t":509,"censored":false,"letters":["CRL_NDA209510_20181005","CRL_NDA209510_20190502"]},{"app":"NDA209511","kind":"NDA","program":"innocoll_pharmaceuticals","sponsor":"Innocoll Pharmaceuticals","tickers":[],"sec_filer":false,"product":null,"product_type":"not_classified","product_sources":[],"first":"2018-11-30","last":"2018-11-30","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-08-28","tentative":[],"t":637,"censored":false,"letters":["CRL_NDA209511_20181130"]},{"app":"NDA209529","kind":"NDA","program":"astellas_pharma_us","sponsor":"Astellas Pharma US, Inc.","tickers":[],"sec_filer":false,"product":"IZERVAY","product_type":"not_classified","product_sources":[],"first":"2017-08-28","last":"2017-08-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-05-26","tentative":[],"t":1002,"censored":false,"letters":["CRL_NDA209529_20170828"]},{"app":"NDA209531","kind":"NDA","program":"biogen","sponsor":"Biogen, Inc.","tickers":["BIIB"],"sec_filer":true,"product":null,"product_type":"not_classified","product_sources":[],"first":"2025-09-22","last":"2025-09-22","n":1,"n_orig":0,"era":"issued","track":"supplement","outcome":"supplement","approved":null,"tentative":[],"t":382,"censored":true,"letters":["CRL_NDA209531_20250922"]},{"app":"NDA209575","kind":"NDA","program":"lannett_holdings","sponsor":"Lannett Holdings, Inc.","tickers":[],"sec_filer":false,"product":"Cocaine Hydrochloride","product_type":"not_classified","product_sources":[],"first":"2018-07-20","last":"2018-07-20","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-01-10","tentative":[],"t":539,"censored":false,"letters":["CRL_NDA209575_20180720"]},{"app":"NDA209863","kind":"NDA","program":"antares_pharma","sponsor":"Antares Pharma, Inc.","tickers":[],"sec_filer":false,"product":"hydrocortisone sodium phosphate","product_type":"not_classified","product_sources":[],"first":"2017-10-20","last":"2017-10-20","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2018-09-28","tentative":[],"t":343,"censored":false,"letters":["CRL_NDA209863_20171020"]},{"app":"NDA209988","kind":"NDA","program":"scpharmaceuticals","sponsor":"scPharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"Furoscix™ “","product_type":"not_classified","product_sources":[],"first":"2018-06-11","last":"2020-12-03","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-10-07","tentative":[],"t":1579,"censored":false,"letters":["CRL_NDA209988_20180611","CRL_NDA209988_20201203"]},{"app":"NDA210063","kind":"NDA","program":"teva_pharmaceuticals_usa","sponsor":"Teva Pharmaceuticals USA","tickers":[],"sec_filer":false,"product":"Fulvestrant","product_type":"not_classified","product_sources":[],"first":"2017-10-26","last":"2017-10-26","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-08-19","tentative":[],"t":662,"censored":false,"letters":["CRL_NDA210063_20171026"]},{"app":"NDA210136","kind":"NDA","program":"braeburn_pharmaceuticals","sponsor":"Braeburn Pharmaceuticals Inc.","tickers":[],"sec_filer":false,"product":"BRIXADI","product_type":"not_classified","product_sources":[],"first":"2018-01-19","last":"2021-12-15","n":4,"n_orig":4,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-05-23","tentative":[],"t":1950,"censored":false,"letters":["CRL_NDA210136_20180119","CRL_NDA210136_20181221","CRL_NDA210136_20201201","CRL_NDA210136_20211215"]},{"app":"NDA210168","kind":"NDA","program":"cipla_usa","sponsor":"Cipla USA, Inc.","tickers":[],"sec_filer":false,"product":"unknown (Cipla USA NDA, product redacted)","product_type":"unknown","product_sources":["https://download.open.fda.gov/crl/CRL_NDA210168_20240322.pdf"],"first":"2024-03-22","last":"2025-06-20","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":931,"censored":true,"letters":["CRL_NDA210168_20240322","CRL_NDA210168_20250620"]},{"app":"NDA210274","kind":"NDA","program":"zhejiang_novus_pharmaceuticals","sponsor":"Zhejiang Novus Pharmaceuticals Co. Ltd.","tickers":[],"sec_filer":false,"product":"Vancomycin Hydrochloride","product_type":"not_classified","product_sources":[],"first":"2018-06-15","last":"2021-08-25","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-01-20","tentative":[],"t":1680,"censored":false,"letters":["CRL_NDA210274_20180615","CRL_NDA210274_20201127","CRL_NDA210274_20210825"]},{"app":"NDA210282","kind":"NDA","program":"hospira","sponsor":"Hospira, Inc.","tickers":[],"sec_filer":false,"product":"Daptomycin","product_type":"not_classified","product_sources":[],"first":"2018-03-19","last":"2018-03-19","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-06-21","tentative":[],"t":1190,"censored":false,"letters":["CRL_NDA210282_20180319"]},{"app":"NDA210526","kind":"NDA","program":"tris_pharma","sponsor":"Tris Pharma, Inc.","tickers":[],"sec_filer":false,"product":"Dyanavel XR","product_type":"not_classified","product_sources":[],"first":"2018-07-25","last":"2021-01-21","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-11-04","tentative":[],"t":1198,"censored":false,"letters":["CRL_NDA210526_20180725","CRL_NDA210526_20210121"]},{"app":"NDA210583","kind":"NDA","program":"recro_pharma","sponsor":"Recro Pharma Inc.","tickers":[],"sec_filer":false,"product":"Meloxicam","product_type":"not_classified","product_sources":[],"first":"2018-05-23","last":"2019-03-22","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-02-20","tentative":[],"t":638,"censored":false,"letters":["CRL_NDA210583_20180523","CRL_NDA210583_20190322"]},{"app":"NDA210605","kind":"NDA","program":"mylan","sponsor":"Mylan GmbH","tickers":[],"sec_filer":false,"product":"insulin glargine","product_type":"not_classified","product_sources":[],"first":"2018-05-17","last":"2019-08-28","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":3067,"censored":true,"letters":["CRL_NDA210605_20180517","CRL_NDA210605_20190828"]},{"app":"NDA210649","kind":"NDA","program":"pharmaceuticals","sponsor":"AB Pharmaceuticals, LLC","tickers":[],"sec_filer":false,"product":null,"product_type":"not_classified","product_sources":[],"first":"2018-03-13","last":"2018-09-12","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-03-15","tentative":[],"t":367,"censored":false,"letters":["CRL_NDA210649_20180313","CRL_NDA210649_20180912"]},{"app":"NDA210730","kind":"NDA","program":"trevena","sponsor":"Trevena, Inc.","tickers":[],"sec_filer":false,"product":"Oliceridine","product_type":"not_classified","product_sources":[],"first":"2018-11-02","last":"2018-11-02","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-08-07","tentative":[],"t":644,"censored":false,"letters":["CRL_NDA210730_20181102"]},{"app":"NDA210735","kind":"NDA","program":"auromedics_pharma","sponsor":"AuroMedics Pharma LLC","tickers":[],"sec_filer":false,"product":"Cyclophosphamide","product_type":"not_classified","product_sources":[],"first":"2018-04-26","last":"2019-10-01","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-08-25","tentative":[],"t":1217,"censored":false,"letters":["CRL_NDA210735_20180426","CRL_NDA210735_20190115","CRL_NDA210735_20191001"]},{"app":"NDA210821","kind":"NDA","program":"valeant_pharmaceuticals_ireland","sponsor":"Valeant Pharmaceuticals Ireland","tickers":[],"sec_filer":false,"product":"tetracaine hydrochloride","product_type":"not_classified","product_sources":[],"first":"2018-11-20","last":"2018-11-20","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-03-12","tentative":[],"t":112,"censored":false,"letters":["CRL_NDA210821_20181120"]},{"app":"NDA210852","kind":"NDA","program":"dr_reddys_laboratories","sponsor":"Dr. Reddy’s Laboratories, Inc.","tickers":["RDY"],"sec_filer":true,"product":"AVT03","product_type":"not_classified","product_sources":[],"first":"2018-07-24","last":"2022-04-18","n":6,"n_orig":6,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-06-07","tentative":[],"t":1779,"censored":false,"letters":["CRL_NDA210852_20180724","CRL_NDA210852_20190503","CRL_NDA210852_20191120","CRL_NDA210852_20200521","CRL_NDA210852_20201106","CRL_NDA210852_20220418"]},{"app":"NDA210862","kind":"NDA","program":"biohaven_therapeutics","sponsor":"Biohaven Therapeutics, Ltd.","tickers":["BHVN"],"sec_filer":true,"product":"Vyglxia (troriluzole), glutamate modulator for spinocerebellar ataxia","product_type":"novel","product_sources":["https://www.neurologylive.com/view/fda-issues-complete-response-letter-spinocerebellar-ataxia-agent-troriluzole"],"first":"2025-11-04","last":"2025-11-04","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":339,"censored":true,"letters":["CRL_NDA210862_20251104"]},{"app":"NDA210864","kind":"NDA","program":"sedor_pharmaceuticals","sponsor":"Sedor Pharmaceuticals, LLC","tickers":[],"sec_filer":false,"product":"Sesquient","product_type":"not_classified","product_sources":[],"first":"2019-03-22","last":"2019-12-20","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-11-05","tentative":[],"t":594,"censored":false,"letters":["CRL_NDA210864_20190322","CRL_NDA210864_20191220"]},{"app":"NDA210875","kind":"NDA","program":"sunovion_pharmaceuticals","sponsor":"Sunovion Pharmaceuticals Inc.","tickers":[],"sec_filer":false,"product":"Kynmobi","product_type":"not_classified","product_sources":[],"first":"2019-01-29","last":"2019-01-29","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-05-21","tentative":[],"t":478,"censored":false,"letters":["CRL_NDA210875_20190129"]},{"app":"NDA210895","kind":"NDA","program":"daiichi_sankyo","sponsor":"Daiichi Sankyo, Inc.","tickers":[],"sec_filer":false,"product":"this action below","product_type":"not_classified","product_sources":[],"first":"2018-08-24","last":"2018-08-24","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-04-03","tentative":[],"t":222,"censored":false,"letters":["CRL_NDA210895_20180824"]},{"app":"NDA210933","kind":"NDA","program":"kala_pharmaceuticals","sponsor":"Kala Pharmaceuticals, Inc.","tickers":["KALA"],"sec_filer":true,"product":"Eysuvis","product_type":"not_classified","product_sources":[],"first":"2019-08-07","last":"2019-08-07","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-10-26","tentative":[],"t":446,"censored":false,"letters":["CRL_NDA210933_20190807"]},{"app":"NDA210934","kind":"NDA","program":"lexicon_pharmaceuticals","sponsor":"Lexicon Pharmaceuticals, Inc.","tickers":["LXRX"],"sec_filer":true,"product":"sotagliflozin (Zynquista) for type 1 diabetes","product_type":"other","product_sources":["https://www.ajmc.com/view/fda-rejects-sotagliflozin-for-type-1-diabetes-lexicon-shifts-focus","https://investors.lexpharma.com/news-releases/news-release-details/lexicon-pharmaceuticals-announces-update-submission-additional"],"first":"2024-12-20","last":"2024-12-20","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":658,"censored":true,"letters":["CRL_NDA210934_20241220"]},{"app":"NDA211039","kind":"NDA","program":"bausch_health_ireland","sponsor":"Bausch Health Ireland Limited","tickers":[],"sec_filer":false,"product":"fluorescein sodium","product_type":"not_classified","product_sources":[],"first":"2019-07-19","last":"2019-07-19","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-03-09","tentative":[],"t":234,"censored":false,"letters":["CRL_NDA211039_20190719"]},{"app":"NDA211150","kind":"NDA","program":"bioprojet_pharma","sponsor":"Bioprojet Pharma","tickers":[],"sec_filer":false,"product":"Wakix","product_type":"not_classified","product_sources":[],"first":"2019-08-14","last":"2019-08-14","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-10-13","tentative":[],"t":426,"censored":false,"letters":["CRL_NDA211150_20190814"]},{"app":"NDA211241","kind":"NDA","program":"sentynl_therapeutics","sponsor":"Sentynl Therapeutics, Inc.","tickers":[],"sec_filer":false,"product":"ZYCUBO (copper histidinate) injection, for Menkes disease","product_type":"novel","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA211241","https://sentynl.com/news/zycubo-fda-approval/"],"first":"2025-09-30","last":"2025-09-30","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2026-01-12","tentative":[],"t":104,"censored":false,"letters":["CRL_NDA211241_20250930"]},{"app":"NDA211302","kind":"NDA","program":"recordati_rare_diseases","sponsor":"Recordati Rare Diseases Inc.","tickers":[],"sec_filer":false,"product":"Cystadrops","product_type":"not_classified","product_sources":[],"first":"2020-01-28","last":"2020-01-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-08-19","tentative":[],"t":204,"censored":false,"letters":["CRL_NDA211302_20200128"]},{"app":"NDA211321","kind":"NDA","program":"proximagen","sponsor":"Proximagen, LLC","tickers":[],"sec_filer":false,"product":"Nayzilam","product_type":"not_classified","product_sources":[],"first":"2019-03-29","last":"2019-03-29","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-05-17","tentative":[],"t":49,"censored":false,"letters":["CRL_NDA211321_20190329"]},{"app":"NDA211363","kind":"NDA","program":"international_medication_systems","sponsor":"International Medication Systems, Limited","tickers":[],"sec_filer":false,"product":"Epinephrine","product_type":"not_classified","product_sources":[],"first":"2018-12-12","last":"2018-12-12","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-08-15","tentative":[],"t":1342,"censored":false,"letters":["CRL_NDA211363_20181212"]},{"app":"NDA211413","kind":"NDA","program":"hq_specialty_pharma","sponsor":"HQ Specialty Pharma Corporation","tickers":[],"sec_filer":false,"product":"Meropenem","product_type":"not_classified","product_sources":[],"first":"2018-10-19","last":"2021-01-08","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-05-08","tentative":[],"t":1662,"censored":false,"letters":["CRL_NDA211413_20181019","CRL_NDA211413_20191226","CRL_NDA211413_20210108"]},{"app":"NDA211566","kind":"NDA","program":"zydus_worldwide_dmcc","sponsor":"Zydus Worldwide DMCC","tickers":[],"sec_filer":false,"product":"sitagliptin","product_type":"not_classified","product_sources":[],"first":"2021-09-02","last":"2023-03-03","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-10-18","tentative":[],"t":776,"censored":false,"letters":["CRL_NDA211566_20210902","CRL_NDA211566_20230303"]},{"app":"NDA211746","kind":"NDA","program":"glenmark_pharmaceuticals","sponsor":"Glenmark Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"GSP","product_type":"not_classified","product_sources":[],"first":"2019-06-20","last":"2019-06-20","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-01-13","tentative":[],"t":938,"censored":false,"letters":["CRL_NDA211746_20190620"]},{"app":"NDA211950","kind":"NDA","program":"clearside_biomedical","sponsor":"Clearside Biomedical, Inc.","tickers":[],"sec_filer":false,"product":"XIPERE","product_type":"not_classified","product_sources":[],"first":"2019-10-18","last":"2019-10-18","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-10-22","tentative":[],"t":735,"censored":false,"letters":["CRL_NDA211950_20191018"]},{"app":"NDA211964","kind":"NDA","program":"supernus_pharmaceuticals","sponsor":"Supernus Pharmaceuticals, Inc.","tickers":["SUPN"],"sec_filer":true,"product":"viloxazine hydrochloride","product_type":"not_classified","product_sources":[],"first":"2020-11-06","last":"2020-11-06","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-04-02","tentative":[],"t":147,"censored":false,"letters":["CRL_NDA211964_20201106"]},{"app":"NDA211970","kind":"NDA","program":"sarepta_therapeutics","sponsor":"Sarepta Therapeutics, Inc.","tickers":["SRPT"],"sec_filer":true,"product":"Vyondys","product_type":"not_classified","product_sources":[],"first":"2019-08-19","last":"2019-08-19","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2019-12-12","tentative":[],"t":115,"censored":false,"letters":["CRL_NDA211970_20190819"]},{"app":"NDA211988","kind":"NDA","program":"heron_therapeutics","sponsor":"Heron Therapeutics, Inc.","tickers":["HRTX"],"sec_filer":true,"product":"Zynrelef","product_type":"not_classified","product_sources":[],"first":"2019-04-30","last":"2020-06-26","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-05-12","tentative":[],"t":743,"censored":false,"letters":["CRL_NDA211988_20190430","CRL_NDA211988_20200626"]},{"app":"NDA212045","kind":"NDA","program":"hikma_pharmaceuticals_usa","sponsor":"Hikma Pharmaceuticals USA Inc.","tickers":[],"sec_filer":false,"product":"phenobarbital sodium","product_type":"not_classified","product_sources":[],"first":"2020-02-28","last":"2020-02-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-04-29","tentative":[],"t":426,"censored":false,"letters":["CRL_NDA212045_20200228"]},{"app":"NDA212097","kind":"NDA","program":"xeris_pharmaceuticals","sponsor":"Xeris Pharmaceuticals, Inc.","tickers":["XERS"],"sec_filer":true,"product":"Gvoke","product_type":"not_classified","product_sources":[],"first":"2024-02-09","last":"2024-02-09","n":1,"n_orig":0,"era":"issued","track":"supplement","outcome":"supplement","approved":null,"tentative":[],"t":973,"censored":true,"letters":["CRL_NDA212097_20240209"]},{"app":"NDA212122","kind":"NDA","program":"astrazeneca","sponsor":"AstraZeneca AB","tickers":["AZN"],"sec_filer":true,"product":"Breztri Aerosphere","product_type":"not_classified","product_sources":[],"first":"2019-09-30","last":"2019-09-30","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-07-23","tentative":[],"t":297,"censored":false,"letters":["CRL_NDA212122_20190930"]},{"app":"NDA212156","kind":"NDA","program":"par_sterile_products","sponsor":"Par Sterile Products, LLC","tickers":[],"sec_filer":false,"product":"Micafungin","product_type":"not_classified","product_sources":[],"first":"2020-05-18","last":"2020-05-18","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-06-16","tentative":[],"t":394,"censored":false,"letters":["CRL_NDA212156_20200518"]},{"app":"NDA212271","kind":"NDA","program":"meitheal_pharmaceuticals","sponsor":"Meitheal Pharmaceuticals Inc.","tickers":[],"sec_filer":false,"product":"Contepo (fosfomycin disodium for injection), IV fosfomycin","product_type":"505b2_new_formulation","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212271"],"first":"2024-12-11","last":"2024-12-11","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-10-22","tentative":[],"t":315,"censored":false,"letters":["CRL_NDA212271_20241211"]},{"app":"NDA212304","kind":"NDA","program":"corium","sponsor":"Corium, Inc.","tickers":[],"sec_filer":false,"product":"ADLARITY","product_type":"not_classified","product_sources":[],"first":"2020-07-23","last":"2020-07-23","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-03-11","tentative":[],"t":596,"censored":false,"letters":["CRL_NDA212304_20200723"]},{"app":"NDA212479","kind":"NDA","program":"therakind","sponsor":"Therakind Limited","tickers":[],"sec_filer":false,"product":"Jylamvo","product_type":"not_classified","product_sources":[],"first":"2021-12-22","last":"2021-12-22","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-11-29","tentative":[],"t":342,"censored":false,"letters":["CRL_NDA212479_20211222"]},{"app":"NDA212501","kind":"NDA","program":"ricon_pharma","sponsor":"Ricon Pharma, LLC","tickers":[],"sec_filer":false,"product":"Cyclophosphamide","product_type":"not_classified","product_sources":[],"first":"2019-07-18","last":"2020-01-14","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-07-30","tentative":[],"t":378,"censored":false,"letters":["CRL_NDA212501_20190718","CRL_NDA212501_20200114"]},{"app":"NDA212782","kind":"NDA","program":"shilpa_medicare","sponsor":"Shilpa Medicare Limited","tickers":[],"sec_filer":false,"product":"bortezomib","product_type":"not_classified","product_sources":[],"first":"2020-03-10","last":"2023-08-01","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-08-26","tentative":[],"t":1630,"censored":false,"letters":["CRL_NDA212782_20200310","CRL_NDA212782_20230801"]},{"app":"NDA212849","kind":"NDA","program":"shandong_luye_pharmaceutical","sponsor":"Shandong Luye Pharmaceutical Co., Ltd.","tickers":[],"sec_filer":false,"product":"Rykindo","product_type":"not_classified","product_sources":[],"first":"2020-01-28","last":"2022-02-18","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-01-13","tentative":[],"t":1081,"censored":false,"letters":["CRL_NDA212849_20200128","CRL_NDA212849_20220218"]},{"app":"NDA212854","kind":"NDA","program":"adamis_pharmaceuticals","sponsor":"Adamis Pharmaceuticals Corporation","tickers":[],"sec_filer":false,"product":"Naloxone HCI","product_type":"not_classified","product_sources":[],"first":"2019-11-22","last":"2020-11-13","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-10-15","tentative":[],"t":693,"censored":false,"letters":["CRL_NDA212854_20191122","CRL_NDA212854_20201113"]},{"app":"NDA212887","kind":"NDA","program":"viiv_healthcare","sponsor":"ViiV Healthcare Company","tickers":[],"sec_filer":false,"product":"CABENUVA®","product_type":"not_classified","product_sources":[],"first":"2019-12-19","last":"2019-12-19","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-01-21","tentative":[],"t":399,"censored":false,"letters":["CRL_NDA212887_20191219"]},{"app":"NDA212888","kind":"NDA","program":"viiv_healthcare","sponsor":"ViiV Healthcare Company","tickers":[],"sec_filer":false,"product":"CABENUVA®","product_type":"not_classified","product_sources":[],"first":"2019-12-19","last":"2019-12-19","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-01-21","tentative":[],"t":399,"censored":false,"letters":["CRL_NDA212888_20191219"]},{"app":"NDA212905","kind":"NDA","program":"verrica_pharmaceuticals","sponsor":"Verrica Pharmaceuticals Inc.","tickers":["VRCA"],"sec_filer":true,"product":"cantharidin","product_type":"not_classified","product_sources":[],"first":"2020-07-13","last":"2022-05-23","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-07-21","tentative":[],"t":1103,"censored":false,"letters":["CRL_NDA212905_20200713","CRL_NDA212905_20210916","CRL_NDA212905_20220523"]},{"app":"NDA212937","kind":"NDA","program":"fennec_pharmaceuticals","sponsor":"Fennec Pharmaceuticals, Inc.","tickers":["FENC"],"sec_filer":true,"product":"PEDMARK","product_type":"not_classified","product_sources":[],"first":"2020-08-10","last":"2021-11-26","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-09-20","tentative":[],"t":771,"censored":false,"letters":["CRL_NDA212937_20200810","CRL_NDA212937_20211126"]},{"app":"NDA213072","kind":"NDA","program":"althera_life_sciences","sponsor":"Althera Life Sciences, LLC","tickers":[],"sec_filer":false,"product":"rosuvastatin","product_type":"not_classified","product_sources":[],"first":"2020-05-26","last":"2020-05-26","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-03-23","tentative":[],"t":301,"censored":false,"letters":["CRL_NDA213072_20200526"]},{"app":"NDA213135","kind":"NDA","program":"braintree_laboratories","sponsor":"Braintree Laboratories, Inc.","tickers":[],"sec_filer":false,"product":"Suflave","product_type":"not_classified","product_sources":[],"first":"2020-03-13","last":"2020-03-13","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2020-11-10","tentative":[],"t":242,"censored":false,"letters":["CRL_NDA213135_20200313"]},{"app":"NDA213218","kind":"NDA","program":"sarfez_pharmaceuticals","sponsor":"Sarfez Pharmaceuticals Inc.","tickers":[],"sec_filer":false,"product":"pd Pe or to section","product_type":"not_classified","product_sources":[],"first":"2020-01-10","last":"2020-01-10","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-06-14","tentative":[],"t":521,"censored":false,"letters":["CRL_NDA213218_20200110"]},{"app":"NDA213260","kind":"NDA","program":"cmp_development","sponsor":"CMP Development LLC","tickers":[],"sec_filer":false,"product":"sildenafil","product_type":"not_classified","product_sources":[],"first":"2020-10-16","last":"2020-10-16","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-02-01","tentative":[],"t":838,"censored":false,"letters":["CRL_NDA213260_20201016"]},{"app":"NDA213378","kind":"NDA","program":"alkermes","sponsor":"Alkermes, Inc.","tickers":["ALKS"],"sec_filer":true,"product":"Lybalvi","product_type":"not_classified","product_sources":[],"first":"2020-11-13","last":"2020-11-13","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-05-28","tentative":[],"t":196,"censored":false,"letters":["CRL_NDA213378_20201113"]},{"app":"NDA213426","kind":"NDA","program":"esteve_pharmaceuticals","sponsor":"Esteve Pharmaceuticals, S.A.","tickers":[],"sec_filer":false,"product":"celecoxib","product_type":"not_classified","product_sources":[],"first":"2020-06-15","last":"2020-06-15","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-10-15","tentative":[],"t":487,"censored":false,"letters":["CRL_NDA213426_20200615"]},{"app":"NDA213478","kind":"NDA","program":"nobelpharma","sponsor":"Nobelpharma Co., Ltd.","tickers":[],"sec_filer":false,"product":"sirolimus","product_type":"not_classified","product_sources":[],"first":"2020-08-13","last":"2020-08-13","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-03-22","tentative":[],"t":586,"censored":false,"letters":["CRL_NDA213478_20200813"]},{"app":"NDA213586","kind":"NDA","program":"teva_neuroscience","sponsor":"Teva Neuroscience, Inc.","tickers":[],"sec_filer":false,"product":"risperidone","product_type":"not_classified","product_sources":[],"first":"2022-04-15","last":"2022-04-15","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-04-28","tentative":[],"t":378,"censored":false,"letters":["CRL_NDA213586_20220415"]},{"app":"NDA213593","kind":"NDA","program":"azurity_pharmaceuticals","sponsor":"Azurity Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"sitagliptin","product_type":"not_classified","product_sources":[],"first":"2021-01-28","last":"2021-01-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-08-30","tentative":[],"t":579,"censored":false,"letters":["CRL_NDA213593_20210128"]},{"app":"NDA213645","kind":"NDA","program":"baxter_healthcare","sponsor":"Baxter Healthcare Corporation","tickers":[],"sec_filer":false,"product":"DAPZURA RT","product_type":"not_classified","product_sources":[],"first":"2021-04-29","last":"2021-04-29","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-01-25","tentative":[],"t":271,"censored":false,"letters":["CRL_NDA213645_20210429"]},{"app":"NDA213895","kind":"NDA","program":"xellia_pharmaceuticals_aps","sponsor":"Xellia Pharmaceuticals, ApS","tickers":[],"sec_filer":false,"product":"Vancomycin","product_type":"not_classified","product_sources":[],"first":"2020-03-20","last":"2020-03-20","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-08-26","tentative":[],"t":524,"censored":false,"letters":["CRL_NDA213895_20200320"]},{"app":"NDA213931","kind":"NDA","program":"ardelyx","sponsor":"Ardelyx, Inc.","tickers":["ARDX"],"sec_filer":true,"product":"tenapanor hydrochloride","product_type":"not_classified","product_sources":[],"first":"2021-07-28","last":"2021-07-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-10-17","tentative":[],"t":811,"censored":false,"letters":["CRL_NDA213931_20210728"]},{"app":"NDA213953","kind":"NDA","program":"marius_pharmaceuticals","sponsor":"Marius Pharmaceuticals, LLC","tickers":[],"sec_filer":false,"product":"testosterone undecanoate","product_type":"not_classified","product_sources":[],"first":"2021-10-22","last":"2021-10-22","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-07-27","tentative":[],"t":278,"censored":false,"letters":["CRL_NDA213953_20211022"]},{"app":"NDA213972","kind":"NDA","program":"lterum_therapeutics_us","sponsor":"lterum Therapeutics U.S. Ltd.","tickers":[],"sec_filer":false,"product":"sulopenem etzadroxil","product_type":"not_classified","product_sources":[],"first":"2021-07-23","last":"2021-07-23","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-10-25","tentative":[],"t":1190,"censored":false,"letters":["CRL_NDA213972_20210723"]},{"app":"NDA213976","kind":"NDA","program":"takeda_pharmaceuticals_usa","sponsor":"Takeda Pharmaceuticals U.S.A., Inc.","tickers":[],"sec_filer":false,"product":"Eohilia","product_type":"not_classified","product_sources":[],"first":"2021-12-17","last":"2021-12-17","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-02-09","tentative":[],"t":784,"censored":false,"letters":["CRL_NDA213976_20211217"]},{"app":"NDA214012","kind":"NDA","program":"novartis_pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","tickers":[],"sec_filer":false,"product":"inclisiran","product_type":"not_classified","product_sources":[],"first":"2020-12-18","last":"2020-12-18","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-12-22","tentative":[],"t":369,"censored":false,"letters":["CRL_NDA214012_20201218"]},{"app":"NDA214273","kind":"NDA","program":"azurity_pharmaceuticals","sponsor":"Azurity Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"sitagliptin","product_type":"not_classified","product_sources":[],"first":"2021-05-28","last":"2021-05-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-07-15","tentative":[],"t":413,"censored":false,"letters":["CRL_NDA214273_20210528"]},{"app":"NDA214315","kind":"NDA","program":"defender_pharmaceuticals","sponsor":"Defender Pharmaceuticals, Inc","tickers":[],"sec_filer":false,"product":"DPI-386, scopolamine intranasal gel","product_type":"505b2_new_formulation","product_sources":["https://www.pharmaceutical-technology.com/news/defenders-plans-for-motion-sickness-nasal-gel-stop-with-fda-rejection/","https://drugs.com/history/dpi-386.html"],"first":"2024-01-25","last":"2024-01-25","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":988,"censored":true,"letters":["CRL_NDA214315_20240125"]},{"app":"NDA214324","kind":"NDA","program":"united_therapeutics","sponsor":"United Therapeutics Corporation","tickers":["UTHR"],"sec_filer":true,"product":"treprostinil","product_type":"not_classified","product_sources":[],"first":"2021-10-15","last":"2021-10-15","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-05-23","tentative":[],"t":220,"censored":false,"letters":["CRL_NDA214324_20211015"]},{"app":"NDA214375","kind":"NDA","program":"polarean","sponsor":"Polarean Inc.","tickers":[],"sec_filer":false,"product":"Xenoview","product_type":"not_classified","product_sources":[],"first":"2021-10-05","last":"2021-10-05","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-12-23","tentative":[],"t":444,"censored":false,"letters":["CRL_NDA214375_20211005"]},{"app":"NDA214410","kind":"NDA","program":"genentech","sponsor":"Genentech, Incorporated","tickers":[],"sec_filer":false,"product":"XOFLUZA","product_type":"not_classified","product_sources":[],"first":"2020-11-23","last":"2020-11-23","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-08-11","tentative":[],"t":626,"censored":false,"letters":["CRL_NDA214410_20201123"]},{"app":"NDA214429","kind":"NDA","program":"sanofi_aventis_us","sponsor":"sanofi-aventis U.S. LLC","tickers":[],"sec_filer":false,"product":"Fexinidazole","product_type":"not_classified","product_sources":[],"first":"2020-11-12","last":"2020-11-12","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2021-07-16","tentative":[],"t":246,"censored":false,"letters":["CRL_NDA214429_20201112"]},{"app":"NDA214439","kind":"NDA","program":"cmp_development","sponsor":"CMP Development LLC","tickers":[],"sec_filer":false,"product":"sildenafil","product_type":"not_classified","product_sources":[],"first":"2021-04-22","last":"2021-04-22","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-02-24","tentative":[],"t":308,"censored":false,"letters":["CRL_NDA214439_20210422"]},{"app":"NDA214520","kind":"NDA","program":"cormedix","sponsor":"CorMedix Inc.","tickers":["CRMD"],"sec_filer":true,"product":"taurolidine","product_type":"not_classified","product_sources":[],"first":"2021-02-26","last":"2022-08-04","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-11-15","tentative":[],"t":992,"censored":false,"letters":["CRL_NDA214520_20210226","CRL_NDA214520_20220804"]},{"app":"NDA214522","kind":"NDA","program":"cmp_development","sponsor":"CMP Development LLC","tickers":[],"sec_filer":false,"product":"sildenafil","product_type":"not_classified","product_sources":[],"first":"2021-02-23","last":"2021-02-23","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-06-17","tentative":[],"t":479,"censored":false,"letters":["CRL_NDA214522_20210223"]},{"app":"NDA214581","kind":"NDA","program":"novitium_pharma","sponsor":"Novitium Pharma LLC","tickers":[],"sec_filer":false,"product":"Hydroxychloroquine Sulfate","product_type":"not_classified","product_sources":[],"first":"2021-02-12","last":"2021-02-12","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-01-14","tentative":[],"t":336,"censored":false,"letters":["CRL_NDA214581_20210212"]},{"app":"NDA214610","kind":"NDA","program":"fresenius_kabi_usa","sponsor":"Fresenius Kabi USA, LLC","tickers":[],"sec_filer":false,"product":"Amino acids, electrolytes, dextrose and lipid injectable emulsion (Fresenius Kabi three-chamber parenteral nutrition)","product_type":"505b2_new_formulation","product_sources":["https://download.open.fda.gov/crl/CRL_NDA214610_20260227.pdf"],"first":"2024-12-11","last":"2026-02-27","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":667,"censored":true,"letters":["CRL_NDA214610_20241211","CRL_NDA214610_20260227"]},{"app":"NDA214628","kind":"NDA","program":"nevakar","sponsor":"Nevakar, Inc.","tickers":[],"sec_filer":false,"product":"Norepinephrine Bitartrate","product_type":"not_classified","product_sources":[],"first":"2021-06-14","last":"2021-06-14","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-10-06","tentative":[],"t":479,"censored":false,"letters":["CRL_NDA214628_20210614"]},{"app":"NDA214697","kind":"NDA","program":"ars_pharmaceuticals","sponsor":"ARS Pharmaceuticals, Inc.","tickers":["SPRY"],"sec_filer":true,"product":"Neffy","product_type":"not_classified","product_sources":[],"first":"2023-09-19","last":"2023-09-19","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-08-09","tentative":[],"t":325,"censored":false,"letters":["CRL_NDA214697_20230919"]},{"app":"NDA214759","kind":"NDA","program":"medac_gesellschaft_fur_klinische_spezialpraparate_mbh","sponsor":"medac Gesellschaft fur klinische Spezialpraparate mbH","tickers":[],"sec_filer":false,"product":"Grafapex","product_type":"not_classified","product_sources":[],"first":"2021-07-30","last":"2021-07-30","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2025-01-21","tentative":[],"t":1271,"censored":false,"letters":["CRL_NDA214759_20210730"]},{"app":"NDA214835","kind":"NDA","program":"laboratorios_farmaceuticos_rovi","sponsor":"Laboratorios Farmacéuticos ROVI, S.A.","tickers":[],"sec_filer":false,"product":"Risvan","product_type":"not_classified","product_sources":[],"first":"2021-09-24","last":"2023-07-27","n":3,"n_orig":3,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-03-29","tentative":[],"t":917,"censored":false,"letters":["CRL_NDA214835_20210924","CRL_NDA214835_20220715","CRL_NDA214835_20230727"]},{"app":"NDA214860","kind":"NDA","program":"acer_therapeutics","sponsor":"Acer Therapeutics Inc.","tickers":[],"sec_filer":false,"product":"sodium phenylbutyrate","product_type":"not_classified","product_sources":[],"first":"2022-06-15","last":"2022-06-15","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-12-22","tentative":[],"t":190,"censored":false,"letters":["CRL_NDA214860_20220615"]},{"app":"NDA214927","kind":"NDA","program":"orphazyme_a_s","sponsor":"Orphazyme A/S","tickers":[],"sec_filer":false,"product":"arimoclomol","product_type":"not_classified","product_sources":[],"first":"2021-06-17","last":"2021-06-17","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-09-20","tentative":[],"t":1191,"censored":false,"letters":["CRL_NDA214927_20210617"]},{"app":"NDA214952","kind":"NDA","program":"cmp_development","sponsor":"CMP Development LLC","tickers":[],"sec_filer":false,"product":"sildenafil","product_type":"not_classified","product_sources":[],"first":"2022-04-28","last":"2022-04-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-04-28","tentative":[],"t":365,"censored":false,"letters":["CRL_NDA214952_20220428"]},{"app":"NDA215000","kind":"NDA","program":"accord_healthcare","sponsor":"Accord Healthcare Inc.","tickers":[],"sec_filer":false,"product":"bendamustine hydrochloride","product_type":"not_classified","product_sources":[],"first":"2021-04-30","last":"2021-04-30","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-05-16","tentative":[],"t":381,"censored":false,"letters":["CRL_NDA215000_20210430"]},{"app":"NDA215029","kind":"NDA","program":"medrx_usa","sponsor":"MEDRx USA, Inc.","tickers":[],"sec_filer":false,"product":"Bondlido (lidocaine topical system 10%)","product_type":"505b2_new_formulation","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215029"],"first":"2024-07-11","last":"2024-07-11","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-09-24","tentative":[],"t":440,"censored":false,"letters":["CRL_NDA215029_20240711"]},{"app":"NDA215040","kind":"NDA","program":"galephar_pharmaceutical_research","sponsor":"Galephar Pharmaceutical Research Inc.","tickers":[],"sec_filer":false,"product":"Legubeti","product_type":"not_classified","product_sources":[],"first":"2023-05-05","last":"2023-05-05","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-02-13","tentative":[],"t":284,"censored":false,"letters":["CRL_NDA215040_20230505"]},{"app":"NDA215064","kind":"NDA","program":"amryt_pharmaceuticals_dac","sponsor":"Amryt Pharmaceuticals DAC","tickers":[],"sec_filer":false,"product":"Filsuvez","product_type":"not_classified","product_sources":[],"first":"2022-02-26","last":"2022-02-26","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-12-18","tentative":[],"t":660,"censored":false,"letters":["CRL_NDA215064_20220226"]},{"app":"NDA215092","kind":"NDA","program":"santen","sponsor":"Santen, Inc.","tickers":[],"sec_filer":false,"product":"Omlonti","product_type":"not_classified","product_sources":[],"first":"2021-11-09","last":"2021-11-09","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-09-22","tentative":[],"t":317,"censored":false,"letters":["CRL_NDA215092_20211109"]},{"app":"NDA215151","kind":"NDA","program":"phathom_pharmaceuticals","sponsor":"Phathom Pharmaceuticals, Inc.","tickers":["PHAT"],"sec_filer":true,"product":"Voquezna","product_type":"not_classified","product_sources":[],"first":"2023-02-07","last":"2023-02-07","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-11-01","tentative":[],"t":267,"censored":false,"letters":["CRL_NDA215151_20230207"]},{"app":"NDA215179","kind":"NDA","program":"shilpa_medicare","sponsor":"Shilpa Medicare Limited","tickers":[],"sec_filer":false,"product":"bortezomib","product_type":"not_classified","product_sources":[],"first":"2021-06-24","last":"2022-04-14","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-05-22","tentative":[],"t":697,"censored":false,"letters":["CRL_NDA215179_20210624","CRL_NDA215179_20220414"]},{"app":"NDA215192","kind":"NDA","program":"akebia_therapeutics","sponsor":"Akebia Therapeutics, Inc.","tickers":["AKBA"],"sec_filer":true,"product":"vadadustat","product_type":"not_classified","product_sources":[],"first":"2022-03-29","last":"2022-03-29","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-03-27","tentative":[],"t":729,"censored":false,"letters":["CRL_NDA215192_20220329"]},{"app":"NDA215212","kind":"NDA","program":"hq_specialty_pharma","sponsor":"HQ Specialty Pharma Corporation","tickers":[],"sec_filer":false,"product":"Meropenem","product_type":"not_classified","product_sources":[],"first":"2021-09-14","last":"2021-09-14","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-07-26","tentative":[],"t":680,"censored":false,"letters":["CRL_NDA215212_20210914"]},{"app":"NDA215244","kind":"NDA","program":"stealth_biotherapeutics","sponsor":"Stealth BioTherapeutics Inc.","tickers":[],"sec_filer":false,"product":"elamipretide (Forzinity)","product_type":"novel","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA215244"],"first":"2025-05-15","last":"2025-05-15","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-09-19","tentative":[],"t":127,"censored":false,"letters":["CRL_NDA215244_20250515"]},{"app":"NDA215291","kind":"NDA","program":"bendarx_usa","sponsor":"BendaRx USA Corporation","tickers":[],"sec_filer":false,"product":"Bendamustine injection (BendaRx), 505(b)(2)","product_type":"unknown","product_sources":["https://download.open.fda.gov/crl/CRL_NDA215291_20240117.pdf"],"first":"2024-01-17","last":"2024-01-17","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":996,"censored":true,"letters":["CRL_NDA215291_20240117"]},{"app":"NDA215320","kind":"NDA","program":"aft_pharmaceuticals","sponsor":"AFT Pharmaceuticals Ltd.","tickers":[],"sec_filer":false,"product":"sirolimus","product_type":"not_classified","product_sources":[],"first":"2022-06-30","last":"2022-06-30","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-10-17","tentative":[],"t":474,"censored":false,"letters":["CRL_NDA215320_20220630"]},{"app":"NDA215344","kind":"NDA","program":"braintree_laboratories","sponsor":"Braintree Laboratories, Inc.","tickers":[],"sec_filer":false,"product":"Suflave","product_type":"not_classified","product_sources":[],"first":"2022-06-06","last":"2022-06-06","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-06-15","tentative":[],"t":374,"censored":false,"letters":["CRL_NDA215344_20220606"]},{"app":"NDA215352","kind":"NDA","program":"eyenovia","sponsor":"Eyenovia, Inc.","tickers":[],"sec_filer":false,"product":"MYDCOMBI","product_type":"not_classified","product_sources":[],"first":"2021-10-22","last":"2021-10-22","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-05-05","tentative":[],"t":560,"censored":false,"letters":["CRL_NDA215352_20211022"]},{"app":"NDA215455","kind":"NDA","program":"lykos_therapeutics","sponsor":"Lykos Therapeutics","tickers":[],"sec_filer":false,"product":"midomafetamine (MDMA) capsules, for MDMA-assisted therapy of PTSD","product_type":"novel","product_sources":["https://www.biospace.com/drug-development/fda-rejects-lykos-mdma-assisted-ptsd-therapy-after-negative-adcomm","https://www.moreblossom.com/stakeholders/resilient-pharmaceuticals"],"first":"2024-08-08","last":"2024-08-08","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":792,"censored":true,"letters":["CRL_NDA215455_20240808"]},{"app":"NDA215559","kind":"NDA","program":"lpsen_biopharmaceuticals","sponsor":"lpsen Biopharmaceuticals Inc.","tickers":[],"sec_filer":false,"product":"palovarotene","product_type":"not_classified","product_sources":[],"first":"2022-12-23","last":"2022-12-23","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-08-16","tentative":[],"t":236,"censored":false,"letters":["CRL_NDA215559_20221223"]},{"app":"NDA215644","kind":"NDA","program":"sun_pharmaceutical_industries","sponsor":"Sun Pharmaceutical Industries Limited","tickers":[],"sec_filer":false,"product":"nilotinib capsules (Sun Pharma)","product_type":"unknown","product_sources":["https://www.globalkeysolutions.net/records/crl/sun-pharmaceutical-industries-limited/9571fd28-2dde-4d28-a63b-9291b4c22d22","https://download.open.fda.gov/crl/CRL_NDA215644_20241025.pdf"],"first":"2024-10-25","last":"2025-06-25","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":714,"censored":true,"letters":["CRL_NDA215644_20241025","CRL_NDA215644_20250625"]},{"app":"NDA215721","kind":"NDA","program":"almatica_pharma","sponsor":"Almatica Pharma, LLC","tickers":[],"sec_filer":false,"product":"zolpidem tartrate","product_type":"not_classified","product_sources":[],"first":"2023-01-13","last":"2023-01-13","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-05-09","tentative":[],"t":116,"censored":false,"letters":["CRL_NDA215721_20230113"]},{"app":"NDA215749","kind":"NDA","program":"accord_healthcare","sponsor":"Accord Healthcare Inc.","tickers":[],"sec_filer":false,"product":"Bendamustine hydrochloride injection (Accord)","product_type":"505b2_copy","product_sources":["https://download.open.fda.gov/crl/CRL_NDA215749_20240307.pdf"],"first":"2024-03-07","last":"2024-03-07","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":946,"censored":true,"letters":["CRL_NDA215749_20240307"]},{"app":"NDA215818","kind":"NDA","program":"fresenius_kabi_usa","sponsor":"Fresenius Kabi USA, LLC","tickers":[],"sec_filer":false,"product":"Fresenius Kabi amino acids, dextrose and lipid injectable emulsion (parenteral nutrition; listed drug Kabiven)","product_type":"505b2_new_formulation","product_sources":["https://api.fda.gov/transparency/crl.json?search=application_number:%22NDA%20215818%22"],"first":"2025-04-25","last":"2026-02-27","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":532,"censored":true,"letters":["CRL_NDA215818_20250425","CRL_NDA215818_20260227"]},{"app":"NDA215973","kind":"NDA","program":"gilead_sciences","sponsor":"Gilead Sciences, Inc.","tickers":["GILD"],"sec_filer":true,"product":"lenacapavir","product_type":"not_classified","product_sources":[],"first":"2022-02-28","last":"2022-02-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-12-22","tentative":[],"t":297,"censored":false,"letters":["CRL_NDA215973_20220228"]},{"app":"NDA215974","kind":"NDA","program":"gilead_sciences","sponsor":"Gilead Sciences, Inc.","tickers":["GILD"],"sec_filer":true,"product":"lenacapavir","product_type":"not_classified","product_sources":[],"first":"2022-02-28","last":"2022-02-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2022-12-22","tentative":[],"t":297,"censored":false,"letters":["CRL_NDA215974_20220228"]},{"app":"NDA216190","kind":"NDA","program":"fidelity_biopharma","sponsor":"Fidelity BioPharma Co.","tickers":[],"sec_filer":false,"product":"tizanidine oral solution 2 mg/5 mL (Ontralfy)","product_type":"505b2_new_formulation","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA216190","https://download.open.fda.gov/crl/CRL_NDA216190_20240329.pdf"],"first":"2024-03-29","last":"2024-03-29","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2024-12-12","tentative":[],"t":258,"censored":false,"letters":["CRL_NDA216190_20240329"]},{"app":"NDA216195","kind":"NDA","program":"xspray_pharma","sponsor":"Xspray Pharma AB","tickers":[],"sec_filer":false,"product":"DASYNOC (dasatinib, HyNap amorphous formulation)","product_type":"505b2_new_formulation","product_sources":["https://www.inderes.fi/en/releases/xspray-pharma-fda-accepts-resubmitted-application-for-market-approval-of-dasynocr-pdufa-date-august-25-2026","https://www.1stoncology.com/blog/?p=112948"],"first":"2024-07-25","last":"2025-10-07","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":806,"censored":true,"letters":["CRL_NDA216195_20240725","CRL_NDA216195_20251007"]},{"app":"NDA216442","kind":"NDA","program":"aldeyra_therapeutics","sponsor":"Aldeyra Therapeutics, Inc.","tickers":["ALDX"],"sec_filer":true,"product":"reproxalap ophthalmic solution, RASP inhibitor for dry eye disease","product_type":"novel","product_sources":["https://www.optometrytimes.com/view/aldeyra-receives-third-complete-response-letter-from-fda-for-reproxalap","https://eyewire.news/news/aldeyra-plans-to-appeal-fda-rejection-of-reproxalap-nda"],"first":"2025-04-02","last":"2026-03-16","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":555,"censored":true,"letters":["CRL_NDA216442_20250402","CRL_NDA216442_20260316"]},{"app":"NDA216482","kind":"NDA","program":"liqmeds_worldwide","sponsor":"Liqmeds Worldwide Limited","tickers":[],"sec_filer":false,"product":"mycophenolate mofetil","product_type":"not_classified","product_sources":[],"first":"2023-01-06","last":"2023-01-06","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-05-01","tentative":[],"t":481,"censored":false,"letters":["CRL_NDA216482_20230106"]},{"app":"NDA216490","kind":"NDA","program":"ascendis_pharma_bone_diseases_a_s","sponsor":"Ascendis Pharma Bone Diseases A/S","tickers":["ASND"],"sec_filer":true,"product":"palopegteriparatide","product_type":"not_classified","product_sources":[],"first":"2023-04-28","last":"2023-04-28","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-08-09","tentative":[],"t":469,"censored":false,"letters":["CRL_NDA216490_20230428"]},{"app":"NDA216586","kind":"NDA","program":"elevar_therapeutics","sponsor":"Elevar Therapeutics, Inc.","tickers":[],"sec_filer":false,"product":"rivoceranib (apatinib) tablets, with camrelizumab for 1L uHCC","product_type":"novel","product_sources":["https://www.fiercepharma.com/pharma/fda-rejects-hengrui-elevar-pd-1-liver-cancer-combo-3rd-time","https://www.cancernetwork.com/view/fda-clears-manufacturing-concern-behind-rivoceranib-camrelizumab-crl-in-hcc"],"first":"2024-05-16","last":"2026-07-09","n":3,"n_orig":3,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":876,"censored":true,"letters":["CRL_NDA216586_20240516","CRL_NDA216586_20250320","CRL_NDA216586_20260709"]},{"app":"NDA216686","kind":"NDA","program":"spes_pharmaceuticals","sponsor":"Spes Pharmaceuticals Inc.","tickers":[],"sec_filer":false,"product":"fosaprepitant","product_type":"not_classified","product_sources":[],"first":"2022-10-19","last":"2022-10-19","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2023-08-22","tentative":[],"t":307,"censored":false,"letters":["CRL_NDA216686_20221019"]},{"app":"NDA216900","kind":"NDA","program":"evergreen_theragnostics","sponsor":"Evergreen Theragnostics, Inc.","tickers":[],"sec_filer":false,"product":"Kit for preparation of gallium Ga 68 edotreotide injection (LNTH-2501; Evergreen/Lantheus)","product_type":"505b2_new_formulation","product_sources":["https://investor.lantheus.com/node/17071","https://www.onclive.com/view/fda-issues-crl-to-pet-diagnostic-imaging-kit-for-gallium-68-edotreotide-in-sstr-nets"],"first":"2026-06-26","last":"2026-06-26","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":105,"censored":true,"letters":["CRL_NDA216900_20260626"]},{"app":"NDA216962","kind":"NDA","program":"abbvie","sponsor":"AbbVie Inc.","tickers":["ABBV"],"sec_filer":true,"product":"Vyalev (foscarbidopa/foslevodopa) subcutaneous infusion","product_type":"505b2_new_formulation","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216962"],"first":"2023-03-17","last":"2024-06-18","n":2,"n_orig":2,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-10-16","tentative":[],"t":579,"censored":false,"letters":["CRL_NDA216962_20230317","CRL_NDA216962_20240618"]},{"app":"NDA216987","kind":"NDA","program":"accord_healthcare","sponsor":"Accord Healthcare Inc.","tickers":[],"sec_filer":false,"product":"bendamustine hydrochloride injection (Accord)","product_type":"unknown","product_sources":["https://download.open.fda.gov/crl/CRL_NDA216987_20240510.pdf"],"first":"2024-05-10","last":"2025-11-06","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":882,"censored":true,"letters":["CRL_NDA216987_20240510","CRL_NDA216987_20251106"]},{"app":"NDA217002","kind":"NDA","program":"minerva_neurosciences","sponsor":"Minerva Neurosciences, Inc","tickers":["NERV"],"sec_filer":true,"product":"Roluperidone, for negative symptoms of schizophrenia","product_type":"novel","product_sources":["https://www.sec.gov/Archives/edgar/data/0001598646/000119312526339171/nerv-20260630.htm"],"first":"2024-02-26","last":"2024-02-26","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":956,"censored":true,"letters":["CRL_NDA217002_20240226"]},{"app":"NDA217186","kind":"NDA","program":"impax_laboratories","sponsor":"Impax Laboratories, LLC","tickers":[],"sec_filer":false,"product":"Crexont Extended Release","product_type":"not_classified","product_sources":[],"first":"2023-06-30","last":"2023-06-30","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-08-07","tentative":[],"t":404,"censored":false,"letters":["CRL_NDA217186_20230630"]},{"app":"NDA217202","kind":"NDA","program":"aop_orphan_pharmaceuticals","sponsor":"AOP Orphan Pharmaceuticals GmbH","tickers":[],"sec_filer":false,"product":"landiolol","product_type":"not_classified","product_sources":[],"first":"2023-05-31","last":"2023-05-31","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-11-22","tentative":[],"t":541,"censored":false,"letters":["CRL_NDA217202_20230531"]},{"app":"NDA217225","kind":"NDA","program":"astellas_pharma_us","sponsor":"Astellas Pharma US, Inc.","tickers":[],"sec_filer":false,"product":"IZERVAY","product_type":"not_classified","product_sources":[],"first":"2024-11-15","last":"2024-11-15","n":1,"n_orig":0,"era":"issued","track":"supplement","outcome":"supplement","approved":null,"tentative":[],"t":693,"censored":true,"letters":["CRL_NDA217225_20241115"]},{"app":"NDA217294","kind":"NDA","program":"sq_innovation","sponsor":"SQ Innovation, Inc.","tickers":[],"sec_filer":false,"product":"Lasix ONYU (furosemide subcutaneous injection, on-body)","product_type":"505b2_new_formulation","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217294"],"first":"2024-01-12","last":"2024-01-12","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-10-07","tentative":[],"t":634,"censored":false,"letters":["CRL_NDA217294_20240112"]},{"app":"NDA217338","kind":"NDA","program":"rb_health_us","sponsor":"RB Health (US) LLC","tickers":[],"sec_filer":false,"product":"naproxen sodium / dextromethorphan HBr / guaifenesin ER tablet (Mucinex 12HR Cold & Fever Multi-Symptom, OTC)","product_type":"505b2_new_formulation","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA217338"],"first":"2024-07-26","last":"2024-07-26","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-12-22","tentative":[],"t":514,"censored":false,"letters":["CRL_NDA217338_20240726"]},{"app":"NDA217347","kind":"NDA","program":"botanix_sb","sponsor":"Botanix SB Inc.","tickers":[],"sec_filer":false,"product":"sofpironium bromide","product_type":"not_classified","product_sources":[],"first":"2023-09-22","last":"2023-09-22","n":1,"n_orig":1,"era":"after_approval","track":"original","outcome":"approved","approved":"2024-06-18","tentative":[],"t":270,"censored":false,"letters":["CRL_NDA217347_20230922"]},{"app":"NDA217363","kind":"NDA","program":"ocuvex_therapeutics","sponsor":"Ocuvex Therapeutics, Inc.","tickers":[],"sec_filer":false,"product":"PDP-716 (brimonidine tartrate ophthalmic suspension 0.35%, once daily)","product_type":"505b2_new_formulation","product_sources":["https://glance.eyesoneyecare.com/stories/2025-11-25/ocuvex-resubmits-fda-crl-for-brimonidine-tartrate-0-35-nda/"],"first":"2026-05-15","last":"2026-05-15","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":147,"censored":true,"letters":["CRL_NDA217363_20260515"]},{"app":"NDA217379","kind":"NDA","program":"nanocopoeia","sponsor":"Nanocopoeia, LLC","tickers":[],"sec_filer":false,"product":"Cavhanza (nilotinib tablets), new nilotinib formulation","product_type":"505b2_new_formulation","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217379"],"first":"2024-06-14","last":"2024-06-14","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2026-05-29","tentative":[],"t":714,"censored":false,"letters":["CRL_NDA217379_20240614"]},{"app":"NDA217382","kind":"NDA","program":"resq_pharma","sponsor":"ResQ Pharma","tickers":[],"sec_filer":false,"product":"Nutrilipid 20% soybean oil emulsion in kit (LipidRescue) for local anesthetic systemic toxicity","product_type":"other","product_sources":["https://www.globalkeysolutions.net/records/crl/resq-pharma/b4fc9ba4-0e7f-4383-813b-1e43890c429d","https://www.pharmafocuseurope.com/news/resq-pharma-receives-pdufa-date-for-lipidrescue-as-a-potential-first-ever"],"first":"2025-06-02","last":"2025-06-02","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":494,"censored":true,"letters":["CRL_NDA217382_20250602"]},{"app":"NDA217433","kind":"NDA","program":"orexo","sponsor":"Orexo AB","tickers":[],"sec_filer":false,"product":"OX124, high-dose naloxone hydrochloride nasal powder","product_type":"505b2_new_formulation","product_sources":["https://orexo.com/media/pressrelease/orexo-shares-new-information-on-ox124-a-high-dose-naloxone-rescue-medication-in-development-for-opioid-overdose-2ead2f42"],"first":"2024-07-15","last":"2024-07-15","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":816,"censored":true,"letters":["CRL_NDA217433_20240715"]},{"app":"NDA217556","kind":"NDA","program":"venatorx_pharmaceuticals","sponsor":"Venatorx Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"cefepime-taniborbactam (IV), beta-lactam/beta-lactamase inhibitor for cUTI","product_type":"novel","product_sources":["https://www.cidrap.umn.edu/antimicrobial-stewardship/fda-rejects-new-drug-application-cefepime-taniborbactam"],"first":"2024-02-22","last":"2024-02-22","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":960,"censored":true,"letters":["CRL_NDA217556_20240222"]},{"app":"NDA217644","kind":"NDA","program":"xspray_pharma","sponsor":"Xspray Pharma AB","tickers":[],"sec_filer":false,"product":"XS003, nilotinib amorphous solid dispersion capsules (Nilopki)","product_type":"505b2_new_formulation","product_sources":["https://www.inderes.fi/en/releases/xspray-pharma-receives-crl-from-us-fda-for-nilopkitm"],"first":"2026-06-04","last":"2026-06-04","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":127,"censored":true,"letters":["CRL_NDA217644_20260604"]},{"app":"NDA217711","kind":"NDA","program":"vyluma","sponsor":"Vyluma, Inc.","tickers":[],"sec_filer":false,"product":"NVK002, atropine sulfate ophthalmic solution 0.01% for pediatric myopia","product_type":"505b2_new_formulation","product_sources":["https://www.assyro.com/regulatory-intelligence/us/letters/complete-response/fda-crl-6b776ac325e4ea6895725c2f"],"first":"2025-08-27","last":"2025-08-27","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":408,"censored":true,"letters":["CRL_NDA217711_20250827"]},{"app":"NDA217719","kind":"NDA","program":"laurus_generics","sponsor":"Laurus Generics, Inc.","tickers":[],"sec_filer":false,"product":"darunavir/ritonavir fixed-dose tablets (Laurus, PEPFAR)","product_type":"505b2_new_formulation","product_sources":["https://api.fda.gov/transparency/crl.json?search=application_number:%22NDA%20217719%22"],"first":"2025-03-10","last":"2025-03-10","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":578,"censored":true,"letters":["CRL_NDA217719_20250310"]},{"app":"NDA217724","kind":"NDA","program":"zealand_pharma_us","sponsor":"Zealand Pharma US, Inc.","tickers":[],"sec_filer":false,"product":"dasiglucagon injection for congenital hyperinsulinism (Zegalogue molecule)","product_type":"other","product_sources":["https://www.hcplive.com/view/fda-issues-second-crl-for-dasiglucagon-zegalogue-in-congenital-hyperinsulinism","https://mfn.se/all/a/zealand-pharma/zealand-pharma-provides-u-s-regulatory-update-on-dasiglucagon-in-congenital-hyperinsulinism-69a20b1b"],"first":"2024-10-08","last":"2024-10-08","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":731,"censored":true,"letters":["CRL_NDA217724_20241008"]},{"app":"NDA218026","kind":"NDA","program":"antares_pharma","sponsor":"Antares Pharma, Inc.","tickers":[],"sec_filer":false,"product":"Hydrocortisone sodium phosphate injection (Antares; likely ATRS-1902 autoinjector)","product_type":"505b2_new_formulation","product_sources":["https://download.open.fda.gov/crl/CRL_NDA218026_20240816.pdf","https://www.biospace.com/antares-pharma-receives-fda-fast-track-designation-for-atrs-1902-for-adrenal-crisis-rescue"],"first":"2024-08-16","last":"2024-08-16","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":784,"censored":true,"letters":["CRL_NDA218026_20240816"]},{"app":"NDA218223","kind":"NDA","program":"mapi_pharma","sponsor":"Mapi Pharma Ltd.","tickers":[],"sec_filer":false,"product":"GA Depot (glatiramer acetate extended-release depot injection, monthly)","product_type":"505b2_new_formulation","product_sources":["https://multiplesclerosisnewstoday.com/news-posts/2024/03/11/fda-declines-us-approval-ga-depot-relapsing-ms-treatment"],"first":"2024-03-08","last":"2024-03-08","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":945,"censored":true,"letters":["CRL_NDA218223_20240308"]},{"app":"NDA218224","kind":"NDA","program":"baxter_healthcare","sponsor":"Baxter Healthcare Corporation","tickers":[],"sec_filer":false,"product":"Dapzura RT (daptomycin for injection, room-temperature lyophilized vial, Baxter)","product_type":"unknown","product_sources":["https://download.open.fda.gov/crl/CRL_NDA218224_20240329.pdf","https://medlibrary.org/lib/rx/meds/dapzura-rt/"],"first":"2024-03-29","last":"2024-03-29","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":924,"censored":true,"letters":["CRL_NDA218224_20240329"]},{"app":"NDA218258","kind":"NDA","program":"hikma_pharmaceuticals_usa","sponsor":"Hikma Pharmaceuticals USA Inc.","tickers":[],"sec_filer":false,"product":"Phenobarbital sodium injection (Hikma), for neonatal seizures","product_type":"other","product_sources":["https://download.open.fda.gov/crl/CRL_NDA218258_20240123.pdf"],"first":"2024-01-23","last":"2024-01-23","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":990,"censored":true,"letters":["CRL_NDA218258_20240123"]},{"app":"NDA218317","kind":"NDA","program":"neuroderm","sponsor":"NeuroDerm, Ltd.","tickers":[],"sec_filer":false,"product":"ND0612 (carbidopa/levodopa continuous subcutaneous infusion)","product_type":"505b2_new_formulation","product_sources":["https://api.fda.gov/transparency/crl.json?search=application_number:%22NDA%20218317%22","https://www.thepharmaletter.com/pharma-news/fda-slaps-crl-on-mitsubishi-tanabe-s-investigational-nd0612"],"first":"2024-05-24","last":"2025-10-21","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":868,"censored":true,"letters":["CRL_NDA218317_20240524","CRL_NDA218317_20251021"]},{"app":"NDA218345","kind":"NDA","program":"amneal_eu","sponsor":"Amneal EU, Limited","tickers":[],"sec_filer":false,"product":"phenylephrine hydrochloride in sodium chloride injection (premixed)","product_type":"unknown","product_sources":["https://download.open.fda.gov/crl/CRL_NDA218345_20240701.pdf"],"first":"2024-07-01","last":"2025-04-02","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":830,"censored":true,"letters":["CRL_NDA218345_20240701","CRL_NDA218345_20250402"]},{"app":"NDA218353","kind":"NDA","program":"university_california_san_francisco","sponsor":"University of California San Francisco","tickers":[],"sec_filer":false,"product":"[18F]floretyrosine (FET) PET, UCSF academic NDA","product_type":"novel","product_sources":["https://download.open.fda.gov/crl/CRL_NDA218353_20250425.pdf","https://www.sec.gov/Archives/edgar/data/0002007191/000162828026061892/pixclaraapprovalvfinal.htm"],"first":"2025-04-25","last":"2025-04-25","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":532,"censored":true,"letters":["CRL_NDA218353_20250425"]},{"app":"NDA218408","kind":"NDA","program":"baxter_healthcare","sponsor":"Baxter Healthcare Corporation","tickers":[],"sec_filer":false,"product":"Baxter product (name redacted in CRL; ends '...chloride'); API field says Dapzura RT, unverified","product_type":"unknown","product_sources":["https://api.fda.gov/transparency/crl.json?search=application_number:%22NDA%20218408%22"],"first":"2024-03-27","last":"2024-03-27","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":926,"censored":true,"letters":["CRL_NDA218408_20240327"]},{"app":"NDA218470","kind":"NDA","program":"accord_healthcare","sponsor":"Accord Healthcare Inc.","tickers":[],"sec_filer":false,"product":"epinephrine injection (Accord)","product_type":"unknown","product_sources":["https://download.open.fda.gov/crl/CRL_NDA218470_20240130.pdf"],"first":"2024-01-30","last":"2024-01-30","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":983,"censored":true,"letters":["CRL_NDA218470_20240130"]},{"app":"NDA218506","kind":"NDA","program":"bayer_healthcare","sponsor":"Bayer HealthCare LLC","tickers":[],"sec_filer":false,"product":"Naproxen sodium capsule (Bayer)","product_type":"505b2_new_formulation","product_sources":["https://download.open.fda.gov/crl/CRL_NDA218506_20240613.pdf","https://www.globalkeysolutions.net/records/crl/bayer-healthcare-llc/47d81f27-90e6-43bd-a0e5-43f8e0e9cdf3"],"first":"2024-06-13","last":"2024-06-13","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":848,"censored":true,"letters":["CRL_NDA218506_20240613"]},{"app":"NDA218528","kind":"NDA","program":"aft_pharmaceuticals","sponsor":"AFT Pharmaceuticals Ltd.","tickers":[],"sec_filer":false,"product":"sirolimus cream (Pascomer), topical sirolimus for facial angiofibroma","product_type":"505b2_new_formulation","product_sources":["https://api.fda.gov/transparency/crl.json?search=application_number:%22NDA%20218528%22","https://www.edisongroup.com/research/pascomer-falls-short-of-fda-mandated-threshold/31152/"],"first":"2024-01-25","last":"2024-01-25","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":["2026-07-20"],"t":988,"censored":true,"letters":["CRL_NDA218528_20240125"]},{"app":"NDA218571","kind":"NDA","program":"milestone_pharmaceuticals_usa","sponsor":"Milestone Pharmaceuticals USA, Inc.","tickers":["MIST"],"sec_filer":true,"product":"etripamil nasal spray (Cardamyst)","product_type":"novel","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA218571"],"first":"2025-03-27","last":"2025-03-27","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-12-12","tentative":[],"t":260,"censored":false,"letters":["CRL_NDA218571_20250327"]},{"app":"NDA218592","kind":"NDA","program":"telix_pharmaceuticals_us","sponsor":"Telix Pharmaceuticals (US) Inc.","tickers":["TLX","TLPPF"],"sec_filer":true,"product":"PIXCLARA (floretyrosine F 18; TLX101-CDx), FET PET agent for glioma","product_type":"novel","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA218592","https://www.sec.gov/Archives/edgar/data/0002007191/000162828026061892/pixclaraapprovalvfinal.htm"],"first":"2025-04-25","last":"2025-04-25","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2026-09-11","tentative":[],"t":504,"censored":false,"letters":["CRL_NDA218592_20250425"]},{"app":"NDA218600","kind":"NDA","program":"bridge_regulatory_affairs","sponsor":"Bridge Regulatory Affairs, LLC","tickers":[],"sec_filer":false,"product":"CAM2029 / Oclaiz (octreotide subcutaneous depot), Camurus","product_type":"505b2_new_formulation","product_sources":["https://www.camurus.com/media/press-releases/2026/camurus-provides-regulatory-update-on-the-us-nda-for-cam2029-oclaiz-in-acromegaly/","https://api.fda.gov/transparency/crl.json?search=application_number:%22NDA%20218600%22"],"first":"2024-10-21","last":"2026-06-10","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":718,"censored":true,"letters":["CRL_NDA218600_20241021","CRL_NDA218600_20260610"]},{"app":"NDA218607","kind":"NDA","program":"unicycive_therapeutics","sponsor":"Unicycive Therapeutics Inc.","tickers":["UNCY"],"sec_filer":true,"product":"oxylanthanum carbonate (OLC) tablets","product_type":"505b2_new_formulation","product_sources":["https://www.ajmc.com/view/oxylanthanum-carbonate-second-crl-deepens-delay-for-patients-with-chronic-kidney-disease","https://ir.unicycive.com/news/detail/124/index.html"],"first":"2025-06-27","last":"2026-06-29","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":469,"censored":true,"letters":["CRL_NDA218607_20250627","CRL_NDA218607_20260629"]},{"app":"NDA218679","kind":"NDA","program":"saol_international_development","sponsor":"Saol International Development Limited","tickers":[],"sec_filer":false,"product":"SL1009, sodium dichloroacetate oral solution, for PDC deficiency","product_type":"novel","product_sources":["https://www.biospace.com/press-releases/saol-therapeutics-announces-the-acceptance-of-resubmission-of-sl1009-dca-by-the-fda-with-pdufa-date-of-dec-30-2026"],"first":"2025-08-27","last":"2025-08-27","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"resubmitted","approved":null,"tentative":[],"t":408,"censored":true,"letters":["CRL_NDA218679_20250827"]},{"app":"NDA218698","kind":"NDA","program":"xtm_consulting","sponsor":"XTM Consulting LLC","tickers":[],"sec_filer":false,"product":"Lopressor (metoprolol tartrate) 12.5 mg tablets","product_type":"505b2_new_formulation","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218698"],"first":"2024-06-12","last":"2024-06-12","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-08-28","tentative":[],"t":442,"censored":false,"letters":["CRL_NDA218698_20240612"]},{"app":"NDA218705","kind":"NDA","program":"itm_solucin","sponsor":"ITM Solucin GmbH","tickers":[],"sec_filer":false,"product":"ITM-11, lutetium Lu 177 edotreotide (n.c.a.) injection","product_type":"novel","product_sources":["https://www.onclive.com/view/fda-issues-crl-to-177lu-edotreotide-for-gep-nets","https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-receives-complete-response-letter-for-177lu-edotreotide-itm-11-763/"],"first":"2026-08-07","last":"2026-08-07","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":63,"censored":true,"letters":["CRL_NDA218705_20260807"]},{"app":"NDA218762","kind":"NDA","program":"accord_healthcare","sponsor":"Accord Healthcare Inc.","tickers":[],"sec_filer":false,"product":"Paclitaxel protein-bound particles for injectable suspension (albumin-bound), Accord","product_type":"505b2_copy","product_sources":["https://download.open.fda.gov/crl/CRL_NDA218762_20240417.pdf"],"first":"2024-04-17","last":"2024-12-05","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":905,"censored":true,"letters":["CRL_NDA218762_20240417","CRL_NDA218762_20241205"]},{"app":"NDA218772","kind":"NDA","program":"scienture","sponsor":"Scienture Inc.","tickers":["SCNX"],"sec_filer":true,"product":"Arbli (losartan potassium oral suspension 10 mg/mL)","product_type":"505b2_new_formulation","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218772"],"first":"2024-08-19","last":"2024-08-19","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-03-13","tentative":[],"t":206,"censored":false,"letters":["CRL_NDA218772_20240819"]},{"app":"NDA218828","kind":"NDA","program":"zealand_pharma_us","sponsor":"Zealand Pharma US, Inc.","tickers":[],"sec_filer":false,"product":"glepaglutide injection (GLP-2 analog) for short bowel syndrome","product_type":"novel","product_sources":["https://www.fiercebiotech.com/biotech/fda-rejects-approval-zealand-pharmas-glp-2-analog-rare-bowel-disease","https://www.zealandpharma.com/pipeline/glepaglutide/"],"first":"2024-12-19","last":"2024-12-19","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":659,"censored":true,"letters":["CRL_NDA218828_20241219"]},{"app":"NDA218879","kind":"NDA","program":"owp_pharmaceuticals","sponsor":"OWP Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"SUBVENITE (lamotrigine) oral suspension","product_type":"505b2_new_formulation","product_sources":["https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA218879"],"first":"2025-01-03","last":"2025-01-03","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-09-16","tentative":[],"t":256,"censored":false,"letters":["CRL_NDA218879_20250103"]},{"app":"NDA218923","kind":"NDA","program":"conjupro_biotherapeutics","sponsor":"Conjupro Biotherapeutics Inc.","tickers":[],"sec_filer":false,"product":"irinotecan liposome injection (CSPC/Conjupro), Onivyde-referencing","product_type":"505b2_copy","product_sources":["https://api.fda.gov/transparency/crl.json?search=application_number:%22NDA%20218923%22","https://www1.hkexnews.hk/listedco/listconews/sehk/2023/1218/2023121800171.pdf"],"first":"2024-10-10","last":"2025-07-30","n":2,"n_orig":2,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":729,"censored":true,"letters":["CRL_NDA218923_20241010","CRL_NDA218923_20250730"]},{"app":"NDA218995","kind":"NDA","program":"achieve_life_sciences","sponsor":"Achieve Life Sciences, Inc.","tickers":["ACHV"],"sec_filer":true,"product":"cytisinicline tablets","product_type":"novel","product_sources":["https://www.sec.gov/Archives/edgar/data/0000949858/000119312526344571/achv-ex99_1.htm","https://www.ajmc.com/view/fda-issues-complete-response-letter-for-cytisinicline-nda-citing-manufacturing-deficiencies"],"first":"2026-06-20","last":"2026-06-20","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":111,"censored":true,"letters":["CRL_NDA218995_20260620"]},{"app":"NDA219029","kind":"NDA","program":"chemo_research_sl","sponsor":"Chemo Research, S.L.","tickers":[],"sec_filer":false,"product":"LPRI-424, dienogest/ethinyl estradiol 2 mg/0.02 mg extended-release COC tablets","product_type":"505b2_new_formulation","product_sources":["https://download.open.fda.gov/crl/CRL_NDA219029_20250529.pdf","https://clinicaltrials.gov/study/NCT03945513"],"first":"2025-05-29","last":"2025-05-29","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":498,"censored":true,"letters":["CRL_NDA219029_20250529"]},{"app":"NDA219045","kind":"NDA","program":"hikma_pharmaceuticals_usa","sponsor":"Hikma Pharmaceuticals USA Inc.","tickers":[],"sec_filer":false,"product":"naloxone HCl nasal spray 4 mg, nonprescription (Hikma)","product_type":"505b2_copy","product_sources":["https://api.fda.gov/transparency/crl.json?search=application_number:%22NDA%20219045%22"],"first":"2024-10-21","last":"2024-10-21","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":718,"censored":true,"letters":["CRL_NDA219045_20241021"]},{"app":"NDA219107","kind":"NDA","program":"apiject_systems","sponsor":"Apiject Systems Corp.","tickers":[],"sec_filer":false,"product":"glycopyrrolate solution in ApiJect prefilled blow-fill-seal syringe","product_type":"505b2_copy","product_sources":["https://apiject.com/wp-content/uploads/2025/09/Apiject-NDA-submission-press-release-final-1.pdf","https://download.open.fda.gov/crl/CRL_NDA219107_20260721.pdf"],"first":"2026-07-21","last":"2026-07-21","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":80,"censored":true,"letters":["CRL_NDA219107_20260721"]},{"app":"NDA219112","kind":"NDA","program":"hospira","sponsor":"Hospira, Inc.","tickers":[],"sec_filer":false,"product":"Diazepam injection (Hospira)","product_type":"unknown","product_sources":["https://download.open.fda.gov/crl/CRL_NDA219112_20250117.pdf"],"first":"2025-01-17","last":"2025-01-17","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":630,"censored":true,"letters":["CRL_NDA219112_20250117"]},{"app":"NDA219122","kind":"NDA","program":"azurity_pharmaceuticals","sponsor":"Azurity Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"Brynovin (sitagliptin oral solution)","product_type":"505b2_new_formulation","product_sources":["https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219122"],"first":"2024-11-04","last":"2024-11-04","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"approved","approved":"2025-01-16","tentative":[],"t":73,"censored":false,"letters":["CRL_NDA219122_20241104"]},{"app":"NDA219195","kind":"NDA","program":"applied_therapeutics","sponsor":"Applied Therapeutics, Inc.","tickers":[],"sec_filer":false,"product":"govorestat (AT-007) for classic galactosemia","product_type":"novel","product_sources":["https://www.biopharmadive.com/news/applied-fda-crl-rejection-govorestat-galactosemia/733684/"],"first":"2024-11-27","last":"2024-11-27","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":681,"censored":true,"letters":["CRL_NDA219195_20241127"]},{"app":"NDA219357","kind":"NDA","program":"hikma_pharmaceuticals_usa","sponsor":"Hikma Pharmaceuticals USA Inc.","tickers":[],"sec_filer":false,"product":"unknown (Hikma NDA; API field says phenobarbital sodium)","product_type":"unknown","product_sources":["https://download.open.fda.gov/crl/CRL_NDA219357_20241223.pdf"],"first":"2024-12-23","last":"2024-12-23","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":655,"censored":true,"letters":["CRL_NDA219357_20241223"]},{"app":"NDA219398","kind":"NDA","program":"corcept_therapeutics","sponsor":"Corcept Therapeutics","tickers":["CORT"],"sec_filer":true,"product":"relacorilant, selective glucocorticoid receptor modulator for hypercortisolism","product_type":"novel","product_sources":["https://www.sec.gov/Archives/edgar/data/0001088856/000162828026050613/cort-20260630.htm"],"first":"2026-01-28","last":"2026-01-28","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"resubmitted","approved":null,"tentative":[],"t":254,"censored":true,"letters":["CRL_NDA219398_20260128"]},{"app":"NDA219624","kind":"NDA","program":"genzyme","sponsor":"Genzyme Corporation","tickers":[],"sec_filer":false,"product":"tolebrutinib tablets for nrSPMS","product_type":"novel","product_sources":["https://pharmaphorum.com/news/no-christmas-present-sanofi-fda-turns-down-ms-drug","https://www.thepharmaletter.com/pharma-news/us-fda-rejects-sanofi-filing-for-tolebrutinib-in-progressive-ms"],"first":"2025-12-23","last":"2025-12-23","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":290,"censored":true,"letters":["CRL_NDA219624_20251223"]},{"app":"NDA219694","kind":"NDA","program":"sydnexis","sponsor":"SYDNEXIS Inc.","tickers":[],"sec_filer":false,"product":"SYD-101, atropine sulfate ophthalmic 0.01% for pediatric myopia","product_type":"505b2_new_formulation","product_sources":["https://www.optometrytimes.com/view/fda-advisory-committee-syd-101-pediatric-myopia-october-30","https://www.healio.com/news/ophthalmology/20251218/fda-declines-to-approve-syd-101-for-slowing-pediatric-myopia"],"first":"2025-10-22","last":"2025-10-22","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"resubmitted","approved":null,"tentative":[],"t":352,"censored":true,"letters":["CRL_NDA219694_20251022"]},{"app":"NDA219846","kind":"NDA","program":"shanghai_auzone_biological_technology","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","tickers":[],"sec_filer":false,"product":"edaravone oral tablet (Auzone), for ALS","product_type":"505b2_new_formulation","product_sources":["https://api.fda.gov/transparency/crl.json?search=application_number:%22NDA%20219846%22","https://convention.bio.org/exhibitors/suzhou-auzone-biological-technology-co"],"first":"2025-10-23","last":"2025-10-23","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":351,"censored":true,"letters":["CRL_NDA219846_20251023"]},{"app":"NDA219870","kind":"NDA","program":"aquestive_therapeutics","sponsor":"Aquestive Therapeutics Inc.","tickers":["AQST"],"sec_filer":true,"product":"dibutepinephrine sublingual film (Anaphylm), epinephrine prodrug","product_type":"other","product_sources":["https://www.contemporarypediatrics.com/view/aquestive-resubmits-nda-for-sublingual-epinephrine-film-anaphylm-after-fda-crl","https://www.sec.gov/Archives/edgar/data/1398733/000139873326000005/anaphylmcrlpressrelease2.htm"],"first":"2026-01-30","last":"2026-01-30","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"resubmitted","approved":null,"tentative":[],"t":252,"censored":true,"letters":["CRL_NDA219870_20260130"]},{"app":"NDA220045","kind":"NDA","program":"eagle_pharmaceuticals","sponsor":"Eagle Pharmaceuticals, Inc.","tickers":[],"sec_filer":false,"product":"Fulvestrant injection (Eagle)","product_type":"unknown","product_sources":["https://download.open.fda.gov/crl/CRL_NDA220045_20260413.pdf"],"first":"2026-04-13","last":"2026-04-13","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":179,"censored":true,"letters":["CRL_NDA220045_20260413"]},{"app":"NDA220049","kind":"NDA","program":"ptc_therapeutics","sponsor":"PTC Therapeutics, Inc.","tickers":["PTCT"],"sec_filer":true,"product":"vatiquinone, 15-LO inhibitor for Friedreich ataxia","product_type":"novel","product_sources":["https://www.ajmc.com/view/fda-issues-crl-for-vatiquinone-in-friedreich-ataxia-requests-more-efficacy-data","https://www.curefa.org/drug-development/vatiquinone-ptc-743/"],"first":"2025-08-18","last":"2025-08-18","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":417,"censored":true,"letters":["CRL_NDA220049_20250818"]},{"app":"NDA220138","kind":"NDA","program":"tris_pharma","sponsor":"Tris Pharma, Inc.","tickers":[],"sec_filer":false,"product":"TRN-257, low-sodium once-nightly oxybate ER oral suspension","product_type":"505b2_new_formulation","product_sources":["https://www.businesswire.com/news/home/20251209571909/en/Tris-Pharma-Announces-FDA-Acceptance-of-NDA-for-Once-Nightly-Low-Sodium-Oxybate-Product-for-Narcolepsy-and-Idiopathic-Hypersomnia","https://download.open.fda.gov/crl/CRL_NDA220138_20260615.pdf"],"first":"2026-06-15","last":"2026-06-15","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":116,"censored":true,"letters":["CRL_NDA220138_20260615"]},{"app":"NDA220140","kind":"NDA","program":"rosemont_pharmaceuticals_holdings","sponsor":"Rosemont Pharmaceuticals Holdings, Inc.","tickers":[],"sec_filer":false,"product":"Valacyclovir for oral suspension (Hyloris; Rosemont commercial partner)","product_type":"505b2_new_formulation","product_sources":["https://www.fiercepharma.com/pharma/fda-fires-another-manufacturing-related-crl-one-hyloris","https://www.vfb.be/Media/Default/pdf/PressRelease_Hyloris_UpdateValacyclovirOralSolution_EN_20260219_FV.pdf"],"first":"2026-03-05","last":"2026-03-05","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":218,"censored":true,"letters":["CRL_NDA220140_20260305"]},{"app":"NDA220184","kind":"NDA","program":"medicasafe","sponsor":"MedicaSafe, Inc.","tickers":[],"sec_filer":false,"product":"MedicaSafe buprenorphine/naloxone cartridges + SmartKey dispensing device (drug-device combination)","product_type":"other","product_sources":["https://api.fda.gov/transparency/crl.json?search=application_number:%22NDA%20220184%22","https://bioworld.com/articles/431094-nih-backed-medicasafe-aims-for-fda-clearance-of-opioid-use-disorder-drug-device-combo"],"first":"2025-12-22","last":"2025-12-22","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":291,"censored":true,"letters":["CRL_NDA220184_20251222"]},{"app":"NDA220283","kind":"NDA","program":"cingulate_therapeutics","sponsor":"Cingulate Therapeutics, LLC","tickers":["CING","CINGW"],"sec_filer":true,"product":"CTx-1301, dexmethylphenidate HCl extended-release tablets","product_type":"505b2_new_formulation","product_sources":["https://www.cingulate.com/news-releases/news-release-details/cingulate-receives-complete-response-letter-fda-ctx-1301","https://www.cingulate.com/news-releases/news-release-details/cingulate-inc-reports-second-quarter-2026-financial-results-and"],"first":"2026-05-29","last":"2026-05-29","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":133,"censored":true,"letters":["CRL_NDA220283_20260529"]},{"app":"NDA220304","kind":"NDA","program":"grace_therapeutics_us","sponsor":"Grace Therapeutics U.S., Inc.","tickers":["GRCE"],"sec_filer":true,"product":"GTx-104, nimodipine injection for IV infusion (aSAH)","product_type":"505b2_new_formulation","product_sources":["https://www.sec.gov/Archives/edgar/data/1444192/000114036126016324/ef20070593_ex99-1.htm","https://www.biopharmawatch.com/news/ACST/grace-therapeutics-announces-2026-fiscal-year-end-financial-results-provides-business-upda-acst-20260618"],"first":"2026-04-23","last":"2026-04-23","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":169,"censored":true,"letters":["CRL_NDA220304_20260423"]},{"app":"NDA220544","kind":"NDA","program":"ascelia_pharma","sponsor":"Ascelia Pharma AB","tickers":[],"sec_filer":false,"product":"Orviglance (manganese chloride tetrahydrate powder for oral solution), oral liver MRI contrast agent","product_type":"other","product_sources":["https://api.fda.gov/transparency/crl.json?search=application_number:%22NDA%20220544%22","https://www.biospace.com/press-releases/ascelia-pharma-provides-update-on-the-orviglance-nda"],"first":"2026-07-02","last":"2026-07-02","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":99,"censored":true,"letters":["CRL_NDA220544_20260702"]},{"app":"NDA220707","kind":"NDA","program":"disc_medicine","sponsor":"Disc Medicine, Inc.","tickers":["IRON"],"sec_filer":true,"product":"bitopertin tablets for erythropoietic protoporphyria","product_type":"novel","product_sources":["https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-receives-complete-response-letter-fda-bitopertin","https://www.marketbeat.com/instant-alerts/disc-medicine-to-seek-traditional-fda-approval-for-bitopertin-after-epp-crl-apollo-data-due-q4-2026-02-23/?.tsrc=rss"],"first":"2026-02-13","last":"2026-02-13","n":1,"n_orig":1,"era":"issued","track":"original","outcome":"no_public_outcome","approved":null,"tentative":[],"t":238,"censored":true,"letters":["CRL_NDA220707_20260213"]}],"pairs":[{"app":"BLA125745","prev":"CRL_UNKNOWN_20250115","next":"CRL_UNKNOWN_20260109","gap":359,"prev_cats":["FAC"],"next_cats":["EFF"],"type":"original","era":"issued","source":"coded"},{"app":"BLA125827","prev":"CRL_UNKNOWN_20250721","next":"CRL_UNKNOWN_20260410","gap":263,"prev_cats":["EFF"],"next_cats":["AAP","EFF"],"type":"original","era":"issued","source":"coded"},{"app":"BLA761082","prev":"CRL_BLA761082_20180510","next":"CRL_BLA761082_20190611","gap":397,"prev_cats":["CMC","FAC"],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"BLA761082","prev":"CRL_BLA761082_20190611","next":"CRL_BLA761082_20201222","gap":560,"prev_cats":["CMC","FAC"],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"BLA761082","prev":"CRL_BLA761082_20201222","next":"CRL_BLA761082_20210802","gap":223,"prev_cats":["CMC","FAC"],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"BLA761126","prev":"CRL_BLA761126_20190924","next":"CRL_BLA761126_20210520","gap":604,"prev_cats":["CMC","FAC"],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"BLA761126","prev":"CRL_BLA761126_20210520","next":"CRL_BLA761126_20230214","gap":635,"prev_cats":["CMC","FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"BLA761147","prev":"CRL_BLA761147_20240405","next":"CRL_BLA761147_20241029","gap":207,"prev_cats":["CMC","FAC"],"next_cats":["FAC"],"type":"original","era":"issued","source":"coded"},{"app":"BLA761147","prev":"CRL_BLA761147_20241029","next":"CRL_BLA761147_20250805","gap":280,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"issued","source":"coded"},{"app":"BLA761219","prev":"CRL_BLA761219_20211124","next":"CRL_BLA761219_20221123","gap":364,"prev_cats":["CMC","DEV","FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"BLA761225","prev":"CRL_BLA761225_20220331","next":"CRL_BLA761225_20230412","gap":377,"prev_cats":["FAC"],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"BLA761266","prev":"CRL_BLA761266_20250103","next":"CRL_BLA761266_20260623","gap":536,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"issued","source":"coded"},{"app":"BLA761271","prev":"CRL_BLA761271_20241205","next":"CRL_BLA761271_20251209","gap":369,"prev_cats":["CMC","FAC"],"next_cats":["CMC","FAC"],"type":"original","era":"issued","source":"coded"},{"app":"BLA761299","prev":"CRL_BLA761299_20221220","next":"CRL_BLA761299_20230628","gap":190,"prev_cats":["CMC","FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"BLA761303","prev":"CRL_BLA761303_20240322_2","next":"CRL_BLA761303_20250730","gap":495,"prev_cats":["AAP"],"next_cats":["FAC"],"type":"original","era":"issued","source":"coded"},{"app":"BLA761308","prev":"CRL_BLA761308_20240516","next":"CRL_BLA761308_20250320","gap":308,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"issued","source":"coded"},{"app":"BLA761308","prev":"CRL_BLA761308_20250320","next":"CRL_BLA761308_20260709","gap":476,"prev_cats":["FAC"],"next_cats":["REG"],"type":"original","era":"issued","source":"coded"},{"app":"BLA761311","prev":"CRL_BLA761311_20230929","next":"CRL_BLA761311_20260629","gap":1004,"prev_cats":["CMC","FAC"],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"mixed"},{"app":"BLA761320","prev":"CRL_BLA761320_20250827","next":"CRL_BLA761320_20251230","gap":125,"prev_cats":["EFF"],"next_cats":["EFF"],"type":"original","era":"issued","source":"coded"},{"app":"BLA761338","prev":"CRL_BLA761338_20240930","next":"CRL_BLA761338_20241217","gap":78,"prev_cats":["REG"],"next_cats":["REG"],"type":"original","era":"issued","source":"coded"},{"app":"BLA761376","prev":"CRL_BLA761376_20240419","next":"CRL_BLA761376_20251016","gap":545,"prev_cats":["CMC","FAC"],"next_cats":["CMC","FAC"],"type":"original","era":"issued","source":"coded"},{"app":"BLA761377","prev":"CRL_BLA761377_20240627","next":"CRL_BLA761377_20250326","gap":272,"prev_cats":["CMC","FAC"],"next_cats":["FAC"],"type":"original","era":"issued","source":"coded"},{"app":"NDA021164","prev":"CRL_NDA021164_20020315","next":"CRL_NDA021164_20040623","gap":831,"prev_cats":["CLP","EFF","NCL","SAF"],"next_cats":["CMC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA021164","prev":"CRL_NDA021164_20040623","next":"CRL_NDA021164_20071102","gap":1227,"prev_cats":["CMC"],"next_cats":["EFF"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA022231","prev":"CRL_NDA022231_20091104","next":"CRL_NDA022231_20200911","gap":3964,"prev_cats":["CMC","EFF","FAC"],"next_cats":["EFF","SAF"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA022231","prev":"CRL_NDA022231_20200911","next":"CRL_NDA022231_20220218","gap":525,"prev_cats":["EFF","SAF"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA022517","prev":"CRL_NDA022517_20100422","next":"CRL_NDA022517_20130130","gap":1014,"prev_cats":["CLP","EFF","NCL"],"next_cats":["EFF"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA022517","prev":"CRL_NDA022517_20130130","next":"CRL_NDA022517_20150130","gap":730,"prev_cats":["EFF"],"next_cats":["EFF"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA200655","prev":"CRL_NDA200655_20131022","next":"CRL_NDA200655_20160915","gap":1059,"prev_cats":["CMC","EFF"],"next_cats":["EFF"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA201110","prev":"CRL_NDA201110_20110228","next":"CRL_NDA201110_20161123","gap":2095,"prev_cats":["CMC","FAC"],"next_cats":["DEV"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA202049","prev":"CRL_NDA202049_20130318","next":"CRL_NDA202049_20190619","gap":2284,"prev_cats":["CMC","EFF","FAC","SAF"],"next_cats":["DEV"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA202408","prev":"CRL_NDA202408_20140331","next":"CRL_NDA202408_20160624","gap":816,"prev_cats":[],"next_cats":[],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA202408","prev":"CRL_NDA202408_20160624","next":"CRL_NDA202408_20190328","gap":1007,"prev_cats":[],"next_cats":[],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA202860","prev":"CRL_NDA202860_20120518","next":"CRL_NDA202860_20130628","gap":406,"prev_cats":[],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA202860","prev":"CRL_NDA202860_20130628","next":"CRL_NDA202860_20190123","gap":2035,"prev_cats":["CMC","FAC"],"next_cats":["DEV","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA204017","prev":"CRL_NDA204017_20130213","next":"CRL_NDA204017_20130717","gap":154,"prev_cats":["CMC","FAC"],"next_cats":["CMC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA204017","prev":"CRL_NDA204017_20130717","next":"CRL_NDA204017_20171221","gap":1618,"prev_cats":["CMC"],"next_cats":["CMC","FAC","NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA204311","prev":"CRL_NDA204311_20141023","next":"CRL_NDA204311_20190806","gap":1748,"prev_cats":["CMC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA204311","prev":"CRL_NDA204311_20190806","next":"CRL_NDA204311_20230113","gap":1256,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA204417","prev":"CRL_NDA204417_20130329","next":"CRL_NDA204417_20150923","gap":908,"prev_cats":["CLP"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA204417","prev":"CRL_NDA204417_20150923","next":"CRL_NDA204417_20170322","gap":546,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA204957","prev":"CRL_NDA204957_20170928","next":"CRL_NDA204957_20190327","gap":545,"prev_cats":["FAC","NCL"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA204957","prev":"CRL_NDA204957_20190327","next":"CRL_NDA204957_20200424","gap":394,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA205394","prev":"CRL_NDA205394_20140131","next":"CRL_NDA205394_20190328","gap":1882,"prev_cats":["CMC","FAC"],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA205394","prev":"CRL_NDA205394_20190328","next":"CRL_NDA205394_20200324","gap":362,"prev_cats":["CMC","FAC"],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA205920","prev":"CRL_NDA205920_20140522","next":"CRL_NDA205920_20161223","gap":946,"prev_cats":["CMC","DEV","NCL"],"next_cats":["DEV"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA206089","prev":"CRL_NDA206089_20141103","next":"CRL_NDA206089_20180322","gap":1235,"prev_cats":["CLP"],"next_cats":[],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA206185","prev":"CRL_NDA206185_20141124","next":"CRL_NDA206185_20150730","gap":248,"prev_cats":["CMC","FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA206185","prev":"CRL_NDA206185_20150730","next":"CRL_NDA206185_20161219","gap":508,"prev_cats":["FAC"],"next_cats":[],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA206610","prev":"CRL_NDA206610_20150227","next":"CRL_NDA206610_20160310","gap":377,"prev_cats":["FAC","NCL"],"next_cats":["NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA206610","prev":"CRL_NDA206610_20160310","next":"CRL_NDA206610_20170201","gap":328,"prev_cats":["NCL"],"next_cats":["NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA206610","prev":"CRL_NDA206610_20170201","next":"CRL_NDA206610_20171206","gap":308,"prev_cats":["NCL"],"next_cats":["NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA206610","prev":"CRL_NDA206610_20171206","next":"CRL_NDA206610_20190606","gap":547,"prev_cats":["NCL"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA206927","prev":"CRL_NDA206927_20141217","next":"CRL_NDA206927_20160504","gap":504,"prev_cats":["CLP","CMC"],"next_cats":["CLP","CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA206968","prev":"CRL_NDA206968_20150227","next":"CRL_NDA206968_20161115","gap":627,"prev_cats":["CMC","FAC","NCL"],"next_cats":["FAC","NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA206968","prev":"CRL_NDA206968_20161115","next":"CRL_NDA206968_20181109","gap":724,"prev_cats":["FAC","NCL"],"next_cats":["FAC","NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA206968","prev":"CRL_NDA206968_20181109","next":"CRL_NDA206968_20201222","gap":774,"prev_cats":["FAC","NCL"],"next_cats":["CMC","NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA208193","prev":"CRL_NDA208193_20170111","next":"CRL_NDA208193_20180625","gap":530,"prev_cats":["CMC"],"next_cats":["CMC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA208276","prev":"CRL_NDA208276_20161007","next":"CRL_NDA208276_20170602","gap":238,"prev_cats":["CMC"],"next_cats":["DEV"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA208288","prev":"CRL_NDA208288_20160506","next":"CRL_NDA208288_20170901","gap":483,"prev_cats":["CLP","CMC","EFF","NCL"],"next_cats":["CMC","NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA208313","prev":"CRL_NDA208313_20151124","next":"CRL_NDA208313_20170523","gap":546,"prev_cats":["DEV","FAC"],"next_cats":["FAC","NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA208419","prev":"CRL_NDA208419_20170926","next":"CRL_NDA208419_20180626","gap":273,"prev_cats":["CMC","FAC"],"next_cats":["CMC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA208574","prev":"CRL_NDA208574_20160601","next":"CRL_NDA208574_20170602","gap":366,"prev_cats":["CMC","FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA208574","prev":"CRL_NDA208574_20170602","next":"CRL_NDA208574_20191104","gap":885,"prev_cats":["FAC"],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA208742","prev":"CRL_NDA208742_20160721","next":"CRL_NDA208742_20170710","gap":354,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA209191","prev":"CRL_NDA209191_20170426","next":"CRL_NDA209191_20171103","gap":191,"prev_cats":["CMC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA209191","prev":"CRL_NDA209191_20171103","next":"CRL_NDA209191_20180222","gap":111,"prev_cats":["FAC"],"next_cats":["CMC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA209471","prev":"CRL_NDA209471_20171222","next":"CRL_NDA209471_20201106","gap":1050,"prev_cats":["CMC","FAC","NCL"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA209510","prev":"CRL_NDA209510_20181005","next":"CRL_NDA209510_20190502","gap":209,"prev_cats":["CMC","FAC"],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA209988","prev":"CRL_NDA209988_20180611","next":"CRL_NDA209988_20201203","gap":906,"prev_cats":["CMC","DEV","EFF"],"next_cats":["DEV","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210136","prev":"CRL_NDA210136_20180119","next":"CRL_NDA210136_20181221","gap":336,"prev_cats":["CMC","NCL"],"next_cats":["CMC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210136","prev":"CRL_NDA210136_20181221","next":"CRL_NDA210136_20201201","gap":711,"prev_cats":["CMC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210136","prev":"CRL_NDA210136_20201201","next":"CRL_NDA210136_20211215","gap":379,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210168","prev":"CRL_NDA210168_20240322","next":"CRL_NDA210168_20250620","gap":455,"prev_cats":["FAC"],"next_cats":["CMC"],"type":"original","era":"issued","source":"coded"},{"app":"NDA210274","prev":"CRL_NDA210274_20180615","next":"CRL_NDA210274_20201127","gap":896,"prev_cats":["CMC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210274","prev":"CRL_NDA210274_20201127","next":"CRL_NDA210274_20210825","gap":271,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210526","prev":"CRL_NDA210526_20180725","next":"CRL_NDA210526_20210121","gap":911,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210583","prev":"CRL_NDA210583_20180523","next":"CRL_NDA210583_20190322","gap":303,"prev_cats":["CMC","EFF","NCL"],"next_cats":[],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210605","prev":"CRL_NDA210605_20180517","next":"CRL_NDA210605_20190828","gap":468,"prev_cats":["CMC","DEV"],"next_cats":["DEV","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210649","prev":"CRL_NDA210649_20180313","next":"CRL_NDA210649_20180912","gap":183,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210735","prev":"CRL_NDA210735_20180426","next":"CRL_NDA210735_20190115","gap":264,"prev_cats":["CMC","NCL"],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210735","prev":"CRL_NDA210735_20190115","next":"CRL_NDA210735_20191001","gap":259,"prev_cats":["CMC","FAC"],"next_cats":["FAC","NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210852","prev":"CRL_NDA210852_20180724","next":"CRL_NDA210852_20190503","gap":283,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210852","prev":"CRL_NDA210852_20190503","next":"CRL_NDA210852_20191120","gap":201,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210852","prev":"CRL_NDA210852_20191120","next":"CRL_NDA210852_20200521","gap":183,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210852","prev":"CRL_NDA210852_20200521","next":"CRL_NDA210852_20201106","gap":169,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210852","prev":"CRL_NDA210852_20201106","next":"CRL_NDA210852_20220418","gap":528,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA210864","prev":"CRL_NDA210864_20190322","next":"CRL_NDA210864_20191220","gap":273,"prev_cats":[],"next_cats":[],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA211413","prev":"CRL_NDA211413_20181019","next":"CRL_NDA211413_20191226","gap":433,"prev_cats":[],"next_cats":["CMC","NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA211413","prev":"CRL_NDA211413_20191226","next":"CRL_NDA211413_20210108","gap":379,"prev_cats":["CMC","NCL"],"next_cats":["NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA211566","prev":"CRL_NDA211566_20210902","next":"CRL_NDA211566_20230303","gap":547,"prev_cats":["CMC"],"next_cats":["CMC","NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA211988","prev":"CRL_NDA211988_20190430","next":"CRL_NDA211988_20200626","gap":423,"prev_cats":["CMC","DEV","NCL"],"next_cats":["NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA212501","prev":"CRL_NDA212501_20190718","next":"CRL_NDA212501_20200114","gap":180,"prev_cats":["FAC"],"next_cats":["FAC","NCL"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA212782","prev":"CRL_NDA212782_20200310","next":"CRL_NDA212782_20230801","gap":1239,"prev_cats":["CLP","CMC"],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA212849","prev":"CRL_NDA212849_20200128","next":"CRL_NDA212849_20220218","gap":752,"prev_cats":["CLP","CMC","DEV","FAC"],"next_cats":["CLP","CMC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA212854","prev":"CRL_NDA212854_20191122","next":"CRL_NDA212854_20201113","gap":357,"prev_cats":["CLP","CMC","DEV","NCL"],"next_cats":["DEV"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA212905","prev":"CRL_NDA212905_20200713","next":"CRL_NDA212905_20210916","gap":430,"prev_cats":["CMC","DEV"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA212905","prev":"CRL_NDA212905_20210916","next":"CRL_NDA212905_20220523","gap":249,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA212937","prev":"CRL_NDA212937_20200810","next":"CRL_NDA212937_20211126","gap":473,"prev_cats":["CMC","FAC"],"next_cats":["FAC","SAF"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA214520","prev":"CRL_NDA214520_20210226","next":"CRL_NDA214520_20220804","gap":524,"prev_cats":["CMC"],"next_cats":["CMC","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA214610","prev":"CRL_NDA214610_20241211","next":"CRL_NDA214610_20260227","gap":443,"prev_cats":["NCL"],"next_cats":["CMC","NCL"],"type":"original","era":"issued","source":"coded"},{"app":"NDA214835","prev":"CRL_NDA214835_20210924","next":"CRL_NDA214835_20220715","gap":294,"prev_cats":["CLP","CMC","DEV","FAC"],"next_cats":["CMC","DEV","FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA214835","prev":"CRL_NDA214835_20220715","next":"CRL_NDA214835_20230727","gap":377,"prev_cats":["CMC","DEV","FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA215179","prev":"CRL_NDA215179_20210624","next":"CRL_NDA215179_20220414","gap":294,"prev_cats":["CMC","FAC"],"next_cats":["CMC"],"type":"original","era":"after_approval","source":"rule"},{"app":"NDA215644","prev":"CRL_NDA215644_20241025","next":"CRL_NDA215644_20250625","gap":243,"prev_cats":["FAC"],"next_cats":["CMC","FAC"],"type":"original","era":"issued","source":"coded"},{"app":"NDA215818","prev":"CRL_NDA215818_20250425","next":"CRL_NDA215818_20260227","gap":308,"prev_cats":["CMC","NCL"],"next_cats":["CMC","NCL"],"type":"original","era":"issued","source":"coded"},{"app":"NDA216195","prev":"CRL_NDA216195_20240725","next":"CRL_NDA216195_20251007","gap":439,"prev_cats":["CMC","FAC","REG"],"next_cats":["CMC","FAC","REG"],"type":"original","era":"issued","source":"coded"},{"app":"NDA216442","prev":"CRL_NDA216442_20250402","next":"CRL_NDA216442_20260316","gap":348,"prev_cats":["EFF"],"next_cats":["EFF"],"type":"original","era":"issued","source":"coded"},{"app":"NDA216586","prev":"CRL_NDA216586_20240516","next":"CRL_NDA216586_20250320","gap":308,"prev_cats":["FAC","REG"],"next_cats":["REG"],"type":"original","era":"issued","source":"coded"},{"app":"NDA216586","prev":"CRL_NDA216586_20250320","next":"CRL_NDA216586_20260709","gap":476,"prev_cats":["REG"],"next_cats":["FAC"],"type":"original","era":"issued","source":"coded"},{"app":"NDA216962","prev":"CRL_NDA216962_20230317","next":"CRL_NDA216962_20240618","gap":459,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"after_approval","source":"coded"},{"app":"NDA216987","prev":"CRL_NDA216987_20240510","next":"CRL_NDA216987_20251106","gap":545,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"issued","source":"coded"},{"app":"NDA218317","prev":"CRL_NDA218317_20240524","next":"CRL_NDA218317_20251021","gap":515,"prev_cats":["CLP","CMC","DEV","FAC","NCL"],"next_cats":["FAC","NCL"],"type":"original","era":"issued","source":"coded"},{"app":"NDA218345","prev":"CRL_NDA218345_20240701","next":"CRL_NDA218345_20250402","gap":275,"prev_cats":["CMC","NCL"],"next_cats":["FAC"],"type":"original","era":"issued","source":"coded"},{"app":"NDA218600","prev":"CRL_NDA218600_20241021","next":"CRL_NDA218600_20260610","gap":597,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"issued","source":"coded"},{"app":"NDA218607","prev":"CRL_NDA218607_20250627","next":"CRL_NDA218607_20260629","gap":367,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"issued","source":"coded"},{"app":"NDA218762","prev":"CRL_NDA218762_20240417","next":"CRL_NDA218762_20241205","gap":232,"prev_cats":["CMC","FAC"],"next_cats":["FAC"],"type":"original","era":"issued","source":"coded"},{"app":"NDA218923","prev":"CRL_NDA218923_20241010","next":"CRL_NDA218923_20250730","gap":293,"prev_cats":["FAC"],"next_cats":["FAC"],"type":"original","era":"issued","source":"coded"}],"filings":{"abbvie":[{"code":"8K_2023-04-27_000019_abbv-20230331xexhibit991","form":"8-K","date":"2023-04-27","url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000019/abbv-20230331xexhibit991.htm"},{"code":"8K_2024-07-25_000026_abbv-20240630xexhibit991","form":"8-K","date":"2024-07-25","url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000026/abbv-20240630xexhibit991.htm"},{"code":"10K_2026-02-20_000008_abbv-20251231","form":"10-K","date":"2026-02-20","url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm"},{"code":"8K_2026-04-29_000013_abbv-20260331xexhibit991","form":"8-K","date":"2026-04-29","url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000013/abbv-20260331xexhibit991.htm"}],"abeona_therapeutics":[{"code":"8K_2024-04-22_015531_ex99-1","form":"8-K","date":"2024-04-22","url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224015531/ex99-1.htm"},{"code":"8K_2024-05-03_017768_ex99-1","form":"8-K","date":"2024-05-03","url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224017768/ex99-1.htm"},{"code":"8K_2024-05-15_019449_ex99-1","form":"8-K","date":"2024-05-15","url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224019449/ex99-1.htm"},{"code":"8K_2024-08-12_031146_ex99-1","form":"8-K","date":"2024-08-12","url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224031146/ex99-1.htm"},{"code":"8K_2024-10-29_042775_ex99-1","form":"8-K","date":"2024-10-29","url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224042775/ex99-1.htm"},{"code":"8K_2024-11-14_045338_ex99-1","form":"8-K","date":"2024-11-14","url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224045338/ex99-1.htm"},{"code":"10K_2026-03-17_010413_form10-k","form":"10-K","date":"2026-03-17","url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226010413/form10-k.htm"}],"achieve_life_sciences":[{"code":"10K_2026-03-24_120690_achv-20251231","form":"10-K","date":"2026-03-24","url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm"},{"code":"8K_2026-05-12_218175_d854692dex991","form":"8-K","date":"2026-05-12","url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/d854692dex991.htm"},{"code":"8K_2026-08-11_344571_achv-ex99_1","form":"8-K","date":"2026-08-11","url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526344571/achv-ex99_1.htm"}],"akebia_therapeutics":[{"code":"8K_2022-03-30_089998_d321381dex991","form":"8-K","date":"2022-03-30","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522089998/d321381dex991.htm"},{"code":"8K_2022-03-30_089998_d321381d8k","form":"8-K","date":"2022-03-30","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522089998/d321381d8k.htm"},{"code":"8K_2022-04-07_098113_d314349d8k","form":"8-K","date":"2022-04-07","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522098113/d314349d8k.htm"},{"code":"8K_2022-05-09_144993_d331553dex991","form":"8-K","date":"2022-05-09","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522144993/d331553dex991.htm"},{"code":"8K_2022-05-13_150303_d721313d8k","form":"8-K","date":"2022-05-13","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522150303/d721313d8k.htm"},{"code":"8K_2022-08-04_212531_d371816dex992","form":"8-K","date":"2022-08-04","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522212531/d371816dex992.htm"},{"code":"8K_2022-08-04_212531_d371816dex991","form":"8-K","date":"2022-08-04","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522212531/d371816dex991.htm"},{"code":"8K_2022-11-03_276930_d402663dex991","form":"8-K","date":"2022-11-03","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522276930/d402663dex991.htm"},{"code":"8K_2022-11-08_280142_d76469d8k","form":"8-K","date":"2022-11-08","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522280142/d76469d8k.htm"},{"code":"8K_2023-01-09_004214_d412017dex991","form":"8-K","date":"2023-01-09","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523004214/d412017dex991.htm"},{"code":"8K_2023-02-21_042806_d437984dex991","form":"8-K","date":"2023-02-21","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523042806/d437984dex991.htm"},{"code":"8K_2023-02-21_042806_d437984d8k","form":"8-K","date":"2023-02-21","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523042806/d437984d8k.htm"},{"code":"8K_2023-03-09_065311_d367644dex991","form":"8-K","date":"2023-03-09","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523065311/d367644dex991.htm"},{"code":"8K_2023-05-08_137689_d439043dex991","form":"8-K","date":"2023-05-08","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523137689/d439043dex991.htm"},{"code":"8K_2023-05-30_156011_d506633dex991","form":"8-K","date":"2023-05-30","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523156011/d506633dex991.htm"},{"code":"8K_2023-05-30_156011_d506633d8k","form":"8-K","date":"2023-05-30","url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523156011/d506633d8k.htm"},{"code":"8K_2023-10-25_000037_exhibit991-akbavadadustatn","form":"8-K","date":"2023-10-25","url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000037/exhibit991-akbavadadustatn.htm"},{"code":"10K_2026-02-26_000020_akba-20251231","form":"10-K","date":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/akba-20251231.htm"}],"aldeyra_therapeutics":[{"code":"8K_2024-04-25_035953_ea020462001ex99-2_aldey","form":"8-K","date":"2024-04-25","url":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024035953/ea020462001ex99-2_aldey.htm"},{"code":"8K_2024-04-25_035953_ea0204620-8k_aldey","form":"8-K","date":"2024-04-25","url":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024035953/ea0204620-8k_aldey.htm"},{"code":"8K_2024-06-13_052234_ea020779101ex99-1_aldeyra","form":"8-K","date":"2024-06-13","url":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024052234/ea020779101ex99-1_aldeyra.htm"},{"code":"8K_2024-06-20_054003_ea020814201ex99-1_aldeyra","form":"8-K","date":"2024-06-20","url":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024054003/ea020814201ex99-1_aldeyra.htm"},{"code":"8K_2024-08-08_066327_ea021084001ex99-2_aldeyra","form":"8-K","date":"2024-08-08","url":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024066327/ea021084001ex99-2_aldeyra.htm"},{"code":"8K_2024-10-03_084844_ea021662501ex99-1_aldeyra","form":"8-K","date":"2024-10-03","url":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024084844/ea021662501ex99-1_aldeyra.htm"},{"code":"8K_2024-11-18_099333_ea022156801ex99-1_aldeyra","form":"8-K","date":"2024-11-18","url":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/ea022156801ex99-1_aldeyra.htm"},{"code":"8K_2025-04-03_072424_d946200dex992","form":"8-K","date":"2025-04-03","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200dex992.htm"},{"code":"8K_2025-04-03_072424_d946200dex991","form":"8-K","date":"2025-04-03","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200dex991.htm"},{"code":"8K_2025-04-03_072424_d946200d8k","form":"8-K","date":"2025-04-03","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200d8k.htm"},{"code":"8K_2025-04-17_032947_ea023875601ex99-1_aldey","form":"8-K","date":"2025-04-17","url":"https://www.sec.gov/Archives/edgar/data/1341235/000121390025032947/ea023875601ex99-1_aldey.htm"},{"code":"8K_2025-05-06_113275_d941544dex992","form":"8-K","date":"2025-05-06","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525113275/d941544dex992.htm"},{"code":"8K_2025-05-06_113275_d941544dex991","form":"8-K","date":"2025-05-06","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525113275/d941544dex991.htm"},{"code":"8K_2025-06-17_054949_ea0245870ex99-1_aldeyra","form":"8-K","date":"2025-06-17","url":"https://www.sec.gov/Archives/edgar/data/1341235/000121390025054949/ea0245870ex99-1_aldeyra.htm"},{"code":"8K_2025-06-26_058035_ea024700001ex99-1_aldeyra","form":"8-K","date":"2025-06-26","url":"https://www.sec.gov/Archives/edgar/data/1341235/000121390025058035/ea024700001ex99-1_aldeyra.htm"},{"code":"8K_2025-07-17_064869_ea024925701ex99-1_aldeyra","form":"8-K","date":"2025-07-17","url":"https://www.sec.gov/Archives/edgar/data/1341235/000121390025064869/ea024925701ex99-1_aldeyra.htm"},{"code":"8K_2025-08-19_109932_aldx-ex99_1","form":"8-K","date":"2025-08-19","url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025109932/aldx-ex99_1.htm"},{"code":"8K_2025-10-28_252200_aldx-ex99_1","form":"8-K","date":"2025-10-28","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525252200/aldx-ex99_1.htm"},{"code":"8K_2025-11-13_278804_aldx-ex99_2","form":"8-K","date":"2025-11-13","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525278804/aldx-ex99_2.htm"},{"code":"8K_2025-11-13_278804_aldx-20251113","form":"8-K","date":"2025-11-13","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525278804/aldx-20251113.htm"},{"code":"8K_2025-12-16_319638_aldx-ex99_1","form":"8-K","date":"2025-12-16","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-ex99_1.htm"},{"code":"8K_2025-12-16_319638_aldx-20251215","form":"8-K","date":"2025-12-16","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-20251215.htm"},{"code":"10K_2026-02-27_083012_aldx-20251231","form":"10-K","date":"2026-02-27","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm"},{"code":"8K_2026-03-17_109511_aldx-ex99_1","form":"8-K","date":"2026-03-17","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-ex99_1.htm"},{"code":"8K_2026-03-17_109511_aldx-20260317","form":"8-K","date":"2026-03-17","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm"},{"code":"8K_2026-05-01_199157_aldx-ex99_1","form":"8-K","date":"2026-05-01","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526199157/aldx-ex99_1.htm"},{"code":"8K_2026-06-10_264514_aldx-ex99_1","form":"8-K","date":"2026-06-10","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526264514/aldx-ex99_1.htm"},{"code":"8K_2026-09-29_405954_aldx-ex99_2","form":"8-K","date":"2026-09-29","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526405954/aldx-ex99_2.htm"},{"code":"8K_2026-09-29_405954_aldx-ex99_1","form":"8-K","date":"2026-09-29","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526405954/aldx-ex99_1.htm"},{"code":"8K_2026-09-29_405954_aldx-20260929","form":"8-K","date":"2026-09-29","url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526405954/aldx-20260929.htm"}],"alkermes":[{"code":"8K_2020-11-17_054254_alks-ex991_15","form":"8-K","date":"2020-11-17","url":"https://www.sec.gov/Archives/edgar/data/1520262/000156459020054254/alks-ex991_15.htm"},{"code":"8K_2020-11-17_054254_alks-8k_20201117","form":"8-K","date":"2020-11-17","url":"https://www.sec.gov/Archives/edgar/data/1520262/000156459020054254/alks-8k_20201117.htm"},{"code":"8K_2021-01-11_000748_alks-ex991_15","form":"8-K","date":"2021-01-11","url":"https://www.sec.gov/Archives/edgar/data/1520262/000156459021000748/alks-ex991_15.htm"},{"code":"8K_2021-02-11_005379_alks-ex992_6","form":"8-K","date":"2021-02-11","url":"https://www.sec.gov/Archives/edgar/data/1520262/000156459021005379/alks-ex992_6.htm"},{"code":"8K_2021-02-11_005379_alks-ex991_7","form":"8-K","date":"2021-02-11","url":"https://www.sec.gov/Archives/edgar/data/1520262/000156459021005379/alks-ex991_7.htm"},{"code":"8K_2021-03-25_015519_alks-ex991_19","form":"8-K","date":"2021-03-25","url":"https://www.sec.gov/Archives/edgar/data/1520262/000156459021015519/alks-ex991_19.htm"},{"code":"10K_2026-02-25_068925_alks-20251231","form":"10-K","date":"2026-02-25","url":"https://www.sec.gov/Archives/edgar/data/1520262/000119312526068925/alks-20251231.htm"}],"alvotech_usa":[{"code":"6K_2022-06-21_177634_d359184dex991","form":"6-K","date":"2022-06-21","url":"https://www.sec.gov/Archives/edgar/data/1898416/000119312522177634/d359184dex991.htm"},{"code":"6K_2022-09-06_238277_d352711dex991","form":"6-K","date":"2022-09-06","url":"https://www.sec.gov/Archives/edgar/data/1898416/000119312522238277/d352711dex991.htm"},{"code":"6K_2022-12-22_310490_d432932dex991","form":"6-K","date":"2022-12-22","url":"https://www.sec.gov/Archives/edgar/data/1898416/000119312522310490/d432932dex991.htm"},{"code":"6K_2023-04-14_101203_d424122dex991","form":"6-K","date":"2023-04-14","url":"https://www.sec.gov/Archives/edgar/data/1898416/000119312523101203/d424122dex991.htm"},{"code":"6K_2023-04-14_101203_d424122d6k","form":"6-K","date":"2023-04-14","url":"https://www.sec.gov/Archives/edgar/data/1898416/000119312523101203/d424122d6k.htm"},{"code":"6K_2023-05-19_149004_d408893dex991","form":"6-K","date":"2023-05-19","url":"https://www.sec.gov/Archives/edgar/data/1898416/000119312523149004/d408893dex991.htm"},{"code":"6K_2023-06-29_178011_d520464dex991","form":"6-K","date":"2023-06-29","url":"https://www.sec.gov/Archives/edgar/data/1898416/000119312523178011/d520464dex991.htm"},{"code":"6K_2023-06-29_178011_d520464d6k","form":"6-K","date":"2023-06-29","url":"https://www.sec.gov/Archives/edgar/data/1898416/000119312523178011/d520464d6k.htm"},{"code":"6K_2023-08-31_002065_c106868_ex99-8","form":"6-K","date":"2023-08-31","url":"https://www.sec.gov/Archives/edgar/data/1898416/000093041323002065/c106868_ex99-8.htm"},{"code":"6K_2023-08-31_002065_c106868_ex99-2","form":"6-K","date":"2023-08-31","url":"https://www.sec.gov/Archives/edgar/data/1898416/000093041323002065/c106868_ex99-2.htm"},{"code":"6K_2023-08-31_002065_c106868_ex99-1","form":"6-K","date":"2023-08-31","url":"https://www.sec.gov/Archives/edgar/data/1898416/000093041323002065/c106868_ex99-1.htm"},{"code":"6KA_2023-09-07_002115_c106868_ex99-1","form":"6-K/A","date":"2023-09-07","url":"https://www.sec.gov/Archives/edgar/data/1898416/000093041323002115/c106868_ex99-1.htm"},{"code":"6K_2023-10-12_006229_f6k_101123","form":"6-K","date":"2023-10-12","url":"https://www.sec.gov/Archives/edgar/data/1898416/000117184323006229/f6k_101123.htm"},{"code":"6K_2023-10-12_006229_exh_991","form":"6-K","date":"2023-10-12","url":"https://www.sec.gov/Archives/edgar/data/1898416/000117184323006229/exh_991.htm"},{"code":"6K_2025-11-03_006876_f6k_110325","form":"6-K","date":"2025-11-03","url":"https://www.sec.gov/Archives/edgar/data/1898416/000117184325006876/f6k_110325.htm"},{"code":"6K_2025-11-03_006876_exh_991","form":"6-K","date":"2025-11-03","url":"https://www.sec.gov/Archives/edgar/data/1898416/000117184325006876/exh_991.htm"},{"code":"6K_2025-12-17_007974_f6k_121725","form":"6-K","date":"2025-12-17","url":"https://www.sec.gov/Archives/edgar/data/1898416/000117184325007974/f6k_121725.htm"},{"code":"20F_2026-03-31_000004_alvo-20251231","form":"20-F","date":"2026-03-31","url":"https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/alvo-20251231.htm"}],"amgen":[{"code":"8K_2016-10-27_749786_d265515dex991","form":"8-K","date":"2016-10-27","url":"https://www.sec.gov/Archives/edgar/data/318154/000119312516749786/d265515dex991.htm"},{"code":"8K_2017-07-25_235011_d427228dex991","form":"8-K","date":"2017-07-25","url":"https://www.sec.gov/Archives/edgar/data/318154/000119312517235011/d427228dex991.htm"},{"code":"8K_2017-10-25_319303_d479780dex991","form":"8-K","date":"2017-10-25","url":"https://www.sec.gov/Archives/edgar/data/318154/000119312517319303/d479780dex991.htm"},{"code":"8K_2018-07-26_227779_d575894dex991","form":"8-K","date":"2018-07-26","url":"https://www.sec.gov/Archives/edgar/data/318154/000119312518227779/d575894dex991.htm"},{"code":"10K_2026-02-13_000010_amgn-20251231","form":"10-K","date":"2026-02-13","url":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm"}],"amphastar_pharmaceuticals":[{"code":"8K_2016-12-27_010637_amph-20161227x8k","form":"8-K","date":"2016-12-27","url":"https://www.sec.gov/Archives/edgar/data/1297184/000155837016010637/amph-20161227x8k.htm"},{"code":"8K_2016-12-27_010637_amph-20161227ex9917713da","form":"8-K","date":"2016-12-27","url":"https://www.sec.gov/Archives/edgar/data/1297184/000155837016010637/amph-20161227ex9917713da.htm"},{"code":"10K_2026-02-26_000009_amph-20251231x10k","form":"10-K","date":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm"}],"aquestive_therapeutics":[{"code":"8K_2026-02-02_000005_q12026-crlmeetingsupplem","form":"8-K","date":"2026-02-02","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000005/q12026-crlmeetingsupplem.htm"},{"code":"8K_2026-02-02_000005_aqst-20260130","form":"8-K","date":"2026-02-02","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000005/aqst-20260130.htm"},{"code":"8K_2026-02-02_000005_anaphylmcrlpressrelease2","form":"8-K","date":"2026-02-02","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000005/anaphylmcrlpressrelease2.htm"},{"code":"8K_2026-02-26_000007_corporatepresentationfeb","form":"8-K","date":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000007/corporatepresentationfeb.htm"},{"code":"8K_2026-03-04_000016_q42025supplementalearnin","form":"8-K","date":"2026-03-04","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/q42025supplementalearnin.htm"},{"code":"8K_2026-03-04_000016_aqst-q425xex991earningsrel","form":"8-K","date":"2026-03-04","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/aqst-q425xex991earningsrel.htm"},{"code":"10K_2026-03-04_000018_aqst-20251231","form":"10-K","date":"2026-03-04","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm"},{"code":"8K_2026-03-30_000022_typeameetingpressrelease","form":"8-K","date":"2026-03-30","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000022/typeameetingpressrelease.htm"},{"code":"8K_2026-05-13_000029_q12026-ex991earningsrelease","form":"8-K","date":"2026-05-13","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/q12026-ex991earningsrelease.htm"},{"code":"8K_2026-05-13_000029_earningsreleasesupplemen","form":"8-K","date":"2026-05-13","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/earningsreleasesupplemen.htm"},{"code":"8K_2026-08-10_000035_humanfactorspkstudyresul","form":"8-K","date":"2026-08-10","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000035/humanfactorspkstudyresul.htm"},{"code":"8K_2026-08-10_000035_hfandclinicalstudystudys","form":"8-K","date":"2026-08-10","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000035/hfandclinicalstudystudys.htm"},{"code":"8K_2026-08-11_000041_q22026-ex991earningsrelease","form":"8-K","date":"2026-08-11","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/q22026-ex991earningsrelease.htm"},{"code":"8K_2026-09-17_000044_ndapressrelease-9x14x202","form":"8-K","date":"2026-09-17","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000044/ndapressrelease-9x14x202.htm"},{"code":"8K_2026-09-17_000044_hcwpresentation9-11x2026","form":"8-K","date":"2026-09-17","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000044/hcwpresentation9-11x2026.htm"},{"code":"8K_2026-09-25_000048_corporatepresentation-se","form":"8-K","date":"2026-09-25","url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000048/corporatepresentation-se.htm"}],"ardelyx":[{"code":"8K_2020-10-14_011468_ardx-20201009xex10d1","form":"8-K","date":"2020-10-14","url":"https://www.sec.gov/Archives/edgar/data/1437402/000155837020011468/ardx-20201009xex10d1.htm"},{"code":"8K_2020-10-14_011468_ardx-20201009x8k","form":"8-K","date":"2020-10-14","url":"https://www.sec.gov/Archives/edgar/data/1437402/000155837020011468/ardx-20201009x8k.htm"},{"code":"8K_2021-07-30_014943_ardx-20210728","form":"8-K","date":"2021-07-30","url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828021014943/ardx-20210728.htm"},{"code":"8K_2021-08-03_015215_ardx-20210729","form":"8-K","date":"2021-08-03","url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828021015215/ardx-20210729.htm"},{"code":"8K_2021-08-13_016911_ardx-20210630xexhibit991","form":"8-K","date":"2021-08-13","url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828021016911/ardx-20210630xexhibit991.htm"},{"code":"8K_2021-10-13_019997_ardx-20211008","form":"8-K","date":"2021-10-13","url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828021019997/ardx-20211008.htm"},{"code":"8K_2021-11-12_022977_ardx-20210930xexhibit991","form":"8-K","date":"2021-11-12","url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828021022977/ardx-20210930xexhibit991.htm"},{"code":"8K_2022-02-10_002151_ardx-20220204","form":"8-K","date":"2022-02-10","url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828022002151/ardx-20220204.htm"},{"code":"8K_2022-02-28_004224_ardx-20211231xexhibit991","form":"8-K","date":"2022-02-28","url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828022004224/ardx-20211231xexhibit991.htm"},{"code":"8K_2022-04-25_010063_ardx-20220425","form":"8-K","date":"2022-04-25","url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828022010063/ardx-20220425.htm"},{"code":"8K_2022-05-05_012619_ardx-20220331xexhibit991","form":"8-K","date":"2022-05-05","url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828022012619/ardx-20220331xexhibit991.htm"},{"code":"8K_2022-08-04_021051_ardx-20220630xexhibit991","form":"8-K","date":"2022-08-04","url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828022021051/ardx-20220630xexhibit991.htm"},{"code":"8K_2022-12-29_032662_ardx-20221227","form":"8-K","date":"2022-12-29","url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828022032662/ardx-20221227.htm"},{"code":"8K_2023-03-02_006039_ardx-20221231xexhibit991","form":"8-K","date":"2023-03-02","url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023006039/ardx-20221231xexhibit991.htm"},{"code":"10K_2026-02-19_000013_ardx-20251231","form":"10-K","date":"2026-02-19","url":"https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/ardx-20251231.htm"}],"ars_pharmaceuticals":[{"code":"8K_2023-09-20_237996_d556858d8k","form":"8-K","date":"2023-09-20","url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312523237996/d556858d8k.htm"},{"code":"8K_2023-09-25_241345_d557739dex991","form":"8-K","date":"2023-09-25","url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312523241345/d557739dex991.htm"},{"code":"8K_2023-11-09_061989_spry-ex99_1","form":"8-K","date":"2023-11-09","url":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023061989/spry-ex99_1.htm"},{"code":"8K_2024-03-21_034678_spry-ex99_1","form":"8-K","date":"2024-03-21","url":"https://www.sec.gov/Archives/edgar/data/1671858/000095017024034678/spry-ex99_1.htm"},{"code":"8K_2024-05-09_056934_spry-ex99_1","form":"8-K","date":"2024-05-09","url":"https://www.sec.gov/Archives/edgar/data/1671858/000095017024056934/spry-ex99_1.htm"},{"code":"8K_2024-08-06_091745_spry-ex99_1","form":"8-K","date":"2024-08-06","url":"https://www.sec.gov/Archives/edgar/data/1671858/000095017024091745/spry-ex99_1.htm"},{"code":"10K_2026-03-09_097478_spry-20251231","form":"10-K","date":"2026-03-09","url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/spry-20251231.htm"}],"ascendis_pharma_bone_diseases_a_s":[{"code":"6K_2023-05-01_128873_d469859d6k","form":"6-K","date":"2023-05-01","url":"https://www.sec.gov/Archives/edgar/data/1612042/000119312523128873/d469859d6k.htm"},{"code":"6K_2023-09-05_046393_asnd-20230630","form":"6-K","date":"2023-09-05","url":"https://www.sec.gov/Archives/edgar/data/1612042/000095017023046393/asnd-20230630.htm"},{"code":"6K_2023-11-07_060212_asnd-20230930","form":"6-K","date":"2023-11-07","url":"https://www.sec.gov/Archives/edgar/data/1612042/000095017023060212/asnd-20230930.htm"},{"code":"6K_2024-05-02_129343_d802163dex992","form":"6-K","date":"2024-05-02","url":"https://www.sec.gov/Archives/edgar/data/1612042/000119312524129343/d802163dex992.htm"},{"code":"6K_2024-05-02_052182_asnd-20240331","form":"6-K","date":"2024-05-02","url":"https://www.sec.gov/Archives/edgar/data/1612042/000095017024052182/asnd-20240331.htm"},{"code":"20F_2026-02-11_046590_asnd-20251231","form":"20-F","date":"2026-02-11","url":"https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm"}],"astrazeneca":[{"code":"6K_2019-07-15_008237_a4976f","form":"6-K","date":"2019-07-15","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495419008237/a4976f.htm"},{"code":"6K_2019-07-25_041809_a19-12893_16k","form":"6-K","date":"2019-07-25","url":"https://www.sec.gov/Archives/edgar/data/901832/000110465919041809/a19-12893_16k.htm"},{"code":"6K_2019-10-01_011267_a2875o","form":"6-K","date":"2019-10-01","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495419011267/a2875o.htm"},{"code":"6K_2019-10-24_011972_a9391q1","form":"6-K","date":"2019-10-24","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495419011972/a9391q1.htm"},{"code":"6K_2020-04-29_004573_a2404l","form":"6-K","date":"2020-04-29","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495420004573/a2404l.htm"},{"code":"6K_2021-08-11_008747_a3440i","form":"6-K","date":"2021-08-11","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495421008747/a3440i.htm"},{"code":"6K_2021-11-12_012039_a1635s","form":"6-K","date":"2021-11-12","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495421012039/a1635s.htm"},{"code":"6K_2022-03-14_003071_a5906e","form":"6-K","date":"2022-03-14","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495422003071/a5906e.htm"},{"code":"6K_2022-04-29_005571_a7847j","form":"6-K","date":"2022-04-29","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495422005571/a7847j.htm"},{"code":"6K_2023-09-06_011565_a5429l","form":"6-K","date":"2023-09-06","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495423011565/a5429l.htm"},{"code":"6K_2026-02-03_000857_a4833r","form":"6-K","date":"2026-02-03","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426000857/a4833r.htm"},{"code":"6K_2026-02-10_001073_a3234s","form":"6-K","date":"2026-02-10","url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426001073/a3234s.htm"},{"code":"20F_2026-02-24_019130_azn-20251231x20f","form":"20-F","date":"2026-02-24","url":"https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm"}],"atara_biotherapeutics":[{"code":"8K_2025-01-16_006191_atra-ex99_1","form":"8-K","date":"2025-01-16","url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025006191/atra-ex99_1.htm"},{"code":"8K_2025-01-21_006992_atra-ex99_1","form":"8-K","date":"2025-01-21","url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025006992/atra-ex99_1.htm"},{"code":"8K_2025-03-07_035482_atra-ex99_1","form":"8-K","date":"2025-03-07","url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025035482/atra-ex99_1.htm"},{"code":"8K_2025-05-06_113811_d905721dex991","form":"8-K","date":"2025-05-06","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312525113811/d905721dex991.htm"},{"code":"8K_2025-05-06_113811_d905721d8k","form":"8-K","date":"2025-05-06","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312525113811/d905721d8k.htm"},{"code":"8K_2025-05-15_120345_d106735dex991","form":"8-K","date":"2025-05-15","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/d106735dex991.htm"},{"code":"8K_2025-07-14_158719_d63996dex991","form":"8-K","date":"2025-07-14","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312525158719/d63996dex991.htm"},{"code":"8K_2026-01-12_010342_d34257dex991","form":"8-K","date":"2026-01-12","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/d34257dex991.htm"},{"code":"8K_2026-01-12_010342_d34257d8k","form":"8-K","date":"2026-01-12","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/d34257d8k.htm"},{"code":"8K_2026-03-03_086793_d121575dex991","form":"8-K","date":"2026-03-03","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526086793/d121575dex991.htm"},{"code":"8K_2026-03-03_086793_d121575d8k","form":"8-K","date":"2026-03-03","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526086793/d121575d8k.htm"},{"code":"8K_2026-03-12_103127_atra-20260312","form":"8-K","date":"2026-03-12","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526103127/atra-20260312.htm"},{"code":"8K_2026-03-16_108344_atra-ex99_1","form":"8-K","date":"2026-03-16","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/atra-ex99_1.htm"},{"code":"10K_2026-03-16_108361_atra-20251231","form":"10-K","date":"2026-03-16","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/atra-20251231.htm"},{"code":"8K_2026-05-07_210413_atra-ex99_1","form":"8-K","date":"2026-05-07","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526210413/atra-ex99_1.htm"},{"code":"8K_2026-05-07_210413_atra-20260507","form":"8-K","date":"2026-05-07","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526210413/atra-20260507.htm"},{"code":"8K_2026-05-12_219420_atra-ex99_1","form":"8-K","date":"2026-05-12","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526219420/atra-ex99_1.htm"},{"code":"8K_2026-08-12_346857_atra-ex99_1","form":"8-K","date":"2026-08-12","url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526346857/atra-ex99_1.htm"}],"biogen":[{"code":"10K_2026-02-06_000013_biib-20251231","form":"10-K","date":"2026-02-06","url":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm"}],"biohaven_therapeutics":[{"code":"10K_2026-03-02_000020_bhvn-20251231","form":"10-K","date":"2026-03-02","url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000020/bhvn-20251231.htm"}],"bristol_myers_squibb":[{"code":"8K_2012-01-26_024350_d286943dex991","form":"8-K","date":"2012-01-26","url":"https://www.sec.gov/Archives/edgar/data/14272/000119312512024350/d286943dex991.htm"},{"code":"8K_2012-04-26_183924_d339268dex991","form":"8-K","date":"2012-04-26","url":"https://www.sec.gov/Archives/edgar/data/14272/000119312512183924/d339268dex991.htm"},{"code":"8K_2012-07-25_313402_d383218dex991","form":"8-K","date":"2012-07-25","url":"https://www.sec.gov/Archives/edgar/data/14272/000119312512313402/d383218dex991.htm"},{"code":"8K_2015-01-27_000020_q42014ex991","form":"8-K","date":"2015-01-27","url":"https://www.sec.gov/Archives/edgar/data/14272/000001427215000020/q42014ex991.htm"},{"code":"8K_2016-01-28_000260_q42015ex991","form":"8-K","date":"2016-01-28","url":"https://www.sec.gov/Archives/edgar/data/14272/000001427216000260/q42015ex991.htm"},{"code":"10K_2026-02-11_000004_bmy-20251231","form":"10-K","date":"2026-02-11","url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm"}],"capricor":[{"code":"8K_2025-07-11_009186_capr-20250711xex99d1","form":"8-K","date":"2025-07-11","url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837025009186/capr-20250711xex99d1.htm"},{"code":"8K_2025-07-11_009186_capr-20250711x8k","form":"8-K","date":"2025-07-11","url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837025009186/capr-20250711x8k.htm"},{"code":"8K_2025-08-11_011047_capr-20250811xex99d1","form":"8-K","date":"2025-08-11","url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/capr-20250811xex99d1.htm"},{"code":"8K_2025-11-10_109119_capr-20251110xex99d1","form":"8-K","date":"2025-11-10","url":"https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/capr-20251110xex99d1.htm"},{"code":"8K_2025-12-03_117981_capr-20251203xex99d1","form":"8-K","date":"2025-12-03","url":"https://www.sec.gov/Archives/edgar/data/1133869/000110465925117981/capr-20251203xex99d1.htm"},{"code":"8K_2025-12-03_117947_capr-20251203xex99d1","form":"8-K","date":"2025-12-03","url":"https://www.sec.gov/Archives/edgar/data/1133869/000110465925117947/capr-20251203xex99d1.htm"},{"code":"8K_2026-03-10_025657_capr-20260310xex99d1","form":"8-K","date":"2026-03-10","url":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310xex99d1.htm"},{"code":"8K_2026-03-10_025657_capr-20260310x8k","form":"8-K","date":"2026-03-10","url":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310x8k.htm"},{"code":"8K_2026-03-12_027037_capr-20260312xex99d1","form":"8-K","date":"2026-03-12","url":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926027037/capr-20260312xex99d1.htm"},{"code":"10K_2026-03-17_029580_capr-20251231x10k","form":"10-K","date":"2026-03-17","url":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm"},{"code":"8K_2026-05-07_057221_capr-20260507xex99d2","form":"8-K","date":"2026-05-07","url":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926057221/capr-20260507xex99d2.htm"}],"cingulate_therapeutics":[{"code":"8K_2025-11-10_021410_form8-k","form":"8-K","date":"2025-11-10","url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315225021410/form8-k.htm"},{"code":"10K_2026-03-18_010882_form10-k","form":"10-K","date":"2026-03-18","url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226010882/form10-k.htm"},{"code":"8K_2026-06-02_026760_form8-k","form":"8-K","date":"2026-06-02","url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/form8-k.htm"},{"code":"8K_2026-06-02_026760_ex99-1","form":"8-K","date":"2026-06-02","url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/ex99-1.htm"},{"code":"8K_2026-08-13_037605_ex99-1","form":"8-K","date":"2026-08-13","url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226037605/ex99-1.htm"}],"citius_pharmaceuticals":[{"code":"8K_2023-07-31_061292_ea182624-8kex99i_citius","form":"8-K","date":"2023-07-31","url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023061292/ea182624-8kex99i_citius.htm"},{"code":"8K_2023-07-31_061292_ea182624-8k_citius","form":"8-K","date":"2023-07-31","url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023061292/ea182624-8k_citius.htm"},{"code":"8K_2023-08-15_067474_ea183558ex99-1_citius","form":"8-K","date":"2023-08-15","url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023067474/ea183558ex99-1_citius.htm"},{"code":"8K_2023-09-08_075179_ea184839-8kex99i_citius","form":"8-K","date":"2023-09-08","url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023075179/ea184839-8kex99i_citius.htm"},{"code":"8K_2023-09-08_075179_ea184839-8k_citius","form":"8-K","date":"2023-09-08","url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023075179/ea184839-8k_citius.htm"},{"code":"8K_2023-09-11_075610_ea184925ex99-1_citius","form":"8-K","date":"2023-09-11","url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023075610/ea184925ex99-1_citius.htm"},{"code":"8K_2023-10-24_006005_ea186984ex99-2_citius","form":"8-K","date":"2023-10-24","url":"https://www.sec.gov/Archives/edgar/data/1506251/000101376223006005/ea186984ex99-2_citius.htm"},{"code":"8K_2023-10-24_006005_ea186984ex99-1_citius","form":"8-K","date":"2023-10-24","url":"https://www.sec.gov/Archives/edgar/data/1506251/000101376223006005/ea186984ex99-1_citius.htm"},{"code":"8K_2023-10-24_006005_ea186984ex2-1_citius","form":"8-K","date":"2023-10-24","url":"https://www.sec.gov/Archives/edgar/data/1506251/000101376223006005/ea186984ex2-1_citius.htm"},{"code":"8K_2023-10-24_006005_ea186984-8k425_citius","form":"8-K","date":"2023-10-24","url":"https://www.sec.gov/Archives/edgar/data/1506251/000101376223006005/ea186984-8k425_citius.htm"},{"code":"8K_2024-01-02_000247_ea190916ex99-1_citius","form":"8-K","date":"2024-01-02","url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024000247/ea190916ex99-1_citius.htm"},{"code":"8K_2024-02-14_013676_ea193588ex99-1_citus","form":"8-K","date":"2024-02-14","url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024013676/ea193588ex99-1_citus.htm"},{"code":"8K_2024-03-18_023483_ea0202010ex99-1_citius","form":"8-K","date":"2024-03-18","url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024023483/ea0202010ex99-1_citius.htm"},{"code":"10K_2025-12-23_125333_ea0270098-10k_citius","form":"10-K","date":"2025-12-23","url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025125333/ea0270098-10k_citius.htm"}],"corcept_therapeutics":[{"code":"8K_2025-12-31_338184_d50993dex991","form":"8-K","date":"2025-12-31","url":"https://www.sec.gov/Archives/edgar/data/1088856/000119312525338184/d50993dex991.htm"},{"code":"8K_2025-12-31_338184_d50993d8k","form":"8-K","date":"2025-12-31","url":"https://www.sec.gov/Archives/edgar/data/1088856/000119312525338184/d50993d8k.htm"},{"code":"8K_2026-02-24_011080_cort022426ex991pressrelease","form":"8-K","date":"2026-02-24","url":"https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort022426ex991pressrelease.htm"},{"code":"10K_2026-02-24_011091_cort-20251231","form":"10-K","date":"2026-02-24","url":"https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/cort-20251231.htm"}],"cormedix":[{"code":"8K_2021-03-01_012383_ea136714ex99-1_cormedix","form":"8-K","date":"2021-03-01","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390021012383/ea136714ex99-1_cormedix.htm"},{"code":"8K_2021-03-01_012383_ea136714-8k_cormedix","form":"8-K","date":"2021-03-01","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390021012383/ea136714-8k_cormedix.htm"},{"code":"8K_2021-04-15_021646_ea139526ex99-1_cormedix","form":"8-K","date":"2021-04-15","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390021021646/ea139526ex99-1_cormedix.htm"},{"code":"8K_2021-04-15_021646_ea139526-8k_cormedix","form":"8-K","date":"2021-04-15","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390021021646/ea139526-8k_cormedix.htm"},{"code":"8K_2021-05-14_026172_ea140743ex99-1_cormedix","form":"8-K","date":"2021-05-14","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390021026172/ea140743ex99-1_cormedix.htm"},{"code":"8K_2021-05-14_026169_ea140818ex99-1_cormedix","form":"8-K","date":"2021-05-14","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390021026169/ea140818ex99-1_cormedix.htm"},{"code":"8K_2021-08-12_042053_ea145524ex99-1_cormedix","form":"8-K","date":"2021-08-12","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390021042053/ea145524ex99-1_cormedix.htm"},{"code":"8K_2021-09-07_046789_ea146989ex99-1_cormedixinc","form":"8-K","date":"2021-09-07","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390021046789/ea146989ex99-1_cormedixinc.htm"},{"code":"8K_2021-11-09_057729_ea150219ex99-1_cormedix","form":"8-K","date":"2021-11-09","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390021057729/ea150219ex99-1_cormedix.htm"},{"code":"8K_2022-02-28_009595_ea156242ex99-2_cormedix","form":"8-K","date":"2022-02-28","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022009595/ea156242ex99-2_cormedix.htm"},{"code":"8K_2022-02-28_009595_ea156242ex99-1_cormedix","form":"8-K","date":"2022-02-28","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022009595/ea156242ex99-1_cormedix.htm"},{"code":"8K_2022-02-28_009595_ea156242-8k_cormedix","form":"8-K","date":"2022-02-28","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022009595/ea156242-8k_cormedix.htm"},{"code":"8K_2022-03-21_013742_ea157150ex99-1_cormedix","form":"8-K","date":"2022-03-21","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022013742/ea157150ex99-1_cormedix.htm"},{"code":"8K_2022-03-28_015306_ea157456ex99-1_cormedix","form":"8-K","date":"2022-03-28","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022015306/ea157456ex99-1_cormedix.htm"},{"code":"8K_2022-03-29_015837_ea157558ex99-1_cormedix","form":"8-K","date":"2022-03-29","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022015837/ea157558ex99-1_cormedix.htm"},{"code":"8K_2022-05-12_025946_ea159840ex99-2_cormedix","form":"8-K","date":"2022-05-12","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022025946/ea159840ex99-2_cormedix.htm"},{"code":"8K_2022-05-12_025946_ea159840ex99-1_cormedix","form":"8-K","date":"2022-05-12","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022025946/ea159840ex99-1_cormedix.htm"},{"code":"8K_2022-08-09_045631_ea164023ex99-1_cormedix","form":"8-K","date":"2022-08-09","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022045631/ea164023ex99-1_cormedix.htm"},{"code":"8K_2022-08-09_045631_ea164023-8k_cormedix","form":"8-K","date":"2022-08-09","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022045631/ea164023-8k_cormedix.htm"},{"code":"8K_2022-08-11_046610_ea164139ex99-1_cormedixinc","form":"8-K","date":"2022-08-11","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022046610/ea164139ex99-1_cormedixinc.htm"},{"code":"8K_2022-11-10_070820_ea168353ex99-1_cormedix","form":"8-K","date":"2022-11-10","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022070820/ea168353ex99-1_cormedix.htm"},{"code":"8K_2023-03-03_016996_ea174602ex99-1_cormedix","form":"8-K","date":"2023-03-03","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023016996/ea174602ex99-1_cormedix.htm"},{"code":"8K_2023-03-30_024301_ea176049ex99-1_cormedix","form":"8-K","date":"2023-03-30","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023024301/ea176049ex99-1_cormedix.htm"},{"code":"8K_2023-04-17_030043_ea177005ex99-1_cormedix","form":"8-K","date":"2023-04-17","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023030043/ea177005ex99-1_cormedix.htm"},{"code":"8K_2023-04-26_032876_ea177512ex99-1_cormedix","form":"8-K","date":"2023-04-26","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023032876/ea177512ex99-1_cormedix.htm"},{"code":"8K_2023-05-15_039770_ea178530ex99-1_cormedix","form":"8-K","date":"2023-05-15","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023039770/ea178530ex99-1_cormedix.htm"},{"code":"8K_2023-05-16_040128_ea178697ex99-1_cormedix","form":"8-K","date":"2023-05-16","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023040128/ea178697ex99-1_cormedix.htm"},{"code":"8K_2023-06-21_050240_ea180659ex99-1_cormedix","form":"8-K","date":"2023-06-21","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023050240/ea180659ex99-1_cormedix.htm"},{"code":"8K_2023-06-30_053572_ea181153ex99-2_cormedix","form":"8-K","date":"2023-06-30","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023053572/ea181153ex99-2_cormedix.htm"},{"code":"8K_2023-06-30_053572_ea181153ex99-1_cormedix","form":"8-K","date":"2023-06-30","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023053572/ea181153ex99-1_cormedix.htm"},{"code":"8K_2023-08-08_064241_ea183017ex99-1_cormedix","form":"8-K","date":"2023-08-08","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023064241/ea183017ex99-1_cormedix.htm"},{"code":"8K_2023-11-14_086937_ea188304ex99-1_cormedix","form":"8-K","date":"2023-11-14","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023086937/ea188304ex99-1_cormedix.htm"},{"code":"10K_2026-03-05_023889_ea0278169-10k_cormedix","form":"10-K","date":"2026-03-05","url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/ea0278169-10k_cormedix.htm"},{"code":"8K_2026-08-07_000044_crmd-8xkxaugust72026xex992","form":"8-K","date":"2026-08-07","url":"https://www.sec.gov/Archives/edgar/data/1410098/000141009826000044/crmd-8xkxaugust72026xex992.htm"},{"code":"8K_2026-08-07_000044_crmd-8xkxaugust72026xex991","form":"8-K","date":"2026-08-07","url":"https://www.sec.gov/Archives/edgar/data/1410098/000141009826000044/crmd-8xkxaugust72026xex991.htm"}],"dbv_technologies":[{"code":"6K_2020-08-04_209288_d11849d6k","form":"6-K","date":"2020-08-04","url":"https://www.sec.gov/Archives/edgar/data/1613780/000119312520209288/d11849d6k.htm"},{"code":"6K_2020-09-09_242192_d21962dex991","form":"6-K","date":"2020-09-09","url":"https://www.sec.gov/Archives/edgar/data/1613780/000119312520242192/d21962dex991.htm"},{"code":"6K_2020-11-02_283937_d25083d6k","form":"6-K","date":"2020-11-02","url":"https://www.sec.gov/Archives/edgar/data/1613780/000119312520283937/d25083d6k.htm"},{"code":"8K_2021-01-14_009145_d110952dex991","form":"8-K","date":"2021-01-14","url":"https://www.sec.gov/Archives/edgar/data/1613780/000119312521009145/d110952dex991.htm"},{"code":"8K_2021-01-14_009145_d110952d8k","form":"8-K","date":"2021-01-14","url":"https://www.sec.gov/Archives/edgar/data/1613780/000119312521009145/d110952d8k.htm"},{"code":"8K_2022-09-08_240203_d401883dex991","form":"8-K","date":"2022-09-08","url":"https://www.sec.gov/Archives/edgar/data/1613780/000119312522240203/d401883dex991.htm"},{"code":"10K_2026-03-26_021504_dbvt-20251231","form":"10-K","date":"2026-03-26","url":"https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/dbvt-20251231.htm"}],"delcath_systems":[{"code":"8K_2013-09-13_000920_form8k","form":"8-K","date":"2013-09-13","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100413000920/form8k.htm"},{"code":"8K_2013-09-13_000920_ex99-1","form":"8-K","date":"2013-09-13","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100413000920/ex99-1.htm"},{"code":"8K_2013-09-16_367944_d598759dex991","form":"8-K","date":"2013-09-16","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312513367944/d598759dex991.htm"},{"code":"8K_2013-10-08_394136_d609859dex991","form":"8-K","date":"2013-10-08","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312513394136/d609859dex991.htm"},{"code":"8K_2013-10-17_001075_exhibit","form":"8-K","date":"2013-10-17","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100413001075/exhibit.htm"},{"code":"8K_2013-10-28_413435_d616533dex991","form":"8-K","date":"2013-10-28","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312513413435/d616533dex991.htm"},{"code":"8K_2013-11-07_001160_exh99_1","form":"8-K","date":"2013-11-07","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100413001160/exh99_1.htm"},{"code":"8K_2013-11-12_001174_ex99_1","form":"8-K","date":"2013-11-12","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100413001174/ex99_1.htm"},{"code":"8K_2014-01-13_000022_ex99_1","form":"8-K","date":"2014-01-13","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100414000022/ex99_1.htm"},{"code":"8K_2014-03-13_000202_ex99_1","form":"8-K","date":"2014-03-13","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100414000202/ex99_1.htm"},{"code":"8K_2014-05-08_000393_ex99-1","form":"8-K","date":"2014-05-08","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100414000393/ex99-1.htm"},{"code":"8K_2014-08-07_000677_ex99_1","form":"8-K","date":"2014-08-07","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100414000677/ex99_1.htm"},{"code":"8K_2014-09-15_341828_d789276dex991","form":"8-K","date":"2014-09-15","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312514341828/d789276dex991.htm"},{"code":"8K_2014-11-06_000968_ex99-1","form":"8-K","date":"2014-11-06","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100414000968/ex99-1.htm"},{"code":"8K_2014-11-10_000980_ex99-1","form":"8-K","date":"2014-11-10","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100414000980/ex99-1.htm"},{"code":"8K_2014-11-18_000999_ex99-1","form":"8-K","date":"2014-11-18","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100414000999/ex99-1.htm"},{"code":"8K_2014-12-15_442643_d838196dex991","form":"8-K","date":"2014-12-15","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312514442643/d838196dex991.htm"},{"code":"8K_2015-01-12_000024_ex99-1","form":"8-K","date":"2015-01-12","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100415000024/ex99-1.htm"},{"code":"8K_2015-02-02_029808_d863028dex991","form":"8-K","date":"2015-02-02","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312515029808/d863028dex991.htm"},{"code":"8K_2015-02-17_050847_d874668dex991","form":"8-K","date":"2015-02-17","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312515050847/d874668dex991.htm"},{"code":"8K_2015-03-10_000206_ex99_1","form":"8-K","date":"2015-03-10","url":"https://www.sec.gov/Archives/edgar/data/872912/000134100415000206/ex99_1.htm"},{"code":"8K_2015-03-11_087342_d888163dex991","form":"8-K","date":"2015-03-11","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312515087342/d888163dex991.htm"},{"code":"8K_2015-04-14_127768_d910054dex991","form":"8-K","date":"2015-04-14","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312515127768/d910054dex991.htm"},{"code":"8K_2015-05-26_200205_d932775dex991","form":"8-K","date":"2015-05-26","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312515200205/d932775dex991.htm"},{"code":"8K_2015-06-10_218820_d940735dex991","form":"8-K","date":"2015-06-10","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312515218820/d940735dex991.htm"},{"code":"8K_2015-09-03_311923_d60387dex991","form":"8-K","date":"2015-09-03","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312515311923/d60387dex991.htm"},{"code":"8K_2015-10-06_338497_d87807dex991","form":"8-K","date":"2015-10-06","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312515338497/d87807dex991.htm"},{"code":"8K_2015-10-09_341406_d19725dex991","form":"8-K","date":"2015-10-09","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312515341406/d19725dex991.htm"},{"code":"8K_2016-01-22_435708_d127150dex991","form":"8-K","date":"2016-01-22","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312516435708/d127150dex991.htm"},{"code":"8K_2016-03-23_515093_d168897dex991","form":"8-K","date":"2016-03-23","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312516515093/d168897dex991.htm"},{"code":"8K_2016-06-07_614729_d198915dex991","form":"8-K","date":"2016-06-07","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312516614729/d198915dex991.htm"},{"code":"8K_2016-10-04_729979_d213700dex991","form":"8-K","date":"2016-10-04","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312516729979/d213700dex991.htm"},{"code":"8K_2016-10-18_740821_d287190dex991","form":"8-K","date":"2016-10-18","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312516740821/d287190dex991.htm"},{"code":"8K_2017-01-30_023046_d338002dex991","form":"8-K","date":"2017-01-30","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312517023046/d338002dex991.htm"},{"code":"8K_2017-02-15_044509_d257646dex991","form":"8-K","date":"2017-02-15","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312517044509/d257646dex991.htm"},{"code":"8K_2017-03-09_076858_d238515dex991","form":"8-K","date":"2017-03-09","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312517076858/d238515dex991.htm"},{"code":"8K_2017-06-05_194811_d407690dex991","form":"8-K","date":"2017-06-05","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312517194811/d407690dex991.htm"},{"code":"8K_2018-03-13_080053_d470730dex991","form":"8-K","date":"2018-03-13","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312518080053/d470730dex991.htm"},{"code":"8K_2019-02-11_033070_d678642dex991","form":"8-K","date":"2019-02-11","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312519033070/d678642dex991.htm"},{"code":"8K_2021-08-11_243492_d179551dex101","form":"8-K","date":"2021-08-11","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312521243492/d179551dex101.htm"},{"code":"8K_2021-12-02_346036_d135126dex991","form":"8-K","date":"2021-12-02","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312521346036/d135126dex991.htm"},{"code":"8K_2022-06-07_168620_d307192dex991","form":"8-K","date":"2022-06-07","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312522168620/d307192dex991.htm"},{"code":"8K_2022-09-12_242346_d385250dex991","form":"8-K","date":"2022-09-12","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312522242346/d385250dex991.htm"},{"code":"8K_2023-01-03_000761_d423418dex991","form":"8-K","date":"2023-01-03","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312523000761/d423418dex991.htm"},{"code":"8K_2023-02-14_037853_d455550dex991","form":"8-K","date":"2023-02-14","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312523037853/d455550dex991.htm"},{"code":"8K_2023-02-14_037853_d455550d8k","form":"8-K","date":"2023-02-14","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312523037853/d455550d8k.htm"},{"code":"8K_2023-03-28_080977_d422467dex991","form":"8-K","date":"2023-03-28","url":"https://www.sec.gov/Archives/edgar/data/872912/000119312523080977/d422467dex991.htm"},{"code":"10K_2026-02-26_012019_dcth-20251231","form":"10-K","date":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/872912/000162828026012019/dcth-20251231.htm"}],"disc_medicine":[{"code":"8K_2026-02-13_051504_iron-ex99_1","form":"8-K","date":"2026-02-13","url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526051504/iron-ex99_1.htm"},{"code":"8K_2026-02-13_051504_iron-20260213","form":"8-K","date":"2026-02-13","url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526051504/iron-20260213.htm"},{"code":"8K_2026-02-17_053066_iron-ex99_1","form":"8-K","date":"2026-02-17","url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526053066/iron-ex99_1.htm"},{"code":"8K_2026-02-17_053066_iron-20260217","form":"8-K","date":"2026-02-17","url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526053066/iron-20260217.htm"},{"code":"8K_2026-02-26_073594_iron-ex99_1","form":"8-K","date":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526073594/iron-ex99_1.htm"},{"code":"10K_2026-02-26_073602_iron-20251231","form":"10-K","date":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm"},{"code":"8K_2026-02-27_082855_iron-20260226","form":"8-K","date":"2026-02-27","url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526082855/iron-20260226.htm"}],"dr_reddys_laboratories":[{"code":"6K_2024-04-22_000380_drr0591_ex99-1","form":"6-K","date":"2024-04-22","url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587224000380/drr0591_ex99-1.htm"},{"code":"6K_2024-05-07_000496_drr0598_ex99-2","form":"6-K","date":"2024-05-07","url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587224000496/drr0598_ex99-2.htm"},{"code":"6K_2024-05-13_000524_drr0602_ex99-1","form":"6-K","date":"2024-05-13","url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587224000524/drr0602_ex99-1.htm"},{"code":"6K_2025-10-31_000655_rdy0817_ex99-1","form":"6-K","date":"2025-10-31","url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587225000655/rdy0817_ex99-1.htm"},{"code":"6K_2025-12-31_000775_rdy0835_ex99-1","form":"6-K","date":"2025-12-31","url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587225000775/rdy0835_ex99-1.htm"},{"code":"6K_2026-01-21_000034_rdy0840_ex99-1","form":"6-K","date":"2026-01-21","url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000034/rdy0840_ex99-1.htm"},{"code":"6K_2026-01-28_000045_rdy0845_ex99-1","form":"6-K","date":"2026-01-28","url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000045/rdy0845_ex99-1.htm"},{"code":"20F_2026-05-29_000381_rdy0899_20f","form":"20-F","date":"2026-05-29","url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000381/rdy0899_20f.htm"}],"eli_lilly":[{"code":"8K_2021-10-26_000213_q321lillysalesandearningsp","form":"8-K","date":"2021-10-26","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947821000213/q321lillysalesandearningsp.htm"},{"code":"8K_2022-02-03_000016_q421lillysalesandearningsp","form":"8-K","date":"2022-02-03","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000016/q421lillysalesandearningsp.htm"},{"code":"8K_2022-04-28_000130_q122lillysalesandearningsp","form":"8-K","date":"2022-04-28","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000130/q122lillysalesandearningsp.htm"},{"code":"8K_2023-02-02_000025_q422lillysalesandearningsp","form":"8-K","date":"2023-02-02","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000025/q422lillysalesandearningsp.htm"},{"code":"8K_2023-04-27_000160_q123lillysalesandearningsp","form":"8-K","date":"2023-04-27","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000160/q123lillysalesandearningsp.htm"},{"code":"8K_2023-11-02_000282_q323lillysalesandearningsp","form":"8-K","date":"2023-11-02","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000282/q323lillysalesandearningsp.htm"},{"code":"10K_2026-02-12_000013_lly-20251231","form":"10-K","date":"2026-02-12","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm"}],"evofem":[{"code":"8K_2018-01-17_012234_d460573d8k","form":"8-K","date":"2018-01-17","url":"https://www.sec.gov/Archives/edgar/data/1618835/000119312518012234/d460573d8k.htm"},{"code":"8K_2018-02-20_050372_d542933dex991","form":"8-K","date":"2018-02-20","url":"https://www.sec.gov/Archives/edgar/data/1618835/000119312518050372/d542933dex991.htm"},{"code":"8K_2019-11-26_000192_exhibit991pressreleasendar","form":"8-K","date":"2019-11-26","url":"https://www.sec.gov/Archives/edgar/data/1618835/000161883519000192/exhibit991pressreleasendar.htm"},{"code":"10K_2026-03-11_009686_form10-k","form":"10-K","date":"2026-03-11","url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/form10-k.htm"}],"evolus":[{"code":"8K_2018-05-16_000040_eolsex991release","form":"8-K","date":"2018-05-16","url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056218000040/eolsex991release.htm"},{"code":"8K_2018-05-16_000040_eols8k51618","form":"8-K","date":"2018-05-16","url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056218000040/eols8k51618.htm"},{"code":"8K_2018-08-02_000096_q218eolsex992","form":"8-K","date":"2018-08-02","url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056218000096/q218eolsex992.htm"},{"code":"10K_2026-03-03_014001_eols-20251231","form":"10-K","date":"2026-03-03","url":"https://www.sec.gov/Archives/edgar/data/1570562/000162828026014001/eols-20251231.htm"}],"fennec_pharmaceuticals":[{"code":"8K_2020-08-11_093089_tm2027233d1_ex99-1","form":"8-K","date":"2020-08-11","url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465920093089/tm2027233d1_ex99-1.htm"},{"code":"8K_2020-08-11_093089_tm2027233d1_8k","form":"8-K","date":"2020-08-11","url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465920093089/tm2027233d1_8k.htm"},{"code":"8K_2021-05-28_073756_tm2117934d1_ex99-1","form":"8-K","date":"2021-05-28","url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465921073756/tm2117934d1_ex99-1.htm"},{"code":"8K_2021-06-22_083941_tm2120370d1_ex99-1","form":"8-K","date":"2021-06-22","url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465921083941/tm2120370d1_ex99-1.htm"},{"code":"8K_2021-11-29_144174_tm2134077d1_ex99-1","form":"8-K","date":"2021-11-29","url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465921144174/tm2134077d1_ex99-1.htm"},{"code":"8K_2021-11-30_144897_tm2134244d1_ex99-1","form":"8-K","date":"2021-11-30","url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465921144897/tm2134244d1_ex99-1.htm"},{"code":"8K_2021-11-30_144897_tm2134244d1_8k","form":"8-K","date":"2021-11-30","url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465921144897/tm2134244d1_8k.htm"},{"code":"10K_2026-03-27_036182_fencf-20251231x10k","form":"10-K","date":"2026-03-27","url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/fencf-20251231x10k.htm"}],"gilead_sciences":[{"code":"8K_2022-04-28_000010_exhibit991earningspressrel","form":"8-K","date":"2022-04-28","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000010/exhibit991earningspressrel.htm"},{"code":"10K_2026-02-24_000006_gild-20251231","form":"10-K","date":"2026-02-24","url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm"}],"grace_therapeutics_us":[{"code":"8K_2026-04-23_016324_ef20070593_ex99-1","form":"8-K","date":"2026-04-23","url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126016324/ef20070593_ex99-1.htm"},{"code":"8K_2026-04-23_016324_ef20070593_8k","form":"8-K","date":"2026-04-23","url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126016324/ef20070593_8k.htm"},{"code":"8K_2026-04-27_016834_ef20071554_ex99-1","form":"8-K","date":"2026-04-27","url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126016834/ef20071554_ex99-1.htm"},{"code":"8K_2026-06-18_025669_ef20076431_ex99-1","form":"8-K","date":"2026-06-18","url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126025669/ef20076431_ex99-1.htm"},{"code":"8K_2026-06-18_025667_ef20076145_ex99-1","form":"8-K","date":"2026-06-18","url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/ef20076145_ex99-1.htm"},{"code":"10K_2026-06-18_025662_ef20070498_10k","form":"10-K","date":"2026-06-18","url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126025662/ef20070498_10k.htm"},{"code":"8K_2026-07-28_029837_ef20078866_ex99-2","form":"8-K","date":"2026-07-28","url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126029837/ef20078866_ex99-2.htm"},{"code":"8K_2026-07-28_029837_ef20078866_ex99-1","form":"8-K","date":"2026-07-28","url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126029837/ef20078866_ex99-1.htm"},{"code":"8K_2026-07-28_029837_ef20078866_8k","form":"8-K","date":"2026-07-28","url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126029837/ef20078866_8k.htm"},{"code":"8K_2026-08-06_031671_ef20079559_ex99-1","form":"8-K","date":"2026-08-06","url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126031671/ef20079559_ex99-1.htm"},{"code":"8K_2026-08-13_032644_ef20079525_ex99-1","form":"8-K","date":"2026-08-13","url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126032644/ef20079525_ex99-1.htm"}],"heron_therapeutics":[{"code":"8K_2019-05-01_130962_d739627dex991","form":"8-K","date":"2019-05-01","url":"https://www.sec.gov/Archives/edgar/data/818033/000119312519130962/d739627dex991.htm"},{"code":"8K_2019-05-01_130962_d739627d8k","form":"8-K","date":"2019-05-01","url":"https://www.sec.gov/Archives/edgar/data/818033/000119312519130962/d739627d8k.htm"},{"code":"8K_2019-05-09_142329_d739275dex991","form":"8-K","date":"2019-05-09","url":"https://www.sec.gov/Archives/edgar/data/818033/000119312519142329/d739275dex991.htm"},{"code":"8K_2019-05-14_146046_d718016dex991","form":"8-K","date":"2019-05-14","url":"https://www.sec.gov/Archives/edgar/data/818033/000119312519146046/d718016dex991.htm"},{"code":"8K_2019-05-21_152334_d752659dex991","form":"8-K","date":"2019-05-21","url":"https://www.sec.gov/Archives/edgar/data/818033/000119312519152334/d752659dex991.htm"},{"code":"8K_2019-08-05_028536_hrtx-ex991_6","form":"8-K","date":"2019-08-05","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459019028536/hrtx-ex991_6.htm"},{"code":"8K_2019-08-20_032608_hrtx-ex991_48","form":"8-K","date":"2019-08-20","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459019032608/hrtx-ex991_48.htm"},{"code":"8K_2019-10-01_036000_hrtx-ex991_6","form":"8-K","date":"2019-10-01","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459019036000/hrtx-ex991_6.htm"},{"code":"8K_2019-10-02_036139_hrtx-ex991_218","form":"8-K","date":"2019-10-02","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459019036139/hrtx-ex991_218.htm"},{"code":"8K_2019-10-28_038027_hrtx-ex991_6","form":"8-K","date":"2019-10-28","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459019038027/hrtx-ex991_6.htm"},{"code":"8K_2019-11-12_042630_hrtx-ex991_17","form":"8-K","date":"2019-11-12","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459019042630/hrtx-ex991_17.htm"},{"code":"8K_2019-12-03_045076_hrtx-ex991_6","form":"8-K","date":"2019-12-03","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459019045076/hrtx-ex991_6.htm"},{"code":"8K_2019-12-16_046060_hrtx-ex991_6","form":"8-K","date":"2019-12-16","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459019046060/hrtx-ex991_6.htm"},{"code":"8K_2020-01-13_000917_hrtx-ex991_6","form":"8-K","date":"2020-01-13","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020000917/hrtx-ex991_6.htm"},{"code":"8K_2020-02-19_005303_hrtx-ex991_6","form":"8-K","date":"2020-02-19","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020005303/hrtx-ex991_6.htm"},{"code":"8K_2020-03-02_007971_hrtx-ex991_6","form":"8-K","date":"2020-03-02","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020007971/hrtx-ex991_6.htm"},{"code":"8K_2020-05-06_021571_hrtx-ex991_6","form":"8-K","date":"2020-05-06","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020021571/hrtx-ex991_6.htm"},{"code":"8K_2020-05-18_025913_hrtx-ex991_16","form":"8-K","date":"2020-05-18","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020025913/hrtx-ex991_16.htm"},{"code":"8K_2020-06-04_028307_hrtx-ex991_15","form":"8-K","date":"2020-06-04","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020028307/hrtx-ex991_15.htm"},{"code":"8K_2020-06-29_031058_hrtx-ex991_41","form":"8-K","date":"2020-06-29","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020031058/hrtx-ex991_41.htm"},{"code":"8K_2020-06-29_031058_hrtx-8k_20200629","form":"8-K","date":"2020-06-29","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020031058/hrtx-8k_20200629.htm"},{"code":"8K_2020-07-24_033338_hrtx-ex991_16","form":"8-K","date":"2020-07-24","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020033338/hrtx-ex991_16.htm"},{"code":"8K_2020-08-05_036807_hrtx-ex991_6","form":"8-K","date":"2020-08-05","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020036807/hrtx-ex991_6.htm"},{"code":"8K_2020-09-08_042727_hrtx-ex991_6","form":"8-K","date":"2020-09-08","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020042727/hrtx-ex991_6.htm"},{"code":"8K_2020-09-16_043657_hrtx-ex991_6","form":"8-K","date":"2020-09-16","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020043657/hrtx-ex991_6.htm"},{"code":"8K_2020-09-28_044749_hrtx-ex991_6","form":"8-K","date":"2020-09-28","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020044749/hrtx-ex991_6.htm"},{"code":"8K_2020-11-05_050909_hrtx-ex991_6","form":"8-K","date":"2020-11-05","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020050909/hrtx-ex991_6.htm"},{"code":"8K_2020-11-13_053742_hrtx-ex991_6","form":"8-K","date":"2020-11-13","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459020053742/hrtx-ex991_6.htm"},{"code":"8K_2021-01-11_000771_hrtx-ex991_645","form":"8-K","date":"2021-01-11","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459021000771/hrtx-ex991_645.htm"},{"code":"8K_2021-01-21_001687_hrtx-ex991_6","form":"8-K","date":"2021-01-21","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459021001687/hrtx-ex991_6.htm"},{"code":"8K_2021-02-24_007839_hrtx-ex991_6","form":"8-K","date":"2021-02-24","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459021007839/hrtx-ex991_6.htm"},{"code":"8K_2021-05-10_025793_hrtx-ex991_6","form":"8-K","date":"2021-05-10","url":"https://www.sec.gov/Archives/edgar/data/818033/000156459021025793/hrtx-ex991_6.htm"},{"code":"10K_2026-02-26_073515_hrtx-20251231","form":"10-K","date":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/818033/000119312526073515/hrtx-20251231.htm"}],"kala_pharmaceuticals":[{"code":"8K_2019-08-08_044885_a19-16890_1ex99d1","form":"8-K","date":"2019-08-08","url":"https://www.sec.gov/Archives/edgar/data/1479419/000110465919044885/a19-16890_1ex99d1.htm"},{"code":"8K_2019-08-08_044885_a19-16890_18k","form":"8-K","date":"2019-08-08","url":"https://www.sec.gov/Archives/edgar/data/1479419/000110465919044885/a19-16890_18k.htm"},{"code":"8K_2019-11-07_010281_ex-99d1","form":"8-K","date":"2019-11-07","url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837019010281/ex-99d1.htm"},{"code":"8K_2020-02-12_000702_ex-99d1","form":"8-K","date":"2020-02-12","url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837020000702/ex-99d1.htm"},{"code":"8K_2020-05-26_006941_tmb-20200526x8k","form":"8-K","date":"2020-05-26","url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837020006941/tmb-20200526x8k.htm"},{"code":"8K_2020-08-06_009498_kala-20200806xex99d1","form":"8-K","date":"2020-08-06","url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837020009498/kala-20200806xex99d1.htm"},{"code":"10K_2026-04-15_043782_kala-20251231x10k","form":"10-K","date":"2026-04-15","url":"https://www.sec.gov/Archives/edgar/data/1479419/000110465926043782/kala-20251231x10k.htm"}],"lexicon_pharmaceuticals":[{"code":"8K_2025-03-06_000008_pressreleaseearningsq403-0","form":"8-K","date":"2025-03-06","url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282225000008/pressreleaseearningsq403-0.htm"},{"code":"10K_2026-03-05_000050_lxrx-20251231","form":"10-K","date":"2026-03-05","url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm"}],"mediwound":[{"code":"6K_2021-06-29_002169_zk2126242","form":"6-K","date":"2021-06-29","url":"https://www.sec.gov/Archives/edgar/data/1593984/000117891321002169/zk2126242.htm"},{"code":"6K_2021-06-29_002169_exhibit_99-1","form":"6-K","date":"2021-06-29","url":"https://www.sec.gov/Archives/edgar/data/1593984/000117891321002169/exhibit_99-1.htm"},{"code":"6K_2021-08-10_002628_exhibit_99-2","form":"6-K","date":"2021-08-10","url":"https://www.sec.gov/Archives/edgar/data/1593984/000117891321002628/exhibit_99-2.htm"},{"code":"6K_2021-08-10_002628_exhibit_99-1","form":"6-K","date":"2021-08-10","url":"https://www.sec.gov/Archives/edgar/data/1593984/000117891321002628/exhibit_99-1.htm"},{"code":"6K_2021-11-16_003600_exhibit_99-2","form":"6-K","date":"2021-11-16","url":"https://www.sec.gov/Archives/edgar/data/1593984/000117891321003600/exhibit_99-2.htm"},{"code":"6K_2022-05-17_002036_exhibit_99-2","form":"6-K","date":"2022-05-17","url":"https://www.sec.gov/Archives/edgar/data/1593984/000117891322002036/exhibit_99-2.htm"},{"code":"6K_2022-08-09_003004_exhibit_99-2","form":"6-K","date":"2022-08-09","url":"https://www.sec.gov/Archives/edgar/data/1593984/000117891322003004/exhibit_99-2.htm"},{"code":"6K_2022-11-09_003891_exhibit_99-2","form":"6-K","date":"2022-11-09","url":"https://www.sec.gov/Archives/edgar/data/1593984/000117891322003891/exhibit_99-2.htm"},{"code":"6K_2022-11-09_003891_exhibit_99-1","form":"6-K","date":"2022-11-09","url":"https://www.sec.gov/Archives/edgar/data/1593984/000117891322003891/exhibit_99-1.htm"},{"code":"6K_2022-11-15_004040_exhibit_99-2","form":"6-K","date":"2022-11-15","url":"https://www.sec.gov/Archives/edgar/data/1593984/000117891322004040/exhibit_99-2.htm"},{"code":"20F_2026-03-05_000749_zk2634458","form":"20-F","date":"2026-03-05","url":"https://www.sec.gov/Archives/edgar/data/1593984/000117891326000749/zk2634458.htm"}],"merck":[{"code":"8K_2013-07-30_057547_a13-17418_1ex99d1","form":"8-K","date":"2013-07-30","url":"https://www.sec.gov/Archives/edgar/data/310158/000110465913057547/a13-17418_1ex99d1.htm"},{"code":"8K_2013-10-28_078137_a13-22871_1ex99d1","form":"8-K","date":"2013-10-28","url":"https://www.sec.gov/Archives/edgar/data/310158/000110465913078137/a13-22871_1ex99d1.htm"},{"code":"8K_2014-07-29_054183_a14-17821_1ex99d1","form":"8-K","date":"2014-07-29","url":"https://www.sec.gov/Archives/edgar/data/310158/000110465914054183/a14-17821_1ex99d1.htm"},{"code":"8K_2015-04-28_030743_a15-9874_1ex99d1","form":"8-K","date":"2015-04-28","url":"https://www.sec.gov/Archives/edgar/data/310158/000110465915030743/a15-9874_1ex99d1.htm"},{"code":"8K_2020-07-31_088675_tm2026006d1_ex99-1","form":"8-K","date":"2020-07-31","url":"https://www.sec.gov/Archives/edgar/data/310158/000110465920088675/tm2026006d1_ex99-1.htm"},{"code":"8K_2021-04-29_056877_tm2114316d1_ex99-1","form":"8-K","date":"2021-04-29","url":"https://www.sec.gov/Archives/edgar/data/310158/000110465921056877/tm2114316d1_ex99-1.htm"},{"code":"8K_2022-02-03_011130_tm222755d1_ex99-1","form":"8-K","date":"2022-02-03","url":"https://www.sec.gov/Archives/edgar/data/310158/000110465922011130/tm222755d1_ex99-1.htm"},{"code":"8K_2024-07-30_083722_tm2420272d1_ex99-1","form":"8-K","date":"2024-07-30","url":"https://www.sec.gov/Archives/edgar/data/310158/000110465924083722/tm2420272d1_ex99-1.htm"},{"code":"10K_2026-02-24_000063_mrk-20251231","form":"10-K","date":"2026-02-24","url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm"}],"mesoblast":[{"code":"6K_2022-08-31_030578_meso-ex991_6","form":"6-K","date":"2022-08-31","url":"https://www.sec.gov/Archives/edgar/data/1345099/000156459022030578/meso-ex991_6.htm"},{"code":"6K_2022-10-05_033508_meso-ex991_6","form":"6-K","date":"2022-10-05","url":"https://www.sec.gov/Archives/edgar/data/1345099/000156459022033508/meso-ex991_6.htm"},{"code":"6K_2022-11-28_038383_meso-ex994_7","form":"6-K","date":"2022-11-28","url":"https://www.sec.gov/Archives/edgar/data/1345099/000156459022038383/meso-ex994_7.htm"},{"code":"6K_2022-11-28_038379_meso-6k_20220930","form":"6-K","date":"2022-11-28","url":"https://www.sec.gov/Archives/edgar/data/1345099/000156459022038379/meso-6k_20220930.htm"},{"code":"6K_2023-02-01_006741_ea172522ex99-2_mesoblast","form":"6-K","date":"2023-02-01","url":"https://www.sec.gov/Archives/edgar/data/1345099/000121390023006741/ea172522ex99-2_mesoblast.htm"},{"code":"6K_2023-02-28_000022_exhibit991q2halfyear","form":"6-K","date":"2023-02-28","url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509923000022/exhibit991q2halfyear.htm"},{"code":"6K_2023-02-28_000017_meso-20221231","form":"6-K","date":"2023-02-28","url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509923000017/meso-20221231.htm"},{"code":"6K_2023-05-03_000037_exhibit991-appendix4capril","form":"6-K","date":"2023-05-03","url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509923000037/exhibit991-appendix4capril.htm"},{"code":"6K_2023-05-26_000043_exhibit991-q3fy2023financi","form":"6-K","date":"2023-05-26","url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509923000043/exhibit991-q3fy2023financi.htm"},{"code":"6K_2023-05-26_000041_meso-20230331","form":"6-K","date":"2023-05-26","url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509923000041/meso-20230331.htm"},{"code":"6K_2024-02-29_000022_meso-20231231","form":"6-K","date":"2024-02-29","url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509924000022/meso-20231231.htm"},{"code":"6K_2024-08-01_000061_exhibit991","form":"6-K","date":"2024-08-01","url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509924000061/exhibit991.htm"},{"code":"6K_2024-08-29_000066_exhibit992","form":"6-K","date":"2024-08-29","url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509924000066/exhibit992.htm"},{"code":"6K_2024-08-29_000066_exhibit991","form":"6-K","date":"2024-08-29","url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509924000066/exhibit991.htm"},{"code":"6K_2024-10-18_000072_exhibit991","form":"6-K","date":"2024-10-18","url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509924000072/exhibit991.htm"},{"code":"6K_2025-10-28_000090_exhibit991annualreportno","form":"6-K","date":"2025-10-28","url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm"},{"code":"20F_2026-08-27_000081_meso-20260630","form":"20-F","date":"2026-08-27","url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509926000081/meso-20260630.htm"}],"milestone_pharmaceuticals_usa":[{"code":"8K_2025-03-28_029047_tm2510765d1_ex99-1","form":"8-K","date":"2025-03-28","url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465925029047/tm2510765d1_ex99-1.htm"},{"code":"8K_2025-03-28_029047_tm2510765d1_8k","form":"8-K","date":"2025-03-28","url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465925029047/tm2510765d1_8k.htm"},{"code":"8K_2025-06-16_059671_tm2518093d1_ex99-1","form":"8-K","date":"2025-06-16","url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465925059671/tm2518093d1_ex99-1.htm"},{"code":"8K_2025-06-16_059671_tm2518093d1_8k","form":"8-K","date":"2025-06-16","url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465925059671/tm2518093d1_8k.htm"},{"code":"8K_2025-07-11_067108_tm2520348d2_ex99-1","form":"8-K","date":"2025-07-11","url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465925067108/tm2520348d2_ex99-1.htm"},{"code":"8K_2025-07-11_067108_tm2520348d2_8k","form":"8-K","date":"2025-07-11","url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465925067108/tm2520348d2_8k.htm"},{"code":"8K_2025-08-12_076468_tm2523169d1_ex99-1","form":"8-K","date":"2025-08-12","url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465925076468/tm2523169d1_ex99-1.htm"},{"code":"8K_2025-11-12_109744_tm2530945d1_ex99-1","form":"8-K","date":"2025-11-12","url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465925109744/tm2530945d1_ex99-1.htm"},{"code":"10K_2026-03-20_032415_mist-20251231x10k","form":"10-K","date":"2026-03-20","url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/mist-20251231x10k.htm"}],"minerva_neurosciences":[{"code":"8K_2023-05-01_128726_d365950dex991","form":"8-K","date":"2023-05-01","url":"https://www.sec.gov/Archives/edgar/data/1598646/000119312523128726/d365950dex991.htm"},{"code":"8K_2024-02-27_047110_d795805dex991","form":"8-K","date":"2024-02-27","url":"https://www.sec.gov/Archives/edgar/data/1598646/000119312524047110/d795805dex991.htm"},{"code":"8K_2024-02-27_047110_d795805d8k","form":"8-K","date":"2024-02-27","url":"https://www.sec.gov/Archives/edgar/data/1598646/000119312524047110/d795805d8k.htm"},{"code":"10K_2026-03-11_101117_nerv-20251231","form":"10-K","date":"2026-03-11","url":"https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/nerv-20251231.htm"}],"ocular_therapeutix":[{"code":"8K_2016-07-25_655920_d178635dex991","form":"8-K","date":"2016-07-25","url":"https://www.sec.gov/Archives/edgar/data/1393434/000119312516655920/d178635dex991.htm"},{"code":"8K_2016-07-25_655920_d178635d8k","form":"8-K","date":"2016-07-25","url":"https://www.sec.gov/Archives/edgar/data/1393434/000119312516655920/d178635d8k.htm"},{"code":"8K_2016-08-09_676014_d208051dex991","form":"8-K","date":"2016-08-09","url":"https://www.sec.gov/Archives/edgar/data/1393434/000119312516676014/d208051dex991.htm"},{"code":"8K_2016-11-30_779941_d293177dex992","form":"8-K","date":"2016-11-30","url":"https://www.sec.gov/Archives/edgar/data/1393434/000119312516779941/d293177dex992.htm"},{"code":"8K_2016-11-30_779941_d293177dex991","form":"8-K","date":"2016-11-30","url":"https://www.sec.gov/Archives/edgar/data/1393434/000119312516779941/d293177dex991.htm"},{"code":"8K_2016-12-14_793042_d299703d8k","form":"8-K","date":"2016-12-14","url":"https://www.sec.gov/Archives/edgar/data/1393434/000119312516793042/d299703d8k.htm"},{"code":"8K_2017-01-23_014724_d335506d8k","form":"8-K","date":"2017-01-23","url":"https://www.sec.gov/Archives/edgar/data/1393434/000119312517014724/d335506d8k.htm"},{"code":"8K_2017-08-08_050259_a17-19111_1ex99d1","form":"8-K","date":"2017-08-08","url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465917050259/a17-19111_1ex99d1.htm"},{"code":"8K_2017-11-07_066633_a17-25197_1ex99d1","form":"8-K","date":"2017-11-07","url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465917066633/a17-25197_1ex99d1.htm"},{"code":"8K_2018-05-08_031296_a18-13071_1ex99d1","form":"8-K","date":"2018-05-08","url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465918031296/a18-13071_1ex99d1.htm"},{"code":"8K_2018-06-29_043027_a18-16247_18k","form":"8-K","date":"2018-06-29","url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465918043027/a18-16247_18k.htm"},{"code":"8K_2018-07-19_045933_a18-17427_18k","form":"8-K","date":"2018-07-19","url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465918045933/a18-17427_18k.htm"},{"code":"10K_2026-02-05_010664_ocul-20251231x10k","form":"10-K","date":"2026-02-05","url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/ocul-20251231x10k.htm"}],"omeros":[{"code":"8K_2021-10-18_013245_omer-20211014xex99d1","form":"8-K","date":"2021-10-18","url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837021013245/omer-20211014xex99d1.htm"},{"code":"8K_2021-10-18_013245_omer-20211014x8k","form":"8-K","date":"2021-10-18","url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837021013245/omer-20211014x8k.htm"},{"code":"8K_2021-11-09_015276_omer-20211109xex99d1","form":"8-K","date":"2021-11-09","url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837021015276/omer-20211109xex99d1.htm"},{"code":"8K_2022-03-01_002558_omer-20220301xex99d1","form":"8-K","date":"2022-03-01","url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837022002558/omer-20220301xex99d1.htm"},{"code":"8K_2022-05-10_008110_omer-20220510xex99d1","form":"8-K","date":"2022-05-10","url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837022008110/omer-20220510xex99d1.htm"},{"code":"8K_2022-08-09_012871_omer-20220809xex99d1","form":"8-K","date":"2022-08-09","url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837022012871/omer-20220809xex99d1.htm"},{"code":"8K_2022-11-09_017140_omer-20221109xex99d1","form":"8-K","date":"2022-11-09","url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837022017140/omer-20221109xex99d1.htm"},{"code":"8K_2023-03-13_003572_omer-20230313xex99d1","form":"8-K","date":"2023-03-13","url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837023003572/omer-20230313xex99d1.htm"},{"code":"8K_2023-05-09_008805_omer-20230509xex99d1","form":"8-K","date":"2023-05-09","url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837023008805/omer-20230509xex99d1.htm"},{"code":"10K_2026-03-31_010636_omer20251231_10k","form":"10-K","date":"2026-03-31","url":"https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/omer20251231_10k.htm"}],"organon":[{"code":"10K_2026-02-24_011125_ogn-20251231","form":"10-K","date":"2026-02-24","url":"https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/ogn-20251231.htm"}],"outlook_therapeutics":[{"code":"8K_2024-11-27_123554_tm2429443d1_ex99-1","form":"8-K","date":"2024-11-27","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465924123554/tm2429443d1_ex99-1.htm"},{"code":"8K_2025-05-15_049411_tm2515284d1_ex99-1","form":"8-K","date":"2025-05-15","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925049411/tm2515284d1_ex99-1.htm"},{"code":"8K_2025-08-14_078622_tm2523462d1_ex99-1","form":"8-K","date":"2025-08-14","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_ex99-1.htm"},{"code":"8K_2025-09-02_086428_tm2524956d1_ex99-1","form":"8-K","date":"2025-09-02","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925086428/tm2524956d1_ex99-1.htm"},{"code":"8K_2025-09-02_086428_tm2524956d1_8k","form":"8-K","date":"2025-09-02","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925086428/tm2524956d1_8k.htm"},{"code":"8K_2025-09-29_094558_tm2527376d1_ex99-1","form":"8-K","date":"2025-09-29","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925094558/tm2527376d1_ex99-1.htm"},{"code":"8K_2025-09-29_094558_tm2527376d1_8k","form":"8-K","date":"2025-09-29","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925094558/tm2527376d1_8k.htm"},{"code":"8K_2025-11-03_105633_tm2530088d1_ex99-1","form":"8-K","date":"2025-11-03","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925105633/tm2530088d1_ex99-1.htm"},{"code":"10K_2025-12-19_123264_otlk-20250930x10k","form":"10-K","date":"2025-12-19","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm"},{"code":"8K_2026-01-02_000066_tm2534608d1_ex99-1","form":"8-K","date":"2026-01-02","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926000066/tm2534608d1_ex99-1.htm"},{"code":"8K_2026-01-02_000066_tm2534608d1_8k","form":"8-K","date":"2026-01-02","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926000066/tm2534608d1_8k.htm"},{"code":"8K_2026-02-11_013470_tm265994d1_ex99-1","form":"8-K","date":"2026-02-11","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926013470/tm265994d1_ex99-1.htm"},{"code":"8K_2026-02-11_013470_tm265994d1_8k","form":"8-K","date":"2026-02-11","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926013470/tm265994d1_8k.htm"},{"code":"8K_2026-02-17_015887_tm266557d1_ex99-1","form":"8-K","date":"2026-02-17","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926015887/tm266557d1_ex99-1.htm"},{"code":"8K_2026-03-05_024189_tm268164d1_ex99-1","form":"8-K","date":"2026-03-05","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926024189/tm268164d1_ex99-1.htm"},{"code":"8K_2026-03-05_024189_tm268164d1_8k","form":"8-K","date":"2026-03-05","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926024189/tm268164d1_8k.htm"},{"code":"8K_2026-03-16_028103_tm268874d1_ex99-1","form":"8-K","date":"2026-03-16","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_ex99-1.htm"},{"code":"8K_2026-04-07_040387_tm2611268d1_ex99-1","form":"8-K","date":"2026-04-07","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926040387/tm2611268d1_ex99-1.htm"},{"code":"8K_2026-04-07_040387_tm2611268d1_8k","form":"8-K","date":"2026-04-07","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926040387/tm2611268d1_8k.htm"},{"code":"8K_2026-04-21_046014_tm2612353d1_ex99-1","form":"8-K","date":"2026-04-21","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926046014/tm2612353d1_ex99-1.htm"},{"code":"8K_2026-04-21_046014_tm2612353d1_8k","form":"8-K","date":"2026-04-21","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926046014/tm2612353d1_8k.htm"},{"code":"8K_2026-05-18_062865_tm2614868d1_ex99-1","form":"8-K","date":"2026-05-18","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926062865/tm2614868d1_ex99-1.htm"},{"code":"8K_2026-05-26_065992_tm2615583d1_ex99-1","form":"8-K","date":"2026-05-26","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/tm2615583d1_ex99-1.htm"},{"code":"8K_2026-05-26_065992_tm2615583d1_8k","form":"8-K","date":"2026-05-26","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/tm2615583d1_8k.htm"},{"code":"8K_2026-06-01_068659_tm2616461d1_ex99-1","form":"8-K","date":"2026-06-01","url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/tm2616461d1_ex99-1.htm"}],"pfizer":[{"code":"8K_2017-08-01_000034_pfe-07022017xex99","form":"8-K","date":"2017-08-01","url":"https://www.sec.gov/Archives/edgar/data/78003/000007800317000034/pfe-07022017xex99.htm"},{"code":"8K_2018-05-01_000039_pfe-04012018xex99","form":"8-K","date":"2018-05-01","url":"https://www.sec.gov/Archives/edgar/data/78003/000007800318000039/pfe-04012018xex99.htm"},{"code":"8K_2018-10-30_000087_pfe-09302018xex99","form":"8-K","date":"2018-10-30","url":"https://www.sec.gov/Archives/edgar/data/78003/000007800318000087/pfe-09302018xex99.htm"},{"code":"8K_2021-11-02_000104_pfe-10032021xex99","form":"8-K","date":"2021-11-02","url":"https://www.sec.gov/Archives/edgar/data/78003/000007800321000104/pfe-10032021xex99.htm"},{"code":"8K_2022-02-08_000003_pfe-12312021xex99","form":"8-K","date":"2022-02-08","url":"https://www.sec.gov/Archives/edgar/data/78003/000007800322000003/pfe-12312021xex99.htm"},{"code":"10K_2026-02-26_000026_pfe-20251231","form":"10-K","date":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm"}],"phathom_pharmaceuticals":[{"code":"8K_2023-05-23_151785_d503681d8k","form":"8-K","date":"2023-05-23","url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523151785/d503681d8k.htm"},{"code":"8K_2023-06-12_164930_d486645d8k","form":"8-K","date":"2023-06-12","url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523164930/d486645d8k.htm"},{"code":"8K_2023-08-10_209005_d491223dex991","form":"8-K","date":"2023-08-10","url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523209005/d491223dex991.htm"},{"code":"8K_2023-08-21_216611_d486896d8k","form":"8-K","date":"2023-08-21","url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523216611/d486896d8k.htm"},{"code":"10K_2026-02-26_073379_phat-20251231","form":"10-K","date":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/phat-20251231.htm"}],"ptc_therapeutics":[{"code":"8K_2025-08-19_011658_tmb-20250819xex99d1","form":"8-K","date":"2025-08-19","url":"https://www.sec.gov/Archives/edgar/data/1070081/000155837025011658/tmb-20250819xex99d1.htm"},{"code":"8K_2025-08-19_011658_tmb-20250819x8k","form":"8-K","date":"2025-08-19","url":"https://www.sec.gov/Archives/edgar/data/1070081/000155837025011658/tmb-20250819x8k.htm"},{"code":"10K_2026-02-19_017575_tmb-20251231x10k","form":"10-K","date":"2026-02-19","url":"https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm"}],"redhill_biopharma":[{"code":"6K_2014-02-04_000518_newsrelease","form":"6-K","date":"2014-02-04","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184314000518/newsrelease.htm"},{"code":"6K_2014-02-04_000518_document","form":"6-K","date":"2014-02-04","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184314000518/document.htm"},{"code":"6K_2014-02-25_000904_newsrelease","form":"6-K","date":"2014-02-25","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184314000904/newsrelease.htm"},{"code":"6K_2014-03-03_001049_newsrelease","form":"6-K","date":"2014-03-03","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184314001049/newsrelease.htm"},{"code":"6K_2014-04-24_001832_newsrelease","form":"6-K","date":"2014-04-24","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184314001832/newsrelease.htm"},{"code":"6K_2014-04-28_001904_newsrelease","form":"6-K","date":"2014-04-28","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184314001904/newsrelease.htm"},{"code":"6K_2014-04-30_001988_exh_991","form":"6-K","date":"2014-04-30","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184314001988/exh_991.htm"},{"code":"6K_2014-05-21_002453_newsrelease","form":"6-K","date":"2014-05-21","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184314002453/newsrelease.htm"},{"code":"6K_2014-07-23_003378_exh_1","form":"6-K","date":"2014-07-23","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184314003378/exh_1.htm"},{"code":"6K_2014-10-01_004548_newsrelease","form":"6-K","date":"2014-10-01","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184314004548/newsrelease.htm"},{"code":"6K_2014-12-01_005730_newsrelease","form":"6-K","date":"2014-12-01","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184314005730/newsrelease.htm"},{"code":"6K_2015-02-09_000688_exh_992","form":"6-K","date":"2015-02-09","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184315000688/exh_992.htm"},{"code":"6K_2015-09-10_005106_newsrelease","form":"6-K","date":"2015-09-10","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184315005106/newsrelease.htm"},{"code":"6K_2015-11-09_006111_newsrelease","form":"6-K","date":"2015-11-09","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184315006111/newsrelease.htm"},{"code":"6K_2016-02-18_007954_exh_991","form":"6-K","date":"2016-02-18","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184316007954/exh_991.htm"},{"code":"6K_2016-03-29_008854_exh_991","form":"6-K","date":"2016-03-29","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184316008854/exh_991.htm"},{"code":"6K_2017-04-13_002098_exh_991","form":"6-K","date":"2017-04-13","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184317002098/exh_991.htm"},{"code":"6K_2017-11-01_006460_exh_991","form":"6-K","date":"2017-11-01","url":"https://www.sec.gov/Archives/edgar/data/1553846/000117184317006460/exh_991.htm"},{"code":"20F_2026-04-27_049055_rdhl-20251231x20f","form":"20-F","date":"2026-04-27","url":"https://www.sec.gov/Archives/edgar/data/1553846/000110465926049055/rdhl-20251231x20f.htm"}],"regeneron_pharmaceuticals":[{"code":"8K_2023-01-09_002091_tm231703d1_ex99-1","form":"8-K","date":"2023-01-09","url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923002091/tm231703d1_ex99-1.htm"},{"code":"8K_2023-08-03_000021_exhibit991q22023","form":"8-K","date":"2023-08-03","url":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000021/exhibit991q22023.htm"},{"code":"8K_2023-11-02_000029_exhibit991q32023","form":"8-K","date":"2023-11-02","url":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000029/exhibit991q32023.htm"},{"code":"8K_2024-10-31_000038_exhibit991q32024","form":"8-K","date":"2024-10-31","url":"https://www.sec.gov/Archives/edgar/data/872589/000180422024000038/exhibit991q32024.htm"},{"code":"8K_2025-04-29_000020_exhibit991q12025","form":"8-K","date":"2025-04-29","url":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm"},{"code":"8K_2025-08-01_000017_exhibit991q22025","form":"8-K","date":"2025-08-01","url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm"},{"code":"8K_2025-10-28_000026_exhibit991q32025","form":"8-K","date":"2025-10-28","url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/exhibit991q32025.htm"},{"code":"10K_2026-02-04_000008_regn-20251231","form":"10-K","date":"2026-02-04","url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm"}],"regenxbio":[{"code":"8K_2026-02-10_043342_rgnx-ex99_1","form":"8-K","date":"2026-02-10","url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526043342/rgnx-ex99_1.htm"},{"code":"8K_2026-02-10_043342_rgnx-20260207","form":"8-K","date":"2026-02-10","url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526043342/rgnx-20260207.htm"},{"code":"8K_2026-03-05_092566_rgnx-ex99_1","form":"8-K","date":"2026-03-05","url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526092566/rgnx-ex99_1.htm"},{"code":"10K_2026-03-05_094013_rgnx-20251231","form":"10-K","date":"2026-03-05","url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm"}],"replimune":[{"code":"8K_2025-07-22_069489_tm2521403d1_ex99-1","form":"8-K","date":"2025-07-22","url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925069489/tm2521403d1_ex99-1.htm"},{"code":"8K_2025-07-22_069489_tm2521403d1_8k","form":"8-K","date":"2025-07-22","url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925069489/tm2521403d1_8k.htm"},{"code":"8K_2025-08-07_074989_tm2522849d1_ex99-1","form":"8-K","date":"2025-08-07","url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925074989/tm2522849d1_ex99-1.htm"},{"code":"8K_2025-09-04_087464_tm2525185d1_ex99-1","form":"8-K","date":"2025-09-04","url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925087464/tm2525185d1_ex99-1.htm"},{"code":"8K_2025-09-18_091066_tm2526397d1_ex99-1","form":"8-K","date":"2025-09-18","url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925091066/tm2526397d1_ex99-1.htm"},{"code":"8K_2025-10-20_100605_tm2529069d1_ex99-1","form":"8-K","date":"2025-10-20","url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925100605/tm2529069d1_ex99-1.htm"},{"code":"8K_2025-11-06_107438_tm2530417d1_ex99-1","form":"8-K","date":"2025-11-06","url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925107438/tm2530417d1_ex99-1.htm"},{"code":"8K_2026-04-13_042141_tm2611633d1_ex99-1","form":"8-K","date":"2026-04-13","url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926042141/tm2611633d1_ex99-1.htm"},{"code":"8K_2026-04-13_042141_tm2611633d1_8k","form":"8-K","date":"2026-04-13","url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926042141/tm2611633d1_8k.htm"},{"code":"10K_2026-06-29_045886_repl-20260331","form":"10-K","date":"2026-06-29","url":"https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm"}],"rocket_pharmaceuticals":[{"code":"8K_2024-06-28_031749_ef20031912_ex99-1","form":"8-K","date":"2024-06-28","url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124031749/ef20031912_ex99-1.htm"},{"code":"8K_2024-06-28_031749_ef20031912_8k","form":"8-K","date":"2024-06-28","url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124031749/ef20031912_8k.htm"},{"code":"8K_2025-02-27_006302_ef20044486_ex99-1","form":"8-K","date":"2025-02-27","url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125006302/ef20044486_ex99-1.htm"},{"code":"8K_2025-05-08_017958_ef20048651_ex99-1","form":"8-K","date":"2025-05-08","url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/ef20048651_ex99-1.htm"},{"code":"8K_2025-08-07_029582_ef20053509_ex99-1","form":"8-K","date":"2025-08-07","url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125029582/ef20053509_ex99-1.htm"},{"code":"10K_2026-02-26_076551_rckt-20251231","form":"10-K","date":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm"}],"sarepta_therapeutics":[{"code":"8K_2019-08-20_032588_srpt-ex991_6","form":"8-K","date":"2019-08-20","url":"https://www.sec.gov/Archives/edgar/data/873303/000156459019032588/srpt-ex991_6.htm"},{"code":"8K_2019-08-20_032588_srpt-8k_20190819","form":"8-K","date":"2019-08-20","url":"https://www.sec.gov/Archives/edgar/data/873303/000156459019032588/srpt-8k_20190819.htm"},{"code":"8K_2020-01-13_000941_srpt-ex991_6","form":"8-K","date":"2020-01-13","url":"https://www.sec.gov/Archives/edgar/data/873303/000156459020000941/srpt-ex991_6.htm"},{"code":"10K_2026-03-02_084144_srpt-20251231","form":"10-K","date":"2026-03-02","url":"https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm"}],"scholar_rock":[{"code":"8K_2025-09-23_092317_tm2526733d1_ex99-1","form":"8-K","date":"2025-09-23","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465925092317/tm2526733d1_ex99-1.htm"},{"code":"8K_2025-09-23_092317_tm2526733d1_8k","form":"8-K","date":"2025-09-23","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465925092317/tm2526733d1_8k.htm"},{"code":"8K_2025-11-14_111931_srrk-20251114xex99d2","form":"8-K","date":"2025-11-14","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465925111931/srrk-20251114xex99d2.htm"},{"code":"8K_2025-11-14_111931_srrk-20251114xex99d1","form":"8-K","date":"2025-11-14","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465925111931/srrk-20251114xex99d1.htm"},{"code":"8K_2026-01-12_002757_srrk-20260112xex99d2","form":"8-K","date":"2026-01-12","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112xex99d2.htm"},{"code":"8K_2026-01-12_002757_srrk-20260112xex99d1","form":"8-K","date":"2026-01-12","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112xex99d1.htm"},{"code":"8K_2026-01-12_002757_srrk-20260112x8k","form":"8-K","date":"2026-01-12","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112x8k.htm"},{"code":"8KA_2026-03-03_022897_tm267900d1_ex99-1","form":"8-K/A","date":"2026-03-03","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926022897/tm267900d1_ex99-1.htm"},{"code":"8K_2026-03-03_022547_srrk-20260303xex99d1","form":"8-K","date":"2026-03-03","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926022547/srrk-20260303xex99d1.htm"},{"code":"10K_2026-03-03_022551_srrk-20251231x10k","form":"10-K","date":"2026-03-03","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926022551/srrk-20251231x10k.htm"},{"code":"8K_2026-03-31_037350_tm2610664d1_ex99-1","form":"8-K","date":"2026-03-31","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926037350/tm2610664d1_ex99-1.htm"},{"code":"8K_2026-03-31_037350_tm2610664d1_8k","form":"8-K","date":"2026-03-31","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926037350/tm2610664d1_8k.htm"},{"code":"8K_2026-05-07_056655_srrk-20260507xex99d2","form":"8-K","date":"2026-05-07","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d2.htm"},{"code":"8K_2026-05-07_056655_srrk-20260507xex99d1","form":"8-K","date":"2026-05-07","url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d1.htm"}],"scienture":[{"code":"10K_2026-03-30_013475_form10-k","form":"10-K","date":"2026-03-30","url":"https://www.sec.gov/Archives/edgar/data/1382574/000149315226013475/form10-k.htm"}],"scilex_pharmaceuticals":[{"code":"8K_2023-06-27_176273_d443585dex101","form":"8-K","date":"2023-06-27","url":"https://www.sec.gov/Archives/edgar/data/1820190/000119312523176273/d443585dex101.htm"},{"code":"10K_2026-04-10_151455_sclx-20251231","form":"10-K","date":"2026-04-10","url":"https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/sclx-20251231.htm"}],"supernus_pharmaceuticals":[{"code":"8KA_2020-08-24_000059_ex991_finaluswmenterpris","form":"8-K/A","date":"2020-08-24","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657620000059/ex991_finaluswmenterpris.htm"},{"code":"8K_2020-11-10_000079_supn-20201109","form":"8-K","date":"2020-11-10","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657620000079/supn-20201109.htm"},{"code":"8K_2020-11-10_000079_ex99111-09x2020","form":"8-K","date":"2020-11-10","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657620000079/ex99111-09x2020.htm"},{"code":"8K_2020-12-23_000090_ex99112-22x2020","form":"8-K","date":"2020-12-23","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657620000090/ex99112-22x2020.htm"},{"code":"8K_2021-02-09_000004_ex99102-08x2021","form":"8-K","date":"2021-02-09","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657621000004/ex99102-08x2021.htm"},{"code":"8K_2022-10-11_000063_supn-20221011","form":"8-K","date":"2022-10-11","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657622000063/supn-20221011.htm"},{"code":"8K_2022-10-11_000063_ex99110-10x2022","form":"8-K","date":"2022-10-11","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657622000063/ex99110-10x2022.htm"},{"code":"8K_2022-11-08_000071_ex99111-08x2022","form":"8-K","date":"2022-11-08","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657622000071/ex99111-08x2022.htm"},{"code":"8K_2023-02-28_000008_ex99102-28x2023","form":"8-K","date":"2023-02-28","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000008/ex99102-28x2023.htm"},{"code":"8K_2023-05-09_000031_ex99105-09x2023","form":"8-K","date":"2023-05-09","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000031/ex99105-09x2023.htm"},{"code":"8K_2023-10-10_000060_ex99110-09x2023","form":"8-K","date":"2023-10-10","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000060/ex99110-09x2023.htm"},{"code":"8K_2023-10-18_109763_tm2328670d1_ex99-1","form":"8-K","date":"2023-10-18","url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923109763/tm2328670d1_ex99-1.htm"},{"code":"8K_2024-04-08_000018_supn-20240408","form":"8-K","date":"2024-04-08","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000018/supn-20240408.htm"},{"code":"8K_2024-04-08_000018_ex99104-08x2024","form":"8-K","date":"2024-04-08","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000018/ex99104-08x2024.htm"},{"code":"8K_2024-05-08_000026_ex99105-08x2024","form":"8-K","date":"2024-05-08","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000026/ex99105-08x2024.htm"},{"code":"8K_2024-08-01_000041_ex-991xsupnspn830ndaresubm","form":"8-K","date":"2024-08-01","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000041/ex-991xsupnspn830ndaresubm.htm"},{"code":"10K_2026-03-02_000011_supn-20251231","form":"10-K","date":"2026-03-02","url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm"}],"telix_pharmaceuticals_us":[{"code":"6K_2025-04-29_000049_pixpr","form":"6-K","date":"2025-04-29","url":"https://www.sec.gov/Archives/edgar/data/2007191/000200719125000049/pixpr.htm"},{"code":"6K_2025-08-28_000065_zircprcrl","form":"6-K","date":"2025-08-28","url":"https://www.sec.gov/Archives/edgar/data/2007191/000200719125000065/zircprcrl.htm"},{"code":"6K_2025-12-22_000077_pxupdatepr","form":"6-K","date":"2025-12-22","url":"https://www.sec.gov/Archives/edgar/data/2007191/000200719125000077/pxupdatepr.htm"},{"code":"6K_2026-02-19_009887_a20260220appendix4eand20","form":"6-K","date":"2026-02-19","url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm"},{"code":"20F_2026-02-20_009943_tlx-20251231","form":"20-F","date":"2026-02-20","url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm"},{"code":"6K_2026-03-16_000013_pixrepr","form":"6-K","date":"2026-03-16","url":"https://www.sec.gov/Archives/edgar/data/2007191/000200719126000013/pixrepr.htm"},{"code":"6K_2026-08-20_058126_announcement","form":"6-K","date":"2026-08-20","url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026058126/announcement.htm"},{"code":"6K_2026-08-20_058126_a20260820telixhy26append","form":"6-K","date":"2026-08-20","url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026058126/a20260820telixhy26append.htm"}],"therapeuticsmd":[{"code":"8K_2017-05-08_002494_txmd-8k_050817","form":"8-K","date":"2017-05-08","url":"https://www.sec.gov/Archives/edgar/data/25743/000138713117002494/txmd-8k_050817.htm"},{"code":"8K_2017-05-08_002494_ex99-1","form":"8-K","date":"2017-05-08","url":"https://www.sec.gov/Archives/edgar/data/25743/000138713117002494/ex99-1.htm"},{"code":"8K_2017-05-31_003091_ex99_1","form":"8-K","date":"2017-05-31","url":"https://www.sec.gov/Archives/edgar/data/25743/000138713117003091/ex99_1.htm"},{"code":"8K_2017-07-17_003644_ex99-1","form":"8-K","date":"2017-07-17","url":"https://www.sec.gov/Archives/edgar/data/25743/000138713117003644/ex99-1.htm"},{"code":"8K_2017-08-03_003882_ex99-1","form":"8-K","date":"2017-08-03","url":"https://www.sec.gov/Archives/edgar/data/25743/000138713117003882/ex99-1.htm"},{"code":"8K_2017-08-10_004045_ex99-1","form":"8-K","date":"2017-08-10","url":"https://www.sec.gov/Archives/edgar/data/25743/000138713117004045/ex99-1.htm"},{"code":"8K_2017-09-12_004625_ex99-1","form":"8-K","date":"2017-09-12","url":"https://www.sec.gov/Archives/edgar/data/25743/000138713117004625/ex99-1.htm"},{"code":"8K_2017-10-04_004944_ex99-1","form":"8-K","date":"2017-10-04","url":"https://www.sec.gov/Archives/edgar/data/25743/000138713117004944/ex99-1.htm"},{"code":"8K_2017-11-13_005435_ex99-1","form":"8-K","date":"2017-11-13","url":"https://www.sec.gov/Archives/edgar/data/25743/000138713117005435/ex99-1.htm"},{"code":"8K_2017-12-19_005903_ex99-1","form":"8-K","date":"2017-12-19","url":"https://www.sec.gov/Archives/edgar/data/25743/000138713117005903/ex99-1.htm"},{"code":"8K_2018-02-20_000732_ex99-1","form":"8-K","date":"2018-02-20","url":"https://www.sec.gov/Archives/edgar/data/25743/000138713118000732/ex99-1.htm"},{"code":"8K_2018-08-03_237291_d592851d8k","form":"8-K","date":"2018-08-03","url":"https://www.sec.gov/Archives/edgar/data/25743/000119312518237291/d592851d8k.htm"},{"code":"8K_2021-05-06_152445_d915418dex992","form":"8-K","date":"2021-05-06","url":"https://www.sec.gov/Archives/edgar/data/25743/000119312521152445/d915418dex992.htm"},{"code":"8K_2021-12-10_060036_txmd-ex991_6","form":"8-K","date":"2021-12-10","url":"https://www.sec.gov/Archives/edgar/data/25743/000156459021060036/txmd-ex991_6.htm"},{"code":"8K_2021-12-10_060036_txmd-8k_20211210","form":"8-K","date":"2021-12-10","url":"https://www.sec.gov/Archives/edgar/data/25743/000156459021060036/txmd-8k_20211210.htm"},{"code":"10K_2026-03-30_036515_ea0275992-10k_therape","form":"10-K","date":"2026-03-30","url":"https://www.sec.gov/Archives/edgar/data/25743/000121390026036515/ea0275992-10k_therape.htm"}],"ultragenyx_pharmaceutical":[{"code":"8K_2025-07-11_095334_rare-20250711","form":"8-K","date":"2025-07-11","url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025095334/rare-20250711.htm"},{"code":"8K_2025-08-05_103026_rare-ex99_1","form":"8-K","date":"2025-08-05","url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025103026/rare-ex99_1.htm"},{"code":"8K_2025-08-18_109570_rare-20250818","form":"8-K","date":"2025-08-18","url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025109570/rare-20250818.htm"},{"code":"8K_2025-09-08_113553_rare-20250908","form":"8-K","date":"2025-09-08","url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025113553/rare-20250908.htm"},{"code":"8K_2025-11-04_264707_rare-ex99_1","form":"8-K","date":"2025-11-04","url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312525264707/rare-ex99_1.htm"},{"code":"8K_2026-01-30_030590_rare-20260130","form":"8-K","date":"2026-01-30","url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526030590/rare-20260130.htm"},{"code":"10K_2026-02-18_057329_rare-20251231","form":"10-K","date":"2026-02-18","url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526057329/rare-20251231.htm"}],"unicycive_therapeutics":[{"code":"8K_2025-06-30_059303_ea024746901ex99-1_unicycive","form":"8-K","date":"2025-06-30","url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025059303/ea024746901ex99-1_unicycive.htm"},{"code":"8K_2025-06-30_059303_ea0247469-8k_unicycive","form":"8-K","date":"2025-06-30","url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025059303/ea0247469-8k_unicycive.htm"},{"code":"8K_2025-08-14_076066_ea025316301ex99-1_unicy","form":"8-K","date":"2025-08-14","url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025076066/ea025316301ex99-1_unicy.htm"},{"code":"8K_2025-10-28_102790_ea026272301ex99-1_unicycive","form":"8-K","date":"2025-10-28","url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025102790/ea026272301ex99-1_unicycive.htm"},{"code":"8K_2025-10-28_102790_ea0262723-8k_unicycive","form":"8-K","date":"2025-10-28","url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025102790/ea0262723-8k_unicycive.htm"},{"code":"10K_2026-03-30_035903_ea0281982-10k_unicycive","form":"10-K","date":"2026-03-30","url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm"},{"code":"8K_2026-08-12_088061_ea030169901ex99-1","form":"8-K","date":"2026-08-12","url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026088061/ea030169901ex99-1.htm"},{"code":"8K_2026-09-29_104314_ea030696701ex99-1","form":"8-K","date":"2026-09-29","url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026104314/ea030696701ex99-1.htm"}],"united_therapeutics":[{"code":"8KA_2016-09-27_146736_a16-19063_1ex99d1","form":"8-K/A","date":"2016-09-27","url":"https://www.sec.gov/Archives/edgar/data/1082554/000110465916146736/a16-19063_1ex99d1.htm"},{"code":"8K_2016-09-27_146684_a16-19063_1ex99d1","form":"8-K","date":"2016-09-27","url":"https://www.sec.gov/Archives/edgar/data/1082554/000110465916146684/a16-19063_1ex99d1.htm"},{"code":"8K_2020-02-26_025010_tm209309d1_ex99-1","form":"8-K","date":"2020-02-26","url":"https://www.sec.gov/Archives/edgar/data/1082554/000110465920025010/tm209309d1_ex99-1.htm"},{"code":"8K_2020-04-29_052714_tm2016909d1_99-1","form":"8-K","date":"2020-04-29","url":"https://www.sec.gov/Archives/edgar/data/1082554/000110465920052714/tm2016909d1_99-1.htm"},{"code":"8K_2020-07-29_000012_uthrq22020-ex991","form":"8-K","date":"2020-07-29","url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255420000012/uthrq22020-ex991.htm"},{"code":"8K_2020-10-28_000019_uthrq32020-exx991","form":"8-K","date":"2020-10-28","url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255420000019/uthrq32020-exx991.htm"},{"code":"8K_2021-02-24_000009_exhibit991uthr12312020","form":"8-K","date":"2021-02-24","url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255421000009/exhibit991uthr12312020.htm"},{"code":"8K_2021-03-03_031015_tm218545d1_8k","form":"8-K","date":"2021-03-03","url":"https://www.sec.gov/Archives/edgar/data/1082554/000110465921031015/tm218545d1_8k.htm"},{"code":"8K_2022-02-24_000006_exhibit991uthr12312021","form":"8-K","date":"2022-02-24","url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255422000006/exhibit991uthr12312021.htm"},{"code":"8K_2022-05-04_000014_uthrq12022-ex991","form":"8-K","date":"2022-05-04","url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255422000014/uthrq12022-ex991.htm"},{"code":"10K_2026-02-25_000006_uthr-20251231","form":"10-K","date":"2026-02-25","url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm"}],"verrica_pharmaceuticals":[{"code":"8K_2020-07-14_192263_d946667dex991","form":"8-K","date":"2020-07-14","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312520192263/d946667dex991.htm"},{"code":"8K_2020-07-14_192263_d946667d8k","form":"8-K","date":"2020-07-14","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312520192263/d946667d8k.htm"},{"code":"8K_2020-07-23_197468_d84560dex992","form":"8-K","date":"2020-07-23","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312520197468/d84560dex992.htm"},{"code":"8K_2020-07-23_197468_d84560dex991","form":"8-K","date":"2020-07-23","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312520197468/d84560dex991.htm"},{"code":"8K_2020-08-05_209871_d938790dex991","form":"8-K","date":"2020-08-05","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312520209871/d938790dex991.htm"},{"code":"8K_2020-11-09_288501_d800150dex991","form":"8-K","date":"2020-11-09","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312520288501/d800150dex991.htm"},{"code":"8K_2020-11-10_289663_d948855dex991","form":"8-K","date":"2020-11-10","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312520289663/d948855dex991.htm"},{"code":"8K_2021-02-17_045850_d130880dex991","form":"8-K","date":"2021-02-17","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312521045850/d130880dex991.htm"},{"code":"8K_2021-07-09_211337_d181869d8k","form":"8-K","date":"2021-07-09","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312521211337/d181869d8k.htm"},{"code":"8K_2021-09-20_277323_d235633d8k","form":"8-K","date":"2021-09-20","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312521277323/d235633d8k.htm"},{"code":"8K_2021-09-29_286746_d218997dex991","form":"8-K","date":"2021-09-29","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312521286746/d218997dex991.htm"},{"code":"8K_2021-11-12_327358_d411044dex991","form":"8-K","date":"2021-11-12","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312521327358/d411044dex991.htm"},{"code":"8K_2021-11-29_342387_d144854dex991","form":"8-K","date":"2021-11-29","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312521342387/d144854dex991.htm"},{"code":"8K_2021-11-29_342387_d144854d8k","form":"8-K","date":"2021-11-29","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312521342387/d144854d8k.htm"},{"code":"8K_2022-05-25_159075_d306825d8k","form":"8-K","date":"2022-05-25","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312522159075/d306825d8k.htm"},{"code":"8K_2022-06-03_167332_d303003d8k","form":"8-K","date":"2022-06-03","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312522167332/d303003d8k.htm"},{"code":"8K_2022-08-11_218004_d358754dex991","form":"8-K","date":"2022-08-11","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312522218004/d358754dex991.htm"},{"code":"8K_2022-09-14_244283_d356833dex991","form":"8-K","date":"2022-09-14","url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312522244283/d356833dex991.htm"},{"code":"10K_2026-03-11_000008_vrca-20251231","form":"10-K","date":"2026-03-11","url":"https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/vrca-20251231.htm"}],"xeris_pharmaceuticals":[{"code":"10K_2026-03-02_000016_xers-20251231","form":"10-K","date":"2026-03-02","url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/xers-20251231.htm"}]}}